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Summary 
The developed world is experiencing a steep increase in diseases based on aberrant 
autoimmune inflammatory responses and allergic conditions. By contrast, such diseases are 
uncommon in countries endemic for parasitic helminths, suggesting that parasite-derived 
immunomodulators may protect against their development. One such molecule, ES-62, 
which is a phosphorylcholine (PC)-containing glycoprotein originally identified from the 
filarial nematode Acanthocheilonema viteae, has shown therapeutic potential in a range of 
inflammatory diseases. Although its mechanism of action is not fully understood, ES-62 is 
known to target dendritic cells (DCs) to subvert T helper cell (TH) differentiation and 
hence modulate the subsequent host immune response to an anti-inflammatory phenotype. 
ES-62 requires Toll-like receptor 4 (TLR4) to mediate its effects, and here, we have 
investigated the mechanisms underpinning ES-62-mediated subversion of TLR4-pro-
inflammatory signalling as exemplified by its canonical ligand, bacterial endotoxin 
(lipopolysaccharide, LPS) that results in the activation of the transcription factor, nuclear 
factor-κB (NF-κB) and consequent secretion of proinflammatory cytokines. 
This study investigated the mechanism of ES-62-mediated uncoupling of NF-κB 
activation by its modulation of TLR4 expression and its associated LPS recognising 
complex TLR4/Myeloid differentiation factor-2 (MD2), as the internalisation, trafficking 
and degradation of this receptor complex has previously been shown to regulate its 
responses to different stimuli. ES-62 and LPS were found to differentially modulate the 
dynamics and expression of the total cellular pool of TLR4, relative to that of the ‘active’ 
LPS recognising TLR4/MD2 complex. Specifically, ES-62 acted to antagonise the 
dynamics of the LPS response, providing a mechanism for its induction of TLR4 
hyporesponsiveness. In addition, as preliminary studies demonstrated an interaction 
between ES-62 and the Platelet activating factor receptor (PAFR), the possibility that ES-
62 might signal via TLR4 in concert with one or more co-receptors was investigated but 
the data did not conclusively support a role for the PAFR as a target of ES-62 action.  
The dissection of the effects of ES-62 on TLR4 signalling was further pursued by 
defining its modulation and/or sequestration of transduction elements associated with the 
TLR4 mediated activation of NF-κB. Of particular interest were PKCα, PKCε and PKCδ 
members of the protein kinase C family that directly interact with TLR4 and its immediate 
signalling adaptors to mediate proinflammatory cytokine (TNF-α, IL-6 and IL-12p70) 
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production. Several isoforms including PKCα have previously been shown to be targeted 
in B cells and mast cells for degradation by ES-62. Here, we utilised pharmacological 
inhibitors of proteosomal and lysosomal protein degradation pathways to demonstrate that 
whilst LPS induces the turnover of PKCs through the proteosome, ES-62 directs their 
degradation through the lysosomes. In conjunction with this, ES-62 and LPS were also 
found to differentially regulate the expression of tumour necrosis factor receptor associated 
factor-6 (TRAF6) and c-Casitas B lineage lymphoma (c-Cbl), E3 ubiquitn ligases, which 
act as scaffolds (via Lysine 63 linked polyubiquitination chains) in the activation and 
stabilisation of NF-κB. However, it was found that ES-62 did not prevent recruitment of 
these various TLR4 signal transducers upon subsequent recognition of LPS, suggesting 
that it acts to attenuate hyper-inflammatory responses without leaving an individual 
immunocompromised to infection. In addition, by mimicking an inflammatory 
environment with exogenous granulocyte macrophage-colony stimulating factor (GM-
CSF), it was found that the actions of ES-62 had more profound effects on the modulation 
of the aforementioned signal transducers and its range of targets were expanded to include, 
myeloid differentiation primary responses gene 88 (MyD88), which transmits the early 
response signals from all the TLR family receptors, except TLR3. 
The lysosomal degradation of these cystolic proteins induced by ES-62 indicated a 
potential role for subversion of TLR-regulated autophagy. This cellular process provides a 
negative feedback mechanism for TLR4 signalling through its targeting of intracellular 
proteins for lysosomal degradation. Detailed investigation revealed that ES-62 induced 
autophagic flux, as defined by an increase in the ratio of light chain-3 type II (LC3-II; a 
component the characteristic autophagic vesicle, the autophagosome) to LC3–I. Moreover, 
ES-62 was observed to induce this mechanism to target the lysosomal degradation of p62 
(an LC3 binding autophagy adaptor protein), which is strongly upregulated by LPS to 
transduce NF-κB activation, potentially limiting its positive role in TLR4 signalling. In this 
context, this study demonstrates a novel interaction between PKCδ and p62 (but not LC3) 
upon LPS stimulation, suggesting as with other systems that the predominant role of p62 in 
DCs is as a mediator of the TLR4-NF-κB signalling axis.  
These effects on DC activation were associated with the capacity of ES-62 matured 
DCs to limit TH1/TH17 pro-inflammatory responses both relative to and following LPS 
stimulation. ES-62 was found to have little effect on costimulatory marker expression 
(cluster of differentiation-40 (CD40), CD80/86 and major histocompatibility complex 
(MHC) class II), placing a major emphasis of its modulation of TLR signalling on the DC 
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mediated cytokine milieu and not its direct interactions with TH cells. In this context, the 
plastic nature of immunomodulation by ES-62 was reflected by its lack of affect on LPS 
induced IL-6 and IL-27 production, crucial for initiating TH1 or TH17 differentiation 
required to fight infection. Rather, it attenuated IL-12p70, IL-23 and TNF-α cytokine 
secretion, which augment adaptive immune responses and drive the hyper-inflammatory 
potential of the TH1 and particularly TH17 phenotype of autoimmune pathology. 
Subsequently, ES-62 matured DCs displayed a limited potential to induce a TH17 
phenotype, as defined by a reduction in IL-17 and IL-22 secretion coupled to an impaired 
ability of such DCs to stimulate antigen (Ag) specific naïve TH cell proliferation, lowering 
the number of responding cells and their proliferative capacity. This occurred even upon 
subsequent stimulation with LPS, however a level of plasticity was observed as these 
effects were partially overcome when DCs were presenting high levels of Ag to naïve TH 
cells, indicating the important role of the microenvironment in regulating the induction of 
different TH phenotypes.  
Collectively these data further advance our understanding of the mechanisms 
underlying ES-62 mediated manipulation of NF-κB activation and cytokine production. 
This not only provides valuable information on how helminths can both augment and 
evade the immune system but demonstrates the therapeutic potential of ES-62 and reveals 
the underlying mechanisms it employs to attenuate pathogenic inflammation. 
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1 Introduction 
1.1 The innate immune system 
In all animals, the innate immune system provides essential protection against 
invading pathogens. This ancient and evolutionary conserved system is the first line of 
defence against invading pathogens; thus many of the cells which make up its network are 
found beneath the skin and other physical barriers of the body to protect us from the 
environment we inhabit. A key component of the innate system is a collection of germ-line 
encoded receptors called pathogen recognition receptors (PRRs), which recognise highly 
conserved molecular structures specific to microbes (Pathogen associated molecular 
patterns, or PAMPs)1. There are many examples of conserved PAMPs: mannans, 
lipopolysaccharide (LPS), peptidoglycans, lipoteichoic acids, unmethylated deoxynucleic 
acid (DNA) or CpG motifs, present in a number of pathogens but not on mammalian cells. 
Upon the recognition of a PAMPs by its relevant PRRs, rapid responses are activated by 
innate cells such as phagocytosis and chemotaxis, which are coupled to the active secretion 
of a number of soluble proteins and bioactive molecules. These include proteins such as 
cytokines (e.g. tumour necrosis factor-α [TNF-α]) and complement as well as lipid 
mediators (e.g. prostaglandins, leukotrienes and platelet activating factor [PAF]), which go 
on to regulate the later functional responses of innate cells that contribute to inflammation. 
Inflammation is an essential component of the innate immune system, as it leads to the 
recruitment and activation of cells such as dendritic cells (DC), macrophages, mast cells, 
eosinophils and neutrophils that exhibit key antimicrobial functions. 
The best understood subgroup of PRRs is the Toll-like receptor family. The 
mammalian Toll-like receptors (TLRs) are derived from an evolutionary ancient 
recognition and signalling system, originally discovered for its part in regulating dorsal 
polarity in developing embryos of the fruit fly, Drosophila Melanogaster. The 
susceptibility of drosophila strains to fungal infections that carried loss-of-function 
mutations in Toll suggested TLRs played an important role in host defence2. Soon after 
this discovery the first mammalian homologue of Toll, TLR4 was identified and shown to 
be essential for the response of mammals to the bacterial endotoxin, LPS2,3. The TLR-
family of receptors has the ability to recognise pathogens or pathogen-derived products and 
initiate signalling events leading to the activation of innate host defences and acute 
inflammatory responses by the induction of anti-microbial genes, inflammatory cytokines 
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and chemokines3. However the scope of TLR function extends beyond the innate immune 
system as it also has important roles in the activation of adaptive immune responses4-6.  
1.1.1 The Toll-like receptors  
The TLRs, members of the Toll/Interleukin-1 receptor superfamily3, are 
transmembrane spanning proteins that are comprised of extraceullar leucine-rich repeats, a 
transmembrane region and an intracellular domain that contains a conserved TIR 
(Toll/Interleukin-1 receptor) domain, the latter of which is also present on their 
intracellular adaptor proteins7. The 11 human and 13 mouse TLRs identified to date sense 
a diverse range of PAMP structures covering lipids, proteins, nucleic acids and 
lipopeptides8 and upon their recognition TLRs form homo- or heterodimers. For example, 
TLR2 forms heterodimers with TLR1 or TLR6 to recognise a large variety of lipopeptides 
found on gram negative bacteria, fungi, parasites and viruses. By contrast, TLR3 
homodimers sense double stranded ribonucleic acid (dsRNA) produced during viral 
replication whilst TLR 7/8 recognise guanosine- or uridine- rich single stranded RNA 
(ssRNA) and TLR9 unmethylated CpG from viral RNA and DNA respectively8. TLR5 and 
TLR11 recognise protein ligands, for example TLR5 is expressed by intestinal cluster of 
differentiation-11c+ (CD11c+) lamina propia cells where it senses bacterial flagellin9. 
TLR10 may heterodimerise with TLR2, but the ligand it recognises is currently unknown. 
The current knowledge of TLR proteins, their stimulatory ligands and the dimers they form 
is summarised in Figure 1.1. 
The most well characterised TLR, TLR4, in conjunction with accessory molecules 
Myeloid Differentiation factor-2 (MD-2) and CD14 recognises LPS from gram-negative 
bacteria10. TLR4 dimerisation results in propagation of the intracellular signals that lead to 
the gene induction of inflammatory cytokines, such as TNF-α, interleukin (IL)-6, IL-1β 
and IL-12 and up-regulation of co-stimulatory molecule expression, which is required for 
the induction of pathogen specific adaptive immune responses. The role of TLR4 in innate 
immunity was first discovered in C3H/HeJ mice, where a missense mutation in TLR4 
renders it unable to respond to bacterial endotoxin11. From these early studies it was 
observed that ligand specificity is not the only distinguishing feature of each TLR. In 
addition to recognising distinct classes of micro-organism individual TLRs differentially 
trigger different signal transduction pathways. For example receptors such as TLR3 and 
TLR4 induce the production of pro-inflammatory cytokines and the type I interferons 
(IFN), whereas others like TLR2 and TLR5 do not induce the latter type I IFN response12. 
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These differences in signalling outcome were explained by the discovery of multiple TIR 
domain-containing adaptor proteins, which link activated receptors to downstream kinases 
that trigger differential signalling pathways13. Thus, different receptors engage distinct 
adaptor combinations and the particular adaptor(s) used determine which signalling 
pathway(s) will be activated. These TIR-containing cytoplasmic adaptor proteins include 
Myeloid Differentiation factor-88 (MyD88), TIR-containing adaptor protein/MyD88 
adaptor-like (TIRAP/Mal), TIR-containing adaptor inducing IFN-β/TIR containing adaptor 
molecule-1 (TRIF/TICAM-1), TRIF-related adaptor molecule (TRAM) and Sterile α and 
HEAT-Armadillo Motifs (SARM)7. The intracellular adaptors utilised by the various 
TLR’s are summarised in Figure 1.1. 
The association of MyD88 with TLRs leads to the activation of the mitogen 
activated protein kinases (MAPKs), extracellular-regulated kinase (ERK), c-Jun N-
terminal kinases (JNK) and p38, coupled with nuclear factor κB (NF-κB) activation 
resulting in the expression of inflammatory cytokine genes14. The LPS sensor TLR4 
mediates NF-κB activation through the adaptors TIRAP-MyD88, while also utilising 
TRAM and TRIF to induce IRF3 activation that is pivotal for the production of type I 
IFNs15. This latter response was identified from analysis of cells from MyD88 deficient 
mice that were still able to respond to endotoxin, but with a noticeably delayed activation 
of NF-κB activation16,17. This delayed activation was shown to reflect the later recruitment 
of TRIF to TLR4 and this pathway was observed to not only activate NF-κB but also IRF3 
and the MAPKs. TRAM was then found to selectively participate in the activation of the 
TRIF-dependent pathways downstream of TLR4, but not TLR3. 
1.1.2 The recognition of LPS by TLR4 
The release of the cell wall component, LPS occurs in infections with Gram-
negative bacteria (e.g. Salmonella). Its recognition by innate cells prepares the immune 
system to eradicate the bacterium and hence, prevent the further spread of infection. The 
regulation of this response is a very important process as an amplified or uncontrolled 
inflammatory response to LPS can lead to septic shock syndrome and death. Structurally, 
LPS is a glycolipid located in the outer membrane of gram negative bacteria, that is 
composed of an amphipathic lipid A component and a core of hydrophilic 
polysaccharides18. The lipid A constituent is the main inducer of immunological responses 
to LPS and is conserved between different bacterial species. 
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The recognition of LPS is mediated by TLR4 on cells of the immune system such 
as macrophages, neutrophils and DCs. However, TLR4 alone cannot recognise LPS, it also 
requires the accessory cell surface proteins, CD14 and MD-2. Specifically, LPS becomes 
associated with LPS-binding protein (LBP) in the circulation, enabling it to bind to the 
cell-surface protein, CD14 which presents LPS to the TL4/MD-2 complex19, where MD-2 
initially binds TLR4 intracellularly and is important in targeting TLR4 to the cell surface20. 
The extracellular domains of members of the TLR family consist of leucine-rich repeats 
(LRRs) with a horseshoe-like shape20 and upon LPS binding the receptor dimerises, 
triggering the recruitment of adaptor proteins to the intracellular TIR domains of the TLRs 
and the initiation of signalling leading to activation of NF-κB. These include MyD88, 
which interacts with all the TLRs except TLR3 and in the case of TLR2 and -4, TIRAP 
(Mal), serves as a bridge for the recruitment of MyD88. The endocytosis of the TLR-
MyD88 complex is required for the recruitment of further signalling adaptors.  
1.1.3 The downstream signalling adaptors and events involved in 
TLR4 mediated activation of NF-κB 
The recognition of LPS by TLR4 results in the activation of the transcription factor 
NF-κB, which in turn induces the production of pro-inflammatory mediators. The NF-κB 
family comprises dimeric transcription factors that contain Rel-homology domains (RHDs) 
that bind to discrete DNA sequences known as κB sites present in promoter and enhancer 
regions of various genes21. The NF-κB family proteins form hetero- and homo-dimers, the 
most common of which activated by TLR signalling is the RelA-p50 complex. Both these 
proteins are transcription factors that regulate the expression of distinct but overlapping 
genes involved in the regulation of innate and adaptive immunity, inflammation, apoptosis, 
proliferation, stress responses and cancer progression21. In the resting cell, NF-κB is 
sequestered in the cytoplasm in an inactive form through its interaction with inhibitory 
protein-κB (IκB isoforms α, β, γ and ε) that masks the nuclear localisation signal, 
preventing nuclear translocation.  
There are several key steps in the activation of NF-κB by TLR4 (summarised in 
Figure 1.2), which begins with the cytoplasmic recruitment of the TIR domain-containing 
adaptor proteins TIRAP (Mal) and MyD88. MyD88 then interacts with the death domains 
of members of the IRAK (IL-1 receptor-associated kinase) family of protein kinases, 
which include IRAK1, -2, -4 and –M22. In this process it is IRAK4 that is initially activated 
and consequently, it phosphorylates and activates IRAK1. After this sequential 
  
8 
phosphorylation of IRAK4 and IRAK1, they dissociate from MyD88 and interact with 
TNF Receptor-Associated Factor-6 (TRAF6), a RING-fingered domain E3 ubiquitin 
ligase, which together with the Ubc13 (Ubiquitin carrier protein N) and Uev1A promote 
the Lys63-linked polyubiquitination of target proteins, including TRAF6 itself23. The 
ubiquitinated form of TRAF6 subsequently recruits a protein kinase complex containing 
TAK1 (transforming growth factor-β-activated kinase-1) and TABs (TAK1 binding 
proteins)24. This complex then activates the IκB kinase (IKK) complex, which consists of 
IKKα, IKKβ and NF-κB essential modifier (NEMO), the latter being the regulatory 
component of the complex. This IKK complex phosphorylates specific serine residues on 
IκB, initiating its rapid polyubiquitination and degradation by the 26S proteosome, 
releasing NF-κB to translocate into the nucleus and mediate inflammatory responses. This 
pathway is known as the ‘canonical pathway’ and is responsible for the TLR mediated 
induction of inflammatory cytokines such as TNF-α and IL-625. However, the NEMO-
TAB-TAK1 complex also initiates the activation of a number of MAPKs (ERK, JNK, 
p38), coupling TLR4 signalling to other cellular processes. The direct role of TRAF6 in 
TLR4 signal propagation and DC maturation is evidenced by studies with TRAF6-
deficient mice. In response to LPS, DCs from these mice are unable to effectively secrete 
IL-6 and IL-12 and up-regulate Major Histocompatibility Complex (MHC) class II to 
induce T cell priming, in response to various microbial stimuli including LPS, both in vitro 
and in vivo26,27.  
1.1.3.1 Ubiquitination and its role in mediating TLR4 responses  
1.1.3.1.1 What is ubiquitination? 
Ubiquitination is an important mechanism for regulating cellular trafficking and the 
induction of proteosomal and non-proteosomal-dependent mechanisms of signal 
degradation that result in the regulation of cellular responsiveness and inflammation28. 
Although the addition of ubiquitin (a 76 amino acid protein) was originally associated with 
targeting misfolded or damaged proteins for proteolysis. It is now known to be important 
for the formation of scaffolding complexes in signal transduction cascades and the 
subsequent activation and regulation of proteins29. Due to its diverse range of functions the 
ubiquitination of the target proteins lysine residues is mediated by three different classes of 
protein: the ubiquitin activating enzyme (E1), the ubiquitin-conjugating enzyme (E2) and 
the E3 ubiquitin-protein ligase30-32. For ubiquitin to be added to a protein the formation of a 
thioester bond between the C-terminal carboxyl group of ubiquitin and a catalytically 
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active cysteine residue of an E1 enzyme in an ATP dependent manner is required. 
Subsequently ubiquitin is transferred to a cysteine residue within the active centre of an E2 
enzyme and finally, ubiquitin is attached to the substrate protein in a process mediated by 
the E3 ligase33. Depending on the class of E3 ligase, this can involve ubiquitin transfer 
onto the E3 ligase, which occurs with HECT (homologous with E6-associated protein C 
terminus) domain containing proteins34, or directly to the target protein from the E2 
enzyme, as with RING (really new interesting gene) and U-box domain containing 
classes35,36. This process is summarised in Figure 1.3. 
As ubiquitin has several lysine (Lys, K) residues in its structure it can itself be a 
target for ubiquitination, allowing formation of polyubiquitin chains, which differ in 
linkage type depending on the lysine residue35,36. Several different chain types (in terms of 
linkage and length) exist, which differ not only structurally but functionally37-40. However, 
the best studied are K48 and K63 linked chains, where K48 linked chains are involved in 
the proteosomal degradation of target proteins41 and K63 linked chains can act as scaffolds 
for the formation of signalling complexes24 as well as having roles in protein trafficking, 
DNA repair and other proteosome-independent mechanisms42. 
1.1.3.1.2 The importance of ubiquitin and the E3 ligases in TLR4 
mediated activation of NF-κB 
The ubiquitination of proteins down stream of TLR4 stimulation is required for the 
activation of NF-κB. For example, the RING-fingered domain E3 ubiquitin ligase, TRAF6, 
is a key member of the TRAF (TNF receptor-associated factor) family of proteins that 
participates in both TLR and TNFR signalling27. This E3 ligase acts as a key scaffolding 
protein involved in the propagation of TLR4 signals and is required for both MyD88 
dependent and independent activation of NF-κB. TRAF6 is coupled to the TLR4 signaling 
complex at the plasma membrane (PM) by IRAK-1/2 and -4 after their phosphorylation 
and activation consequent to their association with MyD88. Subsequently, TRAF6 in 
conjunction with the E2 ligases, Ubc13 and Uev1a, promotes the Lys63-linked 
polyubiquitination of target proteins including TRAF6 itself, the cIAP1/2 (cellular 
inhibitor of apoptosis protein 1/2) proteins and the IKK complex component NEMO23,24. 
The polyubiquitylated cIAP proteins promote the K48-linked polyubiquitination and 
proteosomal degradation of TRAF343, a process which mediates the release of the MyD88-
TRAF6 complex into the cytosol44. Ubiquitinated NEMO and TRAF6 subsequently recruit 
a protein kinase complex involving TAK124. The activation of TAK1, subsequently 
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activates the IKK complex and several MAPKs, culminating in the activation of NF-κB 
and AP-1, respectively24. This involves the IKK mediated phosphorylation of IκB proteins, 
which are recognised by the F-box protein βTrCP – a subunit of the ubiquitin E3 ligase 
complex known as SCFβTrCP, which also contains S-phase kinase-associated protein 1 
(SKP1), CUL1 and RBX1. The SCFβTrCP E3 complex polyubiquitinates phosphorylated 
IκB proteins, which are subsequently degraded by the proteosome. This allows NF-κB to 
enter the nucleus and turn on target gene expression45 
The activation of the TRAM-TRIF pathway by TLR4 occurs subsequent to MyD88 
signalling and acts to maintain the activation of NF-κB and MAPKs as well as to induce 
the production of the type I IFNs via the activation of IFR315. In detail the activation of 
TRIF results in its recruitment of receptor-interacting protein 1 (RIP1)46, which undergoes 
K63-linked polyubiquitination by an E3 ligase of the pellino family, PELI147. 
Ubiquitylated RIP1 then recruits TAB2 and NEMO, leading to NF-κB activation. The 
endocytosed TLR4-TRIF complex also recruits TRAF6 and TRAF3, but not the cIAPs to 
the endosome. TRAF3 subsequently undergoes K63-linked polyubiquitination, which 
activates the kinase TBK1 and IKKε, leading to IRF3 phosphorylation and subsequent 
production of type I IFN. Interestingly, the ability to induce IFNs can be conferred to TLR 
pathways that normally do not induce IFNs (such as the TLR2 pathway) by forced PM 
localisation of TRAF348. The processes and the importance of ubiquitination in both 
MyD88 and TRIF mediated activation of NF-κB is summarised in Figure 1.4. Thus it is 
becoming clear that ubiquitination provides an important mechanism for the regulation of 
protein interactions, activation of signalling pathways and subcellular localisation of 
signalling elements in the activation of NF-κB by TLR4 signalling.  
1.1.3.2 The Protein Kinase C (PKC) family and its involvement in TLR 
signalling and NF-κB activation  
1.1.3.2.1 The PKC family 
The PKC family is comprised of several lipid-sensitive protein serine/threonine 
kinases, which play central roles in the regulation of intracellular signal transduction and 
currently have an expanding repertoire of functions in both adaptive and innate immune 
responses49. Originally identified in 1977 by Nishizuka and colleagues50, the PKC family 
now comprises of at least ten mammalian isoforms divided into 3 sub-families depending 
on their activation requirements. The conventional isoforms: PKC-α, -βI, -βII and -γ 
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require calcium, DAG and phosphatidylserine for activation; the novel isoforms, PKC-δ, -
ε, -θ and -η, require diacylglycerol (DAG) and phosphatidylserine but are calcium 
independent; the atypical isoforms, PKC-ζ, -λ and -ι, require only phosphatidylserine for 
activation51. Thus many of these requirements revolve around the upstream stimulation of 
phospholipase C (PLC), an enzyme that hydrolyses phosphatidylinositol 4,5-bisphosphate 
(PIP2) to generate membrane-bound DAG and inositol triphosphate (IP3), which results in 
the mobilisation of intracellular calcium49. In this respect, it is important to note that many 
PKCs can be pharmacologically activated by tumour-promoting phorbol esters (e.g. PMA), 
which act as DAG substitutes and anchor PKCs in their active conformations to cellular 
membranes52. 
Despite their expression within a broad range of cells and tissues49, each isoform  
shares a similar overall structure consisting of an N-terminal regulatory domain coupled to 
a highly conserved C-terminal kinase domain (Summarised in Figure 1.5 A). In resting 
cells or in the absence of lipid hydrolysis, PKCs are localised primarily in the cytosol53. 
The regulatory N-terminal portion therefore serves two roles; the first being to engage lipid 
second messengers/proteins to tether the enzyme to particular cellular locations, including 
the PM, through two discrete targeting modules, termed C1 and C254. The second is to 
regulate its kinase activity through a pseudo-substrate domain that binds to the substrate 
binding cavity in the catalytic site. This maintains the enzyme in an inactive form until 
binding of lipid second messengers restores catalytic activity by removing this blocking 
portion54. Between the regulatory (N-terminal) and kinase (C-terminal) domains lies a non-
conserved ‘hinge’ region, which is liable for proteolytic cleavage when the PKC is 
activated, leading to the release of an isolated kinase domain fragment termed ‘PKM’ 
(protein kinase M)55.  
1.1.3.2.2 Regulation of PKC activity, localisation and function 
Although often being labelled collectively as protein serine/threonine kinases, 
PKCs are anything but generic in their properties and functions as evidenced by recent 
studies showing they can be: 1) controlled through phosphorylation on serine, threonine 
and tyrosine residues that influence the stability, protease/phosphatase resistance, protein-
protein interactions, subcellular targeting and substrate specificity of the enzyme52; 2) 
cleaved by caspases, generating a catalytically active kinase domain (in some cases, with 
altered enzymology) and a free regulatory domain fragment that can act both as an 
inhibitor of the full length enzyme and as a activator of certain signalling responses52, 3) 
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activated by other lipid cofactors (such as ceramide or arachidonic acid) or lipid-
independent mechanisms allowing PKC to signal throughout the cell, not just at DAG-
containing membranes52. The understanding of these key mechanisms is an important step 
in defining their roles in mediating TLR responses and as such will be outlined. 
1.1.3.2.3 The cleavage of certain PKC isoforms in response to different 
stimuli 
The hinge regions of certain PKCs have been identified as targets for caspase-
dependent cleavage, protein-protein interactions and tyrosine phosphorylation. PKCδ, -θ, -
ε and -ζ undergo caspase-dependent cleavage in response to a range of apoptotic stimuli 
where cleavage at the hinge region results in the release of a catalytic domain fragment53, 
uninhibited by the NH2-terminal regulatory domain56. However, activation loop 
transphosphorylation is required for this cleaved form to be active in all isoforms, except 
PKCδ. In this respect, the PKCδ isoform displays differences in the enzymology and roles 
of the full length and cleaved 40-kDa catalytic domain fragment, the latter of which is 
phospholipid independent and constitutively active57,58. Several studies have found that the 
relative levels of full length and cleaved (active) PKCδ and -ε can have dramatic effects on 
cellular function and the phosphorylation of targets depending on the stimulus56. The 
localisation of the PKCδ catalytic domain is also quite unique, as lacking the membrane 
targeting modules located within the NH2-terminal regulatory domain, it accumulates in 
the nucleus through a NLS and this accumulation is sufficient to induce apoptosis in 
certain cell types59. 
1.1.3.2.4 The phosphorylation of PKCs 
The phosphorylation of PKCs is crucial in the regulation of their activity, 
localisation and stability53 (summarised in Figure 1.5B). Phosphorylation of three key sites 
located at the C-terminal ‘tail’, on most of the PKC family members is important for their 
function; these sites are the activation loop (A-loop), the turn motif (TM) and hydrophobic 
motif (HM) and have been described as maturational and priming events as the majority of 
PKCs are phosphorylated at these sites shortly after synthesis within quiescent cells60,61. 
The absence of phosphorylation at one or more of these sites leads to impairment of 
catalytic activation and enzyme stability. The A-loop is a highly conserved 20-30 residue 
sequence in the cleft of the kinase domain that is flexible and forms part of the peptide 
substrate binding surface. A-loop phosphorylation (at a threonine residue) stabilises the 
active conformation of the enzyme and is generally attributed to the master kinase, PDK-1 
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(3-phosphoinositide-dependent protein kinase-1)62. The TM motif is conserved in all PKC 
isoforms and upon phosphorylation makes important contacts with other residues to help 
stabilise its kinase core63. Interestingly the down-regulation of phosphorylation at the A-
loop, TM and HM sites has been shown to precede the degradation of the PKC isoforms, 
most commonly through a proteosomal-ubiquitin system64-66. This generally occurs upon 
the metabolism of DAG, which results in the translocation of the cPKCs and nPKCs from 
the PM back to the cytoplasm. Dephosphorylation of PKCs can also occur at the sites such 
as the A-loop in response to TNF-α and is a key step in turning off the signalling capacity 
of these kinases67. However despite dephosphorylation serving as an important switch to 
turn off the activity of these enzymes, it does not necessarily predispose the enzyme to 
degradation. For example the down-regulation of PKCα, which occurs through the 
ubiquitin/proteosome pathway does not involve dephosphorylation of the enzyme64,68. 
Recently however, the phosphorylation of these C-terminal regions on nPKCs have 
been implicated in controlling their association with certain proteins and membranes and 
not just in maintaining the enzyme in a conformation that is favourable for catalysis69,70. 
The reasoning for this is: 1) PKCδ can function as a kinase even without A-loop 
phosphorylation (at Threonine 505 [Thr505] in the case of PKCδ)71; 2) Several 
phosphorylations of the nPKCs are not constitutive but are dynamically regulated72; 3) 
Phosphorylations of the nPKCs at the TM and HM can occur by both auto-phosphorylation 
and transphosphorylation mechanisms (depending on the isoform and context).  
Among all the nPKCs, PKCδ appears to be unusual as it retains a modest catalytic 
ability when not phosphorylated at these sites through its ability to stabilise its activation 
loop73,74. Whether it is phosphorylated (Thr505) or self-stabilised, the A-loop can dictate 
the substrate specificity of PKCδ. For example a Thr-507A mutation, which lacks A-loop 
phosphorylation, mimics only some of WT-PKCδ responses in cells, where it can trigger 
apoptosis but cannot activate NF-κB or AP-1 reporter constructs in Jurkat T cells74. The 
notion that the A-loop phosphorylation regulates PKCδ substrate specificity (rather than 
absolute activity) goes some way to resolving discrepancies in the literature regarding 
Thr505 phosphorylation in the control of PKCδ catalytic function72,75. PKCδ also has 
several sites outside the C-terminal tail that are phosphorylated in response to a diverse 
range of stimuli53,73, including Tyrosine 311 (Tyr311), which has generated quite a lot of 
interest due to its role in acting as a docking site for the interaction of PKCδ with several 
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signalling molecules52. Thus current evidence suggests that its intracellular localisation and 
phosphorylation status “fine tune” the enzymological capacity of PKCδ in cells.  
1.1.3.2.5 The localisation of PKCs and its importance in their function 
The spatiotemporal localisation of PKCs is very important in mediating their 
activation and function, which can vary substantially depending on the cell type and the 
particular stimulus52. In this respect the C1 and C2 portions of the NH2-terminal regulatory 
domain are important in tethering and directing PKCs to different cellular locales. For 
example, under certain stimulations, nPKCs (including PKCδ, -ε, -θ, -η) localise through 
their C1B domain to the golgi complex where PKCδ and -θ can induce apoptosis, while 
PKCε modulates secretion from the organelle76,77. However, PKC localisation is not 
restricted to cytoplasmic organelles as full length PKCδ can be detected in the nucleus 
during the initial phase of genotoxic stress in many cell types where its translocation is 
mediated by a bipartite NLS (6 basic amino acids) in its C-terminus52. Interestingly, there 
is some literature suggesting that PKC activity itself can influence PKC cycling (between 
the cytosol and PM), translocation and down-regulation in cells78. 
In terms of cPKCs, for stimulations that induce a biphasic DAG response, PKCα 
and PKCβII are released from the PM and collect in a ‘perinuclear’ site dubbed the 
“pericentron” (a subset of recycling endosomes) through a PLC-independent mechanism 
involving Phospholipase D (PLD)79,80. Interestingly the lipid, ceramide, can act as an 
inhibitory regulator of PKCα/PKCβII signalling at perinuclear membranes81. This 
localisation to the pericentron plays an important role in controlling trafficking of 
continuously recycling membrane signalling proteins such as caveolin-1 (important in the 
formation of caveolae) and certain cell surface receptors. 
Indeed, several PKC isoforms are known to translocate to specialised membrane 
compartments known as caveolae, which are sphingolipid/cholesterol-enriched detergent-
resistant membranes that form flask like invaginations (60-80 nm in diameter) at the PM82. 
Relating to this, the activation of PKCδ is important for the function of acid 
sphingomyelinase (ASM), an enzyme that catalyses the hydrolysis of sphingomyelin to 
form ceramide at the PM83, as this lipid is important in the formation of lipid rafts and the 
localisation of proteins for internalisation via caveolae. Thus, PKCδ promotes local 
ceramide accumulation at the PM and drives raft fusion, providing a mechanism for the 
localisation of signalling proteins to membrane rafts. cPKC and nPKCs can be recovered 
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both at rest or following agonist activation in the caveolae fraction of several cell types59, 
and some caveolin isoforms (caveolin-1 and -3) can physically interact with certain PKC 
isoforms such as PKCα and PKCγ but not others including PKCε84. Indeed the recruitment 
of PKCε and -δ to the PM is important in driving the clustering of FCγRIIA and caveolin-1 
in lipids rafts to facilitate phagocytosis85,86. For example, PKCε translocates to the 
phagosomes and promotes efficient phagocytosis in macrophages where the engagement of 
IgG opsonised particle by FcγR results in the localised accumulation of signalling 
molecules through PLC/PLD production of DAG87. 
PKCα, -δ, and -ε have been found to accumulate in the caveolae fraction isolated 
from cardiomyocytes treated with PMA88. Interestingly, in cardiomyocytes this stimulation 
with PMA not only directs PKCδ to caveolae but subsequently induces its tyrosine 
phosphorylation (at Tyr311) that can be disrupted by cyclodextrin (a cholesterol-binding 
agent that undermines caveolae structural integrity)89. The phosphorylation at Tyr311 by 
Src family kinases, acts as a docking sites for several signalling molecules on PKCδ52 and 
this has been reported in a variety of cell types to occur in response to non-apoptotic 
stimuli53. In this respect, the Src-dependent Tyr-311 and Thr-505 phosphorylation of PKCδ 
may regulate its localisation and subsequent substrate specificity58,90. 
1.1.3.2.6 The role of the PKCs in TLR signalling 
There is now a growing body of evidence indicating that PKCs play important roles 
in TLR mediated activation of NF-κB (Summarised in Figure 1.6), with the majority of 
studies showing that alteration of the activity of particular PKCs in cells of the innate 
immune system, including DC, affected their ability to secrete pro-inflammatory cytokines 
in response to TLR stimuli. Subsequent to this, the TLR4 agonist, LPS has been shown to 
activate most PKC isoforms in innate cells such as monocytes, macrophages, DCs and 
neutrophils91-95. In conjunction with this, studies have shown that acute activation of the 
PKCs with phorbol esters, increases LPS-stimulated cytokine secretion94,96-98, while 
pharmacological inhibition of PKCs attenuates cytokine production96,98,99.  
Recent evidence indicates that each of the TLRs can initiate the 
activation/regulation of different PKCs. In this context, several isoforms including PKCα, 
-δ and -ε appear to have important roles in the propagation of signals from TLR4, 
particularly in relation to the secretion of certain cytokines. For example, it has been 
demonstrated that both PKCε and PKCδ, directly interact with MyD8849,100 and TIRAP101, 
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via their TIR domains, respectively. In this respect, the downregulation of PKCδ leads to a 
decrease in NF-κB activation and the secretion of inflammatory cytokines, in a range of 
innate cells93,102,103. Consistent with this, as demonstrated in PKCδ deficient RAW264.7 
macrophages, PKCδ is important for the TLR4 mediated activation of IKK and 
subsequently, NF-κB101. Interestingly, PKCδ has been suggested to be able to act like an 
IKK to phosphorylate IκB, which is then subsequently ubiquitinated and degraded by the 
26S proteosome allowing nuclear translocation of NF-κB and its binding to κB 
elements104,105. PKCδ is also reported to increase the transactivation potential of NF-κB via 
an IKK/IκB independent pathway that is speculated to involve the direct phosphorylation 
of NF-κB by kinases downstream from PKCδ such as p38 or Akt106-108. Interestingly 
studies have shown a reciprocal regulation of PKCδ by NF-κB, by showing that a NF-κB 
responsive regulatory element in the PKCδ promoter links TNF-α stimulation to increased 
PKCδ mRNA and protein expression109.  
In relation to the diverse cell types in which PKCδ plays a prominent role, PKCδ-/- 
mice exhibit autonomous hyper-proliferation of B cells, leading to the development of 
immune-complex mediated glomerulonephritis and lymphocyte infiltration in many 
organs, indicating PKCδ as an important negative regulator of B cell proliferation52. By 
contrast, in endothelial cells, PKCδ mediated activation of NF-κB is observed to enhance 
protein expression of ICAM-1 (inter-cellular cell adhesion molecule 1) and increased 
neutrophil adhesiveness. There is also a link between PKCδ mediated activation of NF-κB 
and the induction of certain ‘Inhibitors of apoptosis’ (IAP) protein family members in 
human colon cancer cells and increased expression of pro-inflammatory mediators in 
airway epithelial cells52. Interestingly in microglia cells, which express all the TLRs and 
act as the primary sensors of PAMPs in the CNS110, LPS activation of several caspases did 
not induce apoptosis but rather contributed to the downstream signalling of TLR4 in 
microglia. This was attributed to the role of caspases in PKCδ cleavage and ultimately NF-
κB activation. Therefore, inhibition of caspase activity was shown to protect neurons in 
animal models of Alzheimer’s disease and Parkinson’s disease111. 
Another novel isoform, PKCε is an important mediator of macrophage function, 
with evidence indicating a role in LPS signal transduction through its involvement in 
initiating MAPK signalling112. Indeed, although PKCε -/- mice are healthy, they display the 
major defect of being unable to clear gram positive (TLR2) and negative (TLR4) bacterial 
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infections, due to the inability of their macrophages to activate IKK and NF-κB resulting 
in reduced production of TNF-α, Il-1β and nitric oxide (NO)113. PKCε appears to fulfil a 
similar role in DCs112, as experiments utilising specific peptide inhibitors of translocation 
based on PKC-isoenzyme-specific pseudosubstrates, showed that PKCε is crucial for LPS-
induced IKK and NF-κB activation resulting in TNF-α and IL-12p70 secretion but not the 
ability to up-regulate co-stimulatory molecules in monocyte derived DC114. Recently a 
direct link between TLRs and PKCε has been shown100, where stimulation with LPS 
results in PKCε phosphorylation and association with MyD88. Interestingly, knock-down 
of MyD88 specifically results in the reduction of PKCε phosphorylation at Ser346. Thus 
PKCε may be important in integrating different signalling cascades that impact on the 
establishment of an effective immune response.  
However, it is not only the novel isoforms that have a role in the TLR-NF-κB 
signalling axis as the convential isoform, PKCα has also been implicated in mediating a 
number of effects in the TLR signalosome. This conventional PKC isoform has been found 
to be immunoprecipitated with TLR2 from DCs following activation, an association which 
is ablated in MyD88-/- mice suggesting it is MyD88 that acts as the link between PKCα 
and potentially TLR2/4115. This hypothesis is further reinforced by evidence that the 
inhibitor Gö6976 (targets PKCα and -β) prevents TLR-stimulated cytokine secretion by 
neutrophils91 and macrophages116-118. Moreover, 264.7 RAW macrophages expressing a 
dominant negative (DN) PKCα have reduced LPS-stimulated TNF-α and IL-6 
secretion119,120, suggesting a direct link in its propagation of TLR4 signals. However, these 
cells also show defects in phagocytosis and phagosome maturation which are non-TLR 
mediated aspects of innate immunity121,122. In human and mouse DC, the role of PKCα has 
been elucidated by use of its inhibitor Gö6976, DN constructs and PKCα-/- mice115. In 
these studies, PKCα was shown to be crucial for TLR2 mediated activation of MAPK and 
NF-κB leading to the secretion of TNFα, IL-6 and IL-10.  
1.2 Bridging the gap; TLRs are an important component 
of both the adaptive and innate immune systems  
1.2.1 The basics components of the adaptive immune system  
Vertebrates have a second line of defence against invading pathogens, called the 
adaptive immune system which confers Ag-specific responses with memory of infection. 
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This complex network of cells employs a diverse set of somatically rearranged receptors 
including T-cell receptors [TCRs] and B-cell receptors [BCR] expressed by T and B 
lymphocytes that allows recognition of an extremely diverse range of unique Ags. 
Although T and B cells of the adaptive immune system express receptors of enormous 
diversity, full activation of these cells depends on the secretion of cytokines and 
chemokines coupled with the interaction and Ag presentation by the innate immune 
system. The discovery that innate immune cells sense pathogens through PRRs such as 
TLRs revolutionised our understanding of the role of the innate immune system in 
infection and driving adaptive immune responses particularly in relation to T cells1. The 
type of agonist and the PRR it binds is important for promoting the maturation of APCs 
such as DCs (through the activation of proinflammatory transcription factors such as NF-
κB6) and their production of specific cytokines, depending on the pathogen encountered, 
promotes the development of an appropriate effector subset from the pool of naïve CD4+ T 
cells. In this context, naïve T lymphocytes specifically recognise Ags presented by MHC 
complexes on antigen presenting cells (APC) through direct interactions via their TCR, 
resulting in their proliferation (clonal expansion) and differentiation into effector T cells. 
In a process referred to as ‘priming’, naïve T cells initially encounter an Ag intiating their 
differentiation and clonal expansion. The differentiated effector cells gain abilities that 
allow them to direct other cells of the immune system to locate and remove the recognised 
Ag, inducing active secretion of various cytokines. The primary T-cell response also 
generates memory T cells, long-lived cells that give an accelerated response to Ag, 
providing protection from subsequent challenge by the same pathogen.  
In this context, T cells can be divided into two broad groups based on the 
expression of the transmembrane glycoproteins, CD8 and CD4. CD8+ T cells recognise 
Ags presented by MHC class I molecules inducing the differentiation of naïve cells into 
cytotoxic effector T cells that recognise and kill virus infected cells. On the other hand, 
CD4+ T cells (T helper cells; TH) have a more flexible repertoire whereby after recognition 
of pathogenic peptides presented by MHC class II molecules, naïve CD4 T cells can 
differentiate down distinctive pathways that generate effector subsets such as TH1, TH2 and 
TH17. For example; the secretion of IL-12p70 promotes the differentiation of TH1 cells and 
cellular mediated immunity; IL-4 and IL-13 stimulates the clonal expansion of TH2 cells 
which promote humoral immunity; IL-10 induces the development of regulatory TH cells 
(Treg) cells, which help to regulate the immune response; while combinations of IL-1, IL-6, 
TGF-β, IL-18 and IL-23 promote the generation of TH17 cells, which in addition to 
combating infection have been shown to promote infammation123-125. Another interesting T 
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cell subset to emerge in recent years are γδ T cells, which secrete various pro-inflammatory 
cytokines following stimulation with IL-23 in combination with IL-1 or IL-18 (which are 
also secreted by DCs) with no requirement for TCR engagement126,127. Differentiation of 
effector TH cells also allows them to provide help to B cells to trigger immunoglobulin 
(antibody) production.  
The humoral (antibody) immune response mediated by B cells allows the specific 
targeting of pathogens in the extracellular spaces of the body and makes up a significant 
arm of the adaptive immune response. Interesingly, B cells do not merely produce 
antibodies, they also actively secrete cytokines and serve as APCs, where through direct 
interactions (does not require MHC) of the BCR with Ag activated B cells then 
differentiate into memory B cells and/or antibody-secreting plasma cells. In the context of 
natural infections, the BCR can bind native proteins, glycoproteins, polysaccharides, virus 
particles and bacterial cells by recognising certain epitopes on their surfaces. The BCR has 
two roles in B cell activation; firstly it signals to the interior of the cell when Ag is bound, 
and secondly, the B cell Ag receptor delivers bound Ag to intracellular sites, where it can 
be degraded to give peptides that are returned to the B-cell surface bound to MHC class II 
molecules. These peptide presenting MHC class II complexes are recognised by Ag 
specific TH cells that have already differentiated in response to the same Ag. However this 
T-B cell interaction is bidirectional as effector T cells secrete cytokines that induce B cells 
to proliferate and differentiate into antibody secreting and memory B cells.  
Based on their phenotypical, functional and topographical characteristics, B cells 
can be divided into innate-like and adaptive immune cells128. Follicular B cells have an 
important role in T cell dependent immune responses and belong to the adaptive arm of the 
immune system. Through somatic hypermutation in B cell follicles situated in lymphoid 
tissue they generate a clonally rearranged Ag specific BCR, which upon Ag stimulation 
develop either into antibody secreting plasma cells or memory B cells (for long-term 
repsones) both of which rely on T cells to maximise their potential. By contrast, B-1 and 
marginal zone B cells are considered to be more like innate immune cells, generating rapid 
but lower affinity antibody responses that are independent of T cell help. The term ‘B-1’ 
refers to the idea that this population develops earlier during ontogeny where they are 
predominantly enriched in the peritoneal and pleural cavities but can also be found in the 
spleen129. This is relative to the more conventional B-2 cells, which is a term used to 
traditionally describe the main population of mature B cells that develop, after birth, from 
common bone marrow precursors and are located in the bone marrow, spleen and lymph 
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nodes. B-2 cells therefore include both follicular and marginal zone subsets, which are 
currently referred to as separate populations because of their distinct phenotypical and 
functional characteristics. 
1.2.2 The expression of TLRs on T and B cells; enhancing 
adaptive immune responses 
It is well known that positive signalling through the TLRs on APCs dictates the 
maturation state and cytokine milieu that is important in driving the proliferation and 
differentiation of T cells and the adaptive immune response. For example, the TLR4 ligand 
LPS has been shown to promote IL-17 production by Ag-specific memory T cells in mice 
through the induction of IL-1 and IL-23 production by DCs130. However, within the last 
couple of years a number of studies have defined the expression of TLRs on various T cells 
subsets where it is emerging that TLR signalling can promote cytokine secretion and 
regulate their function131. For example, in relation to effector CD4+ T cells, TLR2 
signalling has been demonstrated in TH1 cells to promote their proliferation and production 
of IFNγ132. In relation to the development of a TH17 population, stimulation of CD4+ T 
cells with PAM3Cys, a specific TLR1/2 complex stimulant, induces their proliferation and 
production of IL-17, which is enhanced by concurrent treatment with IL-23133. It has also 
been demonstrated that CD8+ effector T cells also express various TLRs134,135. In this 
context stimulation of mouse CD8+ T cells with TLR2 agonists, enhances the proliferation 
of these cells in response to a CD3-specific antibody by lowering the threshold required for 
co-stimulatory signals136. Recently, IL-17 producing γδ T cells have been demonstrated to 
express higher levels of TLR1, -2, -4, -6 and -9 than IL-17 secreting CD4+ T cells133. In 
this context, γδ T cells that express TLR1 and -2, secrete IL-17 in vitro following 
stimulation with their appropriate ligands, particularly in the presence of IL-23126. Recent 
evidence suggests that certain subsets of γδ T cells are already differentiated in the 
periphery and produce IL-17 in response to local IL-23137, without requiring stimulation 
with either CD3 or CD28 specific antibodies or stimulation with IL-23 and IL-1 derived 
from PAMP activated immune cells127. 
The stimulation of TLRs on T cells can also lead to a number of inflammatory and 
suppressive effects as demonstrated by mouse Tregs. These cells are known to express 
TLR4, -5, -7 and -8138, which is accompanied by mounting evidence that TLR agonists can 
modulate the function of these cells, where the persistent activation of the TLRs can 
overcome the suppressive effects of Treg cells and abrogate tolerance to tumor cells139. In 
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contrast, it has also reported that TLR agonists can directly enhance Treg function as LPS 
(TLR4 agonist) can induce the proliferation and enhance the suppressive function of Treg 
cells138. The TLR1/2 ligand Pam3Cys induces the proliferation of mouse Treg cells and 
although this was associated with loss of the cells suppressive activity, this was temporary 
as it was restored following removal of the TLR agonist140.  
With respect to B cells, they express both Ag-specific receptors (BCR) and the 
TLRs141 and dual BCR and TLR engagement can fine-tune functional B cell responses, 
directly linking cell-intrinsic innate and adaptive immune programmes. Importantly, the 
expression of distinct profiles of TLRs and BCR help to specify differentiation and 
function of key innate like versus adaptive B cell populations. Although B cell 
development and survival both appear unperturbed in the absence of TLR signals142, 
patients with a deficiency in the TLR signalling molecules, MyD88 or IRAK4, possess an 
altered BCR repertoire with an increased proportion of autoreactive B cells, presumably 
owing to alterations in B cell selection processes143. During T cell-independent immune 
responses in mice, dual BCR and TLR signalling rapidly induces marginal zone B cell and 
B-1 cell migration and antibody production141. In addition, following the triggering of T 
cell-dependent immune responses, TLR responsiveness is directly modulated in activated 
follicular B cells, thereby affecting germinal centre responses141. Therefore, individual 
TLR expression profiles permit various effector B cell populations to manifest specific 
response profiles based on antibody production, Ag presentation and cytokine secretion 
following TLR engagement144,145. 
1.3 Dendritic cells; the definitive link between the innate 
and adaptive immune systems 
DCs are recognised as the most highly potent APCs that interpret multiple signals 
through various PRRs, including the TLRs to orchestrate the initiation of the adaptive 
immune response (summarised in Figure 1.7). In this context, many intracellular and 
extracellular pathogens, such as bacteria and viruses will be recognised by PRRs expressed 
on DCs, leading to the upregulation of costimulatory molecules and Ag presentation as 
well as the secretion of a host of cytokines and chemokines, which promote T cell 
responses and enhance B cell responses146. Indeed, in addition to regulating priming or 
tolerance of T cell responses, differential DC maturation dictates the polarisation of TH 
responses and the general phenotype of the immune response to fight distinct types of 
infection. For example, the production of IL-12 and TNF-α is commonly associated with 
  
22 
gram negative bacterial infection and leads to the subsequent generation of TH1 responses, 
characterised by the production of IFNγ, bactericidal activity in macrophages and 
production of opsonising antibodies of the IgG2a class (in the mouse) by B cells147. Indeed, 
many pathogenic PAMPs mature DC to a phenotype that can induce such TH1 mediated 
responses, including bacterial lipopeptide (BLP), LPS and CpG rich nucleic acid fragments 
activate TL2, TLR4 and TLR9, respectively148. Such a DC phenotype is typically 
characterised by strongly up-regulated expression of MHC class II Ags and co-stimulatory 
molecules, like ICAM-1, CD40, CD80 and CD86, leading to the expansion of naïve CD4+ 
T cells and their differentiation to TH1 CD4+ T cells 147. This occurs in conjunction with 
activation of CD8+ T cells and the enhancement of cytotoxic lymphocyte activity, the 
maturation of B lymphocytes, Ig class-switching and the production of antibody146.  
By contrast, infection by parasitic worms does not induce TH1 responses; instead 
helminths typically induce production of the regulatory cytokine IL-10 by DCs, which acts 
to down-regulate TH1 responses. DCs also respond to parasitic worms by inducing TH2 
responses, characterised by the production of IL-4, IL-5 and IL-13 by CD4+ T cells. This 
TH2-polarising phenotype of DCs is associated with lower levels of MHC and co-
stimulatory activity relative to those seen with TH1-polarising DCs149. However, the 
mechanisms underlying the generation of TH1 responses (i.e. the PRRs involved, signalling 
molecules activated and the molecular TH1 signature) are better understood relative to 
those associated with the TH2 responses as little is known about molecules that function as 
TH2-inducing PAMPs. Indeed, over the last decade many studies have shown a tremendous 
versatility in the functions of DC, such that they are able to tailor selective immune 
responses to individual classes of pathogens, although the key regulatory mechanisms 
involved have not been defined146. 
Nevertheless, it appears that many of these processes are accompanied by 
endocytosis of the invading pathogens (or their products) by DCs, and this can be mediated 
by a variety of receptors such as: CD14, scavenger receptor-A (SR-A) and the Fc 
receptors: FcγRI1, FcγRI2b and FcγRIII. The receptor-mediated uptake of these agents 
leads to the activation of Ag processing mechanisms that load microbial peptides, typically 
onto MHC Class II, for presentation to CD4+ T lymphocytes. However, the CD8+ DC 
subtype are efficient in shuttling phagocytosed Ags into the MHC Class I pathway for the 
presentation to CD8+ T lymphocytes146. Upon endocytosis and subsequent activation, DCs 
found residing in peripheral tissues traffic to the draining lymph nodes where they undergo 
further maturation and present Ag to naïve TH cells to stimulate development of certain 
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subsets specific for the cognate peptide (e.g. TH1, TH2, TH17 etc.) depending on the 
cytokine environment. 
Although the engagement of various TLRs results in the production of several key 
proinflammatory cytokines including the type I interferons, TNF-α, IFN-γ, IL-12 and IL-
1150. It appears that different DC phenotypes/subsets express unique repertoires of TLRs 
potentially allowing specialised responses to each class of pathogen at the site of 
inflammation and dictating the precise adaptive immune response required. For example, 
plasmacytoid DCs uniquely express TLR9 and TLR7 allowing them to respond to CpG 
DNA and viral ssRNA151. TLR9 ligation results in the high production of IFN-α and IFN-β 
that promote MHC expression in neighbouring APCs to enhance anti-viral immunity. 
However, these cells do not express TLR4 resulting in a poor response to LPS and 
bacterial infections that are primarily dealt with by TLR4 expressing CD11c+CD11b+ 
myeloid DCs. Phagocytosis in the presence of TLR signals results in trafficking of the 
endocytosed material to a specific phagosome maturation pathway that promotes enhanced 
degradation and the efficient presentation of Ags152.  
1.4 The role of cytokines in mediating immune responses  
The interlocking innate and adaptive branches of the vertebrate immune system 
allow the host to fine tune immune responses to diverse invading pathogens to optimize 
elimination of the pathogen without damage to host tissues. Cytokines are small glyco-
proteins that mediate inter-cellular communication and are important in maintaining this 
balance. Cells from both the innate and adaptive systems respond as well as produce and 
actively secrete cytokines, which have crucial functions in the development, differentiation 
and regulation of immune responses. For example, upon stimulation of TLRs by PAMPs, 
DCs secrete a specific range of cytokines in response to the type of pathogen encountered 
which for LPS/TLR4 signalling include IL-12, IFN-α, IL-6 and TNFα153. These cytokines 
can act directly on newly activated CD4+ T-cells and as stated above bias their clonal 
expansion towards different immune phenotypes. The CD4+ TH cell is a key player of the 
immune system ‘orchestra’ and distinct lineages of these cells selectively produce certain 
cytokines that direct other cells to combat the specific type of invading pathogen 
encountered. Within recent years there has been an expansion of the number of lineages 
beyond the TH1-TH2 paradigm established by Mosmann & Coffman in 1986154, which now 
includes TH17 and Treg cells (A summary of these T cell phenotypes and the stimuli 
required to generate them is provided in Figure 1.8). 
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The nature of the pathogenic stimulus influences the ability of DCs to induce 
particular TH cell phenotypes. For example, the TH1 cell population (associated with 
cellular immunity) produces the cytokines IFN-γ and lymphotoxin-α and their 
development is predominantly mediated by IL-12 secreted by DCs, which activates STAT4 
(signal transducer and activator of transcription 4) in naïve lymphocytes155. Interestingly, 
the production of TH1 inducing cytokines (IL-12p70 and potentially IL-27) by DCs is often 
amplified by positive feedback signals that are provided by the differentiating T cells156. 
These DC cytokines can also activate natural killer (NK) cells, which also produce IFNγ 
and indirectly promote the same type of immunity157. IFNγ is the cytokine that defines TH1 
differentiation and it is known to activate APCs and promote further TH1 differentiation by 
up-regulating the signature transcription factor T-bet (T box 21).  
By contrast, helminth products usually induce the maturation of DCs that drive the 
development of TH2 cells and such differentiation has been associated with the selective 
expression of members of the jagged family of notch ligands158-160. The TH2 phenotype is 
associated with driving humoral responses and constraining cell-mediated inflammation 
alongside the production of IL-4, IL-5 and IL-13. In relation to this, TH2 cells are often 
additionally found to be active producers of the immuno-suppressive cytokines IL-10 and 
transforming growth factor β (TGF-β)155, which are more generally associated with the Treg 
cells. Within recent years there has been the identification of an ever growing number of 
individual TH cell phenotypes dependant on the cytokines they secrete with one of the most 
interesting to emerge being TH17 cells. This TH subset functions mostly at mucosal 
surfaces, triggering pro-inflammatory danger signals to enhance neutrophil mobilisation 
and the expression of antimicrobial factors. However, TH17 cells are also associated with 
driving inflammatory pathology in various autoimmune conditions161. Interestingly, some 
TH17 cells have been shown to secrete IL-10 indicating that they have the capacity to 
regulate the potent inflammatory responses they induce162. Studies of the role of DCs and 
the cytokines they secrete in the development of a TH17 population has identified that their 
differentiation is regulated by the cytokines TGF-β, IL-1, IL-6 and IL-23, which stabilise 
and expand the cell population through the induction of the transcription factors: STAT3 
and retinoic acid receptor-related orphan receptor-γt (ROR-γt)161. Interestingly, the DC 
secreted cytokine, IL-27 specifically inhibits the proliferation of TH17 cells163. 
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1.4.1 Important cytokines associated with DC function 
1.4.1.1 Tumour necrosis factor-α (TNF-α) 
TNF-α was first discovered due to its ability to cause necrosis of some tumours164. 
The regulation of TNF-α production is complex and stimulus-dependent and occurs at both 
the transcriptional and post-transcriptional levels. Human TNF-α is encoded by a single 
gene, which is located on chromosome 6 in the MHC coding region165. It is initially 
expressed as a 26 kDa transmembrane protein, which is subsequently cleaved by a 
metalloproteinase166 to release soluble TNF-α molecules that can then form non-covalently 
linked homotrimers. Mature TNF-α is non-glycosylated and both the membrane bound and 
soluble forms are known to be biologically active167. 
TNF-α is a pro-inflammatory cytokine, which is principally produced by 
monocytes, macrophages and DCs in response to a range of pro-inflammatory 
stimuli168,169. Typically exposure to LPS up-regulates its gene and subsequent protein 
production170. The overproduction of TNF-α is well established as contributing to 
pathogenesis in various autoimmune disorders171 as well as in septic shock172. TNF-α 
induces the activation of B and T cells170 and stimulates APCs, such as DCs, to secrete pro-
inflammatory cytokines (for example IL-1 and IL-6) and chemokines. Interestingly, the 
production of IL-6 in response to TNF-α can lead to the promotion of TH2 differentiation 
through IL-4 induction155 and in relation to this, at the same time IL-6 attenuates TH1 
differentiation through its effects on SOCS1 (suppressor of cytokine signalling) signalling 
promoting the development of TH17 cells.  
TNF-α can influence the function of APCs in a number of ways. It is known to 
activate immature APCs by augmenting their Ag presenting capabilities and up-regulating 
co-stimulatory molecule expression on their surface. However, in mature DCs it can also 
inhibit these functions and may even induce apoptosis and impair Ag presentation155,173. 
Thus, it has emerged that TNF-α is a molecule that can induce a complex array of 
responses. Reflecting this, it exhibits both pro- and anti-apoptotic functions, for example 
TNF-α activates NF-κB, a key inflammatory and apoptotic factor that has also been shown 
to be to inhibit T cell signalling173.  
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1.4.1.2 Interleukin-6 (IL-6) 
IL-6 is defined by several structural motifs including a ‘four helix bundle’ and is 
associated with acute phase responses and the regulation of innate and adaptive 
immunity174. IL-6 was originally discovered in 1986 as a B-cell differentiation factor that 
promotes the differentiation of activated B-cells into immunoglobulin-producing cells175. 
However since that time the effects of IL-6 have been found to be far reaching indeed, 
ranging from a key polarising cytokine in immunity, through to playing important roles in 
the biology of bone176, lipid metabolism and angiogenesis177. Its receptor comprises the IL-
6 receptor-α (IL-6Rα) and glycoprotein 130 (gp130) subunits, the latter being a common 
component of several members of this receptor family. IL-6 is produced by various types 
of cell, such as T-cells, B-cells, monocytes, DCs, fibroblasts and endothelial cells177. 
However, the IL-6 receptor (IL-6R) is mainly expressed by haemopoietic cells, such as T 
cells, monocytes, activated B cells and neutrophils177 and as such the elevated production 
of IL-6 contributes to the pathogenesis of various autoimmune and inflammatory diseases. 
The cytoplasmic domain of gp130 contains several motifs for the propagation of 
intracellular signalling including those for recruiting and activating SHP-2 (Src homology 
domain containing protein tryrosine phosphatase-2)177. Consistent with this, the binding of 
IL-6 to its receptor induces the homodimeriation of gp130 and association with IL-6Rα, 
resulting in the activation of the SHP2-mediated ERK/MAPK pathway and the JAK/STAT 
pathway178. 
Although discovered as a B-cell differentiation factor, IL-6 has also been shown to 
promote antibody production by inducing CD4+ T cells to secrete more IL-21. Thus, it has 
been proposed to enhance humoral immunity179 and supporting this transgenic mice that 
overexpress IL-6 exhibit hypergammaglobulinaemia and autoantibody production180. IL-6 
also plays an important role in the proliferation and differentiation of TH cells, where it 
significantly enhances the proliferation of TH cells stimulated with mitogen181. Within this 
context, IL-6 promotes IL-4-mediated TH2 differentiation and inhibits IL-12 induced TH1 
differentiation182. Moreover,  in vitro studies in mice have shown that co-stimulation with 
IL-6 and TGF-β is essential for the differentiation of TH17 cells from naïve TH cells and 
this role of IL-6 in TH17 development has been confirmed in several autoimmune disease 
models177. 
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1.4.1.3 Interleukin-10 (IL-10) 
IL-10 plays a central role in preventing inflammatory and autoimmune pathologies 
by limiting the immune response to pathogens and host tissues183. The anti-inflammatory 
properties of IL-10 are evidenced by, studies in IL-10-deficient mice, which develop 
inflammatory bowel disease following colonisation of the gut with particular micro-
organisms and display other exaggerated inflammatory responses to microbial 
challenge184,185. Although originally thought to be specifically expressed by TH2 and Treg 
cells, it is currently understood that IL-10 can be expressed by many cell types and has 
been reported to be produced by the TH1, TH2, TH17 and Treg CD4+ subsets as well as 
CD8+ T cells and B cells186,187. It is also expressed by cells of the innate immune system, 
including DCs, macrophages, mast cells, NK cells, eosinophils and neutrophils188. This 
broad expression across immune cells highlights its important role as a feedback regulator 
of many effects of the immune system and not just those associated with TH1 cells but also 
TH2 cells and allergic responses189,190. The anti-inflammatory response of IL-10 is 
mediated by the IL-10 receptor (IL-10Rα), which is coupled to signalling through 
STAT3188. The production of IL-10 by DCs and macrophages acts in an autocrine fashion 
on the IL-10Rα expressed by these cells to help attenuate the extent of their responses and 
in turn the development of TH1, TH2 and allergic responses that can be driven by continued 
activation of these immune cells188,191. The production of IL-10 by TH1, TH2 and TH17 
cells adds another feed back loop to limit innate effector functions of DCs and 
macrophages and the subsequent activation of T cells. 
Both macrophages and DCs can express IL-10 following activation of specific 
PRRs, including TLR4 recognition of LPS both in vitro 192 and in vivo193,194. Interestingly, 
ligation of CD40 on DCs enhances their IL-10 production in response to TLR and dectin 1-
stimulation195, while in macrophages a similar effect is observed upon TLR stimulation 
and ligation of Fc receptors196. Following the stimulation of TLRs (including TLR4) the 
activation of ERK has been shown to be important in IL-10 production197,198, as in ERK-
deficient cells, TLR-mediated secretion of IL-10 by DCs is decreased199. However, other 
signalling elements have been implicated in the LPS induced production of IL-10, 
including TRAF3 and p38200. The production of IL-10 from TH1 cells requires they be 
triggered via the TCR by a high Ag dose in the presence of endogenous IL-12162, whilst in 
TH2 cells, IL-10 secretion is controlled by the IL-4 signalling pathways in conjunction with 
the transcription factors STAT6 and GATA3 (GATA binding protein 3)201,202. By contrast, 
IL-10 production by TH17 cells predominantly occurs in a STAT3 and STAT1 dependent 
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manner203. However the production of IL-10 from all of these subsets is dependent on the 
activation of ERK162. Interestingly the recently identified cytokine IL-27, which is 
produced by DCs has been shown to enhance the expression of IL-10 by TH1, TH2 and 
TH17 cells203. 
1.4.1.4 Transforming growth factor β-1 (TGF-β1) 
TGF-β comprises a well-defined multipotent cytokine family known to regulate 
several patho-physiological events, with TGF-β of T cell, monocyte/macrophage or 
granulocyte origin typically being detected at sites of inflammation204. Among the three 
isoforms, TGF-β1 exhibits the broadest spectrum of biological activities, promoting early 
DC development whilst suppressing immature DC activation and maturation and 
modulating TH polarisation205. It mediates these effects on DC maturation by inhibiting the 
up-regulation of the co-stimulatory molecules CD80 and CD86 thereby reducing the 
efficacy of such DC cells to stimulate T cells146. One way TGF-β may achieve these 
functions is by the down-regulation of key immunomodulatory receptors, for example 
murine bmDC treated with TGF-β1 show decreased expression of TLR4 and this correlates 
with their reduced sensitivity to LPS induced maturation206. It has also been noted that 
TGF-β treatment of splenic CD11c+ DCs inhibits their ability to produce IL-6 and IL-12 in 
response to LPS207. In terms of modulation of TH responses, TGF-β acting alone induces 
FoxP3 expression leading to Treg induction whereas in the presence of IL-6, it results in the 
promotion of TH17 responses123,124. 
1.4.1.5 IL-12p40 and its extended family; IL-12p70, IL-23 and IL-27 
IL-12 was identified as a product of Epstein-Barr virus (EBV)-transformed human 
B-cell lines that can activate NK cells, generate lymphokine-activated killer cells (LAKs) 
and induce IFN-γ production and T cell proliferation208. After further investigation, the 
biologically active form IL-12p70 was found to be a heterodimeric (IL-12p40p35) pro-
inflammatory cytokine that induces the production of IFNγ (from multiple sources) and 
favours the differentiation of TH1 cells forming a vital link between innate resistance and 
adaptive immunity209. The major sources of this cytokine are phagocytes and DCs, which 
produce it in response to parasitic and bacterial infections210. The production of this 
cytokine is able to promote naïve CD4+ T cells to differentiate into mature TH1 effector 
cells211 and is a potent stimulus for TH1, NK and CD8+ T cells to produce IFN-γ212-214. As 
stated above, this heterodimeric protein is composed of two covalently linked subunits, the 
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p35 subunit (IL-12p35) and the p40 subunit (IL-12p40), which is structurally related to 
soluble IL-6 receptor. The IL-12 receptor (IL-12R) is composed of two chains, IL-12Rβ1 
and IL-12Rβ2, and coupled to the JAK-STAT pathway of signal transduction215, with the 
major effector being STAT4. IL-12R is expressed predominantly on activated T cells and 
NK cells215 but has also been identified on other cell types such as DCs216 and B cells217. 
The activation of T cells through the TCR up-regulates the transcription and expression of 
both chains of IL-12R and this can be enhanced by the cytokines IFN-γ and TNFα218. 
Large quantities of IL-12 p40 are produced relative to IL-12 p70 and IL-12p40 is secreted 
both as homodimers and monomers209. In mice the production of p40 homodimers is 
observed in vivo219 and although not biologically active as an agonist, it binds to the IL-
12R with an affinity similar to IL-12 p70 and thus competes for binding220. On this basis it 
has been proposed that in mice formation of the IL-12p40 homodimer may act as a natural 
inhibitor of IL-12. Interestingly the p35 subunit can only be secreted when associated with 
IL-12 p40 and hence, the low abundancy of its transcripts even in activated inflammatory 
cells suggest that its expression is the rate limiting step for IL-12 p70 production221. 
The ability of DCs to produce IL-12 during interactions with T cells and to induce 
TH1 responses including the subsequent production of IFN-γ were first shown in vitro210. 
This was soon followed by in vivo data demonstrating CD8α+ DCs being the first cells to 
secrete IL-12p70 in the spleens of mice exposed to LPS or soluble extracts of Toxoplasma 
gondii222. The initial production of IL-12 p70 occurs rapidly and is independent of IFN-γ 
and signals from T cells223 with several TLR agonists, including those for TLR2, TLR4, 
TLR5 and TLR9, strongly inducing IL-12 p70 production in monocytes, macrophages and 
DCs in a T cell-independent manner224. However, IL-12p40 is also produced during the 
Ag-specific phase of the immune response in a T cell-dependent manner225 with the 
production of IFN-γ up-regulating IL-12p70 production in a positive feedback manner to 
stimulate the further production of IFN-γ by TH and NK cells. This in turn then acts to 
enhance IL-12p70 production from macrophages and DCs226. This positive feed back loop 
is required for optimal IL-12p70 production to induce protective responses against certain 
pathogens such as Leishmania major or Bacillus Calmett-Guerin 227. The activation of IRF 
(interferon regulatory factors) transcription factors by IFN-γ is central to the production of 
IL-12p35 and p40. Specifically IRF1, -2, -5, -7 and -8 are directly involved in IL-12p35 
and p40 production228, with mice lacking IRF1 and -2 being unable to express IL-12p35 
and p40 and IRF8 knock-out mice failing to synthesise IL-12p40229-231. 
  
30 
Interestingly, T cells can also enhance the production of IL-12 through direct cell-
cell interactions, such as the interaction of CD40L on activated T cells with CD40 on DCs 
and macrophages232. IL-12p70 only induces the proliferation of resting peripheral blood TH 
and NK cells in conjunction with mitogenic lectins, alloantigens and CD3 specific 
antibodies233 but it does have a direct proliferative effect on pre-activated TH and NK 
cells233. Stimulation through CD28 (by CD86 on DCs) is synergistic with IL-12p70 such 
that the engagement of both by activated, Ag-presenting DCs results in TH cell 
proliferation and IFN-γ production234. The activation of NK cells by IL-12p70 also 
promotes their production of IFN-γ and enhances their cytotoxicity235. Although IL-12p70 
does not directly affect B-cell proliferation, through its induction of IFN-γ it can induce B 
cell activation and immunoglobulin switching217.  
Although IL-12p70 is important in host defence, its over expression can cause 
persistent inflammation in autoimmune disorders such as multiple sclerosis (MS). 
However, both TGF-β and IL-10 are potent inhibitors of IL-12p70 production236, by 
decreasing NF-κB and AP-1 activation237,238 and the association of the IL-12p40 promoter 
with RNA polymerase239. The inhibition of IL-12p70 production by TGF-β occurs through 
the ability of the latter cytokine to reduce the stability of IL-12 p40 mRNA240. The 
complexity of these cytokine networks is evidenced by the finding that TNF-α, which has 
many overlapping functions with IL-12p70 in regulating inflammatory responses and IFN-
γ production can suppress production of TGF-β241. 
More recently, there has been a major focus on two other cytokines of the IL-12 
family, IL-23 and IL-27. Neither of these cytokines play a role in classical TH1 associated 
immunity. Rather, IL-23 has been shown to promote the expansion of naïve TH cells to the 
TH17 phenotype and hence, this cytokine also plays a dominant role in the development of 
autoimmune inflammation242. On the other hand the principal function of IL-27 in vivo is 
to limit the intensity and duration of innate and adaptive immune responses242, in part by 
antagonising TH17 responses209. Although all of the IL-12 family cytokines IL-12p40, IL-
12p70, IL-23 and IL-27 are produced in response to microbial and host stimuli such as 
positive signalling through the TLR243 and IFN receptors244,245, it is becoming clear that 
these cytokines play divergent roles in guiding the immune system to eliminate invading 
pathogens and prevent excessive damage to host tissues.  
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IL-23 is composed of a p19 (IL-23p19) subunit, identified in 2000 by Kastelein et. 
al246, covalently linked to the IL-12p40 subunit and it is now known that the activation of 
NF-κB through LPS induced TLR4 activation, is essential for the up-regulation of the p19 
subunits mRNA and protein expression in murine DCs 247. Interestingly mRNA for the 
receptor of IL-23 (IL-23R) is found to be upregulated in activated T and NK cells, 
regardless of the polarising conditions242 and consistent with this, the IL-23R is expressed 
on activated/memory T cells, NK cells, DCs and macrophages but not naïve T cells 248. 
Thus, it has been proposed that the relative amounts of IL-12p70 and IL-23 might 
determine whether T cell production of IL-17 or IFN-γ predominates242. Both monocyte 
and myeloid derived DCs have been shown to produce IL-23 in response to LPS and the 
polarisation of TH1 and TH17 responses has again been correlated to the balance of IL-
12p70 and IL-23 secretion249.  
IL-27 comprises the IL-12p40 homolog, Epstein-Barr virus induced molecule 3 
(EBI3) and the IL-27p28 subunit. The IL-27 receptor is composed of the two subunits, 
WSX1 and gp130242 and exhibits an extremely broad expression, not only being expressed 
by various cells of the immune system (APCs, mast cells, NK cells, B and T lymphocytes) 
but also by endothelial cells250. Initial studies indicated a role of IL-27 in the generation of 
TH1 responses, as IL-27 deficient T cells produced less IFN-γ in vitro than wild type cells 
and hence, it was thought to direct early events leading to the development of TH1 
responses251. Consistent with this, IL-27 was shown to induce the early activation of 
STAT1 and expression of the T-bet transcription factor (whose target genes encode 
signature TH1 responses and IFN-γ242) and subsequently the expression of the IL-12Rβ2, 
which is the pre-requisite for mounting a IL-12 dependent TH1 driven immune response252. 
However, more recent studies indicate that in the presence of strongly polarising stimuli, 
i.e. parasitic or bacterial infection, the ability of IL-27 to promote TH1 cell responses is 
secondary to its role as a suppressor of effector T-cell proliferation and cytokine 
production253,254. In this context it has also been shown to specifically inhibit the 
proliferation of TH17 cells163 and act as a negative regulator of mast cell and macrophage 
function253. Studies using the parasitic nematode Trichris muris also indicate a direct 
regulatory role for IL-27 on TH2 responses through inhibition of the secretion of the 
cytokines IL-4, IL-5 and IL-13255. IL-27 can regulate the kinetics and intensity of T cell 
responses but these effects are not restricted to a particular TH cell subset256. In this respect, 
it can enhance the clonal expansion of CD4+ T cells but this effect is most apparent in the 
  
32 
absence of the dominant T cell growth factor IL-2, which acts as a negative regulator of 
IL-27 receptor expression257. 
1.5 The role of co-stimulatory molecules in DC function 
Co-stimulatory molecules are cell-surface proteins on APCs that interact with 
counter molecules on naïve T cells to transmit signals in concert with antigenic stimulation 
that is required for priming or tolerance of T cell responses. Their main function therefore 
is to transmit the appropriate signals to naïve T cells to promote (e.g. CD40-CD40L, 
CD80-CD28 and CD86-CD28) or inhibit (e.g. CTLA-4-CD28) T cell survival, expansion 
and lineage commitment. When DCs arise from myeloid- or lymphoid-derived presursors 
they exhibit an immature phenotype characterised by a high phagocytic capacity and low 
expression of the co-stimulatory molecules CD80, CD86 and CD40258. However, upon 
encountering bacterial, viral and parasite PAMPs, which induce DC maturation via TLR 
signalling and NF-κB activation, cell surface expression of these co-stimulatory molecules 
is upregulated259. During this process DCs will adhere and engulf pathogens via 
phagocytosis utilising a range of receptors including CD14, scavenger receptor-A (SR-A) 
and the Fc receptors: FcγRI, FcγRIIb and FcγRIII146. Once engulfed, proteolysis of the 
pathogens generates antigenic microbial peptides, which are loaded onto MHC Class II 
molecules and presented to CD4+ TH cells, prolonging DC-T cell interactions in the lymph 
node260. Thus, TCR engagement of the peptide-MHC Class II complex in concert with the 
particular signals derived from DC co-stimulatory molecule expression and cytokine 
secretion dictates whether T cell tolerance or priming is established146. 
1.5.1 CD40 
Despite the well defined roles of co-stimulatory molecules in DC-T cell 
interactions the intracellular signalling pathways and regulation of these proteins reveals a 
complex biology that is as yet not fully defined. One such DC-expressed molecule is 
CD40, a 48kDa transmembrane glycoprotein surface receptor that is a member of the 
TNFR superfamily. Its natural ligand is CD40L, also referred to as CD154, a 34-39 kDa 
type II integral membrane protein. Initially CD40L was found to be expressed on CD4+ 
cells, suggesting its main function was in the ability of T cells to stimulate B cell 
proliferation through ligation of CD40. However, recent mRNA and protein expression 
studies have shown CD40L to be expressed on a variety of DCs (including plasmacytoid 
and spleenic DCs), monocytes, epithelial cells and even endothelial cells261,262 and 
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crosslinking of CD40 has even been shown to stimulate non-haemopoietic cells, such as 
epithelial cells, to produce GM-CSF263. Interestingly, it has been reported that CD40 
signalling in DCs induces changes that make them more effective APCs, including the up-
regulation of MHC Class II and other co-stimulatory molecules such as CD80 and 
CD86264,265 as well as producing high levels of inflammatory cytokines and chemokines266. 
The wide expression of CD40 and CD40L, particularly on DC subtypes, suggests that DCs 
may interact with one another through this receptor to regulate their functions. Together 
with the proposed interactions of CD40 with several other proteins, such as C4BP, a 
complement protein that can signal through CD40 on B cells, these findings indicate this 
receptor can act as a bridge between innate and adaptive immunity267. Focusing on the 
intracellular effects of CD40, its cytoplasmic tail contains sites for the recruitment of 
TRAFs and indeed, following CD40 ligation, recruitment of TRAF6 is important in the 
activation of p38 MAPK and JNK, mediating inflammatory cytokine (IL-12p40 and IL-
6262) production and up-regulation of the co-stimulatory markers CD80 and CD8626,268. 
TRAF6 also plays an important role in TLR signalling and consistent with the importance 
of TRAF6 for both TLR and CD40 signalling, DC from TRAF6 -/- mice are unable to up-
regulate MHCII and CD86 and produce IL-12p40 or IL-6 in response to either CD40L or 
LPS27. The overlap of CD40 and TLR signalling pathways through TRAF6 is further 
reinforced by the fact that these signalling cascades converge on the activation of the non-
canonical NF-κB pathway as evidenced by the finding that CD40-mediated DC Ag 
presentation required the activation of NF-κB-inducing kinase (NIK) to activate NF-κB2 
(p52/p100)262.  
1.5.2 CD86 
CD86 is a co-stimulatory molecule that is mainly expressed on APCs such as DCs 
and engages with CD28 on T cells, significantly lowering their activation threshold and 
allowing them to be readily activated269. DCs dynamically regulate CD86 expression levels 
depending on their need to harness or reduce their T cell activating capacity: for example, 
DCs up-regulate CD86 in response to microbial Ag270 to facilitate microbe-specific 
activation of T cells. By contrast, DCs down-regulate CD86 in response to IL-10 and as 
DC secrete IL-10 in response to LPS, this generally immunosuppressive cytokine acts in an 
autocrine manner to prevent the excessive expression of CD86271. Interestingly, the E3 
ubiquitin ligases have been shown to play an important role in regulating CD86 expression 
and Ag presentation by DC in an IL-10 dependent manner272. Ubiquitination is known to 
mediate endocytosis and the subsequent lysosomal or proteosomal degradation of many 
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transmembrane proteins273,274 and it is in this context that the E3 ubiquitin ligase MARCH1 
mediates the ubiquitination of CD86 and MHC Class II molecules to regulate their 
lysosomal degradation.  
Interestingly DC-T cell interactions are frequently viewed as monodirectional with 
T cell activation being dependent on the interaction with DC (or other APCs). However, 
the engagement of various cell surface molecules on the DC by T cells induces 
bidirectional signals that affect DC maturation and activation. For example, ligation of 
CD40 by CD40L expressed on the surface of T cells delivers a potent activation signal for 
DCs275. By contrast, CTLA-4 expressed on the surface of Tregs binds and signals through 
CD80 and CD86, leading to the production of IFN-γ, which acts in an autocrine fashion on 
DC leading them to secrete the enzyme indoleamine 2,3-dioxygenase (IDO)146. When 
naïve T cells interact with such IDO-producing DC, they undergo activation and then rapid 
cell death by apoptosis, resulting in Ag-specific tolerance146. However, T cell-mediated 
feedback of a pro-inflammatory signal to DCs via CD28-CD86 interactions146, induces 
MAP Kinase (p38) and NF-κB signalling resulting in IFN-γ and IL-6 production276, which 
prevents IDO production by IFN-γ. 
1.5.3 Major histocompatibility complex class II (MHC Class II) 
MHC Class II molecules (encoded by the gene locus H2 in mice) are expressed 
predominantly by professional APCs, mainly macrophages, DCs and B cells. MHC Class 
II molecules are heterodimers composed of an α-chain and a β-chain, which are type I 
integral membrane proteins with short cytoplasmic domains and large extracellular 
domains277. Their main function is to present peptides processed from exogeneous protein 
Ags to CD4+ TH cells and hence they are involved in directing the processes of positive 
and negative selection in the thymus, shaping the repertoire during T cell maturation and 
lineage commitment260, as well as triggering TCR-mediated responses of mature T cells in 
the periphery. MHC Class II molecules acquire antgenic cargo for presentation by 
intersection of the endocytic and class II biosynthetic pathways278. This process requires 
the efficient proteolysis of both the Ag to be presented and Class II associated invariant 
chain (Ii), which associates with both the α- and β- dimers to mediate proper folding and 
trafficking of the complex to the late endosomes by occupying the peptide binding cleft 
and preventing unwanted peptide binding278. TLR signalling transiently increases Ii and 
MHC Class II synthesis to optimise Ag presentation under conditions of infection279. 
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However, MHC Class II molecules can also act as receptors to mediate reverse 
signal transduction after interaction with T cell receptors or CD4 molecules (mimicked in 
vitro with agonist antibodies). Thus, engagement of MHC Class II can regulate multiple 
cellular functions in both the APC and stimulated T cells such as cell adhesion, cytokine 
production and co-stimulatory molecule expression280. Signalling via protein kinase C 
(PKC) isoforms280,281 has been shown to play roles both in regulating MHC Class II 
expression and also reverse signalling through these proteins in APCs. For example, 
various PKC isoforms are activated upon LPS-TLR4 binding and PKCδ has been found to 
not only play an important role in the coupling of TLR4 to NFκB but also to the 
upregulation of MHC Class II expression by DCs281. In the context of TLR4 signalling, 
deficiency in MHC Class II expression results in the diminished production of LPS-
induced TNF by human peripheral blood monocytes and mouse macrophages280, resulting 
in greater resistance to endotoxic shock and the reduced production of pro-inflammatory 
cytokines in response to lethal doses of LPS280. Interestingly, it has also been found that 
intracellular pools of MHC Class II via endosome-localised CD40 and the kinase Btk, are 
able to interact with and promote, the activation of both MyD88- and TRIF-dependent 
pathways indicating a novel role for MHC Class II signalling in the TLR4-NF-κB 
pathways280.  
1.6 Immunomodulation by Filarial nematodes 
1.6.1 The West and the rise of inflammatory disease 
The developed world is experiencing a steep increase in the prevalence of a diverse 
range of diseases based on aberrant inflammatory responses, including autoimmune 
disorders like rheumatoid arthritis and allergic conditions such as asthma. The 
immunological phenotype of these diseases reflect both TH1 (typically characterised by 
TNFα/IFN-γ based responses associated with bacterial infections and autoimmune disease) 
and TH2 (classically associated with IL-4/IL-5 driven responses important in helminth 
infections and allergic diseases) immune responses282. The emergence of this diverse range 
of disorders is too rapid to support a solely genetic explanation for their increased 
incidence283. Rather, Strachan formulated the ‘hygiene hypothesis’ to account for this 
phenomenon282, which postulates that the rise of allergic diseases is directly linked to 
inappropriate priming of the immune system, as a result of the decline in infectious 
diseases associated with the implementation of antibiotics, improved hygiene and wide 
spread use of vaccinations. This leaves the immune system with insufficient TH1 
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stimulation and consequently TH2 mediated pathologies such as asthma have become more 
prevalent. Indeed, the geographical distribution of the aforementioned inflammatory 
conditions virtually excludes areas where TH2 driving helminth infections are endemic284. 
However, the hygiene hypothesis does not explain why TH2 type allergies are rising in 
concert with TH1 mediated autoimmune diseases (such as arthritis, multiple sclerosis and 
diabetes) and hence this conundrum suggests that the rise in inflammatory disease cannot 
merely be accounted for by an imbalance in TH1-TH2 priming. This has led to recent 
proposals that, although helminth infections and atopic diseases are associated with similar 
immunological phenomena, immunoregulation by the parasites within the host could 
dampen responses to allergens and TH2 associated pathologies285. 
1.6.2 Filarial nematodes and their orchestration of a TH2 immune 
phenotype  
Helminth parasites are the most common infections that affect deprived 
communities worldwide. With nearly 2 billion individuals infected with a wide range of 
symptoms, ranging from intestinal problems, general malaise, weakness to anaemia, there 
are continuing problems with morbidity and even mortality286-288. Filarial nematodes 
represent a group of helminths that can induce particularly severe morbidity with a 
significant proportion of sufferers presenting with debilitating health problems including 
severe skin lesions, elephantiasis and several forms of eye damage, which can lead to 
blindness. Infection with these organisms is long-term, with individual worms surviving 
for up to 10 years289. The ability of these parasites to survive for these lengths of time 
within a host are dependent on the modulation and suppression of the host immune 
system290. This modulation has been shown to reflect impaired lymphocyte proliferative 
responses and polarisation of cytokine and antibody responses, generally evidenced by 
reduced TH1 associated IFN-γ production and increased IL-4 and anti-inflammatory IL-10 
secretion coupled with elevated levels of IgG4, responses typically associated with a TH2 
phenotype. The switch to IgG4 is also important as this isotype is unable to activate 
complement or bind with a high affinity to phagocytic cells and hence cannot contribute to 
the elimination of pathogens. Indeed, the suppression of TH1 inflammatory mediators by 
APC populations is emerging as a common theme in helminth infection. For example, 
studies on N. brasiliensis excretory-secretory (NES) products indicate that they also 
actively mature DCs to induce a TH2 response by upregulating CD86 and OX40L, 
switching the cytokine profile to release IL-6291.  
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It was from these findings that the hypothesis arose that this phenotype not only 
prolongs parasite survival but is conducive to host health by limiting the development of 
autoimmune disorders that arise from aggressive, pro-inflammatory TH1-like immune 
responses. There is now a large body of evidence that immunomodulators synthesised and 
secreted by the nematodes may be responsible for such immune system deviation. 
1.6.3 The filarial nematode excretory/secretory products and the 
immunomodulation of the host 
For millennia pathogens have been continuously adapting to their complex 
biological niche, a ubiquitously hostile environment as the host immune system actively 
works to eliminate the pathogen. This has driven many infectious agents including 
parasitic worms to evolve immunomodulatory systems to circumvent the normal host 
immune response to foreign agents and limit the inflammatory response. For example, it is 
now known that viral genomes encode decoy proteins that resemble host proteins292, 
intracellular bacteria such as Salmonella have evolved proteins that mimic intracellular 
signalling molecules293 and filarial nematodes secrete molecules that suppress parasite-
induced inflammatory responses and local tissue destruction or disruption. However, these 
evolutionary steps taken by the parasite, have also resulted in “anti-inflammatory” 
intervention mechanisms that prevent their rejection without leading to 
immunosuppression of the host294. This has led to the concept that through this 
evolutionary process, the pathogens themselves have provided a complex method of 
molecular target validation to act as a basis for the development of novel classes of anti-
inflammatory agents.  
The parasitic helminths actively produce excretory and secretory (ES) molecules to 
occupy this biological niche as these immunomodulatory agents suppress inflammation 
and redirect the focus of the hosts immune response. Genomic and expression-based 
analysis of parasitic helminths of veterinary and medical importance (approximately 
20,000 protein coding genes) has yielded large scale repositories of such novel anti-
inflammatory mediators295. Studies investigating several such molecules are beginning to 
provide an insight into such “anti-inflammatory” mechanisms involved in the intervention 
and subversion of host responses. For example, Schistosoma mansoni, (a major species of 
the disease schistosomiasis) secretes a number of defined products including: 
lysophosphatidylserine296, lacto-N-fucopentaose III (LNFPIII)297 and double-stranded 
DNA (dsDNA)298,299 all of which exhibit immunomodulatory actions. These observations 
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have been made alongside other parasite products such as phosphatidylserine secreted by 
S. Mansoni and Ascaris lumbricoides300 and ES-62 secreted from the Acanthocheilonema 
viteae301,302 being reported to suppress pro-inflammatory immune responses through 
subversion of TLR function.  
The TLRs are emerging as prominent targets of many ES products, with direct 
interaction with the receptor commonly associated with motifs that are specific to the 
helminths. For example, Schistosome–derived lysophosphatidylserine contains a helminth-
specific acyl chain, which interacts with TLR2 to promote the differentiation of DCs that 
induce IL-10-producing regulatory T cells296. Many of these molecules target DCs to bias 
them to induce TH2-type immune responses, indicating this to be a conserved evolutionary 
step that takes advantage of the high expression of TLRs on this APC. Many examples of 
this can be found throughout the literature as both S. mansoni- and A. lumbricoides-derived 
phosphatidylserine-containing extracts have been demonstrated to utilise TLR2 to mature 
DCs such that they induce TH2-type immune responses300. This is not always restricted to 
DC modulation as, LNFPII, by inducing alternative activation of macrophages303,304 
(similarly to other helminth products) and modulating DC maturation through its α1,3-
linked fucose moiety in a TLR4-dependent manner297,305 can promote TH2-type immune 
responses297. In addition, the schistosome egg component dsRNA is able to activate DCs 
through TLR3298 and priming of ovalbumin-specific T cells by DCs towards a TH2 cell 
phenotype in the presence of these egg Ags is suppressed in a TLR3-dependent manner299. 
Commonly if these modulators are not directly targeting the TLRs, helminth ES products 
will redirect their associated signalling adaptors and pathways to induce TH2-type anti-
inflammatory responses. For example, this is reflected by the Sm16 lipid bilayer-binding 
protein released by S. mansoni during skin invasion potently inhibiting proinflammatory 
cytokine production from macrophages mediated by TLR3- and TLR4- but not, TLR2306. 
Alongside this the cysteine proteases secreted by S. mansoni and Fasciola hepatica can 
prevent TLR3- and TLR4- mediated induction of nitric oxide, TNF, IL-6 and IL-12 from 
macrophages, which in turn protects mice from endotoxic shock307.  
The molecular pattern phosphorylcholine (PC) is observed throughout nature but is 
commonly associated with pathogen products from a diverse range of organisms, including 
bacteria, fungi, and protozoa, as well as filarial and gastrointestinal nematodes308. In this 
context, the molecule provides a pattern for the hosts immune system to recognise these 
pathogens (for example via antibodies or C-reactive protein), but can also function to 
promote pathogen survival and in particular that of parasitic helminths through the 
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modulation of the host immune response. For example, it has been proposed that 
Echinococcus granulosus utilises the PC-containing component of glycoprotein 5 as a 
candidate TLR ligand for its promotion of TH2-type anti-inflammatory responses309. 
Specifically, in this laboratory group extensive research has shown that many of the anti-
inflammatory functions of ES-62, a secreted product from A. viteae secreted product, ES-
62 is dependent on its PC moiety310. Through this work both synthetic and natural PC 
based compounds have shown great potential in mimicking the immunomodulatory 
activities of ES-62 and other ES products311,312.  
1.6.4 ES-62 
ES-62 is a PC-containing glycoprotein (the number of PC-containing glycans is 
currently unresolved) that was first identified in the rodent filarial nematode 
Acanthocheilonema viteae313, but has well conserved orthologues in human filarial 
nematode parasites including Brugia malayi and Onchocerca volvulus314,315. ES-62 is 
transcribed throughout the helminth lifecycle but its mRNA levels are considerably higher 
in adult worms than L3 larvae (~5 % adult levels) and microfilariae (<0.2 % adult 
levels)315. This is translated into a 62 kDa protein which includes the parasite-specific post-
translational modification of PC attached via an N-type glycan, the latter being trimmed to 
the tri-mannosyl core and then substituted with between one and four N-acetylglucosamine 
residues during oligosasccharide processing316. This immunomodulator is produced from 
cells that underlie the oesophagus at post infective lifecycle stages (L4 larvae and adult 
worms) of the A. viteae parasite and can be detected in the serum of the jird host, Meriones 
lybicus313,315. The native form of ES-62 is a tightly bound tetramer formed from dimers317, 
with a relatively high sequence homology with members of the M28 peptidase family, 
where a weak in vitro (amino)peptidase activity has been observed against synthetic 
substrates283. Furthermore, divalent cations are known to be critical to the function of 
aminopeptidases and ES-62 has a putative metal co-ordination motif in its sequence with a 
strong magnesium (Mg2+) signal being detected in its atomic spectrum318.  
1.6.5 ES-62; a molecular platform for understanding the immune 
response 
ES-62 has been found to have potent immunomodulatory effects on 
DC/macrophages291,301,319, B cells311,320, mast cells321, and to some extent T cells322, where 
the PC moiety is important in these affects. In broad terms, rather than acting in an 
immunosuppressive manner, ES-62 induces a TH2/anti-inflammatory phenotype 
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characterised by reduced levels of IL-12, IFN-γ and pro-inflammatory cytokines as well as 
the production of IgG1 rather than IgG2a antibodies. These effects and our current 
understanding of the signalling pathways targeted by ES-62 in a variety of immune cells 
will be covered in the following sections. A summary of the known interactions and 
immunomodulatory effects ES-62 exerts on the immune system are presented in Figure 
1.9.   
1.6.5.1 The immunomodulation of APCs; the importance of TLR4 in ES-62 
immunomodulation 
The PC moiety of the 62 kDa glycoprotein ES-62, is unusual in that it is attached to 
the protein core via a unique N-type glycan301 and it appears to be the active moiety in 
subverting the host immune response, predominantly by targeting DCs and 
macrophages291,301,323. Both of these cell types are important in establishing the TH1-TH2 
immune phenotypes and the subsequent inflammatory response of the host. Indeed, DCs 
and macrophages derived from bone marrow progenitors exposed to ES-62 in vivo become 
hyporesponsive to subsequent stimulation with LPS160,291,319, promoting a DC phenotype 
that induces a TH2 biased, yet anti-inflammatory response160. However, the modulation of 
these innate immune cells by ES-62 is not, restricted to driving maturation of APCs that 
induce TH2 responses as ES-62 has been shown to prevent the development of both 
TH1/TH17-mediated collagen-induced arthritis310,324, and TH2-associated ovalbumin-
induced airway hypersensitivity in mice321,325.  
So how does ES-62 achieve the modulation of these APCs? Studies investigating 
the effects of ES-62 on macrophages and DCs derived from knockout mice showed that its 
immunomodulatory effects were dependent on the presence of MyD88 and TLR4 but not 
TLR2301. In these studies it was observed that ES-62 subverts the normal pro-inflammatory 
function of TLR4 as well as utilising the receptor for its internalisation into APCs326. The 
ES-62 dependent suppression of IL-12 and TNF-α secretion in response to LPS 
stimulation and the internalisation of this immunomodulator were abrogated in cells from 
TLR4 deficient mice301 and the low level cytokine responses observed in response to ES-
62 are lost in MyD88-deficient cells.  
The internalisation and immuno-modulatory effects of ES-62 may depend on the 
dynamics of pro-inflammatory TLR4 signalling, which is divided into two separate stages; 
the first being an early MyD88-dependent phase that is triggered by receptor-mediated 
endocytosis in clathrin coated pits followed by a later endosomal TRIF mediated phase327. 
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This presents a potential mechanism for inducing TLR4 hypo-responsiveness and the 
suppression of TLR4 associated autoantigen presentation in DCs48,327, as these phases are 
followed by the degradation of TLR4 along with any associated microbial proteins in late 
endocytic vesicles278, resulting in the peptide loading of MHC class II molecules for the 
presentation of Ag and activation of CD4+ TH cells328,329. The activation-induced 
trafficking of TLR4 provides a mechanism by which innate and adaptive immune 
responses are linked and therefore identifies a potential route for ES-62-mediated 
uncoupling of TLR4 associated NF-κB activation. 
Generally activation of TLR4 by LPS induces sustained activation of the NF-κB 
pathway leading to secretion of IL-6, IL-12 and TNFα from DCs330. These pro-
inflammatory responses ultimately promote priming of TH1/TH17 phenotypes248. It has 
been shown that ES-62, despite inducing the transient activation of this pathway is able to 
retain the cell in an immature phenotype that is associated with a decrease in the secretion 
of these pro-inflammatory cytokines331. It is hypothesised that ES-62 subverts TLR4 
signals by interacting with the receptor to ‘re-wire’ the cell by the degradation and 
inhibition of signalling elements important in NF-κB activation and cytokine secretion. 
There are several proposed targets for ES-62 action in DCs, which revolve around proteins 
that associate or are important in TLR4 mediated pro-inflammatory signalling. Of 
particular interest are the PKC family, which were first identified as important targets of 
ES-62 in the immunomodulation of B cells. 
1.6.5.2 Subverting the activation and antibody production of B cells; ES-62 
uncouples BCR signalling  
ES-62 suppresses B cell proliferation following BCR cross-linking. The BCR 
comprises a clonotypic Ag-binding component (surface immunoglobulin, sIg) and its 
accessory immuno-receptor tyrosine-based activatory motif (ITAM)-containing signal 
transducing molecules Igα and Igβ332. Ligation of the BCR triggers protein tyrosine kinase 
(PTK) activity, resulting in tyrosine phosphorylation of the ITAMs and the recruitment of a 
number of key signal-transducing pathways implicated in cellular activation and 
proliferation. These include the PLCγ, phosphoinositide-3-kinase (PI3K) and the Ras-ERK 
MAPK signalling cascades. ES-62 specifically targets key signalling events following 
BCR ligation to attenuate the activation and proliferation of B cells. It does this by 
selectively modulating the expression and activity of certain PKC isoforms in resting and 
BCR stimulated B cells320,333. In this context, ES-62 selectively down-regulates the 
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expression of the α, β, δ, ξ and ι/λ isoforms, predominantly by stimulating proteolytic 
degradation whilst it up-regulates PKCγ and PKCε in murine splenic B cells320. This is 
coupled with modulation PKC signalling resulting from Ag-receptor ligation of B cells 
through the disruption of normal activation and nuclear translation patterns of the PKCα 
and PKCι/λ isoforms. These data were consistent with results which indicated PKCα, -ε 
and -ι/λ transduced key activation signals involved in the regulation of Ag-driven DNA 
synthesis and proliferation in B cells334, such as phosphorylation of nuclear protein lamin B 
and the induction and activation of NF-κB, Fos, Egr-1 and Myc335-339.  
However ES-62 regulation of BCR signalling also targets the receptors recruitment 
of additional key proliferative signals, such as the PI3K and Ras/Erk MAP kinase 
cascades. It does this by activating a low level of signalling through molecules such as 
ERK and MAPK resulting in the induction of negative feedback signalling such that when 
subsequent BCR ligation occurs, ERK activity is rapidly uncoupled by activation of the 
inhibitory phosphatase, PAC-1 preventing the activation of the cell340. 
Although ES-62 attenutates the proliferation of B cells, they still mount an antibody 
response against the molecule, although the isotype and subclass of antibody produced is 
very specific. For example BALB/c mice injected with ES-62 mount an antibody response 
to the molecule resulting in the production of the TH2-associated isotype IgG1, but not 
IgG2a, the latter of which is associated with the TH1 phenotype. Many human studies 
reveal an indirect association between the presence of circulating filarial nematode 
products and the levels of parasite specific IgG1, IgG2 and IgG3 whilst the TH2 associated 
IgG4 subclass is usually found to be elevated and often to a considerable extent341. 
Interestingly the cytokine IL-4, which is commonly associated with filarial infection and 
has the potential to elevate the levels of IgG4, is believed to play an important role in 
determining the isotype and subclass of antibody produced in responses to filarial 
infection. In this context, IL-4 has been shown to synergise with ES-62 to cause B-
lymphocyte proliferation rather than hypo-responsiveness283. This IL-4 mediated rescue 
appears to arise as a consequence of exposure to IL-4 preventing the ES-62 mediated 
degradation of PKCα, as PKCα is important for the mitogenic activation of B 
lymphocytes320. Thus although ES-62 may render conventional B lymphocytes 
hyporesponsive and impair their ability to produce antibody in vivo, in the presence of IL-
4, the cells may be induced to produce antibodies of the IgG4 subclasses. This may be the 
reason why total and specific subclasses of antibody are increased in filariasis patients. 
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 Consistent with these findings the TH2 bias observed for the anti-ES-62 response is 
dependent on IL-4, as IL-4 knockout mice fail to produce IgG1; an IL-10 dependent role 
for PC in blocking the IgG2a response has also been implicated342. Interestingly exposure 
of B1 cells to ES-62 released from osmotic pumps results in their proliferation and IL-10 
production, even in the absence of further stimuli343. 
Similarly, with respect to T cells, ES-62 has been observed to suppress anti-CD3-
induced proliferation of Jurkat T cells and promote concanavalin A-induced growth arrest 
of these cells344, an affect that can be mimicked by PC283. The precise sequence of 
signalling events responsible for these affects remain to be fully elucidated. However the 
ES-62 mediated desensitisation of TCR signalling is associated with disruption of TCR 
coupling to PLD, PKC, PI3K and Ras-ERK MAP kinase signalling. The PC molecule 
appears to be the active moiety in mediating these affects as culture with PC or PC-BSA 
has comparable effects as ES-62 on the coupling of the TCR to PTK activation (ZAP-70, 
Lck and Fyn recruitment) and the Ras-Erk MAP kinase signalling cascades283,308,344. These 
findings are consistent with an earlier report showing that PC-containing molecules of the 
human filarial nematode, Brugia Malayi, inhibit the response of human T cells to 
mitogens345. 
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1.7 Aims of the thesis 
The aims of this project were to dissect the mechanisms by which ES62 modulates 
the maturation and activation of bone marrow derived DCs.  
Specifically, the aims of this project were to: 
1. Identify how engagement of TLR4 by ES-62 and/or LPS induces differential 
effects on the maturation of DCs and subsequent induction of effector T cell 
subsets. 
2. Investigate whether ES-62 utilises additional co-receptors in conjunction with 
TLR4, to mediate its immunomodulatory effects. 
3. Dissect the specific effect of ES-62 on the expression of key proteins important 
in the propagation of TLR4 signals, focusing on mediators required for the 
activation of NF-κB, a proinflammatory transcription factor. 
4. Explore the mechanisms by which ES-62 modulates signal transducer 
expression to downregulate proinflammatory responses. 
These objectives were investigated in murine, bone marrow progenitor derived DCs; a 
well established system for the study of these APCs and the modulation of the immune 
responses by ES-62291,319,326. 
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Figure 1.1 | Transcription-factor activation through TIR-domain containing adaptors 
of the TLR family and the various ligands that stimulate these receptors.  
Collectively, the TLR family recognise a wide variety of PAMPs, and the specificity for 
each receptor within this family is often based on particular motifs shared between 
pathogenic molecules. For example, TLR2 can recognise lipoarabinomannan from 
mycobacteria, peptidoglycan from Gram-positive bacteria , hemagglutinin protein from 
measles virus and tGPI-mutin from Trypanosoma. Members of the TLR family can also 
form complexes to further enhance their recognition repertoire as TLR2/6 recognises 
zymosan from Saccharomyces cerevisiae (S. cerevisiae), while TLR2/1 and TLR2/6 are 
able to discriminate between triacyl- and diacyl-lipopeptide lipid structures, respectively. 
TLR4 recognises gram negative bacterial LPS and envelope proteins from respiratory 
syncytial virus (RSV) and mouse mammary tumor virus (MMTV), where TLR5 is a little 
more limited in its spectrum as to date its is only known to recognise bacterial flagellin. In 
mice, TLR11 recognises components of uropathogenic bacteria and a profilin-like 
molecule of Toxoplasma gondii. The aforementioned receptors generally reside at the 
plasma membrane (TLR1, -2, -4, -5, -6, -11) while TLR3, -7, -8 and -9, are located in the 
endosomes, where they are ideally situated for the recognition of their PAMPs, which 
include nucleic acids synthesised from viruses and bacteria. Specifically, TLR3 recognises 
dsRNA, a product of the replication of viruses and poly IC, while TLR7 detects another 
derivative of many viruses, ssRNA. TLR9 recognises CpG DNA motifs present in the 
genomes of bacteria and viruses, which also includes non-nucleic acids such as hemozoin 
from Plasmodium. The differential engagement of various intracellular adaptors by the 
TLR receptor complexes (for example; TIRAP-MyD88, TRAM-TRIF) allow the positive 
regulation of transcription-factor activation. For example, TLR1, 2 and 6 utilise MyD88 
and TIRAP as adaptors while TLR5, -7, -9 and -11 utilise MyD88 alone. TLR4 utilises a 
range of adaptors including MyD88, TIRAP, TRIF and TRAM. TLR3 utilises TRIF as its 
sole adaptor. The exception to these various adaptors is SARM, which inhibits TRIF-
mediated transcription factor activation. 
(Adapted from Kawai, T. et al., 200714) 
  
46 
Figure 1.2 | The activation of NF-κB through LPS-TLR4 signalling.  
Pro-inflammatory TLR4 signalling can be divided into two separate stages; the first being 
an early MyD88-dependent phase that is triggered by receptor-mediated endocytosis in 
clathrin coated pits, the second a later endosomal TRIF mediated phase. The LPS 
recognition complex is composed of TLR4/MD2 and CD14, which initiates both MyD88- 
(requiring TIRAP) and TRIF-dependent (requiring TRAM) intracellular signalling 
pathways via its TIR domain. The MyD88 pathway stimulates the recruitment of a number 
of intracellular adaptor proteins including members of the IRAK family and TRAF6, the 
latter of which utilises K63-linked ubiquitinaton to form a scaffold for the activation of the 
TAK1 complex. Resulting in the activation of another multiprotein IKK complex, 
composed of IKKα, IKKβ and its regulatory component NEMO, to catalyse the rapid 
phosphorylation of IκB and induce its polyubiquitination and proteosomal degradation. 
This releases the NF-κB complex to translocate into the nucleus, which alongside AP-1 
induces the production of the inflammatory cytokines IL-6, IL-12 and TNF-α from DCs. 
The phosphorylation and translocation of AP-1 is dependent on TAK1 mediated activation 
of the MAPK pathway. In the later TRIF dependent phase, the recruitment of both TRAF3 
and TRAF6 are important for the activation of the kinases TBK1 and IKKi, which mediate 
the phosphorylation and dimerisation of IRF3, resulting in its nuclear translocation for the 
regulation of gene transcription. TRIF also interacts with TRAF6 and RIP1 to mediate the 
activation of NF-κB, where this pathway is required for the induction of the type I IFNs, 
particularly IFN-β. The dissociation of TRIF from TRAM occurs in the late endosomes 
and terminates its signalling capacity, while TLR4 is ubiquitinated via K48 linkages for its 
eventual degradation in the lysosomes.  
(Adapted from Jiang, X. et al., 2011346; Barton G. M. et al., 200913; Kawai, T. et al., 
200714; McGettrick, A. F. et al., 2010347) 
  
47 
Figure 1.3 | The regulation of ubiquitination and fates of the ubiquitin associated 
proteins. 
(A) The process of ubiquitnation begins with the utilisation of ATP by the ubiquitin-
activating enzyme (E1) to form a high-energy, labile E1-thiol ester intermediate to activate 
Ubiquitin (Ub), which is then transferred to a ubiquitin-conjugating enzyme (E2). The 
method of ubiquitin transfer to a substrate is dictated by the type of ubiquitin-protein ligase 
(E3), a protein important in ensuring the specificity of such associations. The E3 proteins 
can be defined by whether they contain either a HECT or RING finger domain. (B) A 
HECT domain-containing E3 ligase transfers the activated ubiquitin from the E2 protein 
onto itself to generate another labile thiol ester intermediate. This is then conveyed to an 
associated substrate through the formation of a stable isopeptide bond between ubiquitin 
and an ε-NH2 group of an internal Lys residue in the substrate. In the generation of a 
polyubiqutin chain additional ubiquitin moieties are added to the initial moiety in a similar 
process. (C) On the other hand, a RING finger domain-containing E3 ubiquitin ligase 
directly transfers the activated ubiquitin from E2 to an internal Lys residue onto an 
associated substrate. (D) In the majority of cases, polyubiquitin chains linked through 
Lys48 of ubiquitin are associated with proteasomal degradation. (E) In contrast, linkages 
through Lys63 of ubiquitin are associated with a raft of proteosomal independent 
(including lysosomal degradation) functions. However, recently evidence has emerged 
suggesting a role for this linkage in targeting proteins for proteosomal degradation348. The 
association of ubiquitinated proteins to the proteosome occurs either directly or by 
shuttling of proteins, where they are degraded to short peptides by the 26S proteosome. (F) 
Subsequently, most of the ubiquitin chain is disassembled by deubiquitinating enzymes 
(DUBS), where in the minority of cases select substrates are processed rather than 
completely degraded by the proteosome. 
(Adapted from Weissman, A.M. et al., 2011349) 
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Figure 1.4 | Ubiquitin-mediated signalling in TLR pathways, particularly focusing on 
TLR4 signalling and the different types of polyubiquitination involved. 
Stimulation of TLR4 leads to the formation of the ‘myddosome’ at the plasma membrane, 
which is composed of the adaptor proteins, MyD88 and TIRAP as well as two members of 
the IRAK family, IRAK1 and IRAK4. The subsequent recruitment and activation of the E3 
ligase TRAF6, is required for the synthesis and linkage of K63-linked polyubiquitin chains 
to cIAP1 and cIAP2 for the ubiquitination and degradation of TRAF3. The degradation of 
TRAF3 releases TRAF6 associated complexes from TLR4 into the cytosol, where it can 
interact and recruit additional components through its associated polyubiquitin chains. 
These include the TAK1 and IKK kinase complexes, which do so through their ubiquitin-
binding subunits TAB2/TAB3 and NEMO, respectively. The binding of these complexes 
to the K63-linked polyubiquitin chains on TRAF6 induces the phosphorylation of IKKβ by 
TAK1 and results in the actvication of IKK. This induces IKK to phosphorylate IκB 
proteins leading to their polyubiquitination by SCFβTrCP (an E3 ubiquitin ligase complex), 
targeting IκB for degradation by the proteosome and freeing NF-κB to translocate to the 
nucleus for the activation of genes involved in immune and inflammatory responses. The 
endocytosis of TLR4, which occurs after MyD88 associaiton, induces the recruitment of 
the adaptor proteins TRAM and TRIF. This complex recruits a number of E3 ligases 
including PEL1, TRAF3 and TRAF6 to mediate the ubiquitination of the signalling 
proteins such as RIP1 to induce the sustained acticaiton of NF-κB and production of the 
type I IFNs.   
(Adapted from Jiang, X. et al., 2011346) 
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Figure 1.5 | Structure and maturation of the various PKC subfamilies. 
In panel A, the structural characteristics associated with the classification of various PKC isoforms 
are defined. The catalytic domains of the various PKCs are conserved but this family to be 
categorised into three subgroups based on their differing regulatory domains. The conventional 
PKC isoforms (cPKC) are composed of: the autoinhibitory pseudosubstrate motif, two DAG 
binding C1 doamins (C1a and C1b) and the calcium-binding C2 domain. The novel PKC isoforms 
(nPKC) can be regulated by DAG but lack a calcum-biniding motif and rather uniquely contain an 
extended N-terminal domain important for receiving regulatory signals. Finally, the catalytic 
activity of atypical isoforms (aPKC) is independent of DAG and calcium, where the regulation of 
this isoform occurs mainly through intracellular localisation, which in itself is regulated by the 
interaction with regulatory proteins and a nuclear localisation signal/nuclear export signal in their 
regulatory domains. The various PKC isoforms share a highly conserved C-terminal tail which 
contains certain motifs termed the A-loop and C terminal associated turn-motif (TM) and 
hydrophobic motic (HM), all of which are important phosphorylation sites. 
In panel B, the prevailing model of the activation and localisation through the phosphorylation of 
the cPKC and nPKC isoforms is presented. After synthesis, the PKCs are phosphorylated at a series 
of sites (represented by the yellow circles) including the A-loop (mediated by PDK-1), followed by 
the TM and HM regions (via mTORC1/mTORC2-dependent pathways), which allows the proteins 
to enter a closed, enzymatically ‘competent’ state. There is mounting evidence that these 
phosphorylations occur at the plasma membrane (PM). The pseudosubstrate occupies the substrate-
binding site and in this state the enzyme predominantly localises to the cytosol, where it is ready 
for activation by the second messenger DAG (and in the case of the cPKC isoforms, calcium 
released by inositol triphosphate production [IP3]) produced after receptor stimulation. It is tyrosine 
kinases coupled to the receptors that are responsible for triggering of PLC-mediated hydrolysis of 
PtdIns(4,5)P2 to DAG. DAG binds to the C1 domains on the PKC as well as DGK, which 
phosphorylates DAG to produce phospatidic acid (PA) to terminate DAG signalling. Binding to 
second messengers is required for the release of the pseudosubstrate motif from the active site and 
for this to be made accessible for signalling effectors. There is mounting evidence however that 
stimulation of receptors may directly induce various phosphorylations on a range of PKC isoforms.   
(Adapted from Spitaler, M. et al., 200454; Freeley, M. et al., 201153; Parker, P.J. et al., 2003350) 
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Figure 1.6 | The known roles of the PKCs in TLR signalling and activation of NF-κB. 
The TLRs mediate the activation and regulation of different PKCs, which can then directly 
interact with various components of the NF-κB activation pathway. The cPKC, PKCα 
associates with TLR2 and TLR4 following its activation, an association which is reliant on 
MyD88, where it mediates the activation of MAPK and NF-κB leading to the secretion of 
TNFα, IL-6 and IL-10. This isoform is also required for the TLR3-mediated IRF-3 binding 
of CBP and IFN-β gene induction. The nPKCs, PKCε and PKCδ interact with TLR4 
through MyD88 and TIRAP, respectively. This recruitment to the TLR4 signalosome is 
important in the activation of IKK complex and NF-κB, where PKCε has also been shown 
to be required for the phosphorylation of TRAM. Interestingly, PKCε is important in TLR4 
signal transduction through its involvement in initiating MAPK signalling and is known to 
be directly involved in the LPS induced secretion of TNF-α and IL-12p70 in DCs but not 
the up-regulation of co-stimulatory molecules. PKCζ is activated upon ligation of TLR2 or 
TLR4. During signalling by these receptors, active PKCζ binds to TLR2, associates with 
TRAF6 and is required for the full transcriptional activation of p65. 
(Adapted from Loegering, D. J. et al., 2011351) 
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Figure 1.7 | Dendritic cells and pathogens 
(A) When immature DCs encounter pathogens and their inflammatory stimuli, such as 
LPS, maturation ensues resulting in the activation and nuclear translocation of NF-κB and 
the interferon regulatory factors (IRFs) for the transcription of multiple genes associated 
with immunity and infalmmation. The costimulatory molecules CD40, CD80 and CD86 as 
well as proinflammatory cytokines (IL-6, IL-1β, TNF-α, IL-12p70, IL-12/23p40 and IL-
23) are produced and support the activation of T cells. (B) In the process of activation and 
maturation, DCs uptake endogenous Ags from the environment and present this on their 
surface through MHC class II molecules to Naïve T cells. MHC class II α- and β-chains 
assemble in the endoplasmic reticulum (ER) and form a complex with the invariant chain 
(Ii). The Ii–MHC class II heterotrimer is transported through the Golgi to the MHC class II 
compartment (MIIC), either directly and/or via the plasma membrane. Endocytosed 
pathogens/proteins and Ii are degraded by resident proteases in the MIIC. A portion of the 
li peptide; the class II-associated Ii peptide (CLIP) fragment remains in the peptide-binding 
groove of the MHC class II dimer and is exchanged for an antigenic peptide with the help 
of the dedicated chaperone HLA-DM (known as H2-M in mice). MHC class II molecules 
are then transported to the plasma membrane to present antigenic peptides to CD4+ T cells. 
The key ligand pairs required in the formation of the DC-T cell immunological synapse 
consists of a central interaction of the T cell receptor (TCR) and MHC:peptide complex 
(C). This reaction is stabilised by a scaffolding network consisting of CD80/86 interactions 
with CD28 and CTLA4 alongside CD40 and its ligand CD40L. There is also a major input 
from cytokine milieu secreted in response to various pathogens by the DCs for the 
maturation of various phenotypes from the naïve TH cell precursors. 
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Figure 1.8 | T helper (TH) cell subset generation 
Activated APCs such as DCs and macrophages engage the T cell receptor (TCR) on naïve 
CD4+ T cells through peptide presenting MHC class II molecules and the appropriate 
costimulatory molecules, triggering the activation of distinct signal transducer and 
activator of transcription (STAT) pathways and their proliferation. The APCs then guide 
the phenotypic maturation of these cells through the specific cytokine environments they 
create (determined by the type of pathogen encountered), dictating the type of immune 
response mounted by the adaptive immune response. The cytokine IL-27 is involved in the 
priming of naïve T cells, where high doses of Ag presented by DCs or the secretion of IL-
12p70 activate STAT4 and favour the development of TH1 cells, which produce IFN-γ and 
mediate cellular immunity. In the case of TH2 cells, IL-4 and the activation of STAT6 
signalling is required for their development, resulting in a cell population that drives 
humoral immunity and the secretion of high quantities of IL-4, IL-5 and IL-13. The 
secretion of IL-23 is involved in the induction of TH17 cells, alongside IL-6, TGF-β and 
the autocrine production of IL-21 by this developing cell population. The presence of IL-
27 inhibits the development of TH17 cells, which secrete IL-17, IL-21 and IL-22 inducing 
strong inflammatory responses. The novel cytokine IL-35 has been demonstrated to play a 
role in the immunosuppressive effects of T regulatory (Treg) cells, alongside IL-10 and 
TGF-β. 
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Figure 1.9 | Immunomodulation by ES-62. 
ES-62 targets multiple cells of the immune system (black arrows [+/induction] and ‘bulb’ 
arrows [-/inhibition]) to achieve immunomodulation, broadly biasing the immune response 
to a TH2/anti-inflammatory phenotype. It targets DCs and macrophages, which are 
important regulators of T cell polarisation, by interacting with TLR4 to interfere with the 
TLR4-NF-κB signalling axis and thus modulate the maturation and secretion of cytokines 
from these innate cells. This is characterised by the production of low levels of IL-12, IFN-
γ, TNF-α and IL-6 by these APCs. In respect to its modulation of B and T cell responses, 
ES-62 targets the signalling triggered following cross-linking of the B- and T-cell antigen 
receptors (BCR and TCR), hence disrupting the responses of these cells to specific Ags. 
This modulation results in the secretion of IL-4 by TH2 cells and production of the TH2 
associated antibody isotypes IgG1 (mouse) and IgG4 (human) by B cells alongside the 
production of IL-10 specifcally by B1 cells. With the recent emergence of the TH17 
phenotype it has been hypothesised that ES-62 may suppress inflammation by targeting IL-
17 responses as it is implicated in the pathogenesis of diseases resulting from both TH1 and 
TH2 driven inflammation. This targeted suppression of IL-17 would limit both types of 
inflammation as well as that driven by TH17 cells but it is as yet unknown whether ES-62 
may target APC driven development of TH17 cells or the direct secretion of cytokines from 
this cell population. The majority of evidence to date suggests ES-62 acts on TH cells 
through DCs, however recent data has suggested it can act directly on TH17 cells in 
vitro352. 
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2 Materials and Methods  
2.1 Animals  
Male and female, 7-10 week old, BALB/c or C57BL/6 background, Sphingosine 1 
and Sphingosine 2 knock-out (KO) mice were used to generate bone marrow derived DCs 
for this study. For the in vitro co-culture experiments, mice homozygous for the transgenic 
TCR which is specific for the chicken Ovalbumin (OVA) peptide323-339 in the context of I-
Ad (DO.11.10 on a BALB/c background)353 and I-Ab (OTII on a C57BL/6 background) 
were used as T cell donors. The tg TCR was detected by flow cytometry using the 
clonotypic monoclonal antibodies KJ1.26 (DO.11.10) and Vα2 (OTII). All animals were 
specified pathogen free and were maintained under standard animal house conditions with 
free access to both water and standard rodent pellets at the University of Glasgow Research 
Facilities in accordance with local and home office regulations. 
2.2 Purification of ES-62 
Endotoxin free ES-62 was prepared from adult Acanthocheilonema viteae worms in 
culture by Dr. lamyaa Rayami and Dr. Justyna Rzepecka (SIPBS, University of 
Strathclyde, UK). Briefly, ES-62 was prepared from 500 ml spent culture medium of adult 
A. viteae (endotoxin-free RPMI 1640 (Invitrogen Life Technologies)) with added 
endotoxin-free glutamine (2 mM), endotoxin-free penicillin (100 U/ml), and endotoxin-
free streptomycin (100 µg/ml)). To remove larval forms (microfilariae) released by the 
adult female worms, the medium was passed through a 0.22-µm pore size filter (Sigma-
Aldrich). It was then transferred to a stirred cell ultrafiltration unit containing a YM10 
membrane (Amicon). After reducing the volume of the sample to 5–10 ml and transferring 
the holding medium to endotoxin-free phosphate buffered saline (PBS), pH 7.2 (Cambrex 
Bioscience), it was further concentrated to 200–500 µl using Centricon microconcentrators 
with a 30-kDa cutoff membrane (Amicon). The sample was then applied to a 30 x 1-cm 
Superose 6 column (HR 10/30; BD Biosciences), fitted to an isocratic FPLC system (BD 
Biosciences) previously equilibrated with endotoxin-free PBS, pH 7.2, at room 
temperature. The column was eluted at a flow rate of 0.5 ml/min and monitored for 
absorbance at 280 nm. More than 95% of the protein eluted as a single peak, and this was 
purified ES-62. The purity and identity of each batch were confirmed by a combination of 
SDS-PAGE and Western blotting, the latter using a rabbit antiserum specific for ES-62. 
Finally the level of endotoxin in the ES-62 samples was confirmed using an Endosafe kit 
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(Charles River Laboratories, Kent, UK). ES-62 is used at a working concentration that has 
an endotoxin reading of <0.0015 endotoxin units per µg of ES-62. 
2.3 Generation of bone marrow derived dendritic cells 
Bone marrow (bm) was isolated from mouse femurs by flushing with cold PBS 
followed by homogenisation with a 23-gauge needle. This solution was then treated to 
remove red cells by incubation with 0.168 M NH4Cl (pH 7.2) on ice for 10 mins. The cells 
were then filtered through Nitex nylon mesh (Cadisch Precision Meshes, London, UK) to 
remove dead cells prior to culture. To prepare bmDC, bone marrow cells were cultured in 
complete medium containing RPMI-1640 (Invitrogen), 2 mM glutamine, 50 U/ml 
penicillin, 50 µg/ml streptomycin, 10% Fetal Calf Serum (FCS; Lonza) supplemented with 
10 ng/ml recombinant murine Granulocyte/Macrophage Colony Stimulating Factor (GM-
CSF; Peprotech) for 6 days in 90 mm petri dishes (Greiner) at 37oC/5% CO2 (2x106 cells 
per dish), with fresh medium supplied on day 4. On day 6, immature bmDC were harvested 
by gentle scraping and used as a source of DCs, which were approximately 65-85% 
CD11c+ DC. Where indicated, these bmDCs (day 6) were further purified (≥ 95%) prior to 
maturation by positive selection using MACS microbead separation (Miltenyi biotec) 
against the CD11c marker. The cells were prepared in MACs buffer - PBS pH 7.2 
supplemented with 0.5% bovine serum albumin (BSA) and 2 mM Ethylene diamine tetra 
acetic acid (EDTA) and then passed through Nitex nylon mesh before being blocked with 
Fc receptor blocking agent (anti-CD16/32) and positively selected on CD11c Microbeads 
using magnetic separation according to the manufacturer’s instructions.  
2.3.1 ES-62 and modulator treatment of bone marrow derived 
dendritic cells 
Purified bmDCs were stimulated with combinations of 2 µg/ml ES-62 and/or 1 
µg/ml LPS (Salmonella Minnesota [Sigma-065K4078]) in 6 well plates for the stipulated 
times. After such times, the culture supernatants were removed for cytokine analysis and 
the cells were assayed by flow cytometry, western blotting and mRNA transcript analysis 
as indicated. 
A number of pharmacological treatments were utilised to inhibit different cellular 
processes throughout the cell. These included inhibitors of lysosomal degradation such as 
ammonium chloride (NH4Cl; 50µM) or the combination of E-64-D (10 µg/ml) and 
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Pepstatin A (10 µg/ml), which raises the pH of lytic granules and inhibits the function of 
lysosomal proteases, respectively. However, it is important to note that ammonium 
chloride has a number of subsidiary effects as it raises the pH of many intracellular 
compartments resulting in interference with transcytosis, endocytosis, fusion of membrane 
vesicles354-357, and receptor recycling358-360.  
The proteosomal degradation inhibitor lactacystin (10 µM), which inhibits the ATP 
independent activities of the proteosome, was also utilised in these studies and the viability 
of bmDCs with this treatment was analysed due to frequent reports in the literature of its 
cytotoxicty. The fluorochrome, 7-AAD (7-amino-actinomycin D) was utilised to identify 
cell viability. This compound is commonly utilised for the exclusion of nonviable 
(unhealthy) cells due to its ability to inerchelate into the DNA cells with compromised 
membranes (a common feature of dying cells). Immature bmDCs treated with lactacystin 
over an 18 h time period (Fig. 2.1), were observed to induce a substantial level of cell 
death (41.9 %, of the total cell population) after 18 h when utilised at 10 µM but not 1 µM 
(12.3 %). Interestingly, this was reduced when the cells were stimulated with LPS (24.4 %; 
with 10 µM lactacystin). Despite the reduction in cell viability, 10 µM lactacystin was 
generally utilised as it is commonly cited as being required to completely inhibit 
proteosomal degradation. However, any potential effects on cell viability were taken into 
account. All other specific pharmacological treatments are covered in the relevant chapters. 
2.4 Purification of DO.11.10 CD4+ CD62L+ T cells 
2.4.1 Isolation of CD4+ CD62L+ T cells 
Purified naïve CD4+CD62L+ T cells from DO.11.10.BALB/c or OTII C57BL/6 
mice were utilised for in vitro culture with bmDC to assess differentiation of TH 
phenotype. Single cell suspensions of lymphocytes were prepared and pooled from the 
spleens, peripheral (axillary, brachial, inguinal, cervical; PLN) and mesenteric lymph 
nodes from DO.11.10 BALB/c mice and forced through Nitex nylon mesh using a syringe 
plunger. The suspensions were washed in 10 ml of sterile RPMI 1640 before being 
centrifuged at 300 x g for 10 mins and the supernatant discarded. These cells were then 
purified using a CD4+CD62L+ T cell isolation kit (Miltenyi Biotec) according to the 
manufacturers instructions. Briefly, lymphocytes were resuspended in MACS buffer (PBS 
pH 7.2 supplemented with 0.5% bovine serum albumin (BSA) and 2 mM EDTA) and 
incubated with a biotin-antibody cocktail which contains biotin-conjugated antibodies 
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against CD8α (Ly-2), CD45 (B220), CD49β (DX5), CD11b (Mac-1), Ter-119, CD25 and 
TCRγδ. Cells were then incubated with anti-biotin microbeads and after washing, the CD4+ 
T cell population was obtained by negative selection using MACS separation. The 
enriched CD4+ T cell population was then incubated with anti-CD62L microbeads and the 
naïve CD4+CD62L+ population was obtained using positive MACS selection. The 
percentage of KJ1.26+CD4+ DO.11.10 T cells in these preparations was determined by 
flow cytometric analysis (Fig. 2.2). 
2.4.2 DNA synthesis assay 
To be able to divide, cells have to replicate their DNA. Thus, if cells are cultured in 
the presence of radiolabelled bases, these become incorporated into their DNA with the 
levels of signal being proportional to the amount of DNA synthesised. The most common 
label used to determine DNA synthesis is [3H]-labeled thymidine, which can be detected 
by scintillation counting. To measure DNA synthesis, triplicate samples of T cells (2.5 x 
105), co-cultured with bmDC (2.5 x 104) were incubated (37oC in a 5% [v/v] CO2 
atmosphere at 95% humidity) in T cell culture medium (RPMI-1640, 2 mM glutamine, 50 
U/ml penicillin, 50 µg/ml streptomycin, 10% FCS, 50 µM β-mercaptoethanol [Invitrogen], 
1% Non-essential amino acids (Invitrogen) and 1mM Sodium Pyruvate [Sigma] for 72 h, 
unless indicated otherwise). [3H] thymidine (0.5 µCi/well, Amersham) was added for 16 
hours before cell harvesting with an automated cell harvester (Perkin Elmer). Incorporated 
label was analysed by liquid scintillation analysis (Microbeta Trilux, Perkin Elmer). 
2.4.3 5,6-Carboxy-Succinimidyl-Fluoresceine-Ester (CFSE) 
staining of cell division 
CFSE is a cell permeable dye that permanently stains cells following its binding to 
exposed amine groups on intracellular proteins361. During each cell division the cell 
undergoes thereafter the amount of cellular dye is halved and this can be detected as a shift 
to lower fluorescence intensity by Fluorescence Acitvated Cell Sorting (FACS) analysis, 
with each 50% reduction of the fluorescence signal representing one division. Briefly, prior 
to the analysis, cells (105/sample) were washed twice (in ice cold PBS) and then loaded 
with 5 µM CFSE in PBS for 10 min at 4oC. The cells were then washed with 40 ml ice 
cold PBS three times, to remove any excess CFSE, after which the cells were resuspended 
in warm T cell culture medium (section 2.4.2). The cells are analysed for CFSE-staining 
(intensity) by FACS analysis of cells in the FL-1 channel (Becton Dickinson 
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FACSCalibarTM flow cytometer). The dilution of CFSE in the cells was then analysed 
using Flowjo software (Tree Star Inc, OR, USA, version 8.8.6) creating gates correlating 
with the number of cycles of proliferation (generations) the cells have undergone (Fig. 
2.2).  
In conjunction with these analyses the division index, proliferation index and 
percentage of dividing cells (% divided) was calculated from these samples utilising the 
proliferation platform program provided by the FlowJo software package. The division 
index is defined as the average number cell divisions that a cell in the original population 
(generation 0 or the undividing cell peak) has undergone and includes the cells that remain 
within the undivided cell peak. The proliferation index is the total number of divisions 
divided by the number of cells that started dividing. As such, the proliferation index only 
takes into account the cells that undergo at least one division, thus only responding cells 
are reflected in the proliferation index. In general, the proliferation index more faithfully 
reflects the biology of the responding system (dividing cells), while the division index 
reflects what the entire system is doing. The percentage of dividing cells (% divided) 
provides a percentage value for the number of cells, which have divided (assuming that no 
cells died during the culture). These statistics are related in the following way:  
Division index = (Proliferation index)(% Divided) 
2.5 In vitro bmDC and T cell co-cultures 
BmDC were prepared and purified as described in section 2.3 The cells were then 
seeded at 2 x106 cells/ml in 6 well plates before being matured (day 6) in the presence or 
absence of 2 µg/ml ES-62 and/or 1 µg/ml LPS (S. Minnesota; Sigma-065K4078) for 24 
hours or the indicated time. On day 7 (or day 8 when cells were pretreated with ES-62 for 
18 h prior to stimulation with LPS) the bmDC were harvested and pulsed with 0, 10, 30, 
100 or 300 nM OVA323-339 peptide for 3 h at 37oC, 5% (v/v) CO2 atmosphere at 95% 
humidity. Following this the cells were washed 3 times with sterile RPMI 1640 medium 
and then cultured (2.5x104 cells) in T cell culture medium (section 2.4.2) with MACS 
sorted, CFSE stained, purified CD4+CD62L+ T cells (2.5 x 105 cells) from 
DO11.10/BALB/c or OTII/C57BL/6 mice in a total volume of 1 ml in 24 well plates for 72 
h at 37oC and 5% CO2. A portion of the cells was analysed by FACS for CFSE staining 
using antibodies raised against the TCR specific for the chicken OVA323-339 peptide bound 
to I-Ad MHC class II molecules (KJ1.26) in the case of the DO11.10/BALB/c mice 
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derived cells or the Vα2 chain of the TCR for OTII/C57BL/6 mice derived cells. The 
remaining cells were treated for RNA extraction and mRNA analysis and the supernatants 
were frozen at -20oC for future cytokine analysis.  
2.6 FACS Analysis  
2.6.1 Staining for surface protein 
Aliquots of cells (105-106 per sample) in 5 ml polystyrene tubes (Falcon, BD) were 
washed (all wash steps were followed by centrifugation at 300 g for 5 min) with 200 µl 
cold FACS buffer (PBS and 10% FCS) at 450 g for 5 min at 4oC. Cells were re-suspended 
in 200 µl Fc receptor (FcR) blocking buffer (anti-CD16/32, clone 2.4G2, hybridoma 
supernatant, 10% mouse serum, 0.1% sodium azide) for 15 min before washing with 1 ml 
cold FACS buffer. Anti-CD16/32 binds to FcγRII/III whilst the immunoglobulin in mouse 
serum binds to FcγRI resulting in the blocking of all FcR preventing non-specific binding 
of antibodies. FcR blocking was followed by the addition of the appropriate fluorochrome-
conjugated or biotinylated primary antibodies for 15-30 min in the dark at 4oC. Details of 
the Ab clones, their specificities and isotype controls used are provided in Table 2.1. The 
cells were then washed with 1 ml cold FACS buffer as before and where appropriate, 
biotinylated antibodies were detected following incubation with fluorochrome-conjugated 
streptavidin for 15-30 min in the dark at 4oC. Finally the cells were washed again in FACS 
buffer, re-suspended in 100-300 µl FACS buffer for analysis using a Becton Dickinson 
FACSCalibarTM flow cytometer and analysed using Flowjo software (Tree Star Inc, OR, 
USA, version 8.8.6) (Fig. 2.3). Where appropriate the fluorchrome 7-AAD was added to 
the samples to exclude nonviable cells (for a detailed descripiotn of this compound please 
refer to section 2.3.1) before two to four-colour analysis was performed on a minimum of 
30,000 events. 
Many of the analyses compare the fluorescence intensity of a stained antigen (Ag) 
between two samples and as such the histograms y-axis is defined as the percentage of 
maximum cell numbers (%-Max). In FlowJo software all recorded events are divided into 
256 “bins”, which are numerical ranges for the parameter on the x-axis for example the 
fluorescence intensity of an Ag. Thus the %-Max is derived from the number of cells in 
each bin divided by the number of cells in the bin that contains the largest number of cells, 
where each graph is scaled to the percentage of its maximum bin (100%). 
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2.6.2 Intracellular protein staining 
Following labelling of appropriate cell surface phenotypic markers as described in 
section 2.6.1, where indicated the cells were processed for intracellular staining in the 
dark. Briefly, cells were resuspended in 500 µl Fixation buffer (BioLegend) for 20 min at 
room temperature, before washing twice in Permeabilisation buffer (BioLegend). After 
resuspension in 100 µl Permeabilisation buffer the appropriate fluorochrome-conjugated or 
unconjugated primary antibodies were added for 15-30 min in the dark at room 
temperature. In the case of the unconjugated antibodies, the cells were washed and an 
appropriate Fluorescein isothiocyanate (FITC)-labelled anti-mouse IgG was then added for 
a further 15-30 min in the dark at room temperature. The cells were then washed one final 
time before resuspension in 100-300 µl FACS buffer for analysis using a Becton Dickinson 
FACSCalibarTM flow cytometer and analysed using Flowjo software (Tree Star Inc, OR, 
USA, version 8.8.6) (Fig. 2.3). Two or three-colour analysis was performed on a minimum 
of 30,000 events. 
2.7 Enzyme-linked immunosorbance assay, ELISA 
Cytokine ELISA analysis was performed using the ELISA kits outlined in Table 2.2 
A according to the manufacturer’s instructions. Briefly IMMULON® 4 HBX flat bottomed 
96 well plates (Thermo scientific, UK) were coated overnight at 4oC with the relevant 
cytokine capture antibody in PBS, pH 7.4 (IL-22, IL-23, IL-12p70, IL-12p40) or 0.1 M 
sodium bicarbonate buffer, pH 9.5 (IL-17A, IL-6, IFN-γ). The plates were then blocked 
with 10 % FCS (IL-17A, IL-6, IFN-γ) or 1 % BSA (IL-22, IL-23, IL-12p70, IL-12p40) in 
PBS for 1 hour at room temperature before incubation with the diluted (in reagent diluent) 
samples and standards for 2 h at room temperature. Biotinylated, cytokine-specific, 
detection antibodies were diluted and added to the plates for 1 h at room temperature. Then 
streptavidin-HRP (Horse Radish Peroxidase) was added for approximately 30 min at room 
temperature before the plates were developed using tetramethylbenzidine (TMB) substrate 
(Insight Biotechnology Limited, Middlesex, UK). Plates were washed at least five times 
between all these stages before the addition of TMB with PBS containing 0.05% Tween-20 
(PBS Tween). Samples tested with the BD kits had the detection antibody and streptavidin-
HRP added at the same step for 1 h. Plates were left to develop in the dark for 15-30 min 
and absorbance at 450 nm was determined in an ELISA plate reader (Sunrise microplate 
reader, Tecan, Switzerland). The cytokine concentration was determined using the 
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absorbance values obtained for the standards. The limit of detection for all cytokines was 
no higher than 15 pg/ml.  
2.8 Preparation of cellular extracts 
2.8.1 Preparation of total cell protein extracts  
Stimulated bmDC were treated as indicated (2x106 cells/treatment) and then 
reactions terminated by washing with ice cold PBS before the addition of 50 µl modified 
Radio-Immunoprecipitation Assay (RIPA) buffer (50 mM Tris buffer, pH 7.4 containing 
150 mM sodium chloride, 2 % (v/v) NP 40, 0.25 % (w/v) sodium deoxycholate, 1 mM 
Ethylene glycol-bis [β-aminoethyl ether] tetra acetic acid [EGTA], 0.5 mM 
phenylmethylsulfonylfluoride [PMSF], 1 in 100 dilutions of HaltTM Protease and 
Phosphatase Inhibitor Cocktails [Thermo Scientific, IL, USA]). After resuspending the 
pellet, the cells were solubilised for 30 minutes on ice before centrifugation of the lysates 
at 16,000 g for 15 minutes. The supernatants containing the whole cell lysates were stored 
at -80oC before being analysed by SDS-PAGE gel electrophoresis and Western Blot 
analysis.  
2.8.2 Preparation of nuclear protein extracts 
An Active Motif Nuclear Extract kit was used to produce nuclear and cystolic 
fractions. The protocol was followed as per the manufacturer’s instructions. Briefly, cells 
(2 x 106) were incubated with the appropriate stimuli at 37oC in a 5% (v/v) CO2 
atmosphere at 95% humidity. Samples were washed with 5 ml of PBS containing 
phosphatase inhibitors to terminate any cellular reactions and then centrifuged at 400 g for 
5 min. The pellets were resuspended in 500 µl hypotonic buffer by pipetting and then 
incubated on ice for 15 min. Following this, 25 µl of detergent (supplied with kit) was 
added and the samples vortexed on the highest setting for 10 s. Samples were then 
centrifuged at 14,000 g for 30 s and the supernatant removed. This supernatant contained 
the cystolic fraction and was stored at -80oC for further use. The pellet was then 
resuspended in 50 µl of complete lysis buffer (containing a 1,4-dithiothreitol (DTT) and 
protease inhibitor cocktail) and vortexed for 10 s. The samples were then left on ice for 30 
min and after a further vortexing centrifuged at 14,000 g for 10 min. The resultant 
supernatant contained the nuclear fraction and was stored at -80oC before being analysed 
by SDS-PAGE gel electrophoresis and Western blotting analysis. 
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2.9 Protein Co-Immunoprecipitation 
To identify specific protein-protein interactions occurring between certain proteins a 
Dynabeads® Co-Immunoprecipitation kit (Invitrogen) was used. The kit allows the 
covalent immobilisation of antibodies onto the dynabeads for the co-immunoprecipitation 
of proteins and their associated protein complexes directly on the bead surface. This 
ensures low background binding as the magnetic nature of the beads allows the easy 
separation of proteins and protein complexes from a lysate and also facilitates their 
washing, buffer changes and elution. However, it is important to note that none of the 
antibodies utilised with the kit were stabilised in glycerol as this compound interferes with 
the coupling process.  
Briefly the coupling process first involved the removal of antibody aggregates from 
the antibody stocks by centrifugation at 16,000 g for 10 min at 4oC. Then 5 µg of antibody 
was coupled per mg of beads by incubation with the appropriate amounts of coupling 
buffers ‘1’ (C1) and ‘2’ (C2) for18 h at 37oC on a shaker (170 rpm). The beads were then 
harvested on the DynaMagTM-2 magnet, the supernatant removed and the beads 
resuspended to a concentration of 10 mg/ml in storage buffer (SB).  
Samples were prepared for co-immunoprecipitation as follows, cells (2 x106) were 
treated with the appropriate stimulations at 37oC in a 5% (v/v) CO2 atmosphere at 95% 
humidity. The cells were then harvested, washed in ice cold PBS and lysed using 
‘Extraction buffer A’, which consisted of IP buffer (supplied), NaCl (100 mM), protease 
inhibitors (Thermo Scientific) and phosphatase inhibitors (Thermo Scientific) diluted to 
their appropriate concentrations in dH2O. The volume of extraction buffer added to the 
cells was determined on the basis of the total concentration of the harvested cells in a 9 to 1 
ratio, i.e: 50 µg of cells required 450 µl of extraction buffer. During this time, 1.5 mg of 
antibody coupled Dynabeads were washed in 900 µl extraction buffer and the supernatant 
discarded, before the cell lysate was applied and the mixture incubated on an orbital rotor 
at 4oC for 1 hour. The magnet was then used to separate the immune complexes from the 
depleted supernatant, and the beads washed in extraction buffer by gentle agitation three 
times. The beads were then washed with the provided last wash buffer (LWB) and 
incubated on an orbital rotor at room temperature for 5 min before the antibody-protein 
interaction broken with extraction buffer (EB), by incubating on an orbital rotor for 5 min 
at room temperature. The supernatants, containing the purified protein complex, generated 
after the beads were removed from suspension by the magnet were analysed by SDS-
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PAGE gel electrophoresis and then Western Blotting. A conformation specific HRP 
conjugated secondary antibody was utilised to detect the primary Western blotting 
antibodies to prevent recognition of heavy and light chain. All antibodies utilised in this 
experimental procedure are listed in Table 2.3. 
2.10 Enrichment of Ubiquitinated Proteins 
The UbiQaptureTM –Q kit (Enzo life sciences) facilitates the isolation of both mono- 
and polyubiquitinated proteins (independent of lysine residue chain linkage) from cell 
extracts through the use of a high-binding affinity matrix. Briefly, cells (2 x106) were 
treated with the appropriate stimulations at 37oC in a 5% (v/v) CO2 atmosphere at 95% 
humidity. The cells were then harvested, washed in ice cold PBS and lysed using modified 
RIPA buffer (formula in section 2.8.1) and 40 µg of protein from each sample diluted with 
PBS at 4oC to a final volume of 100 µl, in a clean screw-top tube. A control ubiquitinated-
protein lysate (8 µl) was also diluted with PBS at 4oC, to a final volume of 100 µl. To 
prepare the UbiQapture-Q matrix, 40 µl of matrix suspension was washed in 200 µl of PBS 
and mixed gently by inversion, before pelleting by centrifugation at 5000 g for 10 s at 4oC. 
The buffer was carefully removed using gel-loading pipette tips and the sample/control 
solution (100 µl) was added to the washed UbiQapture-Q matrix, before gentle inversion 
was utilised to thoroughly mix the samples. The ubiquitinated protein conjugates were 
allowed to bind to the matrix for 18 h at 4oC on an orbital rotor. After this incubation the 
samples were centrifuged at 5000g for 30 s at 4oC and the supernatant carefully removed 
and stored at -80oC as the ‘Unbound Fraction’. The matrix was then washed twice with 200 
µl PBS at 4oC and gently mixed by inversion during each wash. The ubiquitinated proteins 
were then eluted using NuPAGE LDS (Lithium Dodecyl Sulfate) loading buffer with 5% 
(v/v) β-mercaptoethanol diluted in LDS in the proportions: 25 µl LDS buffer, 5 µl β-
mercaptoethanol and 70 µl PBS followed by quenching of the reaction by heating to 70oC 
for 10 minutes. These solutions were then pulse centrifuged to collect the protein solutions 
for analysis by SDS-PAGE gel electrophoresis and then Western blotting.  
2.11 SDS-PAGE gel electrophoresis 
The protein concentration of total cellular and nuclear protein lysates was assessed 
by the BCA protein assay (Pierce). Equal protein amounts of samples were resolved using 
the XCell SureLock Mini-cell kit with NuPAGE Novex ‘high performance pre-cast Bis-
Tris gels and NuPAGE buffers and reagents (all supplied by Invitrogen). The appropriate 
  
64 
volume of 4 x NuPAGE LDS  sample buffer and 10 x NuPAGE reducing agent were added 
prior to heating samples to 70oC for 10 min and samples were resolved using NuPAGE 
Bis-Tris gels (10%, 12% and 4-12%) with NuPAGE MOPS or MES running buffer 
(supplemented with NuPAGE antioxidant) at 200 V for 50 min following the 
manufacturers instructions. Proteins were then transferred onto a nitrocellulose membrane 
(Amersham) using NuPAGE transfer buffer with 20% (v/v) methanol at 30 V for 2 h. 
2.12 Western Blotting 
Following transfer, nitrocellulose membranes were washed once in TBS/Tween (0.5 
M NaCl and 20 mM Tris pH 7.5 with 0.1% (v/v) Tween-20) and blocked for 1 h in 
TBS/Tween containing 5% non-fat milk protein. Membranes were then incubated with the 
appropriate primary detection antibody overnight at 4oC. All antibodies were diluted in 
TBS/Tween with 5% BSA. Following incubation with primary antibody, nitrocellulose 
membranes were washed (5 x 5 min) with TBS/Tween and incubated in the appropriate 
HRP-conjugated secondary antibody (diluted up to 1:5000 in wash buffer containing 5% 
non-fat milk protein) for 1 h at room temperature. Nitrocellulose membranes were then 
washed (5 x 5 min) with TBS/Tween and protein bands were visualised using the ECL 
detection system. Nitrocellulose membranes were incubated in a mixture of equal volumes 
of ECL solution A (2.5 mM luminol, 0.4 mM p-coumaric acid and 100 mM Tris pH 8.5) 
and ECL solution B (0.002% hydrogen peroxide and 100 mM Tris pH 8.5) for 1 min 
before exposing membranes to KODAK X-Ray film. The nitrocellulose films were often 
stripped either at room temperature for 1 h in stripping buffer (100 mM 2-mercaptoethanol, 
2% SDS and 62.5 mM Tris pH 7) or for 30 min shaking at 60oC. Nitrocellulose membranes 
were washed thoroughly in TBS/Tween and checked for residual signal before re-starting 
the Western Blotting protocol. All antibodies and the dilutions utilised in this experimental 
procedure are listed in Table 2.3. 
2.13 Preparation of RNA extracts 
Following in vitro culture, cells were washed twice with cold sterile PBS (Gibco, 
Paisley, UK.) and transferred to microcentrifuge tubes. RNA was extracted using the 
RNeasy micro kit (Qiaqen) according to the manufacturer’s instructions. Briefly, cells 
were lysed and homogenised in a high-salt buffer, which also acts to denature native 
RNases before being applied to a column supporting a silica based membrane which binds 
high levels of RNA. Ethanol is utilised to promote the selective binding of RNA to the 
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column and contaminants are efficiently washed away using additional supplied buffers. 
The purified RNA is then eluted using RNase free water. DNase (Invitrogen) digestion was 
then performed to remove possible genomic DNA contamination by mixing 0.5-2 µg of 
RNA with the appropriate concentration of DNase I reaction buffer and DNase I 
(amplification grade). This solution was then incubated for 15 min at room temperature 
before enzyme inactivation by the addition of 25 mM EDTA solution and heating the 
reaction mixture for 10 min at 65oC. The samples were then stored at -80oC, ready for 
amplification prior to quantitative RT-PCR. 
2.14 Real-time PCR by TaqMan® 
To transcribe the mRNA samples into cDNA the “High Capacity cDNA Reverse 
Transcription Kit” (Applied Biosystems) was used as per the manufacturer’s instructions. 
Briefly the DNase digested mRNA (0.5-2 µg) was incubated with random primers, 4mM 
dNTPs and 50 units MultiScribeTM Reverse Transcriptase diluted in nuclease free water. 
The samples were transferred to an Eppendorf Mastercycler gradient PCR machine which 
heated the samples for 10 min at 25oC followed by 120 min at 37oC before a final step for 
5 min at 85oC. The cDNA samples were stored at -20oC before Taqman quantitative PCR 
was performed. 
TaqMan real-time RT-PCR was performed according to the manufacturer’s 
instructions (Applied Biosystems, Foster City, CA) in a 7900 HT Sequence Detector 
(Applied Biosystems). Triplicate PCR amplifications were performed for each sample in a 
total volume of 10 µl per well containing 1 µl cDNA sample and 9 µl PCR amplification 
buffer. The amplification buffer consisted of: 900 nM of each of forward and reverse 
primers, 250 nM 6-FAM™ dye-labelled, TaqMan® MGB probe and 1 x Taqman® Fast 
Universal PCR master mix (Applied Biosystems). The probe, forward and reverse primers 
for each gene investigated were pre-mixed when supplied by Applied Biosystems and 
diluted 1 in 20 with the Universal PCR master mix and nuclease free H2O to make the 
amplification buffer. The endogenous controls utilised throughout the analysis are, 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and hypoxanthine 
phosphoribosyltransferase (HPRT), both of which are pre-designed Applied Biosystems 
primer/probe kit (GAPDH; Cat # -4352339E, HPRT; Cat # - 4331182). The thermal cycler 
conditions were as follows: 20 seconds at 95oC, followed by 45 two-temperature cycles (3 
seconds at 95oC and 30 seconds at 60oC) with a final step of 60oC for 30 seconds. 
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Data analysis was completed using RQ Manager Software (Applied Biosystems), 
which calculates the threshold cycle, Ct, which represents the PCR cycle when an increase 
in fluorescence above a set threshold can be detected. Samples were normalised by their 
reference reporter GAPDH, by subtracting the Ct value of GAPDH from the Ct value of 
the gene of interest; creating the ∆Ct. To obtain a value for a fold increase relative to 
GAPDH the formula 2-∆Ct was utilised. Multiplication of this value by 100 gives the 
expression of the gene of interest as a percentage of GAPDH. The positive error is the 
standard deviation of the difference, s=√(s12+s22), where s1 and s2 are the standard 
deviations of the Cts of GAPDH and the gene of interest. Details of the primer/probes 
mixes purchased from Applied Biosystems are given in Table 2.2 B. The probes for each 
gene assay consisted of a reporter dye 5’-6-carboxyfluorescein (FAM) and a non-
fluorescent quencher coupled to a minor groove binding (MGB) moiety that stabilises the 
hybridised probe improving allelic discrimination.  
2.15 Immunofluorescence staining 
For all immunofluorescence studies, bmDC were treated and analysed in lab-tek 
permanox (plastic) chamber slides (Nunc, Naperville, IL). The following staining protocol 
was carried out at room temperature, in a darkened chamber and each washing step 
included 3 x 1 min incubations with PBS, unless otherwise stated. Media was removed 
from the cells, which were quickly washed three times in PBS at 37oC before their fixation 
with 4% paraformaldehyde (PFA) for 10 min and permeabilisation with 0.1% triton-x in 
PBS for 15 min. After washing, the cells were incubated with 0.3 M glycine in PBS to 
reduce cellular autofluorescence. Blocking of non-specific binding was performed with 1% 
BSA and 10 % normal goat serum (Invitrogen), or the appropriate species for the 
secondary antibody, for 30 min. The cells were then incubated with primary antibody 
(appropriate dilutions are listed in Table 2.4A), for either 1 h at room temperature or 4oC 
overnight; the specificity of binding was validated by staining with the same primary 
antibody conjugated to its relevant epitope blocking peptide (appropriate dilutions are 
listed in Table 2.4B). After washing, the cells were incubated for 1 h with an appropriate 
fluorophore labelled anti-Ig antibody (appropriate dilutions are listed in Table 2.4 A). 
Finally, the cells were washed and stained with 4',6-diamidino-2-phenylindole (DAPI) at 
300 nM in PBS for 5 min. Following a final wash, the cells were mounted in Pro-long 
Gold anti-fade mounting medium (Invitrogen). Images were acquired and analysed on a 
Zeiss LSM510 confocal microscope with scale bars determined by “LSM Image Browser” 
software (Zeiss). 
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2.16 Densitometry and statistical analysis 
Data presented are representative of the stated number of independent experiments 
involving the indicated statistical analysis using Graphpad software. Densitometry was 
performed using the program ImageJ (NIH).  
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Figure 2.1 | FACS analysis of the effect of lactacystin on the viability of dendritic cells. 
To establish whether the proteosomal degradation inhibitor, lactacystin affected the 
viability of DCs during lengthy treatments, Bm cells matured with GM-CSF for 6 days 
were treated with either 1 µM or 10 µM lactacystin for the indicated times over an 18 h 
period before being analysed by flow cytometry. The dead/nonviable cell control consisted 
of cells heated to 60oC for 15 min. In panels A-B, dot plots of forward scatter (FSC-H) 
versus side scatter (SSC-H) are presented alongside histograms of 7-AAD staning (to 
identify live cells) of viable (live; panel A) and nonviable (dead; panel B) cell controls. 
The dot plots allowed cells of the correct size and granularity associated with DCs to be 
gated where the exclusion (the gating for which was defined from the nonviable cell 
control) of the fluorescent compound 7-AAD marked them as being healthy/viable cells. In 
panels C-E, the gating of viable cells on the basis of 7-AAD staining is presented for cells 
treated with medium or lactacystin (1 µM or 10 µM) for 1 hour before stimulation with 
medium (panel C) or LPS (panel D; 1 µg/ml) for the indicated times (hours). The 
percentage of deceased cells, as defined and gated from the control established in (panel B) 
was plotted for the differentially treated and stimulated cells (panel E).  
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Figure 2.2 | FACS analysis of proliferation of transgenic (Tg) OVA-specific TCR 
CD4+ T cells from D0-11-10 BALB/c mice  
To validate CFSE dilution as a method for the detection of proliferation form BALB/c Ag-
specific transgenic TCR (KJ1.26+) T cells, lymph nodes were harvested from these mice 
and CD4+CD62L+ cells purified by MACS microbead magnetic separation and stained 
with CFSE. These were then cultured (2.5 x 105 cells) with LPS-matured bmDCs (2.5 x 
104 cells), for 3 days. The proliferative analysis of T cells in response to either no (panels 
A, C, E & G) or 100 nM (panels B, D, F & H) OVA323-339 peptide are shown. Dot plots of 
forward scatter versus side scatter allowed gating of a healthy population of lymphocytes 
on the basis of their size and granularity (panels A & B).  
Dot plots displaying lymphocytes double stained with anti-CD4-PerCP and a rat IgG 
isotype control for the anti-clonotypic KJ1.26-biotin-streptavidin-APC (panel C) and anti-
KJ1.26-biotin-streptavidin-APC and a rat IgG isotype control for anti-CD4 PerCP (panel 
D) show the gates set to allow identification of CD4+KJ1.26+ T lymphocytes (panels E & 
F). Analysis of the gated CD4+KJ1.26+ T cells responding to no (panel E) and 100 nM 
(panel F) OVA323-339 peptide in terms of CFSE fluorescence allows the proliferation of the 
Ag specific T cells to be clearly identified and assessed by flow cytometry (panels G & H) 
using FLowJo software, with generation 0 (the gate set at the highest fluorescence of CFSE 
[on the far right of each histogram]) representing undivided cells. 
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Table 2.1 | Antibodies utilised in FACS studies 
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Figure 2.3 | FACS analysis of costimulatory molecule and surface/intracellular TLR4 
expression 
In panels A to C, bone marrow cells were differentiated in the presence of GM-CSF for 6 
days, stained with 7-AAD (to identify live cells) and antibodies against the murine DC 
marker, CD11c and the markers of interest, before being analysed by flow cytometry. The 
dot plots of forward scatter (size) versus side scatter (granularity) allowed the gating of a 
population of cells of the correct size and granularity associated with DCs (panel A). Then 
the viable (live) cells were gated on their ability to exclude 7-AAD as healthy cells don’t 
acquire and accumulate this fluorochrome (panel B). The live cells were subsequently 
gated on CD11c expression, an integrin highly expressed on DCs, and approximately 70-
85 % of the resulting populations were observed to be CD11c+ relative to the appropriate 
isotype control (panel B). Finally the expression of the Ag or marker of interest, which in 
this case was stained with an APC conjugated antibody, on CD11c+ cells is then defined by 
plotting a histogram and analysing its fluorescence relative to an appropriate isotype (panel 
C). 
In panels D to E, bone marrow cells were differentiated in the presence of GM-CSF for 6 
days, stained with antibodies against CD11c (unless stated otherwise) and any other 
markers of interest, before being fixed, permeabilised and stained for both the intracellular 
and surface associated fractions of a protein of interest, which was then analysed by flow 
cytometry. The dot plots of forward scatter (size) versus side scatter (granularity) allowed 
the gating of a population of cells of the correct size and granularity associated with fixed 
and permeabilised DCs (panel D). These cells were subsequently gated on CD11c 
expression, an integrin highly expressed on DCs, and approximately 70-85 % of the 
resulting populations were observed to be CD11c+ relative to the appropriate isotype 
control (panel E). Finally the expression of the Ag or marker of interest, which in this case 
was stained with an APC conjugated antibody, on CD11c+ cells is then defined by plotting 
a histogram and analysing its fluorescence relative to an appropriate isotype (panel F). 
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Tables 2.2 | ELISA kits and real-time PCR TaqMan® primers and probes utilised 
(A) ELISA kits used for cytokine quantification 
(B) Applied biosystems real-time PCR TaqMan® primers and probes 
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Table 2.3 | Antibodies utilised in co-immunoprecipitation and Western blotting 
studies 
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Table 2.4 | Antibodies utilised in immunofluorescence studies 
(A) List of antibodies used for immunofluorescence staining 
(B) List of the immunogenic peptides for the immunofluorescence staining antibodies 
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3 The effect of ES-62 on the maturation of 
dendritic cells 
3.1 Introduction 
3.1.1 ES-62 and TLR4; old friends 
ES-62 is known to directly interact and exert its immuno-modulatory effects on a 
variety of immune cells including B-lymphocytes311,320, macrophages, DCs291,301,319 and 
mast cells321. Specific examples of the effects of ES-62 on cells of the immune system are: 
the inhibition of BCR-mediated B lymphocyte proliferation311,320,340, the induction of IL-10 
production by B1 cells343, reduced levels of pro-inflammatory cytokine secretion by DC 
and macrophages in response to a range of TLR ligands (BLP, LPS, CpG)301 and the 
desensitisation of FcεRI-mediated degranulation and pro-inflammatory mediator release by 
mast cells321. ES-62 has been shown to act via the PRR, TLR4, to selectively modulate the 
activity of a number of signal transduction molecules including MAPKs, PI3Ks, the 
PLD/SPHK/Ca2+ cascade and NF-κB. Thus, rather than acting in a non-specific 
immunosuppressive manner, ES-62 specifically targets the initiation of a pro-inflammatory 
immune response to, for example, prevent the induction of TH1 responses323. However ES-
62 also has the ability to block TH2 responses in situations where they are associated with 
aberrant inflammation321. The latter finding has led to a broadening interest in the effects 
of ES-62 on cytokines such as IL-17. This is due to the current understanding that IL-17 
can act as a master regulator of both TH1 and TH2-type inflammation, in the context of both 
pathogen removal and inflammatory disorders362. 
TLR4 is key for the activity of ES-62. As the most widely studied TLR, it is a 
critical member of the receptor complex responsible for the recognition and response to 
gram-negative bacterial LPS. It also mediates the responses to a range of stimuli including 
host derived heat shock proteins (HSPs), extracellular matrix components (the 
oligosaccharides, hyaluronan, soluble heparin sulphate and fibrinogen) and taxol (a product 
of the pacific yew, Taxus brevifolia, which exhibits potent antitumor activity in humans)3. 
This important role for TLR4 in mediating the effects of ES-62 was identified from studies 
on genetically modified mice where macrophages and DCs from TLR4-KO (but not TLR2 
or TLR6 KO) mice were found to be refractory to the immunomodulatory effects of ES-
62301. Moreover, in macrophages TLR4 has recently been shown to be crucial for the 
internalisation of ES-62326. Interestingly, presumably through a TLR4 mediated 
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mechanism, ES-62 appears to utilise MyD88 for the transduction of intracellular signals in 
macrophages and bmDC as suggested by the use of cells from MyD88-knockout mice326. 
However this interaction with TLR4 is quite unique as macrophages and bmDC from the 
TLR4-mutant C3H/HeJ mice are unable to transduce LPS signals due to a point mutation 
in the intracellular TIR domain but can still respond normally to ES-62301. 
3.1.2 ES-62 and dendritic cells, the role of TLR4 and potential co-
receptor involvement. 
As stated above the anti-inflammatory effects of ES-62 reflect the subversion of 
TLR4 signalling in DCs and macrophages160,291,301,363. Interestingly, evidence of the 
binding partners of ES-62 from pull-down, Far Western and surface plasmon resonance 
(BiaCoreTM) kinetic studies indicates differential, PC-dependent receptor-binding of ES-62 
to monocyte, B- and T-lymphocyte membranes326. Moreover, it has been shown that many 
of the anti-inflammatory effects of ES-62 are dependent on its PC-moiety325. Through this 
work both synthetic and natural PC based compounds have shown great potential in 
mimicking the immunomodulatory activities of ES-62 and other helminth ES 
products311,312. The structure of PC from which these compounds is based is presented in 
Figure 1A. It has also been found that the function of plasmacytoid DCs, which do not 
express TLR4 (at least in resting cells), can be modulated by ES-62 (C. Steiger & M. M. 
Harnett, unpublished data). Collectively, these findings may imply that ES-62 achieves its 
effects by signalling via TLR4 in concert with other receptors or a co-receptor, suggesting 
an additional target for its interference of TLR-induced inflammatory responses via an 
alternative signalling pathway. Consistent with this, preliminary analysis of the 
intracellular signalling pathways (p38 MAPK, PI3K-Akt and NF-κB) triggered by LPS and 
ES-62 in macrophages and DCs identified differential signalling, potentially indicating 
differences in the receptor-coupling mechanisms utilised291,301,326. 
3.1.2.1 Molecular mimicry; ES-62 and platelet activating factor (PAF) 
As stated above, ES-62 appears to modulate DC maturation by subverting 
signalling via the LPS receptor, TLR4301. However, unlike LPS, it does not necessarily 
require TLR4 to be fully functional to mediate its’ subversive effects301. Intriguingly, it has 
emerged that the PC-moiety of the inflammatory glycerophospholipid, platelet activating 
factor (PAF)295,364, is important for binding to the PAF receptor (PAFR), a G-protein 
coupled receptor (GPCR) expressed on many cells of the immune system. This led to the 
hypothesis that the large number of PC-moieties present on the surface of ES-62 could 
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facilitate its interaction with the PAFR followed by its modulation and internalisation into 
the cell. This is the case with a number of pathogen species which employ the ability of PC 
to bind the PAFR for receptor recruitment, entry into the cell and as a mechanism to evade 
the immune system. For example, Salmonella pneumoniae utilises the PC expressed on its 
surface to bind to the PAFR on host cells and become rapidly internalised365,366. In the 
context of immune cell function, PAF binding induces the modulation of certain B cell 
activation responses in a similar fashion to the suppression of B cell responses induced by 
ES-62367.  
Preliminary studies using native ES-62 and PC-free rES-62 on rat brain capillary 
endothelial cells (RBCEC) and primary neurons from wild type and PAFR knockout mice 
(PAFR KO) suggested that ES-62 can also bind to the PAF receptor in a PC-dependent 
manner (E. Tuomamen and W. Harnett, unpublished results). These findings could suggest 
that ES-62 may achieve its effects by signalling via TLR4 in concert with a co-receptor, 
such as the PAFR. This is an attractive hypothesis as the PAFR can be recruited as a 
secondary effector of LPS/TLR4 signalling322 leading to the exacerbated release of several 
pro-inflammatory cytokines (TNF-α, IL-6, IL-1) and other mediators including PAF368,369. 
Moreover, Nakamura and colleagues showed that bacterial LPS can also directly activate 
the PAFR, enhancing the effect of PAF and the local production of TNF-α, resulting in the 
increased ability of leukocytes and other immune system cells to deal with invading 
pathogens295,364,369-372. In any case, there is some degree of crosstalk between LPS/TLR4 
and PAF/PAFR mediated signalling as LPS primed mice showed enhanced sensitivity 
towards PAF resulting in increased mortality associated with the accumulation of PAF 
receptor mRNA in peritoneal macrophages370. The mechanisms behind this priming effect 
are gradually being elucidated by in vitro studies, with the PAF induced phosphorylation of 
p38 being greatly potentiated in neutrophils pre-treated with LPS364. The subversion of 
PAF, its receptor and/or its intracellular signalling pathways could therefore allow ES-62 
to engineer a favourable phenotype in those immune system cells, which do not express 
TLR4, such as plasmacytoid DCs. 
3.1.2.2 The biology of PAF and its G-protein couple receptor, PAFR 
PAF (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) (Fig. 1 B) is a potent 
proinflammatory mediator, the production of which is dysregulated in pathological 
situations where it can acts as a primary and secondary messenger373. For example, it 
appears to play a key role in the pathogenesis of bronchial asthma and anaphylactic 
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shock374. PAF mediates its effects through homotypic and heterotypic cell-to-cell 
communication, resulting in the activation of platelets, neutrophils, macrophages, 
lymphocytes and endothelial cells295,375-377. All of these cells can produce PAF, further 
promoting the migration of granulocytes to sites of inflammation and mediating the 
adhesion of neutrophils to endothelial cells377. In addition, PAF is mitotic for fibroblasts 
and regulates lymphocyte function378. PAF is produced both de novo and through 
remodelling pathways, the latter being regulated by extracellular signals379, with the half-
life of PAF being relatively short due to rapid degradation by PAF acetylhydrolases380. A 
model of Candida albicans infection reinforced the importance of the PAFR in 
determining the early cytokine environment, especially IFN-γ and TNF-α, in pathogen 
removal381. 
The PAFR gene is encoded on human chromosome 1 and generates two distinct 
mRNA species (transcripts 1 & 2) although only a single 39kDa protein is produced382, 
with NF-κB and SP-1 upregulating the expression of transcript 1 in immune system 
cells382,383. As stated above, following the interaction of the PAFR with its ligand, it 
modulates certain B cell activation responses in a similar fashion to the suppression of B 
cell responses induced by ES-62367. Signalling through the PAFR has also been implicated 
in mediating the production of IL-8, phagocytosis and CD11/CD18 expression by 
neutrophils. Moreover, the activation of neutrophils in response to Zymosan particles, a 
Saccharomyces cerevisiae PAMP, appears to require an initial burst of PAF secretion26. 
The PAFR becomes rapidly desensitised upon stimulation with PAF due to 
phosphorylation-dependent internalisation and consequent ubiquitin-dependent, 
proteosomal- and lysosomal-mediated degradation. Thus, intracellular PAFR is localised to 
the endosomes, due to ligand-driven receptor internalisation, where recruitment of cell 
trafficking and intracellular signalling proteins can occur384. Interestingly functional PAFR 
has also been identified as being expressed on the nuclear envelope of isolated piglet brain 
microvascular endothelial cells in vitro and in situ385. Thus, the ability of extracellular PAF 
to activate pro-inflammatory responses including its own intracellular generation, suggests 
locally produced PAF could be generated in the vicinity of its cognate nuclear receptors to 
modulate gene transcription385.  
3.1.2.3 Pathogen and parasite utilisation of the PAFR 
The PC component common to PAF and ES-62 is also utilised by a number of 
different pathogens for receptor recruitment and/or entry into host cells. For example, the 
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PAFR is also rapidly internalised following binding366 of S. pneumoniae which expresses 
PC on its surface365. Within this context it is becoming increasingly apparent that parasites 
have evolved to exploit this receptor as a means to evade the immune system. For example, 
the PAFR has been implicated as playing an important role in the protective immune 
response of the murine host against infection with the intracellular protozoan parasite 
Trypanosoma cruzi. Thus a number of studies have shown that mice pre-treated with a 
PAFR antagonist and followed by T. cruzi infection have increased blood parasitaemia and 
enhanced infection-associated lethality386. A similar protective role for PAF during 
infection with the closely related parasite Leishmania amazonensis has also been shown by 
utilising PAFR agonists and antagonists in vitro and in vivo387. Thus, the administration of 
the agonist carbamyl PAF (C-PAF) to C57BL/6 derived macrophages significantly 
inhibited parasite infectivity and growth in these cells in vitro. By contrast, the antagonist 
WEB2086 increased the infectivity of the parasite in macrophages in vitro while it 
dramatically increased lesion sizes and parasite loads in regional lymph nodes and spleen 
in vivo. Moreover, the infection of PAFR-/- mice with L. amazonensis showed dramatic 
alterations in cytokine production with a shifting away from a protective TH1 response381. 
Interestingly, entry of the Leishmania parasite into the DC, whilst maintaining an 
“immature” DC phenotype and promoting anti-inflammatory responses, still allows the DC 
to respond to other exogenous stimuli388. The amastigote form of the parasite is thought to 
avoid inducing maturation of DCs, not through deactivating host processes but rather via 
selective interaction with particular surface receptors, as antibody-opsonised amastigotes 
do not result in DC maturation389.  
The roles for PAF and its receptor during filarial/gastrointestinal nematode 
infection have been poorly documented. However, Nippostrongylus brasiliensis-infected 
rats have been shown to have elevated systemic levels of PAF during the process of worm 
elimination390, a stage at which the parasites secrete an acetylhydrolase that functionally 
inhibits PAF activity391,392. In addition, Negrao-Correa et al. (2004) have performed 
preliminary studies on the role of PAFR in mobilising the immune system in response to 
the parasitic nematode, Strongyloides venezuelensis, which infects the gastrointestinal tract 
using PAFR-/- mice393. These authors found that during the course of infection such PAFR-
/- mice showed relatively decreased intestinal inflammation against the worms resulting in 
their increased survival but decreased fecundity. This was associated with reduced levels 
of TH2 cytokines, as well as IL-10 and TNF-α and also suppression of goblet cell 
hyperplasia in these mice.  
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Collectively these studies suggest that the involvement of PAF and the PAFR in the 
mobilisation of immune responses, particularly those of the innate immune system, has 
driven the evolution of pathogens towards strategies that target them for subversion of the 
immune response. This has led to the idea that ES-62 could utilise its PC moieties to 
interact with the PAFR and/or elicit its immunomodulatory effect and gain access into host 
cells or alternatively, it may desensitise cells to subsequent activation by LPS/PAF 
signalling via the PAFR283,308. These are particularly interesting when taking into 
consideration the above stated preliminary results suggesting that ES-62 can bind to the 
PAFR in a PC-dependent manner (E. Tuomamen & W. Harnett, unpublished results). 
3.1.2.4 PAFR-mediated signal transduction pathways and the effect of 
agonists and antagonists 
The PAFR is known to be expressed at the plasma membrane of many immune 
system cells including human neutrophils, P338D1 murine macrophages, human peripheral 
mononuclear leukocytes, rat brain and liver Kupffer cells364,394. Where studies utilising a 
range of PAFR agonists and antagonists have clarified its role in the activation of MAPKs, 
PI3Ks, PLA2, PKC and Src pathways on such cells322,364 and have shown that PAF/PAF 
receptor signalling plays important roles in a number of pro-inflammatory responses, 
including LPS induced shock395. Due to the importance of PAF in mediating inflammatory 
responses a wide range of specific PAFR agonists and antagonists are available for its 
study. For example, C-PAF (Fig. 1C), which is an analogue of PAF that exhibits stereo-
specific binding to the PAFR, has been demonstrated to induce the expression of the 
proinflammatory signal transducers, iNOS and COX-2 while increasing ERK1/2 MAPK 
phosphorylation and activation of NF-κB in various cells of a model of septic shock57. In 
respect to antagonists, the classical compound utilised is WEB2086 (Fig. 1D), derived 
from the hetrazepine family of compounds; it is a potent and highly specific antagonist. Its 
binding site on the PAFR has been shown, using human platelets, to be identical to that of 
PAF364,394,396. However, characterisation of this antagonist has revealed that whilst the 
mechanism of action of PAF can be partially explained through its interaction with 
receptors on the target cell surface, many of its’ effects reflect the blocking of the 
internalisation of PAF and its subsequent activation of intracellular PAFRs397. The potency 
of this compound has been shown in human breast cancer cells where it was able to inhibit 
their growth398 and in various models of inflammation399. More recently WEB2086 has 
been suggested to act, as an inverse agonist, as the compound has a higher affinity for the 
inactive rather than the active state of the PAFR. This would result in the reduction of 
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basal activation of effector mechanisms and subsequent receptor internalisation and 
transport within the cell400.  
By contrast, another potent and commonly utilised PAFR antagonist CV3988 (Fig. 
1E) (rac-3-(N-n-octadecylcarbamoyloxy)-2-methoxypropyl 2-thiazolioethyl phosphate) 
acts as a competitive antagonist, due to its structural similarity to PAF. It has been shown 
to effectively inhibit PAF-induced platelet aggregation and hypotension by preventing the 
specific binding of [3H]PAF to its receptor on platelets401. Studies have also shown that it 
is able to protect mice from gram-positive septic shock induced by LTA397,401. Interestingly 
computational models of the putative PAFR, suggest that both of the antagonists share 
common spatial features as well as lipophilic and hydrophilic regions with which they 
interact within the constraints of the hypothetical receptor. 
3.1.3 TH17 cells; could ES-62 target this inflammatory population? 
Within recent years there has been a major focus on the role of the cytokine IL-17 
in driving inflammation in response to a number of pathogenic stimuli. The most well 
characterised source of IL-17 within the body is the TH17 cell. The differentiation of this 
CD4+ T cell population is regulated by the transcription factors, STAT3 and ROR-γt as 
well as the cytokines TGF-β, IL-1, IL-6 and IL-23, which stabilise and expand the cell 
population161. This TH subset functions mostly at mucosal surfaces, triggering pro-
inflammatory danger signals that enhance neutrophil mobilisation and expression of 
antimicrobial factors. However TH17 cells are also associated with driving the 
inflammatory pathology in various autoimmune conditions161. The current understanding 
of the differentiation of TH17 cells from naïve precursors is that it is a three-step process, 
as summarised in Figure 3.2.) The initiation of development of these cells begins with the 
antigenic stimulation of naïve precursors in the presence of TGF-β1 and IL-6; 2) Autocrine 
secretion of IL-21 then reinforces their differentiation; 3) IL-23 maintains the TH17 
population and increases its pathogenicity402. A number of polymorphisms in the receptor 
for IL-23 are now known to be associated with a wide range of autoimmune diseases, 
leading to the concept of an IL-23-IL-17 inflammatory axis402. However, a lack of IL-23 
attenuates host protection against Citrobacter rodentium infection despite the presence of 
normal TH17 populations124, indicating IL-23 can operate in a pro-inflammatory manner 
independently of IL-17.  
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There are many forms of IL-17 secreted by immune cells (IL-17A-F), but the IL-
17A homodimer is by far the best characterised member of the IL-17 family161. IL-17A is 
often associated with driving autoimmunity, due to its potent strength of signalling relative 
to the other family members403. The pro-inflammatory programme of gene expression 
induced by IL-17A signalling through its receptor (IL-17RA) is mediated by TRAF6 and 
NF-κB, making it reminiscent of the innate immunity receptors such as TLR4161. In this 
respect, IL-17A is known to activate components of the canonical NF-κB pathway, p50 
and p65404, and TRAF6-/- mice are defective in IL-17A mediated activation of NF-κB405. 
This suggests that TH17 cells promote signals that are typical of early inflammatory events 
and this helps to bridge innate and adaptive immunity. 
Although the functions of IL-17B-F remain poorly defined (apart from IL-17E), 
they are known to stimulate the transcription of an array of pro-inflammatory genes similar 
to that of IL-17A406-408. This is also coupled with recent studies indicating that they can act 
to regulate the function of the TH17 cells themselves409, where there is an intriguing level 
of cross-talk within this cytokine family to promote inflammation, as ectopic expression of 
IL-17C in conjunction with production of IL-17B by CD4+ T cells exacerbates CIA408.  
Thus, the potential role of IL-17 as a master regulator of TH1 and TH2-type 
responses362, and indeed many proinflammatory actions within the body, indicate it is 
potentially a key target of the anti-inflammatory action of ES-62. Through its known 
modulation of both TH1 and TH2 cell driven inflammation, as well as the inherent plasticity 
of T cell subsets410, it is believed that ES-62 may target the maturation of DCs to inhibit 
their induction of a TH17 subset in response to inflammatory signals. Indeed, a recent 
publication by this laboratory group has highlighted the importance of this limitation of IL-
17 responses by ES-62 through its attenuation of the development and severity of a mouse 
model of collagen induced arthritis (CIA)352. TH17 cells are also associated with the 
production of the cytokine IL-22, an important mediator of immune functions that has been 
shown to act as both a pro- and anti-inflammatory molecule155,402, where DCs have also 
been shown to provide a T cell independent source of IL-22411. It has been implicated in 
the development of inflammatory disorders, as for example, blocking IL-22 production 
prevents the development of IL-23 driven psoriasis412,413. However, there is also evidence 
that IL-22 can protect in several inflammatory disorders414,415 and upregulate the secretion 
of anti-microbial peptides from non-hemopoietic cells to enhance mucosal immunity to 
extracellular bacterial infections in the gut402. 
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3.1.4 Sphingosine kinases (SPHK) and their potential as targets 
for ES-62 mediated responses  
The sphingosine kinases (SPHKs) comprise two isoforms, SPHK1 and SPHK2, 
which catalyze the phosphorylation of sphingosine to generate sphingosine-1-phosphate 
(S1P). Sphingosine is a membrane lipid that can be rapidly metabolised following the 
stimulation of various plasma membrane receptors. For example sphingomyelin (a key 
molecule in the synthesis of several important bioactive lipids416) can be converted by 
sphingomyelinase to ceramide and subsequently, by ceramidase to sphingosine and 
ultimately to S1P by SPHK (Fig. 3.3). The resting levels of S1P in most cells is extremely 
low as its synthesis and degradation is tightly regulated by the enzymes in the sphingolipid 
metabolic pathway417. Studies indicate that both SPHK1 and SPHK2 are involved in the 
homeostasis of S1P levels but loss of either of these isoforms does not ablate the blood to 
tissue S1P gradient, indicating a level of redundancy between these enzymes418,419. Having 
both cell-intrinsic and cell-extrinsic functions in immunity, S1P is the ligand of a family of 
five G-protein-coupled receptors (GPCRs), labelled S1PR1-5420. The expression of S1PR1 
is common to most immune system cells but S1PR2-5 have a more limited distribution, for 
example, T cells express S1PR1 and -4 while macrophages express S1PR1 and -2417. The 
main function of these receptors appears to be associated with regulation of cell migration, 
where a low concentration of S1P promotes chemotaxis421. In the case of DCs this 
chemotactic response also appears to be associated with its cellular differentiation and 
activation, as immature DCs express only S1PR1, which switches to S1PR3 upon 
maturation accentuating its chemotactic responses to S1P417. 
Many studies of the biology of the SPHKs have focused on their roles in 
inflammation and in respect to DCs showing that both isoforms are important in 
modulating cellular responses to LPS and other PAMPs416. In this context, the recognition 
of Gram-negative bacterial lipopeptides and LPS by TLR2 and TLR4 respectively, 
stimulate the up-regulation of SPHK1422. Many of these findings have come from the study 
of Sepsis, an overwhelming systemic inflammatory response resulting from bacterial 
infections, where mouse models revealed NF-κB to be a major downstream target of 
SPHK responses423,424. The administration of SPHK1 inhibitors to mice suppress LPS-
induced production of inflammatory cytokines, the nuclear translocation of the p65 subunit 
into the nucleus and the degradation of IRAK-1; of which the latter two elements are both 
associated with NF-κB activation425. The activation of TLR2 and TLR4 also enhances the 
cytoplasmic production of S1P in phagocytes but not its release, suggesting that it is the 
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intracellular functions of this molecule that are important in TLR signalling425. In this 
context, PKCδ is understood to be involved in the activation and phosphorylation of 
SPHK1, leading to its translocation to the membrane, where it can metabolise S1P426. This 
combined with its emerging roles in TLR signalling104,105, suggests direct links in the 
involvement of the SPHKs in NF-κB activation as summarised in Figure 3.4. However, 
splenocytes from SPHK1 deficient mice have been found to exhibit enhanced LPS induced 
IL-12 but not IL-6 and IL-10 secretion that can be compensated for by S1PR1 agonists427. 
This suggests additional cell extrinsic roles of S1P during inflammation425. Thus, the 
exposure of human monocyte derived DC to S1P during maturation with LPS impairs their 
ability to initiate TH1 cell responses and promotes TH2 responses of naïve CD4+ T cells by 
suppressing IL-12p70 and promoting IL-4 and IL-10 production through an unknown 
mechanism428,429.  
Collectively, many of the reported studies suggest that S1P appears to mature DCs 
to a phenotype that favours skewing T cell lineage development towards a TH2 phenotype 
while dampening TH1 responses425, which is accompanied by an increase in endocytosis of 
mature DCs through the engagement of SIPR3430. These observations reflect similar effects 
of ES-62 on DCs160,291,301, suggesting the SPHKs and subsequently S1P may be targets of 
its modulation of DC maturation and cytokine responses in response to positive TLR 
signalling. In support of this, recent studies have shown that key molecules, such as PKCα 
and PLD, involved in the activation of SPHKs are targets for the anti-inflammatory effects 
of ES-62 in mast cells and T cells321. Interestingly, it has recently been reported that S1P, 
predominantly through S1PR1, can substitute for IL-23 in vitro to increase the activity and 
number of IL-17 secreting CD4+ T cells grown in the presence of IL-1β, IL-6 and TGF-
β1431,432. This S1P-promoted differentiation of TH17 cells occurs in parallel with the 
suppression of TH1 and TH2 associated cytokines, and similarly to what is observed with 
IL-23, can be overcome by the actions of IL-27 and the TH1 and TH2 cytokines, IFN-γ or 
IL-4 respectively. With the recently realised potential of ES-62 in limiting TH17 associated 
responses352, this immunomodulator may attenuate S1P production (through the SPHKs) 
due to its aforementioned roles in the development and expansion of this inflammatory 
subset.  
  
85 
3.1.5 The localisation and trafficking of TLR4 and its modulation 
by ES-62 
TLRs can be classified not only by the molecules they recognise, but also by their 
subcellular localisation, either stably or dynamically. In this case they can be roughly split 
into two groups: TLR1, -2, -4 , -5 and -6 are generally found on the cell surface10, and 
recognise pathogenic surface components such as LPS, while TLR3, -7, -8 and -9 are 
detected intracellularly, localised within endosomal compartments, where they can 
recognise nucleic acids derived from the genome of viruses and bacteria347. Thus, the 
localisation and trafficking of the particular TLRs is central to the sensing of their ligands, 
although the precise nature of the compartments where intracellular TLRs meet 
internalised ligand remains poorly defined. However, it is also clear that TLRs that are 
normally present at the cell surface can enter into the endocytic pathway following their 
activation and these receptors are also rapidly recruited to phagosomes or endosomes 
containing microbial cargo329,433. Over recent years it has become apparent that these 
trafficking pathways play an important role in regulating the activation of APCs, 
particularly in response to different stimuli and impact on the outcomes of their signalling 
pathways347. 
The responsiveness of TLR4 to LPS is regulated through two mechanisms: the 
levels present on the plasma membrane and its localisation within the cell. The movement 
between these cellular environments acts to prevent prolonged and excessive activation. 
Studies have shown that the TLR4-MD2-CD14 complex cycles between the plasma 
membrane and the golgi until it is engaged by LPS434,435, where it rapidly accumulates in 
lipid rafts (cholesterol-enriched membrane microdomains) upon which both TIRAP and 
MyD88 are recruited436. Neither of these adaptor proteins co-localise with TLR4 in resting 
cells, with MyD88 found in condensed particles throughout the cytosol, with no clear 
association to cellular organelles such as golgi, ER, endosomes or lysosomes437,438, which 
provides a barrier to the unregulated activation of the pathway. By contrast, in resting cells 
TIRAP utilises its PIP2 binding domain to localise to PIP2-rich regions such as lipid rafts, 
to which both TLR4 and MyD88 migrate upon LPS stimulation48,438. The presence of 
TIRAP within these domains is crucial as it serves to recruit its signalling adaptor partner, 
MyD88 from its cytoplasmic pool to participate in the transduction of TLR4 signals at the 
plasma membrane438. The aggregation of the activated receptor complex briefly recruits 
several IRAKs and TRAF6, which then dissociate and activate NF-κB within the cytosol. 
During this process the cell internalises the TLR4 complex through a process known as 
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endocytosis, during which TIRAP and MyD88 dissociate from the receptor. This 
involvement of lipid rafts and endocytosis in the formation and internalisation of the TLR4 
complex indicates a potential for ES-62 to exploit this mechanism through its own 
interactions with TLR4 301,326. 
During the initiation of endocytosis and trafficking to the endolysosomes of this 
complex, the concentration of PIP2 decreases resulting in the dissociation of TIRAP from 
TLR4. This allows the association of TRAM and TRIF, resulting in the activation of the 
type 1 IFN pathway in the endosomes329. In this case TRAM functions as to recruit TRIF, 
which functions as the signalling transducer48. The translocation of dynamin and clathrin to 
the endocytic vacuole that forms around the TLR4/TRAM/TRIF complex is essential for 
its internalisation329,439,440. Dynamins are GTPases that are involved in the budding of 
vesicles from the plasma membrane and clathrin is a scaffold protein that forms the 
clathrin coated pits through which endocytosis occurs329. Thus TLR4 does not induce the 
simultaneous activation of both MyD88- and TRIF- dependent pathways: instead, TLR4 
induces the sequential activation of these signalling pathways. 
It has been noted that in preventing TLR4 internalisation there is an increase in 
LPS-induced NF-κB activation329. Coupled with evidence that TLR4 is ubiquitinated and 
that this ubiquitination promotes its degradation, it was suggested that the endocytosis and 
degradation of TLR4 and its associated complex was important in regulating its activation 
of NF-κB347. In conjunction with this, TLR4 has been shown to be tyrosine phosphorylated 
upon LPS stimulation, a process important for the targeting of transmembrane proteins for 
lysosomal degradation441. However, such tyrosine phosphorylation appears to be essential 
for the activation of the TRAM-TRIF pathway and the induction of type-1 IFNs347. In this 
respect, in resting cells TRIF and TRAM are localised in the cytosol and the plasma 
membrane, respectively440,442 but they both rapidly (within 30 min) translocate to the 
endosomes upon stimulation with LPS to interact with the CD14, MD-2 and TLR4 
complex (all components are essential for this interaction)439. Interestingly, in terms of the 
induction of the type-1 IFNs, the transport of TLR4 into the endolysosomes and the 
recruitment of TRAM and TRIF serve to engage this complex with the cytosolic E3 
ubiquitin ligase,TRAF3, a crucial protein in the propagation of all IFN signals13.  
Following the trafficking of TLR4 in response to external stimuli, any associated 
microbial proteins are degraded, promoting the loading of microbial Ags onto MHC class 
II molecules for presentation to and activation of CD4+ TH cells328,329. Thus, LPS-induced 
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trafficking of TLR4 through the clathrin-dependent endosomal route provides a mechanism 
for linking innate and adaptive immune responses and provides a potential target for 
immunomodulation by ES-62. Consistent with this, in mast cells, ES-62 is known to 
promote the alternative routing of TLR4 to caveolae lipid raft compartments, resulting in 
its degradation321. This therefore provides a mechanism for inducing TLR4 
hyporesponsiveness and also suppressing TLR4-associated (auto)-Ag presentation328,329. 
Evidence for this type of immunomodulation also exists from other helminth derived 
immunomodulators. For example, Schistosoma Egg Antigen (SEA), interacts through 
multiple receptors including TLR4and targets its trafficking into a lysosome associated 
membrane glycoprotein 2 (LAMP2; a common lysosomal and endosomal marker) negative 
compartment in a clathrin-independent manner443. This distinctive compartmentalisation of 
TLR4, relative to that induced by canonical PAMPs, could also be a critical component of 
the subversion of TLR4 signalling by ES-62 and other helminth products.  
  
88 
3.1.6 Aim of this study  
The current understanding of the effects of ES-62, and indeed many parasitic 
helminth immuno-modulators on APCs, particularly DCs, is that it matures them to induce 
a TH2-like, anti-inflammatory immune response. However ES-62 can act to reduce both 
TH1 and TH2 –type inflammatory responses indicating roles for its effects on other, broader 
regulators of inflammation. One such target that remains a gap in our understanding of the 
effects of ES-62 is IL-17, which is emerging as a master regulator of TH1 and TH2-type 
responses362. Thus a major aim of this section was to identify whether through modulation 
of DC maturation, ES-62 attenuates the ability of these APCs to induce the lineage 
differentiation of TH17 cells and the secretion of IL-17 (and its associated cytokines) in 
response to TLR4 recognition of LPS. These studies were performed in both C57BL/6 and 
BALB/c mice which have generally been considered to be genetically pre-disposed to 
generate TH1 and TH2 inflammatory responses respectively, to identify whether the genetic 
background of the bmDCs influenced the immunomodulatory effects of ES-62. The 
expression of the transmembrane glycoproteins CD40, CD80, CD86 and MHC class II on 
bmDCs would also be defined due to their importance in the interaction and transmission 
of antigenic (MHC class II) and costimulatory signals (CD40, CD80 and CD86) for driving 
the activation of naïve T cells. This would clarify whether their limited upregulation 
induced by ES-62 in response to LPS recognition reported for DCs160,301 is involved in the 
potential attenuation of TH17 development by this immunomodulator.   
Through TLR4, LPS is known to stimulate and up-regulate SPHK1422, and recent 
studies have shown that the SPHKs and key molecules involved in the activation of these 
enzymes in mast cells and T cells are targets for modulation by ES-62321. It was therefore a 
further aim to exploit the availability of Sphk1 and -2 -/- mice to explore the role of these 
enzymes in the propagation of inflammatory signals through TLR4 in DCs. These 
investigations would focus on their involvement in the propagation of a potential TH17 
phenotype and therefore determining whether there are any similarities with the anti-
inflammatory effects of ES-62.  
Current evidence suggests that ES-62 may utilise its PC moieties to bind and signal 
via TLR4 in concert with one or more co-receptors326. Consistent with this, preliminary 
analysis of the intracellular signalling pathways (p38 MAPK, PI3K-Akt and NF-κB) 
triggered by LPS and ES-62 in macrophages and DCs identified differential signalling, 
potentially indicating differences in the receptor-coupling mechanisms utilised291,301,326. 
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 The PAFR and its ligand PAF, a PC containing lipid mediator, play a key role in 
the coordination of pro-inflammatory responses for pathogen removal and as such is 
considered a strong candidate as an interacting partner for ES-62. However, within the 
current literature there is little information relating to the role of the PAFR in DC 
maturation and LPS responses. Thus as a first step to analysing whether the PAFR is a 
target for ES-62, the role of PAF signalling in LPS-mediated maturation of bmDCs and 
their subsequent ability to prime and polarise naïve T cells would be defined using the 
PAFR agonist, C-PAF and the competitive and non-competitive inhibitors, CV3988 and 
WEB2086, respectively. This characterisation would provide the platform for the 
investigation of the potential involvement of the PAFR in ES-62 mediated 
immunomodulation of DCs by identifying whether such signalling is a target of its 
downregulation of (hyper)-cytokine production in response to LPS. In respect to TLR4, 
due to the importance of its localisation and trafficking in regulating its activation status to 
different stimuli, it was planned to determine the effect of ES-62 on the internalisation, 
trafficking and degradation both TLR4 and its functional complex TLR4/MD2 throughout 
bmDCs.  
In brief the aims of this study were to define whether: 
• ES-62 in its interactions with TLR4, induces bmDC maturation that drives the 
lineage differentiation of TH17 cells and the secretion of IL-17 (and its associated 
cytokines) in a similar fashion to that reported for LPS and/or whether it attenuates 
the ability of LPS-matured APCs to induce the clonal expansion of functional TH17 
cells  
• ES-62 exhibits differential effects on bmDCs derived from C57BL/6 and BALC/c 
in terms of their ability to induce polarised TH cell subsets. 
• the anti-inflammatory/immunomodulatory effects of ES-62 on bmDC were 
mimicked in bmDC derived from Sphk1 and -2 -/- mice. 
• the PAFR plays a role in the LPS-mediated maturation of bmDCs and their ability 
to stimulate the priming and polarisation of naïve T cells as well as to establish 
whether ES-62 utilises this receptor in its downregulation of (hyper)cytokine 
production in response to LPS. 
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• ES-62 and LPS differentially modulate the internalisation, localisation and 
expression of TLR4 and its functional complex TLR4/MD2. 
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3.2 Results 
3.2.1 ES-62- and LPS-induced maturation result in the differential 
ability of DCs to stimulate TH cell proliferation and TH17 
polarisation 
As the basis to define the effects ES-62-mediated maturation may have on the 
biology of a DC and its subsequent ability to respond to infection as indicated by the pro-
inflammatory stimulus, LPS, the effects of the canonical TLR4 agonist versus ES-62 were 
defined in terms of the ability of the DCs to prime proliferation and cytokine production by 
naïve, Ag-specific CD4+CD62L+ T cells. Firstly, proliferation of naïve OVA-specific tg 
TCR CD4+ TH cells from a DO.11.10.BALB/c background in response to ES-62- or LPS-
matured bmDC loaded with increasing concentrations of OVA peptide. This was achieved 
by measurement of DNA synthesis as indicated by [3H] thymidine incorporation into 
replicating DNA in cells (Fig. 3.5). This revealed, as expected, the widely established dose 
dependent OVA peptide stimulated increase in DNA synthesis induced by LPS-matured 
bmDC indicative of a DC phenotype capable of TH cell priming. As previously shown160, 
bmDC maturation in response to ES-62 was also capable of priming clonal expansion of 
TH cells, albeit to a lesser extent than observed with LPS. This was defined by calculating 
the half maximal effective concentration (EC50) of agonist (OVA peptide) for each 
stimulus, whereby ES-62 and LPS matured DC exhibited EC50 values of 166 nM and 27.74 
nM OVA peptide, respectively. Directly related to this was the attenuated ability of ES-62 
matured DCs to induce similar maximal and basal levels of cellular proliferation relative to 
LPS.   
However, as this assay only provides a snapshot of DNA synthesis over a short 
interval (56-72 hours) of the total culture period (3 days) and doesn’t indicate whether only 
a subset of cells are undergoing proliferation, the cell tracking dye, CFSE was utilised to 
provide a greater depth of analysis. Thus, the number of cell divisions undergone by Ag-
specific TH cells was established in parallel experiments in which the TH cells were 
prestained with CFSE prior to culture with the bmDCs. CFSE-labelled naïve 
DO.11.10/BALB/c CD4+CD62L+ TH cells stimulated with ES-62 and LPS-matured bmDC 
loaded with a range of Ag concentrations (0, 10 and 100 nM OVA peptide), confirmed that 
maturation of the DCs with LPS enabled them to induce greater levels of Ag specific TH 
cell division relative to those stimulated with ES-62, an effect that is exacerbated at the 
lower concentrations of Ag (Fig. 3.6 B-D). On further analysis, the proliferation index 
(section 2.4.3) reveals that ES-62 maturation only marginally lowers the level of division 
  
92 
from the responding Ag specific TH cell population relative to LPS (Fig. 3.6 E). The 
division index and %-divided values reveal, however, that although there is little difference 
in the divisions undergone by the responding cell population between ES-62 and LPS, ES-
62 maturation is reducing the number of responding Ag specific TH cells, particularly at 
low Ag concentrations (10 nM OVA peptide). 
Similarly, experiments performed on bmDCs and OVA-specific tg TCR TH cells 
(OTII) derived from C57BL/6 background mice revealed differential priming abilities of 
DC resulting from LPS and ES-62 maturation, which were again exacerbated at the lower 
concentrations of Ag (Fig. 3.7 B-D). However, whilst both ES-62- and LPS-induced 
maturation produced DCs capable of priming Ag-specific proliferation, in this case, the 
ES-62-matured DC were more effective at inducing proliferative responses at lower 
concentrations of Ag. Consistent with this, at low Ag concentrations (10 and 30 nM OVA 
peptide), ES-62 matured bmDCs induced a higher proliferation index from the responding 
Ag specific TH cell population relative to LPS, although this parameter was reversed at the 
highest concentration of Ag (300 nM OVA peptide) (Fig. 3.7 E). Similarly to BALB/c 
derived bmDCs, however, the division index and %-divided values indicate ES-62 
maturation is reducing the number of responding Ag specific TH cells at Ag concentrations 
≤100 nM OVA peptide relative to LPS, although this appears to be overcome at high 
dosage of Ag. 
The production of several important pro-inflammatory and regulatory cytokines, 
IL-17A, IL-22, IFN-γ and IL-10 from the BALB/c and C57BL/6 background cells was also 
measured in response to the OVA peptide stimulus (0-300 nM; Fig. 3.8). Whilst 
maturation of BALB/c bmDCs by LPS and ES-62 induced essentially identical levels of 
OVA-specific IL-10 production by TH cells, the ability of bmDC to induce OVA-specific 
IL-17A production was reduced following maturation with ES-62 relative to that observed 
with LPS over the entire OVA concentration range. Levels of IFN-γ were also assayed but 
were below detectable levels (Fig. 3.8 A and results not shown), consistent with our earlier 
studies showing that ES-62-matured bmDC induced less IFN-γ than either immature or 
LPS-matured bmDC on this background160. These data suggested that ES-62-matured 
bmDCs were less effective than LPS-matured bmDCs at priming TH17 responses in a 
BALB/c background but this did not reflect an increased propensity to prime counter-
regulatory Treg (IL-10) or TH1 (IFN-γ) responses. Normalised data from several 
experiments from BALB/c background derived cells confirmed that ES-62 matured 
bmDCs, only induce low levels of IL-17A secretion relative to LPS at high Ag loads (Fig. 
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3.8 B). In contrast, the C57BL/6 background ES-62 matured bmDCs, were incapable of 
inducing secretion of IL-17A from TH cells in response to OVA challenge (Fig. 3.8 C). 
Indeed, on this genetic background, they resembled immature DC which were also 
incapable of inducing IL-17A secretion and showed reduced production of IL-22 alongside 
increased IFN-γ generation relative to that induced by LPS-matured bmDC. As previously 
shown160, ES-62-matured bmDC appeared to be even less effective at inducing IFN-γ than 
immature DC, especially at high Ag concentrations. 
3.2.2 The induction of an IL-17A secreting TH17 phenotype from 
naïve CD4+ T cell precursors; a reversal of ES-62 
hyporesponsiveness by LPS 
As ES-62 induced a phenotype of DC that was poor at priming TH17 responses, the 
plasticity of this phenotype was investigated and whether the TH17 priming capabilities of 
a DC could be restored upon their subsequent exposure to LPS (as a surrogate for 
infection). As IL-17 constitutes a key component of the host response to infection, it would 
not be of benefit to the host if such a state of ES-62-induced hyporesponsiveness was 
irreversible rather than dynamic. Investigation of the plasticity of ES-62-matured bmDC 
(BALB/c background), in terms of their responses to subsequent exposure to LPS revealed 
that such cells induce an intermediate level of priming of TH cell clonal expansion relative 
to maturation with either ES-62 or LPS alone (Fig. 3.9 B-D). The division index revealed 
that at the higher Ag concentrations (100 and 300 nM OVA peptide) subsequent exposure 
to LPS could induce ES-62 matured bmDCs to stimulate Ag specific TH cell division to 
levels more comparable to that observed with LPS-matured bmDC, particularly in terms of 
the percentage of cells undergoing division (%-divided; Table 3.1).  
Moreover, analysis of the ability of such ES-62/LPS-matured bmDC to prime 
development of a OVA-specific TH17 phenotype from naïve tg TCR CD4+ 
DO.11.10.BALB/c T cells, revealed that compared to bmDC matured with LPS alone, 
those “pre-matured” with ES-62 showed reduced IL-17 and IL-22 cytokine responses (Fig. 
3.10 A). However the IL-17, but not IL-22, responses were higher than those induced by 
either ES-62-matured or immature bmDCs showing that exposure to ES-62, whilst 
dampening subsequent responses, does not leave the host in an immunocompromised state 
to heterologous infection. Such suppression of cytokine release was reflected at the mRNA 
transcript level suggesting that pre-exposure to ES-62 was acting to prevent the induction 
of such pro-inflammatory gene expression (Fig. 3.10 B).  
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To further address the mechanisms by which exposure to ES-62 resulted in IL-17 
hyporesponsiveness, the effect of ES-62 on DC-derived cytokines that promote/antagonise 
TH17 responses was investigated. Thus bmDCs were analysed for a range of cytokines that 
are associated with driving different immune phenotypes (Fig. 3.11): TNF-α, IL-12p70 
and IL-12p40 (associated with TH1 inflammatory responses) as well as IL-6, IL-23 and IL-
27 (important mediators in differentiating, maintaining and antagonising the TH17 
phenotype, respectively). As expected, this revealed that whilst immature or ES-62-
matured bmDC produced little of any of these pro-inflammatory cytokines, LPS strongly 
stimulated their production. Interestingly, therefore, the maturation of bmDCs with ES-62 
had a significant impact on the levels of TNF-α, IL-12 p70, IL-12 p40 and IL-23 secreted 
upon subsequent stimulation with LPS, although ES-62 appeared to have little effect on 
such LPS-induced IL-6 and IL-27 secretion. These data are consistent with previous 
studies showing that ES-62 prevents bmDCs from driving TH1 associated inflammatory 
responses through its reduction of LPS-stimulated IL-12p70 and TNF-α production, whilst 
itself inducing small increases in cytokine secretion301. Moreover, they suggest that ES-62 
selectively modulates only certain molecular mechanisms employed by DCs to stimulate 
TH17 cellular differentiation and maintenance. 
3.2.3 DC co-stimulatory markers are not a major target of ES-62 
mediated immunomodulation  
To further explore the mechanisms by which ES-62 may be mediating its effects, 
flow cytometry was utilised to identify whether the parasite product was also affecting DC-
TH cell interactions by modulating the cell surface expression of DC co-stimulatory 
molecules. The expression of CD40, CD86 and MHC class II were investigated due to the 
well established finding that they are upregulated in response to LPS/TLR4 signalling, as 
well as their importance in mediating DC-mediated priming of TH1/17 phenotypes444,445. In 
this context, CD40 signalling has been reported to be involved in the secretion of IL-6 and 
IL-12p70 making it a potential target during ES-62’s subversion of bmDC maturation. 
Likewise, the role of CD86 as a counterstructure of CD28, the key costimulatory molecule 
for T cell priming, makes it a prime target for ES-62 modulation. Expression of the antigen 
presentation machinery, MHC Class II was also analysed to determine whether ES-62 was 
modulating the Ag availability/presentation to T cells. 
LPS-induced maturation resulted in the time (2, 6 and 18 h)-dependent up-
regulation of CD40, while analogous treatment with ES-62 had negligible effects on the 
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percentage of cells expressing this molecule (Fig. 3.12 A-B). It is important to note for this 
result that the very low numbers of CD40 positive DCs analysed under ES-62 simulation 
likely skewed the corresponding GMF (Geometric Mean Fluorescence) results observed. 
Interestingly given the inhibitory effects of ES-62 on TH17 differentiation, exposure to ES-
62 prior to stimulation with endotoxin upregulated CD40 expression relative to that seen 
with LPS alone, particularly at the later time points of LPS stimulation (6 and 18 h) (Fig. 
3.12 C-D). However, similar differential patterns of expression in response to LPS and/or 
ES-62 were not observed for CD86 and MHC Class II molecules (Fig. 3.13 & Fig. 3.14, 
respectively). These results confirmed earlier studies that ES-62 induced an “immature” 
phenotype of DC in respect to CD86 and MHC class II expression that is perhaps 
consistent with its anti-inflammatory responses.  
However, mouse immune responses in the BALB/c background are generally 
associated with TH2 responses and hence, as responses to ES-62 in healthy mice are also 
typically TH2 in nature (e.g. IgG1 antibody responses) it was considered possible that ES-
62 may exhibit more dramatic polarising effects on bmDC from the C57BL/6 background 
which is usually associated with initiating strong TH1/17 responses445. Thus, the effect of 
ES-62 on costimulatory molecule expression on bmDC derived from C57BL/6 mice was 
also analysed. Perhaps consistent with the TH1/TH17 responses observed in C57BL/6 mice, 
LPS induced a strong up-regulation of CD40, CD86 and MHC class II expression on the 
surface of bmDC (Fig. 3.15). However, as observed with BALB/c-derived bmDC, ES-62-
treated bmDCs maintained an immature phenotype and prior exposure of the bmDCs 
derived from C57BL/6 mice to ES-62 were able to marginally attenuate the subsequent 
LPS up-regulation of CD86 and MHC class II upregulation (Fig. 3.16). Although this 
limited effect suggests that the modulation of TH cell differentiation through DCs by ES-62 
most likely reflects its effects on cytokine production. 
3.2.4 The role of SPHK1 and -2 in LPS mediated maturation of 
bmDCs; do they play a part in immunomodulation by ES-62 
To investigate how ES-62 suppressed priming of TH17 cells, SPHK, which has 
been proposed to play a role in development of such responses, was investigated as a 
potential target of ES-62 in the attenuation of this pro-inflammatory phenotype. In this 
respect, it was decided to determine whether LPS-matured bmDC from Sphk1 and -2 
deficient mice (C57BL/6 background) showed defects in their ability to prime TH17 
differentiation. LPS-matured bmDC from either Sphk1-/- or Sphk2-/- mice were indeed 
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found to be deficient in their ability to prime wild type (WT) OVA-specific IL-17 
responses of OTII CD4+ T cells. This was reflected by an inability to secrete IL-17A 
coupled with a slight induction of IFN-γ (albeit very low concentrations) suggesting the 
potential involvement of a compensating shift in the TH1/TH17 counter-regulatory balance 
(Fig. 3.17). By contrast, the division and proliferation indices of LPS matured Sphk1-/-, but 
not Sphk2-/- bmDC, revealed they induced a greater number of OVA-specific clonal naïve 
OTII TH cells to respond and proliferate to Ag, relative to WT (Fig. 3.18). Moreover, both 
Sphk1-/- and Sphk2-/- bmDC were able to induce proliferation of a large proportion of OTII 
T cells in the absence of Ag. 
There are conflicting results that exist in the current literature about the exact role 
that the SPHKs play in the secretion of inflammatory cytokines that regulate the TH1/TH17 
balance. For example, S1P has been suggested to be anti-inflammatory by reducing IL-
12p70 production446, and suppressing TH1 responses in vivo447. However, other studies 
place S1P and SPHK1 at the centre of coordinating pro-inflammatory responses in 
rheumatoid arthritis and colitis448,449. Thus, as ES-62 has been shown to target SPHK 
responses, the effects on Sphk1 or -2 deficiency on LPS-mediated maturation of bmDCs in 
terms of costimulatory molecule expression and the secretion of a panel of cytokines 
associated with the development of TH1 and TH17 cells were determined.  
These studies showed, consistent with the earlier reports that S1P suppressed IL-12 
production, that bmDCs deficient in either of SPHK1 and -2 in bmDC exhibit significantly 
increased LPS-stimulated IL-12p40, IL-12p70 and IL-27, but not IL-23 responses, 
indicating that these enzymes are important in the regulation of IL-12 family subunits in 
response to LPS-TLR4 signalling (Fig. 3.19). This is also reflected by the tendency of 
resting Sphk -/- cells (in medium) to produce higher levels of these cytokines than WT cells 
(Fig. 3.19 B), and in this context, Sphk2-/- bmDCs also show higher levels of TNF-α 
secretion. Although the basal secretion of TGF-β1 by bmDCs appeared to be relatively 
high, SPHK1 deficient cells were significantly (P<0.05) impaired in their secretion of this 
cytokine, both under resting and LPS-stimulated conditions. Although these effects do not 
reflect the actions of ES-62, they are consistent with the promotion of TH1 differentiation 
in Sphk -/- cells.  
Analysis of surface expression of DC co-stimulatory molecules revealed that these 
cytokine responses were accompanied by reduction in basal and LPS-stimulated expression 
of CD80 and CD86 but not MHC Class II molecules, confirming that the effects on TH17 
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polarisation were not simply due to lack of Ag presentation (Fig. 3.20). Moreover, 
although reduced presumably because of the effects on basal levels, LPS-mediated 
upregulation of costimulatory molecule expression was still observed indicating that loss 
of either SPHK did not simply maintain the cells in an immature state.  
Collectively, therefore the effects of ES-62 were not mimicked by either Sphk1 or 
Sphk2 deficiency: rather, the cells from the Sphk null mice showed opposite effects on IL-
12 from that observed with ES-62. Although, these data suggest therefore that ES-62 is not 
mediating its effects by selective inhibition of either Sphk1 or -2, at this stage this 
possibility cannot be completely ruled out due potential redundancy/adaptation effects 
occurring in the Sphk -/- mice. 
3.2.5 The role of the PAFR in LPS induced cytokine secretion by 
bmDC 
The lipid mediator PAF plays an important role in leukocyte mediated phagocytosis 
of particles, including bacteria, and consequent production of pro-inflammatory cytokines, 
such as TNF-α and IL-8369. The role of PAF and its receptor in the stimulation of cytokine 
secretion in bmDC (BALB/c background) was therefore investigated using the synthetic 
analogue of PAF, C-PAF in a number of in vitro assays. This PAF analogue cannot be 
metabolised by the cell and thus provides a potent and persistent signal through the 
receptor. The competitive and non-competitive inhibitors of the PAFR, CV3988 and 
WEB2086, respectively, the latter of which is reported to act as an inverse agonist that 
attenuates receptor signal propagation throughout the cell, were used to probe the role of 
PAFR signalling in basal and LPS-stimulated DC responses. 
To identify whether signalling through the PAFR by PAF played a role in DC 
maturation and pro-inflammatory responses, bmDC were probed for PAFR expression 
(Fig. 3.21) and cytokine production following stimulation with C-PAF (Fig. 3.22). 
Although the antibody appeared to recognise some additional protein bands, it was the p39 
band that represented expression of the PAFR by DCs (Fig. 3.21), and as such it appeared 
as though the expression of this receptor could be downregulated by ES-62. Moreover, in 
relation to its role in immune responses, increasing concentrations of C-PAF stimulated the 
secretion of cytokines, of both a pro-inflammatory and modulatory nature relative to 
unstimulated cells (Fig. 3.22 A-F), except for IL-12 p40 and p70 with the noticeable up-
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regulation of IL-23 production perhaps indicating a role for the PAFR in fine-tuning TH17 
responses.  
As PAF had been proposed to mediate some of its pro-inflammatory signals via 
nuclear signalling leading to induction of gene expression364,367, and enhance LPS/TLR4 
signalling, the expression of Cbl-b, c-Cbl and TRAF6 mRNA in response to C-PAF was 
analysed by Taqman real time PCR. This was to address whether PAFR signalling 
facilitated upregulation of these key mediators of TLR4 responses and the secretion of pro-
inflammatory cytokines including IL-12 p70, TNF-α and IL-10146. Stimulating bmDCs 
with C-PAF modulated expression of all these transcripts (Fig. 3.22 G-I), where the steady 
increase of TRAF6 mRNA expression from 0.18 % ± 0.02 % (relative to GAPDH) in 
resting cells to 0.26 % ± 0.02 % was contrasted by the transient downregulation of c-Cbl 
and Cbl-b transcripts. Collectively, these results suggested that PAFR signalling modulates 
key adaptors of LPS responses. 
To explore the role of the PAFR in LPS signalling and maturation of bmDC, the 
effect of the non-competitive inhibitor WEB2086 was tested on LPS-mediated pro-
inflammatory responses. The pre-incubation of bmDC with WEB2086 appeared to 
specifically reduce the secretion of IL-12 family (IL-12p40, p70 and IL-23) cytokines as 
well as IL-10 but not TNF-α in response to LPS in a concentration dependent manner (Fig. 
3.23, A-E). Incidentally, these studies revealed that the cytokines analysed responded in a 
differential concentration dependent manner to LPS: for example, TNFα and IL-12p70 
responses reached a plateau between 1-10 ng/ml of endotoxin whilst secretion of IL-12p40, 
IL-23 and IL-10 were maximal at 1 ng/ml. Moreover, the inhibitory effects of WEB2086 
were generally overcome at the highest concentration of LPS (1000 ng/ml) perhaps 
suggesting that at high concentrations of endotoxin, LPS/TLR4 signalling may circumvent 
its requirement for PAFR signalling or alternatively, stimulate PAFR up-regulation 
(expression or signalling) by the cell. Interestingly, in the light of these results the 
competitive PAFR inhibitor, CV3988 (at 30 µM) was only able to attenuate the secretion 
of TNF-α at LPS concentrations of 10 ng/ml and above (Fig. 3.23, F-H) and had little 
effect on the inhibition of IL-12p70, although it was able to attenuate the secretion of IL-10 
in response to LPS in a similar fashion to WEB2086.     
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3.2.6 The involvement of the PAFR in shaping the LPS induced 
maturation of bmDC and its ability to stimulate T cell 
responses 
A potential role for the PAFR in exacerbating LPS-stimulated cytokine production 
was suggested by the above C-PAF and WEB2086 treatment results. However, the ability 
of C-PAF to induce pro-inflammatory responses in the absence of endotoxin suggests that 
this receptor may also play LPS-independent roles in DC maturation. To address whether 
PAF/PAFR signalling would modulate LPS-induced cytokine production, bmDC were 
matured with LPS in the presence or absence of C-PAF or alternatively, unstimulated and 
LPS-treated samples were pretreated with WEB2086 and the release of pro-inflammatory 
cytokines analysed (Fig. 3.24).  
Firstly it was observed that pretreating bmDCs with WEB2086 to inhibit the PAFR 
slightly attenuated the ability of the LPS-stimulated DCs to secrete IL-6 but not TNF-α, 
IL-23, IL-12p70 or IL-10, relative to those exposed to endotoxin alone (Fig. 3.24). 
However in the case of IL-12 p40, an increase was observed but was not found to be 
significant. On the other hand although C-PAF generally subtlety enhanced (albeit not 
significantly) secretion of most of these cytokines in response to LPS (1 µg/ml) 
stimulation, rather unexpectedly C-PAF co-stimulation with LPS inhibited the secretion of 
IL-6, although again this was not found to be significant. Collectively these results with 
PAFR agonists and antagonists had only marginal effects on LPS responses suggesting 
that, if any, the PAFRs role may be to ‘fine-tune’ cytokine secretion in response to low 
(limiting) levels of PAMPs (e.g. LPS) and/or pathogen Ag. Thus, the ability of C-PAF or 
WEB2086 to modulate the ability of LPS-matured bmDC to prime Ag-specific TH cell 
responses and polarise them to a TH1/TH17 pro-inflammatory phenotype was also 
investigated.  
Consistent with a role for PAFR in LPS-mediated pro-inflammatory responses, 
treatment with WEB2086 prior to LPS-induced maturation significantly inhibited the 
ability of bmDC to prime OVA-specific IFN-γ, IL-21 and IL-22 production (Fig. 3.25). 
However, in the case of IFN-γ and IL-21 this only occurred at lower concentrations of 
OVA peptide perhaps reflecting the well-established finding that high concentrations of Ag 
drive TH1 responses153. By contrast, IL-17 production was unaffected and IL-4 responses 
were stimulated. Collectively, therefore, these results indicate that blocking PAFR 
signalling in bmDC suppresses priming and polarisation of TH1 but not TH17 responses, 
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results consistent with our finding that WEB2086 inhibits IL-12p70 secretion from bmDC 
cultures (Fig. 3.23 & 3.24). Moreover, this suppression of TH1 responses does not appear 
to be a result of the induction of Tregs as IL-10 is also reduced and hence rather resembles a 
change in the TH1/TH2 balance. Intriguingly, the lack of effect on IL-17 secretion in 
response to LPS, suggests only certain TH17-associated cytokines are affected by 
antagonising the PAFR in DCs, nevertheless the IL-17 results are somewhat inconsistent 
with our observed inhibition of IL-23 responses as this is important in the development of 
such a phenotype (Fig. 3.23 D). The finding that inhibiting PAFR signalling attenuated 
induction of IL-22 secretion are consistent with observations from our laboratory group in 
several animal models of disease, where we are rarely able to detect IL-17 and IL-22 
production by the same cell types, thus PAF-R signalling could be important for the 
development of a TH22, but not TH17 phenotype. Interestingly, the concurrent stimulation 
with C-PAF and LPS stimulated an increase in IL-17 secretion at 100 nM OVA peptide 
relative to that observed with LPS-matured bmDCs, coupled with a similar although not as 
marked affect on IL-22 secretion. Counter intuitively, it also resulted in the Ag-
independent release of IL-4 but this was downregulated by increasing concentrations of 
OVA. Given the inhibitory effects of WEB2086, maturation of bmDCs with C-PAF and 
LPS had surprisingly little effect on bmDC stimulated TH cell differentiation towards a 
TH1/TH22 phenotype suggesting that the effects of WEB2086 were perhaps targeting PAF-
R signalling resulting from secondary production of PAF acting on intracellular PAFR, 
whilst C-PAF was stimulating surface PAFR.  
Analysis of the effects of blocking DC-PAFR signalling on priming of naïve T cells 
in terms of clonal expansion (proliferation) revealed suppression of the TH1-like phenotype 
did not simply reflect inhibition of priming. If anything, WEB2086-treated bmDCs 
stimulated the T cells to enter further rounds of cell division, with this effect being 
particularly pronounced at the lowest concentration of OVA peptide (10 nM) and indeed in 
the absence of Ag (Fig. 3.26 B-D). In this context, the proliferation index indicated that 
inhibition of DC-PAFR signalling with WEB2086 enhanced the average number of 
divisions as well as the % of responding Ag specific TH cells in the population upon LPS 
maturation (Fig. 3.26 E). In contrast, concurrent maturation of bmDCs with both LPS and 
C-PAF reduced the average number of divisions and the % of responding cells relative to 
those matured with endotoxin alone, albeit only slightly. These results therefore suggest 
that PAFR signalling may allow a DC to fine-tune the priming and clonal expansion of 
naïve TH cells depending on the inflammatory environment.  
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Although only marginal effects were observed with WEB2086 treatment of 
immature DC on DC-TH cytokine secretion (Fig. 3.27), there were some limited effects of 
the inhibitor on TH cell proliferation induced by such DCs (Fig. 3.28 A-C). Thus, 
immature DC treated with the antagonist WEB2086, were able to induce a larger number 
of Ag specific TH cells to respond and begin proliferating at the higher concentrations of 
OVA peptide relative to the immature DCs, as observed by the higher division index and 
%-divided values (Fig. 3.28 D). Perhaps surprisingly as shown by the proliferation index, 
C-PAF treated bmDCs were also able to stimulate an increase in the levels of proliferation 
above that of immature DCs (control) both in the absence and presence of OVA peptide 
(300 nM) although in contrast to WEB2086, C-PAF generally decreased the levels of 
cytokines secreted by TH cells relative to below those observed with control immature DCs 
(Fig. 3.27). 
3.2.7 ES-62 maturation of bmDC and its effect on the ability of C-
PAF and WEB2086 to modulate responses to LPS 
The data outlined above suggested that blocking of PAF-R signalling partially 
suppressed the pro-inflammatory responses of bmDC and their subsequent ability to 
modulate the priming of naïve TH cells into particular subtypes, most notably TH1. As this 
latter effect is similar to that previously reported for ES-62, and preliminary data suggests 
that ES-62 may bind to the PAFR in neuronal cells (E.T. Tuomamen & W. Harnett, 
unpublished data), it was interesting to note that Western blotting analysis (Fig. 3.21) 
revealed ES-62 to down-regulate the expression of the PAFR over a 6 h period (albeit that 
the antibody was not stringently specified for the PAFR). 
In light of this, the effect of ES-62 on the responses to LPS-maturation of DCs was 
studied in conjunction with the stimulation or inhibition of the PAFR. The responses of 
ES-62-matured bmDC to subsequent exposure to LPS showed some interesting differences 
when the cells were concomitantly treated with C-PAF (Fig. 3.29). Thus, the concurrent 
treatment of C-PAF with LPS significantly rescued ES-62 mediated down-regulation of 
IL-12 p40 and TNF-α, while this was also the case for IL-23 it was not found to be 
significant. These trends were replicated by the pretreatment of bmDCs with WEB2086, 
but in the cases of IL-12 p40 and TNF-α this rescue was not as marked as that with C-PAF 
but it did have a greater affect on stabilising LPS induced secretion of IL-23. In contrast, 
both stimulation (C-PAF) and inhibition (WEB2086 and CV3988) of the PAFR in 
conjunction with ES-62 maturation resulted in a dramatic reduction in IL-6 by the bmDCs 
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in response to LPS, which was normally rather refractory to modulation by ES-62. Overall 
however, although the PAFR antagonists mimicked the actions of ES-62 in some cases 
(e.g. TNF-α) they exhibited opposite effects in others (e.g. IL-23). Thus, as exogenous 
PAF could generally overcome the effects of ES-62, these findings might suggest that the 
parasite product could be limiting the release of PAF consequent to LPS-signalling rather 
than targeting PAFR signalling per se. Moreover, as we found ES-62 to downregulate total 
PAFR expression, these results may be indicative of ES-62 downregulating intracellular 
rather than surface receptor expression. Perhaps consistent with this proposal, analysis of 
the mRNA expression of c-Cbl and TRAF6 revealed that ES-62, like WEB2086, had no 
effect on the LPS-mediated upregulation of c-Cbl expression but inhibited the LPS-
mediated upregulation of TRAF 6 expression, which was not rescued by exogeneous PAF 
(Fig. 3.30). 
3.2.8 Targeting the source of NF-κB activation; the modulation of 
expression and localisation of TLR4 by ES-62 
ES-62-mediated inhibition of LPS-induced cytokine production, but not 
upregulation of costimulatory molecule expression, suggested that it is targeting the 
specific dynamics and components of the TLR4-NF-κB axis to enforce its actions. In this 
context, full TLR4-driven NF-κB activation has been shown to be dependent on both early 
MyD88-TIRAP lipid raft signalling and a late clathrin-mediated endosomal TRAM-TRIF-
coupled phase. This presented the question, does ES-62 modulate the surface and/or total 
expression of TLR4 and/or its active LPS recognising complex, TLR4/MD2 by subverting 
their intracellular trafficking and degradation? 
In answer to this ES-62 and LPS were found to exhibit differential effects on TLR4 
expression and trafficking. In bmDCs derived from C57BL/6 mice, FACs analysis using an 
antibody that recognised all TLR4 expressed, revealed that LPS but not ES-62 induced a 
significant increase in both total (extra- and intra-cellular sources of the receptor) and 
surface expression of this receptor over 18 h (Fig. 3.31). However, although not 
significant, ES-62 appeared to transiently upregulate TLR4 expression at early time points 
and this was also detected in bmDCs derived from BALB/c mice by Western Blot analysis, 
which was also reflected in the kinetics of TLR4 mRNA transcript expression (Fig. 3.32). 
Interestingly, LPS induced the downregulation of TLR4 mRNA levels, perhaps suggesting 
that the observed increase in protein expression in response to this TLR4 ligand was as a 
result of inhibition of TLR4 degradation. Therefore, in the context of ES-62 maturation 
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inhibiting the secretion of certain cytokines upon challenge with LPS, it also prevented the 
LPS-mediated upregulation of TLR4 (Fig. 3.33).  
By contrast, LPS but not ES-62, induced the strong downregulation of the 
TLR4/MD2 complex from the surface of bmDCs (Fig. 3.34) and both TLR4 ligands 
slightly reduced the levels of this complex throughout the cell (total). This evidence of 
LPS–induced internalisation of the TLR4/MD2 complex is consistent with its known 
endosomal trafficking, which is required for LPS-signalling and promotion of Ag 
processing and presentation. ES-62 maturation of bmDCs was able to significantly prevent 
this LPS-mediated removal of the TLR4/MD2 complex from the cell surface, and its 
subsequent LPS-driven reduction that accompanies its internalisation (Fig. 3.35). 
Interestingly, this LPS-induced internalisation of TLR4/MD2 complexes was more 
pronounced in bmDC from BALB/c mice but in this case, ES-62 maturation was unable to 
prevent this process (Fig. 3.36, B-D). Thus, in conclusion, the ability of ES-62 to dampen 
LPS functional responses does not reflect the simple downregulation of TLR4 or its active 
complex, TLR4/MD2 from the surface of bmDCs.  
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3.3 Discussion 
3.3.1 ES-62 maturation of DCs attenuates their ability to induce 
TH17 responses upon subsequent TLR4 recognition of LPS 
Collectively, and consistent with previous data291,301,323, the results described above 
suggest that ES-62 is altering the signalling patterns, maturation and activation of bmDCs 
to actively modulate the host immune response. Here, ES-62 matured DCs were observed 
to fail to induce the production of IL-17A and IL-22 from TH cells, introducing the concept 
that ES-62 does not induce a strong TH17 response in a fashion similar to LPS (Fig. 3.8). 
However, rather surprisingly given the tendency of ES-62 to drive TH2 responses, when 
stimulated with low concentrations of Ag, the TH cells primed by ES-62-matured DC, 
appeared to secrete relatively high concentrations of IFN-γ, suggesting that the particular 
microenvironment may regulate the induction of different TH phenotypes depending on the 
levels of Ag presented to naïve TH cells. For example, it has been demonstrated that IFN-γ 
inhibits the development of TH17 cells both in vitro and in vivo, through down-regulation 
of the IL-23 receptor (IL-23R)450. Thus, the low Ag induced secretion of IFN-γ by ES-62, 
coupled with its reduction of IL-23 secretion from the DCs in response to endotoxin (Fig. 
3.11), may reflect ES-62 induced changes in the environmental cytokine milieu of the 
cells, which may result in the prevention of naïve TH cells that receive only a relative low 
Ag stimulus from developing into a TH17/pro-inflammatory phenotype. In this context, 
ES-62 also impaired the ability of DCs to stimulate Ag specific TH cell proliferation, 
lowering both the number of responding cells and the divisions undergone (Fig. 3.5 - 3.7), 
again reflecting the ability of ES-62 to dampen but not ablate the host’s ability to initiate 
adaptive immune responses. 
Interestingly, this dampening effect was demonstrated by the marked reduction in 
the ability of ES-62 matured DCs to induce the development of a TH17 phenotype upon 
stimulation with LPS. This plasticity of immunomodulation is essential to prevent 
immunocompromising the host with respect to subsequent infection and was demonstrated 
by these effects being (partially) overcome at the highest concentration of Ag (300nM, 
OVA peptide), through the secretion of significant amounts of IL-17A but not IL-22 (Fig. 
3.10). This was accompanied by an increased proliferation of TH cells, comparable to that 
observed with endotoxin alone (Fig. 3.9). In this respect, the ES-62-mediated attenuation 
of the LPS induced secretion of IL-23 from DCs (Fig. 3.11) may limit the terminal 
differentiation of the TH17 cells, as IL-23 is required for cells differentiating down this 
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route to lose the ability to secrete IL-10 and upregulate IL-22 expression123. These results 
indicate that the modulation of DCs by ES-62 is not, therefore, restricted to driving 
maturation of DCs that solely induce TH2 responses160, but rather allows some flexibility in 
their biology such that it can respond to other inflammatory stimuli whilst preventing 
hyperinflamation. Consistent with this, it has been reported that ES-62 can prevent the 
development of TH1/TH17-mediated CIA310,324, and recent results suggest ES-62 limits the 
inflammatory potential of TH17 cells by suppressing their development as well as their 
capacity to secrete the inflammatory cytokine IL-17A352.  
In the present study, ES-62 alters the cytokine profile secreted by DCs in response 
to LPS, reducing the levels of IL-12p70, IL-23 and the IL-12/23p40 subunit, shared by 
both these cytokines, with little effect on IL-6 (Fig. 3.11). These data indicate a direct 
intervention of the cytokine milieu by ES-62 to potentially limit the development of both 
TH1 and TH17 phenotypes of inflammation. The lack of effect on IL-6 secretion in 
response to LPS, a cytokine that is crucial for the development of a TH17 phenotype could 
suggest that ES-62 targets the terminal differentiation of the pro-inflammatory and 
potentially pathogenic TH17 cell, but not the initiation of cellular differentiation down this 
route444. Interestingly, therefore, ES-62 pre-treatment did not affect IL-27 production to 
suppress effector T-cell proliferation and cytokine production253,254, in relation to the TH17 
phenotype163. Indeed, as this cytokine is able to initiate activation of STAT1 and T-bet, the 
signature TH1 transcription factors242, this lack of effect on IL-27 could account for the low 
level and potentially counter-regulatory TH1 response that was induced instead. In this 
context, the reduction of IL-12p70 secretion may act to counterbalance the subsequent IL-
27-mediated induction of the expression of the IL-12Rβ2, the pre-requisite for mounting a 
IL-12 dependent TH1 driven immune response252 as it would attenuate this response, 
limiting the polarisation of a TH1 phenotype.  
Typically exposure to LPS up-regulates the gene and subsequent protein production 
of TNF-α170, but ES-62 limits its production as documented previously at both the 
cytokine and mRNA level in macropahges and DCs291,363. TNF-α is known to induce the 
activation of B and T cells170, influencing the function of APCs by augmenting their Ag 
presenting capabilities and up-regulating co-stimulatory molecule expression on the 
surface of immature but not mature DCs and it is also involved in the activation of NF-
κB155. Thus ES-62 may maintain a limited production to allow protective immune 
activation whilst preventing pathological inflammation. By contrast, ES-62 had little effect 
on the expression of CD40, CD86 and MHC Class II or their upregulation by LPS. The 
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fact that treatment with ES-62 does not affect the ability of bmDCs to interact with TH cells 
(and vice versa), by modulating such  costimulatory receptor expression, places a major 
emphasis on the cytokine milieu induced by its maturation and the subsequent impact on 
the modulation of TH responses. 
3.3.1.1 Both SPHK1 and -2 potentially have a role in modulation of LPS 
maturation of bmDCs. 
These results posed the question; how does maturation with ES-62 affect the 
mechanisms utilised by DCs to impact upon the subsequent priming and polarisation of the 
TH cells? Recently, the PLD/SPHK axis has emerged as an important target for ES-62321, 
as it inhibits FcεRI-mediated degranulation and proinflammatory cytokine secretion in 
mast cells by inhibiting PLA/SPHK activity in a TLR4-dependent manner. Based on these 
results the availability of Sphk-/- (KO) mice provided the perfect opportunity to investigate 
the stated question and whether their absence mimicked the effects of ES-62. However, 
although the data from SPHK1 and -2 KO DCs suggested similarities they indicated that 
the effects of this immunomodulator on DC function cannot be solely accounted for by the 
inhibition of the SPHKs.  
For example, LPS-matured DCs from either SPHK KOs, were unable to induce the 
production of IL-17A from naïve TH cells upon stimulation with high concentrations of Ag 
(300nM OVA peptide), in a similar fashion to ES-62 matured bmDCs. These data were 
also consistent with the production of S1P being implicated in the promotion of TH17, via 
the modulation of TH polarising functions of DCs when exposed to bacterial products429. In 
this context, as with ES-62, SPHK1 and -2 KO cells show a slight induction of IFN-γ 
under LPS stimulation, which in relation to the down-regulation of IL-17A suggests the 
SPHKs are important in counter-regulating TH1-TH17 responses (Fig. 3.17) and perhaps 
reflects the significant increase in IL-27 production, dually promoting IFN-γ-TH1 
responses whilst suppressing that of TH17163. By contrast, and unlike the situation observed 
with ES-62, the secretion of IL-23 remains unaffected and a significant increase in both IL-
12p70 and the IL-12/23 p40 subunit are observed in the presence and absence of LPS 
stimulation (Fig. 3.19). Directly related to this, splenocytes from SPHK1 deficient mice are 
also found to exhibit enhanced secretion of IL-12p70 in response to endotoxin427. Despite 
the IL-6 secretion from these cells was not determined, the observed reduction of TGF-β1 
may relate to its involvement in the modulation of TH responses, as TGF-β in conjunction 
with IL-6, promotes TH17 responses123,124. Thus the reduction in TGF-β1 may reflect a role 
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of these kinases in the modulation of the TH1/TH17 balance in response to LPS-TLR4 
signalling.  
The above cytokine responses were accompanied by a decrease in the expression of 
CD80 and CD86 but not MHC class II. Findings consistent with previous reports that 
pharmacological inhibition or introduction of a DN SPHK1 can result in the reduction of 
these costimulatory molecules on DCs423. Interestingly, therefore, in this study the absence 
of SPHK1 and -2 was accompanied by a significant increase in LPS-stimulated 
upregulation of these costimulatory molecules relative to immature cells, suggesting that 
the absence of the SPHKs does not retain the bmDCs in an immature state, and may reflect 
aredundancy of functions between SPHK1 and -2.  
3.3.1.2 The role of the PAFR in mediating maturation of DCs 
Stimulation of the PAFR, coupled with its actions as a secondary transducer of LPS 
responses322, results in the exacerbated release of several pro-inflammatory cytokines 
(TNF-α, IL-6, IL-1) and other mediators including PAF itself368,369 occurring through 
activation of MAPK, PI3K, PLA2, PKC and Src pathways in various cells of the immune 
system322,364. Thus it was not surprising to observe the secretion of several 
proinflammatory and modulatory cytokines upon the stimulation of the PAFR receptor 
with the agonist C-PAF on DCs (Fig. 3.22 A-F), particularly as this compound has 
previously been shown to induce the expression of iNOS and COX-2 as well as ERK1/2 
MAPK phosphorylation and activation of NF-κB57. However, whilst C-PAF induced 
substantial increases in IL-23 and TNF-α, surprisingly the levels of IL-6 and IL-12/23p40 
remained unchanged, suggesting this agonist-receptor interaction is more selective in 
determining cytokine environments than LPS. 
To investigate the effect of C-PAF on the expression of several mediators of LPS-
TLR4 responses, the mRNA transcript expression of several E3 ubiquitin ligases, TRAF6, 
c-Cbl and Cbl-B were assessed (Fig. 3.22 G-I). TRAF6 acts as a key scaffolding protein 
involved in the propagation of TLR4 signals and is required for both MyD88 dependent 
and independent activation of NF-κB 23,24. Thus it was interesting to observe that 
stimulation of the PAFR with increasing concentrations of C-PAF resulted in the gradual 
increase in the mRNA transcript expression of this key intracellular mediator. Thus, PAFR 
signalling may promote the ability of DCs to respond to prolonged stimulation with LPS 
by the upregulation of TRAF6. Where DCs from TRAF6 deficient mice demonstrate 
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maturation defects in response to LPS, which result in a similar reduction of IL-12 
secretion (and notably also IL-6)26,27. This reasoning is reinforced by the observation that 
inhibition of signalling through the PAFR by WEB2086 (between 30-100 µM) attenuates 
the secretion of IL-12p70, IL-23 and their shared subunit IL-12/23p40, which are all 
associated with positive TLR4 signalling requiring functional TRAF6 (Fig. 3.23). 
Collectively, these results suggest that the regulation of TRAF6 by PAFR signalling may 
not have dramatic effects on the secretion of certain cytokines but may play a role in the 
ability of DCs to regulate certain immune phenotypes. This could perhaps be achieved 
through the modulation of additional E3 ligases such as c-Cbl, which has been implicated 
in the regulation of DC activation and maturation451,452, via the stabilisation of the p50 
subunit of NF-κB and its precursor p105453. Consistent with this, deficiency of c-Cbl has 
been shown to lead to higher levels of interleukin (IL)-12 p70 and IL-6 secretion454, whilst 
the related E3-ligase, Cbl-B, is directly involved in regulating acute lung inflammatory 
responses to LPS, by controlling the association between TLR4 and MyD88455. Thus, early 
in the inflammatory response (mimicked by low levels of C-PAF), PAFR signalling may 
prime the DC to respond to inflammatory stimuli, such as LPS and induce subsequent 
inflammatory responses by downregulating the ability of these cells to express both c-Cbl 
and Cbl-B. However at high concentrations, which would reflect induction of a strong 
inflammatory stimulus, these could be upregulated to limit the inflammatory responses 
mediated by DCs and stabilise the latent NF-κB complex coupled with disrupting TLR4-
MyD88 interactions. Such a mechanism could explain the observed upregulation of c-Cbl 
and reduction in IL-6 secretion upon the simultaneous stimulation of the PAFR on DCs 
with LPS and C-PAF (Fig. 3.24; Fig. 3.30), as c-Cbl expression has recently been directly 
linked to the regulation of IL-6 secretion454.  
By analysing the concentration dependent effect of LPS signalling, it was clear that 
although IL-12p70 and IL-23 share the common IL-12/23 p40 subunit (maximal secretion 
at 1 ng/ml endotoxin), the generation of the IL-12p70-specific p35 subunit is a rate limiting 
step in the secretion of IL-12p70 (maximal secretion at 10 ng/ml endotoxin). Based on 
these observations, our preliminary data suggests that inhibition of PAFR signalling (by 
WEB2086 and CV3988) attenuated the secretion of a range of cytokines analysed (Fig. 
3.23), although significant levels of inhibition were not achieved. Therefore the secondary 
role PAF plays in LPS responses may be dictated by the availability and expression of the 
PAFR, where its expression is positively upregulated by LPS stimulated activation of NF-
κB and SP-1382,383. In this context, it may also reflect, the role of intracellular PAF-PAFR 
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interactions, coupled with the potential of LPS to directly bind and influence PAFR 
signalling, enhancing the effects of PAF and therefore immune cells to deal with invading 
pathogens295,364,369-372. 
Perhaps consistent with the decrease of IL-6 and TNF-α secretion (Fig. 3.24), 
pretreatment with WEB2086 limited the subsequent ability of DC to stimulate IL-22, IL-
10, IFN-γ and IL-21 production, although in most cases (except that of IL-22) these effects 
could be overcome by high concentrations of OVA323-339 peptide loaded onto the APCs 
(Fig. 3.25).These results suggest that positive signalling through the PAFR on DCs by 
either autocrinely produced PAF or by the direct interaction of LPS is important for the 
induction of IL-6 secretion and the development of a TH17 or related phenotype444. The 
selective reduction of IL-22, relative to IL-17, may reflect involvement of PAFR signalling 
in modulating IL-23 secretion, as despite WEB2086 treatment LPS stimulation induces the 
production of relatively high levels of IL-17444. In this context, the PAFR may impact on 
the development of a TH22 population by DCs as within this lab group IL-17 and IL-22 co-
production in models of inflammation is rarely observed (M. Pineda & M. M. Harnett, 
unpublished data). Recently, it has become clear that TNF-α and IL-6 are both important 
in the differentiation of a TH22 phenotype456. Thus whilst a dramatic reduction in IL-6 
secretion is observed upon inhibition of PAFR signalling in DCs, there are little or no 
effects on TNF-α, perhaps explaining why these DCs stimulate a reduction but not ablation 
of IL-22 secretion (Fig. 3.24 - 3.28), which can drive diseases such as psoriasis412,413, or 
protect against several inflammatory disorders414,415 of a TH17 phenotype.  
The inhibition of PAFR signalling resulted in an increase in the ability of these 
cells to stimulate TH cell proliferation in response to immature or LPS-matured DCs, 
enhancing both the proliferation and division index (including the percentage of dividing 
cells) above that of endotoxin treated DCs (Fig. 3.26 & 3.28). This was consistent with 
preliminary data showing that DC from PAFR KO mice could induce Ag-independent 
proliferation of TH cells (R. Eason & M. M. Harnett, unpublished data). In this respect, it 
may also reflect the potential of WEB2086 to act as an inverse agonist, as the compound 
has a higher affinity for the inactive rather than active state of the PAFR, resulting in the 
reduction of basal activation of effector mechanisms and subsequent receptor 
internalisation and transport within the cell400.  
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3.3.1.3 The potential role of PAFR in mediating the immunomodulatory 
effects of ES-62 
Several of these inhibitory effects on the PAFR demonstrated similarities to 
observations made when DCs were treated with ES-62; for example inhibition of PAFR 
signalling resulted in a reduction of IL-23 (Fig. 3.23) and TNF-α (Fig. 3.29) from the DCs 
although, unlike the situation with ES-62, inhibition of the PAFR could also result in a 
reduction in the secretion of IL-6 (Fig. 3.24). Similarly, although the reduction in TH-IL-22 
secretion was reminiscent of that observed with ES-62-treated DC, this was not 
accompanied by a reduction in IL-17 production (Fig. 3.25). Interestingly, therefore, 
utilising C-PAF with LPS reverses ES-62 induced reduction of IL-12/23p40, TNF-α and 
IL-23 secretion (Fig. 3.29). This suggests that engagement and subsequent internalisation 
of the PAFR by C-PAF attenuates the ES-62 mediated modulation of the secretion of 
several cytokines in response to LPS. Thus ES-62 may potentially hijack this receptor to 
engage DCs via its PC moiety and utilise it in its internalisation and subsequent cytokine 
modulation of the cells in a similar fashion to PAF binding. This results in receptor 
internalisation and trafficking via the endosomes, where recruitment of cell trafficking and 
intracellular signalling proteins can occur even to the nuclear envelope384,385. Thus by 
removing or engaging the signalling capacity of this receptor, which in turn affects its 
internalisation and localisation within the cells, cytokine secretion can be disrupted. 
3.3.2 ES-62 and TLR4 
The internalisation and immunomodulatory effects of ES-62 on APCs301,326 appear 
to be dependent on the presence of TLR4. Thus, the dynamics of pro-inflammatory TLR4 
signalling, which can broadly be divided into two separate stages involving an early 
MyD88-dependent phase, triggered by receptor-mediated endocytosis in clathrin coated 
pits followed by a later endosomal TRIF mediated phase327 may provide a potential 
mechanism for inducing TLR4 hypo-responsiveness and the suppression of TLR4 
associated autoantigen presentation48,327. In DCs these phases are followed by the 
degradation of TLR4 along with any associated microbial proteins in late endocytic 
vesicles278. This results in the peptide loading of MHC class II molecules for the 
presentation of Ag and activation of CD4+ TH cells328,329. Hence, the LPS induced 
activation and trafficking of TLR4 through the clathrin-dependent endosomal route 
provides a mechanism for linking innate and adaptive immune responses. Identifying a 
potential route for ES-62-mediated uncoupling of TLR4 associated NF-κB activation.  
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One task of this study was to question whether ES-62 not only requires TLR4 for 
its internalisation and immunomodulatory effects but whether it directly modulates the 
expression and localisation of TLR4 and its associated complex partners. Interestingly, 
there appeared to be a disparity between the dynamics and expression of the total cellular 
pool of TLR4 relative to that of the TLR4/MD2 complex in response to LPS. Thus, LPS 
stimulated the upregulation of the surface expression of the total TLR4 pool while 
internalising and downregulating the “active” TLR4/MD2 complex (Fig. 3.31 & Fig. 
3.34). The observed up-regulation of TLR4 on the surface of the DCs may reflect 
utilisation of this pool for the recycling of TLR4/MD2 complexes. However, as the 
TLR4/MD2 complex is not replenished on the cell surface within the time frame examined, 
a negative feedback mechanism may uncouple the ability of TLR4 to associate with MD2 
and prevent subsequent LPS signalling and activation of NF-κB, whilst maintaining TLR4 
on the cell surface to mediate other potential cellular functions. Interestingly, the 
expression of TLR4 mRNA shows a decrease in response to LPS stimulation suggesting 
that the observed increase in the total cellular pool of TLR4 likely reflects a decrease in its 
degradation but not that of the TLR4/MD2 complex (Fig. 3.33). This may also suggest that 
the increase in TLR4 may result from the recruitment of TLR4 from the pre-existing pool 
of TLR4/MD2 or the specific degradation of MD2. 
In relarion to these observations, ES-62 does not induce internalisation and 
degradation of TLR4-TLR4/MD2 expression but acts to antagonise the effects of LPS 
(Fig. 3.34 & Fig. 3.36). Collectively, these antagonistic effects by ES-62 on total and 
MD2-associated pools of TLR4 by ES-62 may provide a mechanism for inducing TLR4 
hyporesponsiveness and the suppression of TLR4-associated (auto)antigen 
presentation328,329. Evidence for this type of immunomodulation exists from other helminth 
derived immunomodulators. For example, SEA utilises TLR4 (and severlal other 
receptors) to traffic into a LAMP2 negative compartment in a clathrin-independent 
manner443. Thus, the differential compartmentalisation of TLR4 may be a critical 
component of the subversion of TLR4 signalling by ES-62 and other helminth products. 
However, despite earlier studies indicating that the presence of TLR4 is essential for the 
internalisation of ES-62 by APCs301,326, neither TLR4 or TLR4/MD2 complexes showed 
any noticeable down-regulation in response to ES-62, perhaps suggesting that 1) the 
internalisation of ES-62 is not accompanied by TLR4 which is being utilised simply as an 
anchor, or 2) the internalisation of ES-62 reflects its dissociation from TLR4 in early 
endosomes and the recycling of TLR4 back to the cell surface and/or perhaps 
replenishment from TLR4/MD2 localised at the golgi434,435. In any case, these data 
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indicated that in DC, ES-62 was not initiating the internalisation of the receptor complex 
and the subsequent activation of the TRIF/TRAM signalling cascade perhaps going some 
way to explaining ES-62’s targeting of the TLR4-NF-κB axis. These findings are 
summarised in Figure 3.37. 
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Figure 3.1 | Chemical structure of PAF, C-PAF, WEB2086 and CV3988  
(A) The structure of phosphorylcholine (C5H15NO4P+). (B) The natural ligand of the 
PAFR, PAF (1-O-alkyl-2-acetyl-sn-glycero-3-phoshocholine; C26H54NO7P) is a potent 
phospholipid activator and mediator of many leukocyte functions including platelet 
aggregation. (C) The chemical structure of C-PAF (C26H55N2O7P), an analogue of PAF 
with stereo-specific binding to both high and low affinity PAFR, which the cell is unable to 
metabolise. Stick diagrams of the non-competitive and competitive antagonists of the 
PAFR, WEB2086 (D) and CV3988 (E), respectively. Both antagonists have a plethora of 
effects, but specifically, WEB2086 (C22H22ClN5O2S) has been shown in vitro, to decrease 
human platelet and neutrophil aggregation, while in vivo it has displayed anti-allergic and 
anti-inflammatory activity in various models. In this context, CV3988 (C28H53N2O7PS) 
inhibits PAF-induced human platelet aggregation, while in vivo it can attenuate PAF-
induced hypotension, contraction of isolated rat colon, acute pancreatitis and the lethality 
of systemically administered endotoxin in rats. 
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Figure 3.2 | The differentiation of TH17 cells.  
The differentiation of the TH17 subset is dependent on the concentration of the growth 
factor TGF-β in the surrounding environment, which in conjunction with IL-6 activates the 
transcription factors STAT1 and T-bet on the activated naïve CD4+ T cells. After which, 
the cells are induced to upregulate the expression of the IL-23R and the production of IL-
23 by mature DCs, this alongside IL-1β signalling through the IL-1 receptor, guides the 
development of cells to a TH17 phenotype. This is reinforced by the autocrine secretion of 
IL-21 by these cells. The final steps in the differentiation process are defined by the 
transcription factors, RORγt and STAT3. TH17 cells secrete a specific cytokine profile 
including: IL-17A, IL-17F, IL-22, IL-21, IL-9, IL-26 and CCL20. However, there is now a 
high degree of flexibility recognised in the TH17 subset, such that they can switch patterns 
of cytokine production dependent on the surrounding cytokine milieu. These varied TH17 
derived cytokines are responsible for a number of mediator functions in host defence 
(although often pro-inflammatory) as well as being linked to several autoimmune diseases. 
(Adapted from Olsen, N.J. et al., 2011444) 
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Figure 3.3 | The synthesis of S1P.  
Stimulation of various tyrosine-kinase, G-protein-coupled, cytokine and immunoreceptor 
tyrosine-based activation motif (ITAM)-bearing receptors activates sphingomyelinases 
(SMase), which cleave sphingomyelin to yield ceramide, ceramidases (CERase) then 
cleave ceramide to form sphingosine. Finally sphingosine-1-phosphate (S1P) is synthesised 
by phosphorylation of sphingosine in a reaction catalysed by sphingosine kinase 1 
(SPHK1) at the plasma membrane (A). This reaction is also catalysed by SPHK2 at the 
endoplasmic reticulum (ER), mitochondria and nucleus (B). In response to a number of 
varying stimuli including cytokine recognition, S1P synthesised at the plasma membrane is 
released by specific transporters to regulate a number of immune functions, by binding to 
the extracellular portion of specific S1P receptors (S1PRs) to initiate signalling 
pathways.The production of S1P at the endoplasmic reticulum, mitochondria and nucleus 
is tightly regulated as its synthesis leads to the activation of numerous intracellular targets. 
This control comes through the irreversible degradation by S1P lyase or dephosphorylation 
to sphingosine by S1Pase (S1P phosphatase).  
(Adapted from Spiegel et al., 2011425) 
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Figure 3.4 | The actions of S1P and the SPHKs in TLR4 signalling. 
The recognition of LPS by TLR4 promotes recruitment of MyD88 via TIRAP allowing the 
formation of a complex, which includes TRAF6 and members of the IRAK family. The 
recruitment of TRAF6 is important in the activation of the TAK1 complex via its self 
ubiquitination, which triggers the IKK complex composed of IKKα, IKKβ and the 
regulatory component NEMO to induce the phosphorylation, polyubiquitination and 
degradation of IκB via the 26S proteosome, allowing NF-κB to translocate into the 
nucleus. Concurrently TAK1 also triggers the MAPK pathway, resulting in AP-1 
activation (through phosphorylation) and the subsequent production of proinflammatory 
cytokines. In this context, Sphingosine-1-phosphate (S1P) generation by sphingosine 
kinase 1 (SPHK1) enhances the autoubiquitinylation of TRAF6. The importance of SPHK1 
in this process has been demonstrated via its inhibition, which suppresses the nuclear 
translocation of the NF-κB subunit, p65/RelA into the nucleus and the degradation of 
IRAK-1. The dashed arrows indicates the potential involvement of the MAPKs in 
regulating SPHK1 activity and the subsequent production of S1P, as well as the recently 
elucidated role of PKCδ in the phosphorylation and activation of SPHK1, leading to its 
translocation to the membrane.  
(Adapted from Spiegel et al., 2011425) 
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Figure 3.5 | DNA synthesis induced by BALB/c-derived bmDC, matured by LPS or 
ES-62, in vitro.  
BmDC were derived from bone marrow cells obtained from BALB/c mice by culture in 
vitro in the presence of GM-CSF for 6 days. These cells (2x106/well in a total of 2 mls) 
were then stimulated with either LPS (1 µg/ml) or ES-62 (2 µg/ml) for 18 h on day 6. On 
day 7, the bmDCs were pulsed with OVA323-339 peptide at the indicated concentrations for 
3 h. The bmDC (2.5x104 cells/well) were then co-cultured with OVA-specific transgenic 
(tg) TCR CD4+CD62L+ T cells (DO.11.10.BALB/c; 2.5x105 cells/well) for 56 hours before 
DNA synthesis was assessed by pulsing the cells with 0.5 µCi/well [3H] thymdine for the 
last 16 hours of culture (total of 72 hours), followed by measurement of incorporated label 
using a scintillation counter. Data are presented as mean counts per minute (cpm) ± SD of 
triplicate values alongside the maximal, basal and EC50 values calculated for each 
stimulus; the data are from a single experiment. 
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Figure 3.6 | T cell proliferation induced by BALB/c-derived bmDC, matured by LPS 
or ES-62, in vitro.  
BmDC were derived from bone marrow cells obtained from BALB/c mice by culture in 
vitro in the presence of GM-CSF for 6 days. These cells (2x106/well in a total of 2 mls) 
were then stimulated with either LPS (1 µg/ml) or ES-62 (2 µg/ml) for 18 h on day 6. On 
day 7, the bmDCs were pulsed with OVA323-339 peptide at the indicated concentrations for 
3 h. The bmDC (2.5x104 cells/well) were then co-cultured with OVA-specific transgenic 
(tg) TCR CD4+CD62L+ T cells (DO.11.10.BALB/c; 2.5x105 cells/well) stained with CFSE 
(5 µM) for 72 hours before being analysed by flow cytometry (FL1 channel).  
In panel A, the gating of healthy cells of the correct size and granularity associated with T 
lymphocytes, were defined by their expression of KJ1.26 (Ag specific TCR). In panel B, 
data are shown as histograms of CFSE fluorescence versus %-Max (section 2.6.1) of the 
KJ1.26+ T cells, for the differentially treated bmDCs (concentration of OVA peptide-top 
right of plot). The number of cell divisions is indicated by the intensity of CFSE 
fluorescence relative to the non-proliferating cell peak, with the gating for each generation 
of cells marked on each plot (Generation 0; peak with highest CFSE fluorescence). In 
panel C, data are shown as histograms of CFSE fluorescence versus the number of KJ1.26+ 
T cells, for the differentially treated bmDCs. In panel, D, the percentage of KJ1.26+ cells in 
the population undergoing a particular number of divisions beginning at ‘Generation 0’ is 
defined relative to the total number of KJ1.26+ cells in the analysis (Concentration of OVA 
peptide is stated above the graph). In panel E, the division index, proliferation index and % 
divided values are provided for each treatment and subsequent OVA peptide stimulus. The 
data in panels B-E is of a single experiment representative of 2. 
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Figure 3.7 | T cell proliferation induced by C57BL/6-derived bmDC, matured by LPS 
or ES-62, in vitro.  
BmDC were derived from bone marrow cells obtained from C57BL/6 mice by culture in 
vitro in the presence of GM-CSF for 6 days. These cells (2x106/well in a total of 2 mls) 
were then stimulated with either LPS (1 µg/ml) or ES-62 (2 µg/ml) for 18 h on day 6. On 
day 7, the bmDCs were pulsed with OVA323-339 peptide at the indicated concentrations for 
3 h. The bmDC (2.5x104 cells/well) were then co-cultured with OVA-specific transgenic 
(tg) TCR CD4+CD62L+ T cells (OT2 C57BL/6; 2.5x105 cells/well) stained with CFSE (5 
µM) for 72 hours before being analysed by flow cytometry (FL1 channel).  
In panel A, the gating of healthy cells of the correct size and granularity associated with T 
lymphocytes, were defined by their expression of the Vα2 chain of the TCR. In panel B, 
data are shown as histograms of CFSE fluorescence versus the %-Max (section 2.6.1) of 
the Vα2+ cells (concentration of OVA peptide-top right of plot); the number of cell 
divisions is indicated by the levels of CFSE fluorescence relative to the non-proliferating 
cell peak, with the gating for each generation of cells marked on each plot (Generation 0; 
peak with highest CFSE fluorescence). In panel C, data are shown as histograms of CFSE 
fluorescence versus the number of Vα2+ T cells, for the differentially treated bmDCs. In 
panel D, the percentage of Vα2+ cells in the population undergoing a particular number of 
divisions beginning at ‘Generation 0’ is defined relative to the total number of Vα2+ cells 
in the analysis. In panel E, the division index, proliferation index and % divided values are 
provided for each treatment and subsequent OVA peptide stimulus. The data in panels B-E 
is of a single experiment representative of 2. 
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Figure 3.8 | The differential effects of LPS- and ES-62-induced maturation of bmDC 
on TH polarisation and cytokine production, in vitro. 
BmDC were derived from bone marrow cells obtained from BALB/c and C57BL/6 mice 
by culture in vitro in the presence of GM-CSF for 6 days. These cells (2x106 /well) were 
then stimulated with either LPS (1 µg/ml) or ES-62 (2 µg/ml) for 18 h on day 6. On day 7, 
the bmDCs were pulsed with OVA323-339 peptide at the indicated concentrations for 3 h 
before co-culture with D0.11.10 tg or OTII tg TCR CD4+CD62L+ T cells (2.5x105 
cells/well) for the BALB/c and C57BL/6 derived bmDCs, respectively for 72 h. In panel 
A, the secretion of IL-17A and IL-10 in the culture supernatants from BALB/c background 
cells was measured by ELISA. Data are presented as the mean values (pg/ml) of triplicate 
estimates ± SD from a single experiment. In panel B, the secretion of IL-17A induced by 
either LPS (1 µg/ml) or ES-62 (2 µg/ml) matured bmDCs at increasing concentrations of 
OVA peptide323-339 was normalised to LPS matured bmDCs pulsed with 300nM peptide 
(100 %). Data were acquired from three independent experiments and presented as the 
normalised values of the mean levels (pg/ml) of triplicate estimates from the individual 
experiments ± SEM, n=3. In panel C, IL-17A, IL-22 and IFN-γ from the culture 
supernatants of C57BL/6 background cells were measured by ELISA. Data are presented 
as the mean values (pg/ml) of triplicate estimates ± SD from a single experiment. 
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Figure 3.9 | The effect of ES-62 on LPS-stimulated bmDCs induction of T cell 
proliferation, in vitro. 
BmDC were derived from bone marrow cells obtained from BALB/c mice by culture in 
vitro in the presence of GM-CSF for 6 days. These cells (2x106/well in a total of 2 mls) 
were then pre-treated with medium or ES-62 (2 µg/ml) for 18 h on day 6 and subsequently 
with medium or LPS (1 µg/ml) for 18 h on day 7. On day 8, the bmDCs were pulsed with 
OVA323-339 peptide at the indicated concentrations for 3 h. The bmDC (2.5x104 cells/well) 
were then co-cultured with OVA-specific transgenic (tg) TCR CD4+CD62L+ T cells 
(DO.11.10.BALB/c; 2.5x105 cells/well) stained with CFSE (5 µM) for 72 hours before 
being analysed by flow cytometry (FL1 channel).  
In panel A, the gating of healthy cells of the correct size and granularity associated with T 
lymphocytes, were defined by their expression of CD4 and KJ1.26 (Ag specific TCR). In 
panel B, data are shown as histograms of CFSE fluorescence versus the %-Max (section 
2.6.1) of CD4+KJ1.26+ T cells, for the differentially treated bmDCs (concentration of OVA 
peptide-top right of plot). The number of cell divisions is indicated by the levels of CFSE 
fluorescence relative to the non-proliferating cell peak with the gating for each generation 
of cells marked on each plot (Generation 0; peak with highest CFSE fluorescence). In 
panel C, data are shown as histograms of CFSE fluorescence versus the number of 
CD4+KJ1.26+ T cells, for the differentially treated bmDCs. In panel, D, the percentage of 
CD4+KJ1.26+ cells in the population undergoing a particular number of divisions 
beginning at ‘Generation 0’ is defined relative to the total number of CD4+KJ1.26+ cells in 
the analysis (Concentration of OVA peptide-top right of graph). The data in panels B-D is 
of a single experiment representative of 2. 
  
122 
Table 3.1 | Analysis of proliferative parameters of TH cells – primed by bmDCs 
treated with ES-62 and/or LPS 
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Figure 3.10 | The effect of ES-62 on the subsequent LPS maturation of bmDC in 
terms of polarisation of TH cells, in vitro. 
BmDC were derived from bone marrow cells obtained from BALB/c mice by culture in 
vitro in the presence of GM-CSF for 6 days. These cells (2x106/well in a total of 2 mls) 
were then pre-treated with media or ES-62 (2 µg/ml) for 18 h on day 6 and subsequently 
with ± LPS (1 µg/ml) for 18 h on day 7. On day 8, the bmDCs were pulsed with OVA323-
339 peptide at the indicated concentrations for 3 h before co-culture with D0.11.10 tg 
CD4+CD62L+ T cells (2.5x105 cells/well) for 72 h. In panel A, the secretion of IL-17A and 
IL-22 in the culture supernatants was measured by ELISA. Data are presented as the mean 
values (pg/ml) of triplicate estimates ± SD from a single experiment. In panel B, the 
production of IL-17A and IL-22 mRNA transcript from these cells was measured by 
Taqman real-time PCR and defined as a percentage relative to GAPDH mRNA expression. 
The results are presented as the mean levels of triplicate estimates ± SD from a single 
experiment. The statistical analysis of the ELISA results was performed by a Student t-test 
where *p<0.05, ** P<0.01 and ***p<0.001, relative to the immature (untreated) cells at 
the relevant OVA peptide concentration. 
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Figure 3.11 | The effect of ES-62 maturation on the subsequent LPS-stimulated 
cytokine responses of BALB/c bmDCs.  
BmDC were derived from bone marrow cells obtained from BALB/c mice by culture in 
vitro in the presence of GM-CSF for 6 days. These bmDC (2x106/well in a total of 2 ml) 
were then pretreated with medium or ES-62 (2 µg/ml) for 18 h followed by maturation 
with medium or LPS (1 µg/ml) for a further 18 h. The culture supernatants were analysed 
by ELISA for the cytokines, TNF-α; IL-6; bioactive IL-12 p70; IL-12/23 p40; IL-23 or IL-
10. Data were acquired from four independent experiments and presented as the mean of 
the means of triplicate estimates (pg/ml) from the individual experiments ± SEM, n=4. The 
statistical analysis performed is by one way-ANOVA, utilising a Tukey post test, where 
*p<0.05, ** P<0.01 and ***p<0.001.  
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Figure 3.12 | CD40 expression of BALB/c-derived bmDC: modulation by ES-62, in 
vitro.  
BmDC were derived from bone marrow cells obtained from BALB/c mice by culture in 
vitro in the presence of GM-CSF for 6 days. These cells (2x106/well in a total of 2 mls) 
were then pre-treated with medium or ES-62 (2 µg/ml) for 18 h followed by stimulation 
with either medium, ES-62 (2 µg/ml) or LPS (1 µg/ml) for the indicated times over an 18 h 
period. The control (untreated) cells were incubated under the same conditions for the 
length of the experiment (36 h). CD11c+, 7-AAD- gated-cells were analysed by flow 
cytometry for the CD40 costimulatory marker utilising a FITC conjugated antibody (FL1 
channel). In panel A, data for bmDCs treated with ES-62 and LPS over 18 h are presented 
as histograms of fluorescent intensity of CD40 staining versus the %-Max (section 2.6.1). 
In panel B, the percentage of positively stained cells induced by both treatments was 
calculated using the relevant isotype control antibody and is indicated by the marker on the 
histograms; this is presented alongside the geometric mean fluorescence (GMF) of the 
CD40 positive cells. In panel C, data for bmDCs pre-treated with media or ES-62 before 
subsequent stimulation with LPS for the indicated times are presented as histograms of 
fluorescent intensity of CD40 staining versus the %-Max. In panel D, the percentage of 
positively stained cells induced by the differential treatments was calculated using the 
relevant isotype control antibody and is indicated by the marker on the histograms; this is 
presented alongside the geometric mean fluorescence (GMF) of the CD40 positive cells. 
The data presented are from a single experiment.  
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Figure 3.13 | CD86 expression of BALB/c-derived bmDC: modulation by ES-62, in 
vitro.  
BmDC were derived from bone marrow cells obtained from BALB/c mice by culture in 
vitro in the presence of GM-CSF for 6 days. These cells (2x106/well in a total of 2 mls) 
were then pre-treated with medium or ES-62 (2 µg/ml) for 18 h followed by stimulation 
with either medium, ES-62 (2 µg/ml) or LPS (1 µg/ml) for the indicated times over an 18 h 
period. The control (untreated) cells were incubated under the same conditions for the 
length of the experiment (36 h). CD11c+, 7-AAD- gated-cells were analysed by flow 
cytometry for the CD86 costimulatory marker utilising a FITC conjugated antibody (FL1 
channel). In panel A, data for bmDCs treated with ES-62 and LPS over 18 h are presented 
as histograms of fluorescent intensity of CD86 staining versus the %-Max (section 2.6.1) 
cell numbers. In panel B, the percentage of positively stained cells induced by both 
treatments was calculated using the relevant isotype control antibody and is indicated by 
the marker on the histograms; this is presented alongside the geometric mean fluorescence 
(GMF) of the CD86 positive cells. In panel C, data for bmDCs pre-treated with media or 
ES-62 before subsequent stimulation with LPS for the indicated times are presented as 
histograms of fluorescent intensity of CD86 staining versus the %-Max cell numbers. In 
panel D, the percentage of positively stained cells induced by the differential treatments 
was calculated using the relevant isotype control antibody and is indicated by the marker 
on the histograms; this is presented alongside the geometric mean fluorescence (GMF) of 
the CD86 positive cells. The data presented are from a single experiment. 
  
127 
Figure 3.14 | MHC Class II expression of BALB/c-derived bmDC: modulation by ES-
62, in vitro.  
BmDC were derived from bone marrow cells obtained from BALB/c mice by culture in 
vitro in the presence of GM-CSF for 6 days. These cells (2x106/well in a total of 2 mls) 
were then pre-treated with medium or ES-62 (2 µg/ml) for 18 h followed by stimulation 
with either medium, ES-62 (2 µg/ml) or LPS (1 µg/ml) for the indicated times over an 18 h 
period. The control (untreated) cells were incubated under the same conditions for the 
length of the experiment (36 h). CD11c+, 7-AAD- gated-cells were analysed by flow 
cytometry for MHC Class II expression utilising a FITC conjugated antibody (FL1 
channel). In panel A, data for bmDCs treated with ES-62 and LPS over 18 h are presented 
as histograms of fluorescent intensity of MHC Class II staining versus the %-Max (section 
2.6.1). In panel B, the percentage of positively stained cells induced by both treatments 
was calculated using the relevant isotype control antibody and is indicated by the marker 
on the histograms; this is presented alongside the geometric mean fluorescence (GMF) of 
the MHC Class II positive cells. In panel C, data for bmDCs pre-treated with media or ES-
62 before subsequent stimulation with LPS for the indicated times are presented as 
histograms of fluorescent intensity of MHC Class II staining versus the %-Max. In panel 
D, the percentage of positively stained cells induced by both treatments was calculated 
using the relevant isotype control antibody and is indicated by the marker on the 
histograms; this is presented alongside the geometric mean fluorescence (GMF) of the 
MHC Class II positive cells. The data presented are from a single experiment. 
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Figure 3.15 | LPS induction of costimulatory molecules in C57BL/6-derived bmDC, in 
vitro.  
BmDC were derived from bone marrow cells obtained from C57BL/6 mice by culture in 
vitro in the presence of GM-CSF for 6 days. These cells (2x106/well in a total of 2 mls) 
were then stimulated with either medium or LPS (1 µg/ml) for 18 h. CD11c+, 7-AAD- 
gated-cells were analysed by flow cytometry for the expression of MHC Class II and CD86 
utilising FITC conjugated antibodies (FL1 channel), while CD40 expression was defined 
utilising a biotinylated antibody detected by a streptavidin-APC conjugate (FL4 channel). 
In panel A, data for bmDCs treated with medium or LPS for 18 h are presented as 
histograms of fluorescent intensity of CD40, CD86 and MHC class II staining versus the 
%-Max (section 2.6.1). In panel B, the percentage of positively stained cells induced by 
both treatments was calculated using the relevant isotype control antibody and is indicated 
by the markers on the histograms; this is presented alongside the geometric mean 
fluorescence (GMF) of the positive cells. The data presented are from a single experiment. 
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Figure 3.16 | The effect of ES-62 and/or LPS maturation on CD86 and MHC Class II 
expression in C57BL/6-derived bmDC, in vitro.  
BmDC were derived from bone marrow cells obtained from C57BL/6 mice by culture in 
vitro in the presence of GM-CSF for 6 days. These cells (2x106/well in a total of 2 mls) 
were then pre-treated with medium or ES-62 (2 µg/ml) for 18 h followed by stimulation 
with either medium, ES-62 (2 µg/ml) or LPS (1 µg/ml) for a further 18 h. CD11c+, 7-AAD- 
gated-cells were analysed by flow cytometry for CD86 and MHC Class II expression 
utilising a FITC conjugated antibody (FL1 channel) and bitotinylated antibody detected by 
a streptavidin-PerCP conjugate (FL3 channel), respectively. In panel A, data for the 
differentially treated bmDCs are presented as histograms of fluorescent intensity of Ag 
staining versus the %-Max (section 2.6.1). In panel B, the percentage of positively stained 
CD86 and MHC Class II cells induced by both treatments was calculated using the relevant 
isotype control antibody and is indicated by the marker on the histograms. In panel C, the 
geometric mean fluorescence (GMF) of the CD86 and MHC Class II positive cells is 
presented. The data presented are from a single experiment. 
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Figure 3.17 | The importance of SPHK1 and SPHK2 in LPS-induced maturation of 
bmDC on TH polarisation and cytokine production, in vitro. 
BmDC were derived from bone marrow cells obtained from Sphk1-/- and Sphk2-/- and wild 
type (WT) C57BL/6 background mice by culture in vitro in the presence of GM-CSF for 6 
days. These cells (2x106/well in a total of 2 mls) were treated with medium or LPS (1 
µg/ml) for 18 h on day 6. On day 7, the bmDCs were pulsed with OVA323-339 peptide at the 
indicated concentrations for 3 h before being co-cultured with OTII tg CD4+CD62L+ T 
cells (2.5x105 cells/well) for 72 h. In panel A and B, the secretion of IL-17A (panel A) and 
IFN-γ (panel B) in the culture supernatants of both the media and LPS stimulated cells was 
measured by ELISA. Data are acquired from two independent experiments and presented 
as the means of the replicates from the individual experiments ± SD, n=6.  
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Figure 3.18 | The roles of SPHK1 and SPHK2 in T cell proliferation induced by 
bmDC, matured by LPS, in vitro.  
BmDC were derived from bone marrow cells obtained from Sphk1-/-, Sphk2-/- and wild 
type (WT) C57BL/6 mice by culture in vitro in the presence of GM-CSF for 6 days. These 
cells (2x106/well in a total of 2 mls) were then stimulated with either medium or LPS (1 
µg/ml) for 18 h on day 6. On day 7, the bmDCs were pulsed with OVA323-339 peptide at the 
indicated concentration for 3 h. The bmDC (2.5x104 cells/well) were then co-cultured with 
OVA-specific transgenic (tg) TCR CD4+CD62L+ T cells (OT2 C57BL/6; 2.5x105 
cells/well) stained with CFSE (5 µM) for 72 hours before being analysed by flow 
cytometry (FL1 channel).  
In panel A, the gating of healthy cells of the correct size and granularity associated with T 
lymphocytes, were defined by their expression of the CD4 and the Vα2 chain of TCR. In 
panels B-C, data are shown as histograms of CFSE fluorescence versus the %-Max 
(section 2.6.1) of CD4+Vα2+ T cells for medium (panel B) and LPS (panel C) treated 
bmDCs (concentration of OVA peptide above the plot). The number of cell divisions is 
indicated by the levels of CFSE fluorescence relative to the non-proliferating cell peak 
with the gating for each generation of cells marked on each histogram (Generation 0; peak 
with highest CFSE fluorescence). In panels D-E, data are shown as histograms of CFSE 
fluorescence versus the number of CD4+Vα2+ T cells, for the medium (panel D) and LPS 
(panel E) treated bmDCs. In panel F, the percentage of CD4+KJ1.26+ cells in the 
population undergoing a particular number of divisions beginning at ‘Generation 0’ is 
defined relative to the total number of CD4+Vα2+ cells in the analysis for the LPS 
stimulated samples as no discernable proliferation was induced by the medium treated 
bmDCs (Concentration of OVA peptide-top left of graph). In panel G, the division index, 
proliferation index and % divided values are provided for the LPS treated bmDCs for each 
phenotype and OVA peptide stimulus. The data in panels B-G is of a single experiment 
representative of 2. 
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Figure 3.19 | The role of SPHK1 and SPHK2 in LPS stimulated cytokine responses by 
bmDC, in vitro.  
BmDC were derived from bone marrow cells obtained from Sphk1-/-, Sphk2-/- and wild 
type (WT) C57BL/6 background mice by culture in vitro in the presence of GM-CSF for 6 
days. These cells (2x106/well in a total of 2 ml) were treated with medium or LPS (1 
µg/ml) for 18 h. The culture supernatants were analysed by ELISA for the cytokines, TNF-
α; bioactive IL-12 p70; IL-12/23 p40; IL-23, IL-27 and TGF-β1. In panel A, the 
expression of these cytokines in response to medium and LPS maturation are presented, 
while panel B, displays the cytokine production of only the medium treated (resting) cells 
of the various phenotypes analysed. Data were acquired from two independent experiments 
and presented as the means of the replicates from the individual experiments ± SD, n=6. 
The statistical analysis performed is by one way-ANOVA, utilising a Tukey post test 
where *p<0.05, ** P<0.01 and ***p<0.001.  
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Figure 3.20 | The function of SPHK1 and SPHK2 in LPS stimulated bmDC co-
stimulatory molecule expression. 
BmDC were derived from bone marrow cells obtained from Sphk1-/-, Sphk2-/- and wild 
type (WT) C57BL/6 mice by culture in vitro in the presence of GM-CSF for 6 days. These 
cells (2x106/well in a total of 2 mls) were then stimulated with either medium or LPS (1 
µg/ml) for 18 h on day 6. On day 7, CD11c+, 7-AAD- gated-cells were analysed by flow 
cytometry for the costimulatory markers CD80, MHC Class II and CD86. A FITC 
conjugated antibody (FL1 channel) was utilised for each marker. In panel A, data for 
bmDCs treated with medium or LPS over 18 h are presented as histograms of fluorescent 
intensity of CD80 staining versus the %-Max (section 2.6.1). In panel B, the percentage of 
positively stained cells induced by both treatments was calculated using the relevant 
isotype control antibody and is indicated by the marker on the histogram. This is presented 
alongside the geometric mean fluorescence (GMF) of the CD80 positive cells. Panels C-D, 
and E-F, presents the identical analysis of MHC Class II and CD86 expression, 
respectively. Data presented are from a single experiment. 
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Figure 3.21 | Modulation of PAFR protein expression by ES-62. 
BmDCs (2x106/well in a total of 2 ml) were stimulated with ES-62 (2 µg/ml) over a period 
of 1, 3 and 6 h. The control (unstimulated) cells were incubated under the same conditions 
for the length of the experiment (6 h). In panel A, total protein extracts were purified from 
the samples and assayed by Western blotting for PAFR expression at 39 kDa. In panel B, 
the densitometric analysis of the protein was normalised against the relevant β-actin 
loading control. The values were then adjusted and expressed as a fold change relative to 
the control (unstimulated DC, normalised to 1) cells. 
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Figure 3.22 | The effect of the PAF analogue, C-PAF, on the secretion of a panel of 
pro-inflammatory and immuno-modulatory cytokines.  
BmDC (2x106/well in a total of 2 mls) were stimulated with the indicated concentrations of 
C-PAF (0.01, 0.1 and 1 nM) for 18 h. In panels A-F, the culture supernatants were 
analysed by ELISA for the cytokines, TNF-α (panel A); bioactive IL-12 p70 (panel B); IL-
23 (panel C) IL-12/23 p40 (panel D) or IL-10 (panel F). The ELISA Data are 
representative of two separate experiments and presented as the mean of triplicate values ± 
SD of a single experiment. In panels G-H, the production of Cbl-b (panel G), c-Cbl (panel 
H) and TRAF6 (panel I) mRNA transcript from these cells was measured by Taqman real-
time PCR and defined as a percentage relative to HPRT (Cbl-b and c-Cbl) and GAPDH 
(TRAF6) mRNA expression. The results are presented as the mean levels of triplicate 
estimates from the individual experiments ± SD. 
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Figure 3.23 | The effects of the PAFR inhibitors, WEB2086 and CV3988, on LPS-
induced cytokine secretion from bmDC.  
BmDC (2x106/well in a total of 2 mls) were pre-treated with medium, WEB2086 (panels 
A-E; 10 µM, 30 µM and 100 µM) or CV3988 (panels F-H; 10 µM and 30 µM) for 30 
minutes prior to stimulation with LPS (0.01, 0.1, 1 and 10 µg/ml) for a further 18 h. The 
culture supernatants were analysed by ELISA for the cytokines, TNF-α; bioactive IL-12 
p70; IL-12/23 p40; IL-23 or IL-10. The Data are representative of two separate 
experiments and are presented as the mean of triplicate values (pg/ml) ± SD from a single 
experiment. 
 
 
  
137 
Figure 3.24 | The effect of C-PAF and WEB2086 on the secretion of a panel of pro-
inflammatory and immuno-modulatory cytokines in response to LPS.  
BmDC (2x106/well in a total of 2 mls) were pre-treated with medium or 30 µM WEB2086 
for 30 min before stimulation with 1 µg/ml LPS. In addition bmDC were stimulated with 
LPS in combination with 1 nM C-PAF for 18 h, and the culture supernatants were analysed 
by ELISA for the cytokines, TNF-α; bioactive IL-12 p70; IL-12/23 p40; IL-23; IL-6 or IL-
10. The data are pooled from three independent experiments and presented as the mean 
values of the means of triplicate estimates (pg/ml) from the individual experiments ± SEM, 
n=3. The statistical analysis performed is by unpaired Students t-test where *p<0.05, ** 
P<0.01 and ***p<0.001.  
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Figure 3.25 | The effect of C-PAF and WEB2086 on LPS matured bmDC priming of 
antigen-specific T cell cytokine production, in vitro. 
BmDC were derived from bone marrow cells obtained from BALB/c mice by culture in 
vitro in the presence of GM-CSF for 6 days. On day 6 these cells (2x106/well in a total of 2 
mls) were pre-treated with medium or 30 µM WEB2086 for 30 min before stimulation 
with 1 µg/ml LPS or alternatively the bmDC were treated with LPS in combination with 1 
nM C-PAF for 18 h. On day 7, the bmDCs were washed and pulsed with OVA323-339 
peptide at the indicated concentrations for 3 h before co-culture with D0.11.10 tg TCR 
CD4+CD62L+ T cells (2.5x105 cells/well) for 72 h. The culture supernatants were analysed 
by ELISA for the cytokines, IL-17A; IL-22; IFN-γ; IL-4; IL-21 and IL-10. Data were 
acquired from two independent experiments and presented as the means of the replicates 
from the individual experiments ± SD, n=6. The statistical analysis performed is by two 
way-ANOVA, utilising a Bonferroni post test where *p<0.05, ** P<0.01 and ***p<0.001. 
The significance of each result represented is relative to the ‘LPS stimulated’ sample at the 
relevant OVA peptide concentration. 
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Figure 3.26 | The effect of C-PAF and WEB2086 on LPS matured bmDC induced 
antigen-specific T cell clonal expansion, in vitro. 
BmDC were derived from bone marrow cells obtained from BALB/c mice by culture in 
vitro in the presence of GM-CSF for 6 days. On day 6, these cells (2x106/well in a total of 
2mls) were pre-treated with medium or 30 µM WEB2086 for 30 min before stimulation 
with 1 µg/ml LPS or alternatively the bmDC were matured with LPS in combination with 
1 nM C-PAF for 18 h. On day 7, the bmDCs were washed and pulsed with OVA323-339 
peptide at the indicated concentrations for 3 h, the bmDC (2.5x104 cells/well) were then 
co-cultured with OVA-specific transgenic (tg) TCR CD4+CD62L+ T cells 
(DO.11.10.BALB/c; 2.5x105 cells/well) stained with CFSE (5 µM) for 72 h before being 
analysed by flow cytometry (FL1 channel).  
In panel A, the gating of healthy cells of the correct size and granularity associated with T 
lymphocytes, were defined by their expression of CD4 and KJ1.26 (Ag specific TCR). In 
panel B, data are shown as histograms of CFSE fluorescence versus the %-Max (section 
2.6.1) of CD4+KJ1.26+ T cells, for the differentially treated bmDCs (concentration of OVA 
peptide-top left of plot). The number of cell divisions is indicated by the levels of CFSE 
fluorescence relative to the non-proliferating cell peak with the gating for each generation 
of cells marked on each plot (Generation 0; peak with highest CFSE fluorescence). In 
panel C, data are shown as histograms of CFSE fluorescence versus the number of 
CD4+KJ1.26+ T cells, for the differentially treated bmDCs. In panel, D, the percentage of 
CD4+KJ1.26+ cells in the population undergoing a particular number of divisions 
beginning at ‘Generation 0’ is defined relative to the total number of CD4+KJ1.26+ cells in 
the analysis (Concentration of OVA peptide-top right of graph). In panel E, the division 
index, proliferation index and %-divided values are provided for each treatment and 
subsequent OVA peptide stimulus. The data in panels B-E is of a single experiment 
representative of 2. 
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Figure 3.27 | The effect of C-PAF and WEB2086 on antigen-specific T cell cytokine 
production by bmDC in vitro. 
BmDC were derived from bone marrow cells obtained from BALB/c mice by culture in 
vitro in the presence of GM-CSF for 6 days. On day 6 these cells (2x106/well in a total of 2 
mls) were treated with medium, WEB2086 (30 µM) or C-PAF (1 nM) for 18 h. On day 7, 
the bmDCs were washed and pulsed with OVA323-339 peptide at the indicated 
concentrations for 3 h before co-culture with D0.11.10 tg TCR CD4+CD62L+ T cells 
(2.5x105 cells/well) for 72 h. The culture supernatants were analysed by ELISA for the 
cytokines, IL-17; IL-22; IFN-γ; IL-4; IL-21 and IL-10. Data were acquired from two 
independent experiments and presented as the means of the replicates from the individual 
experiments ± SD, n=6. The statistical analysis performed is by two way-ANOVA, 
utilising a Bonferroni post test where *p<0.05, ** P<0.01 and ***p<0.001. The 
significance of each result represented is relative to the ‘Immature’ sample at the relevant 
OVA peptide concentration. 
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Figure 3.28 | The effect of C-PAF and WEB2086 on antigen-specific T cell clonal 
expansion by bmDC, in vitro. 
BmDC were derived from bone marrow cells obtained from BALB/c mice by culture in 
vitro in the presence of GM-CSF for 6 days. On day 6, these cells (2x106/well in a total of 
2mls) were treated with medium, WEB2086 (30 µM), C-PAF (1 nM) for 18 h. On day 7, 
the bmDCs were washed and pulsed with OVA323-339 peptide at the indicated 
concentrations for 3 h, the bmDC (2.5x104 cells/well) were then co-cultured with OVA-
specific transgenic (tg) TCR CD4+CD62L+ T cells (DO.11.10.BALB/c; 2.5x105 cells/well) 
stained with CFSE (5 µM) for 72 h before being analysed by flow cytometry (FL1 
channel). 
In panel A, CD4+KJ1.26+ TH cells were analysed and the data are shown as histograms of 
CFSE fluorescence versus the %-Max (section 2.6.1) of CD4+KJ1.26+ T cells, for the 
differentially treated bmDCs (concentration of OVA peptide-top left of plot). The number 
of cell divisions is indicated by the levels of CFSE fluorescence relative to the non-
proliferating cell peak with the gating for each generation of cells marked on each plot 
(Generation 0; peak with highest CFSE fluorescence). In panel B, data are shown as 
histograms of CFSE fluorescence versus the number of CD4+KJ1.26+ T cells, for the 
differentially treated bmDCs. In panel C, the percentage of CD4+KJ1.26+ cells in the 
population undergoing a particular number of divisions beginning at ‘Generation 0’ is 
defined relative to the total number of CD4+KJ1.26+ cells in the analysis (Concentration of 
OVA peptide-top right of graph). In panel D, the division index, proliferation index and %-
divided values are provided for each treatment and subsequent OVA peptide stimulus. The 
data in panels A-D is of a single experiment representative of 2. 
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Figure 3.29 | ES-62 modulation of cytokine secretion by bmDCs treated with 
WEB2086 and C-PAF.  
BmDC (2x106/well in a total of 2 mls) were pre-treated with medium, WEB2086 (30 µM) 
or CV3988 (30 µM) for 30 min before maturing the cells with medium or ES-62 for a 
further 18 h. After which, each group of cells were stimulated with 1 µg/ml LPS in 
combination with medium or 1 nM C-PAF for 18 h. The culture supernatants were 
analysed by ELISA for the cytokines, TNF-α; bioactive IL-12 p70; IL-12/23 p40; IL-23; 
IL-6 and IL-10. The data are pooled from three independent experiments and presented as 
the mean values (pg/ml) of the means of triplicate estimates from the individual 
experiments ± SEM, n=3. The statistical analysis performed is by two way-ANOVA, 
utilising a Bonferroni post test, where; *p<0.05, ** P<0.01 and ***p<0.001. The 
significance of each result represented is relative to the relevant ‘LPS stimulated’ sample. 
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Figure 3.30 | ES-62 modulation of c-Cbl and TRAF6 mRNA production following 
treatment of bmDCs with PAFR agonists and antagonists.  
BmDC (2x106/well in a total of 2 mls) were pre-treated with medium, WEB2086 (30 µM) 
or CV3988 (30 µM) for 30 min before maturing the cells with medium or ES-62 for a 
further 18 h. After which, each group of cells were stimulated with 1 µg/ml LPS in 
combination with medium or 1 nM C-PAF for 18 h. The production of c-Cbl and TRAF6, 
mRNA transcript from these cells was measured by Taqman real-time PCR and defined as 
a percentage relative to HPRT (c-Cbl) and GAPDH (TRAF6) mRNA expression. The data 
are presented as the mean levels of triplicate estimates from a single experiment ± SD, 
which is representative of two. 
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Figure 3.31 | The cell surface and total TLR4 expression of C57BL/6-derived bmDC, 
following maturation with LPS or ES-62, in vitro.  
BmDC were derived from bone marrow cells obtained from C57BL/6 mice by culture in vitro in 
the presence of GM-CSF for 6 days. These cells (2x106/well in a total of 2 mls) were then 
stimulated with LPS (1 µg/ml) or ES-62 (2 µg/ml) at the times indicated over an 18 h period. The 
untreated (control) cells were incubated under the same conditions for the length of the experiment 
(18 h). In panel A, CD11c+7-AAD- gated-cells were analysed by flow cytometry for TLR4 utilising 
an APC conjugated antibody (FL4 channel). The data for differentially stimulated bmDCs are 
presented as histograms of fluorescent intensity of TLR4 staining versus the %-Max (section 
2.6.1). The percentage of positively stained cells induced by both treatments was calculated using 
the relevant isotype control antibody, indicated by the marker on the histograms. In panel B, the 
percentage of TLR4 positive cells was normalised and expressed relative to untreated (control) 
cells, which are expressed as 100%. The data was acquired from three independent experiments 
and presented as their mean normalised values ± SEM, n=3. The statistical analysis performed is a 
Kruskal-Wallis test, utilising a Dunn’s Multiple Comparison Post Test (α = p<0.05), expressed 
relative to the untreated (control) cells. In panel C, the Geometric Mean Fluorescence (GMF) of the 
TLR4 positive cells determined in panel B were normalised to the untreated cells (control; 100 %) 
and presented as the mean of these normalised values ± SEM, n=3.  
In panel D, permeablised CD11c+ gated-cells were analysed by flow cytometry for TLR4 
expression, with the data generated and presented as in panel A. In panel E, the percentage of 
TLR4 positive cells was normalised and expressed relative to untreated (control) cells, which are 
expressed as 100 %. Data was acquired from ES-62 and LPS stimulated cells from one and three 
independent experiments, respectively. The data are presented as the mean normalised values ± 
SEM where for LPS, n=3 and ES-62, n=1. In panel F, the Geometric Mean Fluorescence (GMF) of 
the TLR4 positive cells determined in panel E were normalised to the untreated cells (control; 100 
%) and presented as the mean of these normalised values ± SEM, where for LPS n=3 and ES-62, 
n=1. The statistical analysis performed is a Kruskal-Wallis test, utilising a Dunn’s Multiple 
Comparison Post Test (where α = p<0.05), relative to the untreated (control) cells (100 %). 
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Figure 3.32 | Protein and mRNA transcript expression of TLR4 in BALB/c-derived 
bmDC, matured by LPS or ES-62, in vitro. 
In panel A, BmDCs (2x106/well in a total of 2 ml) were stimulated with ES-62 (2 µg/ml) 
over a period of 1, 3 and 6 h. The control (unstimulated) cells were incubated under the 
same conditions for the length of the experiment (6 h). Total protein extracts were purified 
from the samples and assayed by Western blotting for PAFR expression at 39 kDa. This is 
presented alongside the densitometric analysis of the protein, which was normalised 
against the relevant β-actin loading control then adjusted and expressed as a fold change 
relative to the control (unstimulated DC, normalised to 1) cells. 
In panel B, the total RNA was purified from CD11c expressing bmDCs (2x106/well in a 
total of 2 ml) stimulated with either ES-62 (2 µg/ml) or LPS (1 µg/ml) for the indicated 
times. The production of TLR4 mRNA transcript from these cells was measured by 
Taqman real-time PCR and defined as a percentage relative to GAPDH mRNA expression. 
The data are presented as the mean levels of triplicate estimates from a single experiment ± 
SD. 
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Figure 3.33 | The cell surface and total TLR4 expression of C57BL/6-derived bmDC, 
matured by LPS and/or ES-62, in vitro. 
BmDC were derived from bone marrow cells obtained from C57BL/6 mice by culture in 
vitro in the presence of GM-CSF for 6 days. These cells (2x106/well in a total of 2 mls) 
were then pre-treated with medium or ES-62 (2 µg/ml) for 18 h followed by stimulation 
with either medium, ES-62 (2 µg/ml) or LPS (1 µg/ml) for a further 18 h. The untreated 
(control) cells were incubated under the same conditions for the length of the experiment 
(36 h). 
In panel A, unpermeabilised CD11c+7-AAD- (surface) and permeabilised CD11c+ (total) 
gated-cells were analysed by flow cytometry for TLR4 utilising an APC conjugated 
antibody (FL4 channel). The data for the differentially stimulated bmDCs are presented as 
histograms of the fluorescence intensity of TLR4 staining versus the %-Max (section 
2.6.1). The percentage of positively stained cells induced by the differential treatments was 
calculated using the relevant isotype control antibody, indicated by the marker on the 
histograms. In panel B, the percentage of TLR4 positive cells was normalised and 
expressed relative to the untreated (control) cells, which are expressed as 100 %. The data 
was acquired from three independent experiments and presented as the mean normalised 
values ± SEM, n=3. The statistical analysis performed is a Kruskal-Wallis test, utilising a 
Dunn’s Multiple Comparison Post Test (α = p<0.05). In panel C, the geometric mean 
fluorescence (GMF) of TLR4 expression throughout (surface and intracellular) TLR4 
positive cells is presented from a single representative experiment. 
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Figure 3.34 | The cell surface and total TLR4/MD2 expression of C57BL/6-derived 
bmDC, matured by LPS or ES-62, in vitro.  
BmDC were derived from bone marrow cells obtained from C57BL/6 mice by culture in 
vitro in the presence of GM-CSF for 6 days. These cells (2x106/well in a total of 2 mls) 
were then stimulated with LPS (1 µg/ml) or ES-62 (2 µg/ml) at the times indicated over an 
18 h period. The untreated (control) cells were incubated under the same conditions for the 
length of the experiment (18 h). In panel A, CD11c+7-AAD- gated-cells were analysed by 
flow cytometry for the TLR4 complex, TLR4/MD2, utilising a APC conjugated antibody 
(FL4 channel). The data for differentially stimulated bmDCs are presented as histograms 
of fluorescent intensity of TLR4/MD2 staining versus the %-Max (section 2.6.1). The 
percentage of positively stained cells induced by both treatments was calculated using the 
relevant isotype control antibody, indicated by the marker on the histograms. In panel B, 
the percentage of TLR4/MD2 positive cells was normalised and expressed relative to the 
untreated (control) cells, which are expressed as 100 %. The data was acquired from three 
independent experiments and presented as the mean of normalised values ± SEM, n=3. The 
statistical analysis performed is a Kruskal-Wallis test, utilising a Dunn’s Multiple 
Comparison Post Test (α = p<0.05), expressed relative to the untreated cells (control; 100 
%). In panel C, the Geometric Mean Fluorescence (GMF) of the TLR4/MD2 positive cells 
determined in panel B were normalised to untreated cells (control; 100 %) and presented as 
the mean of these values ± SEM, n=3.  
In panel D, permeablised CD11c+ gated-cells were analysed by flow cytometry for 
TLR4/MD2 expression, with the data generated and presented as in panel A. In panel E, 
the percentage of TLR4/MD2 positive cells was normalised and expressed relative to the 
untreated (control) cells, which are expressed as 100 %. In panel F, the Geometric Mean 
Fluorescence (GMF) of the TLR4/MD2 positive cells determined in panel E is presented. 
The data in panels D-F are from a single representative experiment. 
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Figure 3.35 | The cell surface and total TLR4/MD2 expression of C57BL/6-derived 
bmDC, matured by LPS and/or ES-62, in vitro. 
BmDC were derived from bone marrow cells obtained from C57BL/6 mice by culture in 
vitro in the presence of GM-CSF for 6 days. These cells (2x106/well in a total of 2 mls) 
were then pre-treated with medium or ES-62 (2 µg/ml) for 18 h followed by stimulation 
with either medium, ES-62 (2 µg/ml) or LPS (1 µg/ml) for a further 18 h. The untreated 
(control) cells were incubated under the same conditions for the length of the experiment 
(36 h). 
In panel A, unpermeabilised CD11c+7-AAD- (surface) and permeablised CD11c+ (total) 
gated-cells were analysed by flow cytometry for TLR4/MD2 utilising an APC conjugated 
antibody (FL4 channel). The data for differentially stimulated bmDCs are presented as 
histograms of the fluorescence intensity of TLR4/MD2 staining versus the %-Max (section 
2.6.1). The percentage of positively stained cells induced by the differential treatments was 
calculated using the relevant isotype control antibody, indicated by the markers on the 
histograms. In panel B, the percentage of TLR4/MD2 positive cells was normalised and 
expressed relative to the untreated (control) cells, which are expressed as 100 %. The data 
was acquired from three independent experiments and presented as the mean normalised 
values ± SEM, n=3. The statistical analysis performed is a Kruskal-Wallis test, utilising a 
Dunn’s Multiple Comparison Post Test (α = p<0.05). In panel C, the geometric mean 
fluorescence (GMF) of TLR4/MD2 expression throughout (surface and intracellular) the 
TLR4/MD2 positive cells is presented from a single representative experiment. 
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Figure 3.36 | TLR4/MD2 cell surface expression of BALB/c-derived bmDC, matured 
by LPS and/or ES-62, in vitro.  
BmDC were derived from bone marrow cells obtained from BALB/c mice by culture in 
vitro in the presence of GM-CSF for 6 days. These cells (2x106/well in a total of 2 mls) 
were then pre-treated with medium or ES-62 (2 µg/ml) for 18 h followed by stimulation 
with either medium, ES-62 (2 µg/ml) or LPS (1 µg/ml) for the indicated times over an 18 h 
period. The untreated (control) cells were incubated under the same conditions for the 
length of the experiment (36 h). CD11c+, 7-AAD- gated-cells were analysed by flow 
cytometry for the TLR4 complex, TLR4/MD2 utilising an APC conjugated antibody (FL4 
channel).  
In panel A, data for bmDCs treated with ES-62 and LPS for the indicated times are 
presented as histograms of fluorescent intensity of TLR4/MD2 staining versus the 
percentage of maximum cell numbers. In panel B, the percentage of positively stained cells 
induced by both treatments was calculated using the relevant isotype control antibody and 
is indicated by the marker on the histograms; this is presented alongside the geometric 
mean fluorescence (GMF) of the TLR4/MD2 positive cells. In panel C, data for bmDCs 
pre-treated with medium or ES-62 before subsequent stimulation with LPS for the 
indicated times are presented as histograms of the fluorescence intensity of TLR4/MD2 
staining versus the %-Max. In panel D, the percentage of positively stained cells induced 
by both treatments was calculated using the relevant isotype control antibody and is 
indicated by the marker on the histograms; this is presented alongside the geometric mean 
fluorescence (GMF) of the TLR4/ND2 positive cells. Collectively, the data presented are 
from a single experiment. 
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Figure 3.37 | The differential effects of ES-62 on the expression and localisation of 
TLR4 and the LPS signalling complex TLR4/MD2 in bmDCs  
Panel A, stimulation of bmDC with LPS progressively increases the pool of TLR4 on the 
surface whilst decreasing that of the TLR4/MD2 fraction, some of which is known to be 
targeted for degradation in the lysosomes347. The effects of ES-62 are not as striking but 
there does appear to be a transient up-regulation of total (surface and intracellular) TLR4 
expression between 1-6 h (of both protein [as determined by flow cytometry and Western 
blotting studies] and mRNA transcript), which may suggest a cycling of the receptor 
between the plasma membrane and endosomes. In contrast, ES-62 appears to maintain a 
steady-state surface expression of the TLR4/MD2 complex while inducing a slight 
reduction of the complex throughout the cell, indicating a potential link with its possible 
lysosomal degradation. 
Panel B, on the other hand when ES-62 was utilised to mature DCs they could not 
efficiently internalise TLR4/MD2 in response to LPS, and increased levels were observed 
throughout the cell. A similar case occurs with TLR4 as ES-62 prevents the up-regulation 
of TLR4 on the surface in response to LPS, yet also shows higher total levels of TLR4. 
Within this context the data also suggests that ES-62 maybe utilising TLR4 alone or via the 
formation of other novel TLR4 signalling complexes (i.e. not associated with MD2) but 
this is unconfirmed. 
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4 Immunomodulation of the dendritic cell by ES-
62; its effects on the activation of NF-κB by 
TLR4 
4.1 Introduction 
4.1.1 The subversion of NF-κB activation by ES-62 requires TLR4 
The TLR family of PRRs are important for pathogen recognition by the innate 
immune system and the most widely studied of these, TLR4, is a critical member of a 
complex responsible for driving responses to bacterial LPS. This receptor initiates 
intracellular signalling via TIR domains through the association of adaptor proteins such as 
MyD88, leading to the activation of the transcription factor NF-κB 21 and the secretion of 
IL-6, IL-12/23p40, IL-12p70 and TNF-α from DCs330. It has been demonstrated that ES-
62, despite inducing transient activation of this pathway, is able to retain the DCs in an 
‘immature’ state, which is associated with a decrease in their ability to secrete several 
proinflammatory cytokines in response to LPS301,323. The requirement of both TLR4 and 
MyD88 in mediating the immunomodulatory effects of ES-62, have been demonstrated in 
macrophages and DCs derived from TLR4-/- and MyD88-/- mice301. Further to this, TLR4 
but not MyD88 is crucial for the internalisation of ES-62 into APCs 326, however, the low 
level cytokine responses induced by ES-62 in MyD88-deficent cells are lost301. 
In recent years the recognition of LPS by TLR4 has been shown to activate most 
PKC isoforms in several innate cells such as macrophages and DCs, inducing the secretion 
of a number of pro-inflammatory cytokines (as summarised in Figure 1.6)91-95. This is of 
particular interest as the subversion of TLR4 signals by ES-62 in APCs, modulates 
signalling elements important in NF-κB activation and cytokine secretion. For example, 
both PKCε and PKCδ are known to directly interact with MyD8849,100 and TIRAP101, 
respectively. These associations induce PKCδ to mediate the activation of p38 and Akt106-
108, which coupled with the phosphorylation and subsequent degradation of IκB through 
IKK are important in NF-κB signalling101. PKCε acts within a similar context but is known 
to be crucial for LPS stimulated TNF-α and IL-12p70 secretion in DCs112,114. Similarly 
PKCα is also important in LPS-stimulated TNF-α and IL-6 secretion119,120, where it has 
been immunoprecipitated with TLR2 in DCs upon its activation. In this context, this 
association is ablated in MyD88-/- mice, suggesting that MyD88 acts as the link between 
PKCα and TLR2 with a potential for association to TLR4115. 
  
152 
In relation to this, the immunomodulation of B cells by ES-62 was observed to 
involve the selective regulation (expression and activity) of certain PKC isoforms in 
resting and BCR stimulated B cells320,333. This involved the induced proteolytic 
degradation of the α, β, δ, ζ and ι/λ isoforms, coupled with the up-regulation of PKCγ and 
PKCε in murine splenic B cells320. In these studies, modulation of PKCα was found to be 
crucial due to its role in proliferation, where it disrupted its normal activation and nuclear 
translation patterns, contributing to ES-62-mediated inhibition of BCR-stimulated 
proliferation. In particular, the modulation of PKCα, -δ and -ι/λ, were observed to be 
important due to their roles in the transduction of key activation signals for the 
phosphorylation of nuclear protein lamin B and the induction and activation of NF-κB, 
Fos, Egr-1 and Myc335-339. 
Subsequent to these studies, it has been found that ES-62 causes a similar 
degradation of PKCα in T cells and mast cells. In mast cells, the degradation of PKCα 
provides the molecular mechanism by which ES-62 mediates their desensitisation321, as it 
is necessary for PLD-coupled, SPHK-mediated, calcium mobilisation. This release of 
calcium is important for FcεRI-mediated NF-κB activation, mast cell degranulation and 
pro-inflammatory mediator release. The characterisation of this immunomodulation 
revealed that the complexing of ES-62 and TLR4 at the plasma membrane resulted in the 
sequestration of PKCα, which was followed by caveolae/lipid raft-dependent 
internalisation and non-proteosomal degradation at the peri-nuclear region of the cell321. 
Sequestration of PKCα does not take place when ES-62 is substituted by LPS, highlighting 
the differences between the two molecules with respect to the consequences of their 
interaction with TLR4. It has also been found that several other isoforms (PKCδ, -β and -ι) 
are degraded in response to ES-62, (lymphocytes and mast cells), which is most likely 
involved in limiting the activation of NF-κB but this has not been confirmed at present. 
Based on these observations, it has been hypothesised that the PKCs are an important 
target for modulation in DCs by ES-62. This is due to their emerging importance in NF-κB 
activation and the induction of proinflammatory cytokine secretion by TLR4 signalling. 
4.1.2 Ubiquitination, an important cellular process involved in 
TLR4 mediated activation of NF-κB and potential mechanism 
for the effects of ES-62 
The ubiquitination of proteins downstream of TLR4 stimulation is required for the 
activation of NF-κB. For example, the RING-fingered domain E3 ubiquitin ligase, 
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TRAF627, acts as a key scaffolding protein involved in the propagation of TLR4 signals 
and is required for both MyD88 dependent and independent activation of NF-κB (as 
described in section 1.1.3.1.2 and Figure 1.4). Briefly, TRAF6 in conjunction with the E2 
ligases, Ubc13 and Uev1a, promotes the K63-linked polyubiquitination of target proteins 
including TRAF6 itself and the IKK complex component NEMO23,24. Unlike K48-linked 
polyubiquitination, which normally targets proteins for degradation by the proteasome, 
K63-linked polyubiquitin chains act as scaffolds to assemble protein kinase complexes and 
mediate their activation through proteasome-independent mechanisms24. For example, K63 
linked polyubiquitination plays an important role in the activation of TAK1 by TRAF6, 
which subsequently activates IKK and the MAPKs44, culminating in the activation of NF-
κB and AP-1, respectively24. Specifically, DCs from TRAF6 deficient mice demonstrate 
maturation defects in response to LPS, both in vitro and in vivo26,27, being unable to 
effectively secrete both IL-6 and IL-12 and up-regulate numerous costimulatory molecules, 
limiting their ability to induce T cell priming.  
Similarly, recent evidence has indicated that the E3-ligase c-Cbl, may play several 
roles in the TLR-NF-κB signalling axis and hence has been implicated in the regulation of 
several innate immune responses, including activation of DCs451,452. c-Cbl is a RING-
domain containing E3 ubiquitin ligase and is part of the cbl (casita b lineage lymphoma) 
family of mammalian proteins. It is most commonly associated with its role as a negative 
regulator of TCR signalling, whereby blocking its RING domain leads to heightened 
responses457. However, c-Cbl has been shown to stabilise the p50 subunit of NF-κB and its 
precursor p105 in DCs, whilst a deficiency of c-Cbl leads to higher levels of IL-12p70 and 
IL-6454. This finding may reflect that p105 can also act as a IκB protein through its 
carboxy-terminal ankyrin repeats453. Interestingly the closely related E3 ligase, Cbl-b has 
also been shown to be involved in regulating acute lung inflammatory response to LPS, by 
controlling the association between TLR4 and MyD88455.  
Because of the important roles of the E3 ubiquitin ligases in innate immune cell 
function and the TLR-NF-κB signalling axis it is not surprising there is evidence that 
products secreted by filarial nematodes target this class of proteins. For example, the 
human filarial nematode, Brugia malayi, which releases PC-containing proteins331, up-
regulates expression of the E3 Ubiquitin ligases: CBL, ITCH (itchy homologue E3 
ubiquitin protein ligase) and NEDD4 (neural precursor cell expressed, developmentally 
down-regulated 4) in vivo458. Moreover, TH2 hypo-responsiveness during chronic 
  
154 
schistosomiasis in mice is associated with the expression of GRAIL (gene related to anergy 
in lymphocytes) where it is thought to have a role in the consequent induction of T cell 
anergy28. ES-62 may therefore utilise this regulatory process and modulate key proteins 
involved in the ubiquitination process to induce its anti-inflammatory effects, potentially 
via the degradation of TLR4 coupled signalling mediators involved in the activation of NF-
κB. 
4.1.3 Autophagy and the cell: a potential avenue for 
immunomodulation by ES-62? 
Autophagy, derived from the Greek word meaning to ‘eat oneself’, is an 
evolutionary conserved pathway in eukaryotic cells for the transport of cytosolic 
components for degradation by the lysosomes that is engaged in response to various 
stimuli including starvation, heat shock and oxidative stress. There are three separate 
methods of autophagy termed microautophagy, macroautophagy and chaperone-mediated 
autophagy459. Microautophagy involves the direct budding of vesicles with cytosolic 
proteins into the lysosomal lumen, macroautophagy assembles a double membrane vesicle 
around the cargo (termed an ‘autophagosome’), which is then targeted for fusion with 
lysosomes and chaperone-mediated autophagy imports signal peptide containing proteins 
via LAMP-2A into the lysosomes460.  
The eukaryotic cell utilises two main degradation systems to recycle 
macromolecules: the proteosome and the lysosome and in both systems hydrolytic activity 
is compartmentalised from the surrounding cytoplasm460. Next to the proteosome, which is 
normally associated with the degradation of malfolded and short lived proteins, the 
autophagic-lysosomal pathway is the only known disposal mechanism of intracellular 
organelles and protein aggregates too large for the proteosome in eukaryotic cells460. Due 
to the unique ability of autophagy to degrade cellular components of various sizes, it is 
now understood to be utilised to dispose of microorganisms, such as viruses, bacteria and 
protozoa that invade the cell461,462. In conjunction with this, the autophagy machinery 
interfaces with most cellular stress-response pathways, including those involved in 
controlling immune responses and inflammation463. This interface entails the direct 
interaction and cross-talk of autophagy associated proteins and immune signalling 
molecules as both systems exert direct affects on one another464. This complex relationship 
may underlie why defects in autophagy (through autophagy gene mutation and/or 
  
155 
microbial antagonism) lead to the pathogenesis of many infectious diseases and 
inflammatory disorders. 
Autophagy is an important mechanism of cellular homeostasis and has also been 
shown to act as an effector for TLR-mediated innate and adaptive immune responses465. In 
respect to the functions of ES-62, this process has become of particular interest due to its 
ability in providing a negative feedback mechanism for dampening down LPS/TLR4-
mediated pro-inflammatory responses. Thus the mechanisms and immunological functions 
of autophagy will be outlined, particularly in relation to the mechanisms which ES-62 may 
exploit. 
4.1.3.1 The mechanisms of autophagy 
Over the last decade there has been an intense interest in the involvement of 
macroautophagy, which from this point forward will be referred to as ‘autophagy’, in 
immune mechanisms and pathogen removal. This is because the same autophagic 
machinery used to selectively degrade cytosolic components is utilised in the destruction of 
microorganisms by redirecting their surrounding phagosome to the lysosomal pathway466. 
In this respect, autophagosomes have now been shown to fuse with endosomes, 
multivesicular bodies and MHC class II loading compartments467. The understanding of the 
membrane dynamics of autophagosome formation (Fig. 4.1 A) has progressed rapidly 
since the discovery of the ATG (autophagy-related) genes in yeast468. The basic dynamics 
involved in the formation of the double membrane autophagosome begins with the creation 
of an isolation membrane (or phagophore), which engulfs a portion of the cytoplasm 
(usually 0.5-1 µm in diameter). The outer membrane of the autophagosome then fuses with 
a lysosome to become an autolysosome leading to the enzymatic degradation of its 
contents. Interestingly, recent studies indicate that the endoplasmic reticulum (ER) is 
crucial for autophagosome formation as electron tomography has demonstrated a direct 
connection with ER cisternae and autophagosomal membranes469,470. 
The basic molecular mechanisms required for the formation of the isolation 
membrane and their development into autophagsomes are based on studies of cellular 
nutrient starvation, through the inhibition of the mammalian target of rapamycin (mTOR). 
The process is initiated by the translocation of the ULK1 complex (an mTOR substrate), 
consisting of ULK1/2 (UNC-51-like kinase), ATG13, FIP200 (focal adhesion kinase 
family interacting protein of 200 kDa) and ATG101 from the cytosol to certain domains of 
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the ER or closely attached structures471,472. The ER-associated multispanning membrane 
protein, VMP1 (vacuole membrane protein 1) is important at both early and late stages of 
autophagosome formation due to its interactions with beclin-1471,473,474. Specifically, the 
translocation of the ULK1 complex induces the recruitment of a class III PI3K complex, 
which includes vacuolar sorting protein 34 (VSP34), VSP15, beclin-1 and ATG14471,475 to 
the ER for the localised production of phophatidylinositol-3-phosphate (PtdIns3P). This 
phospholipid mediates the recruitment of other diffusely distributed effectors such as 
DFCP1476 (double FYVE-containing protein 1) and WIPI (WD-repeat domain 
phosphoinositide-interacting) family proteins, to drive the formation of the ER associated 
omegasome, a precursor to the isolation membrane477. The major isoform of WIPI in many 
cell types, WIPI2, has been identified as the potential trigger for the development of the 
omegasome into an isolation membrane478.  
The elongation of the isolation membrane mediated by the ATG12-ATG5-
ATG16L1 complex requires the E1-like enzyme ATG7, which activates LC3, a homolog 
of yeast ATG8 with at least three isoforms, LC3A, –B and –C. ATG7 couples 
phosphatidylethanolamine (PE) via the E2-like enzyme ATG3 to LC3, converting the 
soluble LC3-I form to the vesicle associated LC3-II form 468,479. The shift in LC3 
localisation upon the induction of autophagy has been clearly visualised under the 
microscope, from a diffuse cytosolic distribution to a distinct punctuate pattern associated 
with the formation of autophagosomes480. LC3 has an important role in membrane fusion 
completing the formation of the autophagosome but also acts as a tether to attach the 
autophagic cargo to the growing isolation membrane through specific adaptor proteins. For 
example, p62/SQSTM1 (sequestosome 1), binds polyubiquitinated protein aggregates 
targeting them for degradation in the autophagolysosomes through its association with 
LC3-II in the developing autophagosome460. In addition to the ER, other membranes 
sources have been implicated in autophagosome formation including both plasma and 
nuclear membranes, for which the function of ATG9 maybe essential481-483. This 
multispanning membrane protein is commonly associated with multiple autophagosome 
precursors throughout the cell and is continual trafficked between the trans-golgi network 
and endosomes484. The details of the complex interplay of proteins involved in mediating 
autophagic flux is outlined in Figure 4.1 B. 
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4.1.3.2 Selective autophagy and immunity 
The selective ability of autophagy allows it to be utilised for the removal of 
intracellular bacteria, parasites and viruses by phagocytic cells, including DCs and 
macrophages in a process termed ‘xenophagy’485. Although the dynamics of this process 
remain unknown it is capable of forming large vacuoles to accommodate the varying sizes 
of pathogen. For example, the diameter of group A Streptococcus-containing 
autophagosome-like vacuoles (GcAV) can be as large as 10 µm, markedly bigger than 
autophagosomes induced in metabolic turnover (0.5-1.5 µm)486. These vacuoles are 
generated by the RAB7-dependent fusion of smaller isolation membranes and indicate a 
high level of flexibility in the formation of these structures487. It is now emerging that 
autophagy proteins are also important for microbial recognition, where they are recruited 
to phagosomes to induce phagolysosomal maturation. For example, the self ligand and cell 
surface receptor SLAM (signalling lymphocytic activation molecule) functions as a 
microbial sensor that recruits a beclin 1-class III PI3K complex to phagosomes containing 
Gram-negative bacteria, facilitating phagolysosomal fusion and activation of the 
antibacterial NOX2 complex488. However, autophagy proteins also have autophagosomal 
independent functions in pathogen removal, as IFN-γ stimulation can induce the ATG5 
dependent destruction of Toxoplasma gondii vacuoles in infected macrophages489-491.  
The mechanisms utilised by cells to target intracellular bacteria to 
autophagolysosomal compartments are similar to those utilised for the selective autophagy 
of endogenous cargo. These include interactions with molecular tags (such as 
polyubiquitin), adaptor proteins such as p62 or NBR1 (neighbour of BRCA1 gene 1; which 
recognise these tags and contain an LC3-interacting region (LIR) characterised by a 
WXXL or WXXI motif) and LC3485. In particular, adaptor proteins are important for the 
selective targeting of designated cargo (endogenous and pathogenic) to newly forming 
LC3-positive isolation membranes. For example, a mechanism involving ubiquitin and p62 
is required for the transfer of intracellular bacteria such as Salmonella typhimurium, 
Shigella flesneri and Listeria monocytogenes to the autophagosomes492. 
As autophagy is a constitutive process, it has an important role in the continuous 
input of both endogenous and pathogenic Ags for presentation by MHC complexes on 
APCs279. It is for these reasons that autophagy has been observed to have roles in the 
enhancement of Ag donor cell cross-presentation to CD8+ T cells493, DC cross-presentation 
of phagocytosed Ags to CD4+ T cells494, and MHC class I presentation of intracellular Ags 
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to CD8+ T cells481. Interestingly, a role for the autophagic delivery of endogenously 
synthesised Ags has been demonstrated to be important for the MHC class II presentation 
of certain viral Ags, in vitro493. It has been proposed that in the process of the generation of 
peptides for presentation to CD4+ T cells, autophagy-protein-dependent processes allow 
this machinery access to the interior of the phagosome (much like with autophagosomes). 
In this respect, the specific deletion of Atg5 in the DCs of mice infected with HSV (herpes 
simplex virus) and Listeria results in defects in the priming of CD4+ T-cell responses, 
where the mice succumb more rapidly to lethal disease after intravaginal HSV infection494. 
These DCs specifically showed defects in phagosome-to-lysosome fusion and the cross 
presentation of MHC class II molecules of phagocytosed Ags containing TLR ligands, 
with no affect on the activity and cross-presentation of peptides by MHC class I molecules.  
4.1.3.3 TLR and cytokine induced autophagy 
So how do immune system cells modulate autophagy? Various cytokines and 
receptor signalling pathways have been implicated in modulating this mechanism, 
including those of the TLRs, CD40L, TNF-R, TRAIL, TNF-α and IFNs460,495. There is 
now mounting evidence, that TLR2, -3, -4, -7/8 and -9 accelerate the process of 
phagocytosis and up-regulate the autophagic machinery, as indicated by the increased 
prevalence of LC3 positive organelles upon positive TLR signalling496,497. In this context, 
both TLR4 and -7/8 mediate the strongest induction of autophagosome formation460. In 
conjunction with this, signalling through TLRs leads to the activation of several PI3Ks 
implicated in regulating autophagy, which help in modulating the inflammatory 
response495. TLR-dependent autophagy generally requires several hours to occur (spanning 
2 to 24 h), suggesting that a TLR mediated transcription program might be involved in the 
accumulation of mulitlamellar structures in the cytoplasm, with the objective of surveying 
the cell interior for infectious agents that may have escaped into the cytosol495,496. 
Interestingly, as the PKCs are known to be important in TLR functions, a conserved role 
for PKCδ in the regulation of gram-negative bacterium degradation by autophagy in 
mammalian cells has been demonstrated in a DAG and Ubiquitin-dependent manner498. 
In response to TLR ligand stimulation, LC3 can be directly recruited to the surface 
of the phagosome in a process termed LC3 associated phagocytosis (LAP). This process 
promotes the rapid maturation of the phagosome as it does not require the formation of the 
double membrane phagophore as with conventional autophagosomes495. In conjunction 
with this, several reports implicate TLR ligand signalling in the recruitment of both LC3 
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and beclin-1 to conventional phagosomes, followed by the activation of several PI3Ks, 
which accelerates their maturation and destructive capacity279. Collectively, it is becoming 
clear that LAP reduces opportunities for microorganisms to subvert their degradation and 
the subsequent pathogen associated peptide generation for presentation by MHC 
complexes on APCs. In this context, TLR induced autophagy also enhances peptide 
presentation on MHC class II molecules, directing the fusion of phagosomes that contain 
TLR-ligand-enveloped particles with lysosomes496,497. For example, induction of 
autophagy in Macrophages and DCs with LPS or rapamycin enhanced presentation of 
mycobacterial Ag on MHC class II molecules499.  
The induction of such responses by TLRs occurs through the actions of their direct 
signalling adaptors MyD88 and TRIF. Both of these adaptors associate with beclin-1, a key 
autophagy-associated protein, which is upregulated upon TLR activation279. However, 
there is also an important role for the downstream effectors of TLR4-TRIF induced 
signalling pathways, as the pharmacological inhibition of p38497 or knockdown of RIP-1 
completely blocks conventional LPS induced autophagy. Consistent with this, LPS induces 
the up-regulation of several autophagy genes, LC3, Atg12 and Atg5495. However, p38 
inhibitors only have a moderate effect on the recruitment of LC3 to phagosomes, indicating 
that p38 has a limited role in TLR-dependent LAP496.  
Several cytokines have been shown to regulate autophagy including the type I and 
–II IFNs, TNF-α and the TH2 cytokines IL-4 and IL-13. The type I IFNs tend to induce 
autophagy for the clearance of viruses such as HSV1, while type II has been shown to 
directly up-regulate autophagosome formation for clearance of mycobacterium460. 
Interestingly, the ability of TNF-α to stimulate autophagy only seems to occur in cells with 
low levels of NF-κB activation500. In general, the TH1 polarising pro-inflammatory 
cytokines tend to promote autophagy, while the TH2 cytokines such as IL-4 and IL-13 
appear to block its induction501. The rationale behind such a paradigm is that as TH2 
cytokines stimulate humoral based immunity there is no requirement of autophagy to 
remove intracellular pathogens. Interestingly, it has been hypothesised that the cytoplasmic 
receptors which recognise PAMPs provide docking sites for the formation of the isolation 
membrane, as suggested by studies with Franciscella tularensis. Although this gram-
negative bacterium escapes the phagosome, it is still eventually found in autophagosomes 
and it is thought its engagement with NALP3 (Nacht domain-, leucine-rich repeat-, and 
PYD-containing protein 3), a member of the NOD-like receptor (NLR) family is required 
for this engulfment by autophagosomal vesicles502.  
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4.1.3.4 The link between autophagy and NF-κB signalling; p62 
The binding of p62 to a cleaved and post-translationally modified form of LC3 
termed, LC3 type II (LC3-II), an important component of the autophagosome membrane, 
allows it to deliver ubiquitinated proteins into the autophagosome for degradation503. 
Interestingly p62 (also known as the ‘sequestrome’ or SQSTM1) is not only important in 
the propagation of autophagy but is also an adaptor/scaffold protein crucial for selective 
signal transduction, preventing non-specific access of enzymes to irrelevant substrates. p62 
has a number of domains that allow it to participate in a diverse range of cellular processes 
including inflammation, neurogenesis, osteoclastogenesis and T cell differentiation. These 
include: a PB1 (Phox and Bem1p-1) domain, enabling its association to the homotypic 
region in atypical PKCs, a ZZ zinc finger that binds to the TNF-α signalling adaptor RIP1, 
a TBS sequence for binding to TRAF6 and finally a UBA (ubiquitin associated) domain 
allowing it to bind to mono- and poly-ubiquitin chains504.  
It is these multiple binding domains that are important for the proposed role of p62 
in NF-κB activation as well as its trafficking of proteins into autophagosomes. For 
example, it has been shown that TLR induced activation of p62 and its subsequent 
interactions with TRAF6 help to coordinate orderly regulation of ubiquitin mediated 
processes in activated macrophages, ensuring cytokine secretion associated with NF-κB 
activation505. The importance of this p62-TRAF6 interaction for the modulation of NF-κB 
activation has also been shown in a number of different systems including RANK (receptor 
activator of NF-κB) triggered osteoclasts506. Thus, it is becoming clear that p62 acts as a 
scaffold to regulate K63 poly ubiquitination via its interaction with TRAF6 and 
subsequently NF-κB activation507. In this respect, p62 and TRAF6 have been co-localised 
to discrete punctuate structures upon stimulation of p62 signalling pathways508. Several of 
the identified affects of p62 have been summarised in Figure 4.2. 
4.1.4 Aims of this study 
The immunomodulation by ES-62, most notably through its degradation (via both 
proteosomal and lysosomal routes) of several PKC isoforms is an important aspect of its 
affect on a variety of immune cell types301,320,321,333. Thus, based on these observations a 
major aim of this section was to define the role of these multi-functional kinases in ES-62 
modulation of DC responses, particularly in relation to its affects on proinflammatory 
cytokine secretion. Due to the previously defined induction of PKC degradation by ES-62 
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through both protesomal and lysosomal routes, another objective of this study was to 
identify if a similar mechanism was employed in DCs. The investigation also incorporated 
the characterisation of the effect of LPS on such signals and their potential subversion by 
ES-62, to provide a comparison between how the expression of these proteins varies upon 
TLR4 recognition of both pro-inflammatory and anti-inflammatory ligands. 
There has been a wealth of information in the recent literature defining the roles of 
ubiquitination and the mediators of this process, as the E3 ubiquitin ligases, in the 
downstream transduction of TLR4 coupled activation of NF-κB. Of particular interest to 
the immunomodulatory affects of ES-62 are the E3 ligases TRAF6 and c-Cbl, both of 
which are important in regulating the activation of NF-κB24,451,452 and subsequently the 
secretion of IL-12 p70 (and IL-6) from DCs26,27,454. In this context, the regulation of IL-
12p70 (and its subunit IL-12/23p40) secretion is an important aspect of ES-62 
immunomodulation of macropahges and DCs in response to inflammatory stimuli (LPS). 
Thus, this study also set out to identify ES-62’s affect on TRAF6 and c-Cbl expression, 
which was coupled with an investigation of whether ubiquitination has a role in such 
responses.  
Autophagy is a cellular process that targets intracellular proteins for lysosomal 
degradation, which is commonly utilised in TLR-mediated innate and adaptive immune 
responses461,465. In this context, recent evidence suggests it could provide a negative 
feedback mechanism for dampening down of LPS/TLR4-mediated pro-inflammatory 
responses465. It was therefore hypothesised that ES-62 could induce/subvert autophagic 
flux for the trafficking and degradation of TLR4 and its associated signalling adaptor 
proteins in the lysosomes. This proposal was investigated in this study relative to the 
effects of proinflammatory TLR4 signalling (LPS).  
In brief, due to the emerging roles for the E3 ubiquitin ligases, PKCs and autophagy 
proteins in the TLR4 signalosome the aims of this study were to define whether: 
• ES-62 and LPS differentially modulated the expression of E3 ubiquitin ligases, 
PKCs and autophagy proteins implicated as components in the TLR4 signalsome in 
DC 
• ES-62 and LPS differentially trafficked TLR4 signalsome components for 
proteosomal and lysosomal degradation 
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• ES-62 subverted TLR4-coupled autophagy-mediated negative feedback 
mechanisms to induce an anti-inflammatory phenotype 
• ES-62-mediated degradation of TLR4 signalsome components correlated with 
suppression of DC pro-inflammatory responses 
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4.2 Results 
4.2.1 Activation of NF-κB and cytokine secretion, the differential 
effects of LPS & ES-62 
As a first step to investigate the molecular changes initiated by ES-62 and LPS on 
the activation of NF-κB, their effects on two common isoforms of the inhibitory 
component (IκB) of the complex were analysed. It was observed that LPS induced the 
early degradation of both IκB-α and -β within 2 h of stimulation (indicating NF-κB 
activation), after which their levels returned to basal by 18 h (Fig. 4.3). By contrast, ES-62 
had little or no effect on either IκB-α and -β expression over an 18 h time-course, 
consistent with its noted lack of induction of cytokine responses (Fig. 3.11). This result 
was found to be representative of the effect of ES-62 on the expression of both isoforms of 
IκB, from the collated data of several experiments (Fig. 4.4 A-B). To address how LPS 
was inducing the degradation of IκB and whether ES-62 was stabilising its expression, 
inhibitors of vesicular transport (ammonium chloride[NH4Cl]), lysosomal degradation (E-
64-D/Pepstatin A and ammonium chloride) and proteosomal degradation (lactacystin), 
were utilised to determine whether blocking of such signals could convert ES-62-TLR4 
signalling to an LPS-TLR4 phenotype or vice versa (Fig. 4.3 & Fig. 4.4 C-D).  
The results indicated that in blocking lysosomal degradation and interfering with 
vesicular transport (ammonium chloride), IκB-α accumulated upon LPS stimulation, 
although this was reduced to basal levels after 18 h (Fig. 4.3). This perhaps suggests that 
under these conditions the cell switches to the proteosome to degrade this protein. On the 
other hand, treatment with E-64-D/Pepstatin A did not alter the early (2 h) transient 
degradation of either IκB-α or IκB-β but it did prevent their protracted downregulation (≥ 
6 h). Under these conditions the suggested lysosomal component of IκB-α and IκB-β 
degradation could be due to the sustained TRIF-mediated NF-κB activation phase13. Here, 
treatment of the cells with lactacystin did not yield conclusive results due to the toxicity of 
this compound (as demonstrated in Fig. 2.1) as cells treated post 18 h displayed marked 
variation of protein expression, as defined from the loading control (results not shown). 
Thus, although this could not be confirmed by the use of lactacystin, it was assumed that 
the early degradation of IκB induced by LPS (within 2 h), was occurring through the 
proteosome as this is commonly reported in the literature330. The disparity between the 
effects of ammonium chloride and E-64-D/Pepstatin A suggest the former’s subsidiary 
modulation of vesiclular transport354-357, in particular the internalisation of cell surface 
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proteins358-360, may have a direct effect on the internalisation and function of TLR4 upon 
LPS recognition. Consistent with the finding that ES-62 did not markedly alter IκB 
expression, inhibition of lysosomal degradation (E-64-D/Pepstatin A) did little to alter this 
result (Fig. 4.3). However, ammonium chloride did change the dynamics of ES-62 
mediated regulation of IκB-α, inducing the gradual accumulation of the protein, which 
could be attributed to the multiple effects of this agent on cellular homeostasis.  
To further define whether ES-62 had any regulatory effects on the expression of 
IκB-α upon LPS stimulation, combinations of these TLR4 agonists were utilised in 
conjunction with E-64-D/Pepstatin A, ammonium chloride and lactacystin (Fig. 4.4 and 
Fig. 4.5). In Figure 4.5 A-B, the immature DCs (unstimulated control) yielded a lower 
expression of IκB-α than would be expected from unstimulated cells as observed in other 
samples (Figs. 4.3-4.4). As such, due to the negligible effects of ES-62 (18 h) on IκB-α 
expression identified over several experiments, the ES-62 treated sample (Media 18 h + 
ES-62 18 h) was utilised as the basal control from which the expression of the others were 
adjusted to. This analysis revealed ES-62 did not inhibit the downregulation of IκB-α in 
response to LPS, a result unaltered by inhibiting lysosomal degradation, despite previous 
studies suggesting that this immunoodulator acts to suppress the early (< 18 h) LPS 
mediated downregulaiton of IκB291,319 (Fig. 4.3). 
In this context, ES-62 may act to target hyper rather than normal inflammatory 
responses. In the above experiments, GM-CSF, the cytokine responsible for the 
differentiation of DCs, was removed during their maturation with LPS and/or ES-62. This 
cytokine, in addition to being a key factor in the generation of immature DC from 
progenitor cells is strongly elevated in pro-inflammatory conditions509. Therefore these 
experiments were repeated with GM-CSF maintained in the media to mimic a pro-
inflammatory environment. This approach revealed an interesting pattern of IκB-α and -β 
expression upon stimulation of bmDCs with both ES-62 and/or LPS (Fig. 4.6). For 
example, ES-62 treatment induced a cyclical expression of IκB-α and -β. Specifically, for 
IκB-α, the prior maturation of DCs with ES-62 consistently lowered its expression in 
response to LPS, the greatest of these effects occurring after a 3 h stimulus. By contrast, 
under the same conditions ES-62 up-regulated the expression of IκB-β.  
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4.2.2 ES-62 modulation of key proteins in the propagation of TLR4 
pro-inflammatory signals; MyD88 and TIRAP 
Having established that the TLR4 ligands, LPS and ES-62 were differentially 
modulating IκB expression, the next step was to analyse their effect on the direct signalling 
transducers TIRAP and MyD88, which are important for the early activation of NF-κB and 
several MAPKs (ERK, JNK and p38). Given that previous studies with ES-62 and MyD88-
/- mice indicated this adaptor was required for the ES-62 induced low level production of 
cytokines by macrophages301,331, it was hypothesised that MyD88 and TIRAP were 
potential targets of this immunomodulator in DCs. 
Western blot analysis of MyD88 expression indicated ES-62 transiently (within 6 
h) upregulated this adaptor, albeit only slightly (Fig. 4.7 A-B), where over several 
experiments this was also found to be the case after an 18 h stimulation as well (Fig. 4.7 C-
D). By contrast, after an initial downregulation (2 h) LPS also stimulated the reproducible 
upregulation of MyD88 after 18 h (Fig.4.7 A-D), a finding supported by flow cytometry of 
cells stained intracellularly with the same polyclonal antibody from the Western blotting 
study (Fig. 4.8 B-C). Taqman RT-qPCR revealed that MyD88 mRNA expression peaked 
at 6 h to 3.957 ± 0.641 % above the endogenous GAPDH control in response to LPS (Fig. 
4.8 D), which precedes the increase in MyD88 protein at 18 h. Consistent with its minor 
induction of MyD88 protein expression (between 6-18 h), ES-62 had little or no effect on 
upregulating mRNA transcript. In this respect, ES-62 was observed to transiently increase 
TIRAP (MAL) expression in a similar fashion to MyD88 (Fig. 4.9 A-B). However, neither 
TLR4 ligand significantly modulated TIRAP expression after a prolonged stimulation of 
18 h (Fig. 4.9 C-D). 
In relation to the results above, when the expression levels of MyD88 and TIRAP 
were investigated following the pretreatment of the bmDCs with E-64-D/Pepsatain A, ES-
62 but not LPS stimulation induced a considerable level of lysosomal turnover of these 
proteins (Fig. 4.10). Indeed, blocking of lysosomal degradation converted the levels of 
MyD88 expression in not only ES-62-treated but unstimulated DCs to levels approaching 
that observed in LPS-matured cells (Fig. 4.10 A-B). By contrast, this treatment slightly 
reduced MyD88 upregulation by LPS, with a similar pattern observed for TIRAP, although 
the inhibitor-induced reduction in LPS-associated expression was more pronounced (Fig. 
4.10 C-D). Collectively, these results suggest that ES-62 (or immature DCs) may actively 
suppress MyD88 levels to prevent aberrant (hyper)inflammatory responses and that LPS 
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traffics some undefined negative regulator of MyD88 and TIRAP through a lysosomal 
route to maintain such affects. Alternatively, as a high turnover of the protein occurs 
through the lysosomes, by pharmacologically shutting off this route of degradation, upon a 
strong LPS signal, the cells may shunt these functions to the proteosome.  
Due to the potential of ES-62 modulating its cellular effects dependeing on the 
inflammatory environment it was decided to analyse MyD88 expression with the addition 
of GM-CSF to the stimulation media. Interestingly, these preliminary results suggested that 
when GM-CSF was present (Fig.4.7 E-F), ES-62 induced the down-regulation of MyD88 
expression whilst LPS maintained its upregulation of this adaptor. These differential 
effects are consistent with previous studies in this laboratory showing that ES-62 
downregulates MyD88 expression in a variety of cells including: T cells undergoing IL-1-
driven TH17 polarisation352, Bm derived macrophages from BALB/c and MRL/Lpr mice 
and human monocytes (unpublished data).  
4.2.3 Roles for the E3 Ubiquitin ligases, TRAF6 and c-Cbl, in 
disruption of TLR4-NF-κB based inflammation by ES-62 
The differential effects of LPS and ES-62 on MyD88/TIRAP expression suggested 
that ES-62 was indeed targeting components of the TLR4-NF-κB pathway to imprint its 
anti-inflammatory effects on DCs. Therefore, the effects of both TLR4 ligands were 
analysed on the E3 Ubiquitin ligases, TRAF6 and c-Cbl, which are involved in both 
MyD88-dependent and independent transduction of TLR4 signals. It was hypothesised that 
based on ES-62-mediated reduction of IL-12p70, IL-23 and TNF-α secretion upon LPS 
challenge (Fig. 3.11), this immunomodulator would down-regulate or otherwise impair the 
function of TRAF6. In the case of c-Cbl it was hypothesised that it may up-regulate this E3 
ubiquitin ligase to stabilise the NF-κB inhibitory complex, preventing effective secretion 
of pro-inflammatory cytokines.  
Both ES-62 and LPS exhibited differential effects on TRAF6 expression with LPS 
transiently downregulating this protein, which was then steadily replenished to levels 
above basal (unstimulated cells), while in contrast, following the early upregulation of 
TRAF6 (2 h), ES-62 then induced its marked reduction (18 h; Fig. 4.11). To dissect the 
mechanisms underlying such differential responses, the effects of these TLR4 ligands was 
again addressed using the inhibitors E-64-D/Pepstatin A, ammonium chloride and 
lactacystin. Although E-64-D/Pepstatin A was unable to prevent the degradation of TRAF6 
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in response to LPS at the 2 h time point (indeed it accentuated it), ammonium chloride had 
little effect on LPS-induced modulation, acting only to prevent its upregulation after an 18 
h treatment (Fig. 4.11 A-B). By contrast, lactacystin clearly prevented the reduction of 
TRAF6 levels in response to LPS, suggesting that endotoxin directs its rapid degradation 
through the proteosome. Therefore, in support of the hypothesis of differential regulation 
by the TLR4 ligands, both E-64-D/Pepstatin A and ammonium chloride were able to 
prevent the oscillating pattern of TRAF6 expression observed in response to ES-62 (Fig. 
4.11 A & C). In respect to E-64-D/Pepstatin A, a steady time-dependent increase in the 
expression of this E3 ubiquitin ligase was observed, treatment with ammonium chloride 
resulted in a similar accumulation although not as marked. In addition, although delaying 
the effects of ES-62, lactacystin did not ultimately prevent the degradation of TRAF6. 
Collectively, these data suggest that lysosomal degradation plays a role in ES-62-, but not 
LPS-mediated down-regulation of TRAF6, which appears to be predominantly occuring 
via the proteosome. The dynamics of TRAF6 protein expression in response to LPS and 
ES-62 are consistent with their modulation of its mRNA expression. Thus, ES-62 induced 
an early increase in the mRNA transcript, within 6 h of stimulation, followed by a return to 
basal levels by 18 h (Fig. 4.11 D). While in contrast, LPS gradually increased TRAF6 
mRNA expression progressively during the course of treatment, not reaching maximal 
production till 18 h of stimulation.  
Upon further investigation of the protracted effects of these TLR4 agonists on 
TRAF6 epxression and the role of the lysosomes in their regulation, both immature and 
ES-62- but not LPS-treated DCs diplayed a low level of lysosomal turnover of this E3 
ligase (Fig. 4.12). Indeed, the inhibition of lysosomal degradation (E-64-D/Pepstatin A) 
converted the ES-62 response to resemble that of LPS (albeit not as strong). Although, 
when the length of treatment was extended to 36 h the expression of TRAF6 returned to 
just above basal levels. Rather unexpectedly, prior maturation with ES-62 only marginally 
suppressed the upregulation of TRAF6 in response to LPS, with E-64-D/Pepstatin A 
having little effect.  
The collated data from several experiments demonstrated that overall, TRAF6 was 
significantly (p < 0.05) and reproducibly downregulated by ES-62 (0.61 ± 0.12, n=6) 
within an 18 h stimulation relative to its strong up-regulation by LPS (1.99 ± 0.21, n=6) 
(Fig. 4.13 A-B). These downregulatory effects of ES-62 were ablated upon pre-treatment 
of the cells with either E-64-D/Pepstatin A (1.62 ± 0.31 n=3) or ammonium chloride 
(1.381 ± 0.41, n=3), with the former inducing a significantly (p < 0.05) greater increase. 
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Moreover, pretreatment with ES-62 repeatedly decreased the LPS induced upregulation of 
TRAF6 (1.42 ± 0.37, n=6). In addition, ammonium chloride exacerbated TRAF6 
expression upon LPS stimulation of ES-62 matured cells while E-64-D/Pepstatin A was 
unable to replicate this latter effect (Fig. 4.13 A & C). Of note, neither inhibitor had any 
significant effects on LPS induced up-regulation of TRAF6 expression. The mimicking of 
an inflammatory environment with GM-CSF exacerbated ES-62’s downregulation of 
TRAF6 expression throughout an 18 h time course (Fig. 4.14 A-B). This effect was 
maintained (exacerbated even) when the cells were subsequently challenged with 
endotoxin (Fig. 4.14 C-D). Interestingly, under the same consitions IκB-β was also up-
regulated by ES-62 maturation, which was unaffected by subsequent treatment with LPS 
(Fig. 4.14 C & E).  
These results demonstrated that ES-62 could suppress aberrant hyper-inflammation 
through the modulation of TRAF6 expression and similarly, both TLR4 ligands induced 
diametric effects on c-Cbl expression. LPS stimulated the progressive downregulation of c-
Cbl with time (within 18 h), whereas ES-62 dynamically upregulated this E3 ligase (Fig. 
4.15 A-D), a reproducible pattern over several experiments (Fig.4.15 D). These changes in 
protein expression were partially mirrored at the mRNA level, with an increase that 
plateaued within 6 h of ES-62 treatment (Fig. 4.15 E), whilst LPS induced an initial 
transient increase in mRNA, which did not drop below basal levels. This suggested that the 
decrease in c-Cbl protein reflected degradation rather than suppression of its production. 
Consistent with this, pretreatment of the bmDCs with E-64-D/Pepstatin A, ammonium 
chloride and lactacystin rescued LPS induced downregulation of c-Cbl but it was only the 
latter compound that led to its accumulation within the cells (Fig. 4.15 A-B). Rather 
surprisingly, all of the inhibitors blocked the upregulatory effects of ES-62, perhaps 
indicating some complex time-dependent interplay between endosomal/proteosomal 
degradation of TLR4-NF-κB regulatory elements (Fig. 4.15 A & B). 
The differential effects on c-Cbl expression exhibited by these anti-(ES-62) and 
pro-(LPS)inflammatory TLR4 ligands were reproducible with clear up-regulation and 
substantial down-regulation of c-Cbl by ES-62 (1.88 ±1.01, n=4) and LPS (0.53 ± 0.24, 
n=4), respectively (Fig. 4.16). Moreover, inhibiting lysosomal degradation with E-64-
D/Pepstatin A not only blocked ES-62-mediated upregulation of c-Cbl (0.76 ± 0.14, n=2) 
but also dramatically reduced the down-regulation observed with LPS (1.048 ± 0.08, n=2). 
Of interest, pretreatment of the bmDCs with ES-62 prevented the LPS induced down-
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regulation of c-Cbl, with its expression (0.86 ± 0.08, n=2) remaining above that induced by 
LPS (0.53 ± 0.24, n=4). Thus, it was very interesting to find that in the presence of GM-
CSF, ES-62 profoundly down-regulated c-Cbl (Fig. 4.17 A-B) and the subsequent 
exposure of such ES-62 matured cells to LPS reversed this downregulation after both a 1 h 
and 6 h stimulation (Fig. 4.17 C-D). Interestingly, LPS in conjunction with GM-CSF 
stimulated a gradual increase in the levels of c-Cbl over 6 h. Collectively, these results 
indicate that the effect of immuno-modulatory molecules, such as ES-62 and LPS on the 
signalling components of the TLRs vary depending on the inflammatory environment of 
the cell. 
4.2.4 The emerging role of PKCs in the TLR4-NF-κB signalling axis 
and the role of ES-62 in its subversion 
The TLR4 agonist, LPS has been shown to activate most PKC isoforms in innate 
cells such as monocytes, macrophages, DCs and neutrophils91-95. In conjunction with this, 
studies have shown that acute activation of the PKCs with phorbol esters, increases LPS-
stimulated cytokine secretion94,96-98, while their pharmacological inhibition attenuates their 
production96,98,99. In this context, several isoforms, including PKCα, PKCδ and PKCε have 
important roles in TLR4 induced cytokine secretion, through their direct involvement in 
the TLR4-NF-κB activation axis in cells of the innate immune system, including DCs. The 
role of PKCs in mediating many important innate cell functions and the regulation of 
TLR4 responses, particularly in relation to their involvement in pro-inflammatory cytokine 
secretion was therefore the basis for our investigation of the targeted subversion of DC 
function by ES-62. Firstly, the effect of ES-62 stimulation on the expression of a wide 
range of PKC isoforms was defined (Fig. 4.18-4.22), whereby the immunomodulator had 
little affect on the expression of PKCθ, -ι and -β (Fig. 4.18) but was observed to markedly 
regulate the expression of PKCα (Fig. 4.19), -ε (Fig. 4.20) and -δ (Fig. 4.22). 
4.2.4.1 PKCα 
With respect to PKCα, treatment with both ES-62 (2.17 ± 0.86, n=2) and LPS (1.28 
± 0.01, n=2) progressively and consistently up-regulated its expression over 18 h (Fig. 4.19 
A-D). Moreover, when the phosphorylation of PKCα at threonine 638 (Thr638; an auto-
phosphorylation site located within the C-terminal ‘tail’) was analysed over an 18 h time 
course (Fig. 4.19 E-F), it appeared that ES-62 may be transiently (< 6h) activating PKCα, 
a result consistent with our previous studies in B cells320,333. However, ES-62-mediated 
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upregulation of PKCα was not observed in the pro-inflammatory environment mimicked 
by the presence of GM-CSF, as levels appear to oscillate around basal levels defined by 
immature (unstimulated) cells within a 6 h stimulatory window (Fig. 4.19 G-H). As PKCα 
is known to play a role in IL-6 secretion, this result provides an explanation for the lack of 
ES-62-mediated suppression of this cytokines produciton upon subsequent LPS stimulation 
(Fig. 3.11). This result may go some way to explaining how DCs can maintain their ability 
to allow immune responses to be initiated to LPS and invading gram negative bacteria, 
when exposed to parasite immunomodulatory products.  
4.2.4.2 PKCε 
By contrast, it was hypothesised that the reduction of IL-12p70 secretion by ES-62 
in response to LPS could be linked to the downregulation of PKCε and indeed, it was 
found that ES-62 led to the progressive (Fig. 4.20), and reproducible (after an 18 h 
stimulus; Fig. 4.21; 0.56 ± 0.14, n=3) reduction of this isoform. These effects were rescued 
by pre-treating the bmDCs with the lysosomal inhibitors ammonium chloride and E-64-
D/Pepstatin A, the former inducing the cyclical up-regulation of PKCε (peaking 2 h after 
treatment; Fig. 4.20 B & D). Interestingly, the rescue of PKCε expression by E-64-
D/Pepstain A above basal levels after an 18 h stimulus with ES-62 was found to be a 
significant and consistent phenomenon (1.45 ± 0.19 n=3; Fig. 4.21 B) but the proteosomal 
inhibitor lactacystin, had no effect on such degradation (Fig. 4.20 B & D). On the other 
hand, LPS treatment induced the reproducible upregulation of PKCε expression in 
response to LPS after an 18 h stimulus (1.49 ± 0.21, n=3; Fig. 4.21 B), which remained 
unaltered by prior treatment with E-64-D/Pepstatin A and ammonium chloride. The 
differential trafficking/signalling of TLR4 and PKCε relative to ES-62 was apparent when, 
ammonium chloride pretreatment induced an inverse transient effect after 2 h LPS 
treatment (Fig. 4.20 C-D). Interestingly, pretreatment with lactacystin strongly upregulated 
PKCε, indicating that in response to LPS, the cell may activate negative feedback 
mechanisms to prevent its excessive accumulation and the hyper-secretion of pro-
inflammatory cytokines.  
With respect to the induction of PKCε mRNA transcript production, ES-62 appears 
to uncouple (to some extent) transcription and translation of PKCε, as the high levels of 
mRNA at 6 h are not translated into similar levels of protein (Fig. 4.20, E). This suggests 
that in an attempt to maintain homeostatsis upon ES-62 downregulation of PKCε, bmDCs 
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upregulate mRNA transcript (within 6 h) but its turnover through the lysosomes may 
negate these compensatory effects. Interestingly, LPS induced the up-regulation of both 
PKCε protein and mRNA transcript expression throughout an 18 h treatment. The prior 
maturation of bmDCs with ES-62 had a slight inhibitory affect on the LPS induced 
upregulation of PKCε (1.20 ± 0.30, n=3), which was rescued (albeit not significantly) by 
pretreatment with E64-D/Pepstatin A (1.57 ± 0.07, n=3). These data reinforce the concept 
that ES-62 maturation of DCs does not markedly inhibit the cell from responding to normal 
inflammatory stimuli. 
4.2.4.3 PKCδ 
The results for PKCε, based on the current literature, may provide a direct link 
between ES-62’s modulation of cytokine secretion in DCs and its down-regulation of 
components in the TLR4-NF-κB signalling axis. However, in respect to direct NF-κB 
activation, PKCδ has been shown to play a crucial role for the TLR4 mediated activation 
of IKK101, with recent evidence showing it can phosphorylate IκB (which masks the NLS 
of NF-κB) allowing the nuclear translocation of NF-κB104,105. Thus, the effect of PKCδ 
expression and the potential avenues of its degradation by ES-62 in its attenuation of 
proinflammatory cytokine responses were investigated. Over several experiments, ES-62 
was observed to transiently induce a slight but non-significant up-regulation of PKCδ 
expression through 2 h (1.09 ± 0.21, n=3), which was significantly down-regulated after 6 
h (0.53 ± 0.07, n=3) and maintained at these lower levels over an 18 h stimulation (0.48 ± 
0.05, n=6) (Fig. 4.22 A & E). The effects of LPS were more subtle, with a slight, but non-
significant downregulation observed within 2 h of stimulation (0.80 ± 0.07, n=3), that 
slowly recovered to basal levels over an 18 h treatment (0.98 ± 0.12, n=3) (Fig. 4.22 B & 
E). In a similar fashion to observations made with PKCε, ES-62 appeared to uncouple the 
translation of rising levels of PKCδ mRNA transcript 2 h post stimulation (Fig. 4.22, F). In 
relation to LPS, the increasing levels of PKCδ transcript may reflect the recovery of 
protein expression over the 18 h stimulation. Again, the downregulatory effects of ES-62 
could be rescued by the pre-treatment of the cells with the lysosomal degradation inhibitors 
E-64-D/Pepstatin A and ammonium chloride (Fig. 4.22 A & D) but it is important to note 
that, unlike PKCε, treatment with E-64-D/Pepstatin A induced the accumulation of the 
protein, perhaps reflecting the steady increase of mRNA transcript observed over time. 
However, similarly to that observed for PKCε, ammonium chloride treatment led to the 
cyclical up-regulation of PKCδ.  
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The pronounced downregulatory effect of ES-62 on PKCδ expression (0.48 ± 0.05, 
n=6), by the lysosomal inhibitors, E-64-D/Pepstatin A (1.30 ± 0.05, n=3) and ammonium 
chloride (1.82 ± 0.54, n=2) were consistent and reproducible (Fig. 4.23). In relation to this, 
when ES-62 matured cells were stimulated with LPS, although not significant, PKCδ 
expression tended to be reduced below that observed with endotoxin alone and rather 
unexpectedly, treatment with E-64-D/Pepstatin A had little effect on this trait. Again LPS 
stimulation had little affect on the long-term expression of PKCδ, with neither lysosomal 
degradation inhibitor able to change this outcome but lactacystin considerably up-regulated 
the levels of PKCδ, while not preventing its degradation indued by ES-62 (Fig. 4.22 B-C). 
In this context, the lysosomal inhibitors did not drastically alter the LPS response, although 
there appeared to be an inverse transient effect at 2 h with ammonium chloride treatment. 
This suggested that differential trafficking of TLR4 and subsequently PKCδ signalling 
occurs between ES-62 and LPS. In a similar fashion to PKCε the strong up-regulation of 
PKCδ in response to the inhibition of proteosomal degradation indicated that in response to 
LPS, the cell may activate negative feedback mechanisms to prevent its excessive 
accumulation and the hyper-secretion of pro-inflammatory cytokines.    
4.2.4.3.1 The modulation of PKCδ localisation and cleavage by ES-62 
The spatiotemporal localisation of PKCδ is very important in regulating its function 
and activation as it is not restricted to the cytoplasm and is often detected in the nucleus of 
many cell types, where its translocation is mediated by a bipartite NLS (6 basic amino 
acids) in its C-terminus52. Interstingly, PKCδ is often cleaved upon various cellular stimuli 
where both the enzymology and roles of the full length and cleaved catalytic domain 
fragment, which is phospholipid independent and constitutively active, differ 
considerably57,58. Thus, to investigate whether ES-62 induces the cleavage and 
redistribution of these two different formats of PKCδ from the cytoplasm to the nucleus in 
bmDCs, nuclear and cytoplasmic preparations of cells stimulated with ES-62 over 18 h 
were analysed by Western blotting (Fig. 4.24). After the normalisation of each result to the 
relevant control, the stimulation of bmDCs with ES-62, was observed to induce the 
transient increase in the nucleus of both full length (78 kDa) and cleaved (38 kDa) forms of 
PKCδ (Fig. 4.24 A-C). This was accompanied by a compensatory decrease in the levels of 
PKCδ in the cytoplasm. This experiment also provided the opportunity to investigate the 
internalisation and localisation of ES-62 in bmDCs as it is known to be internalised and 
trafficked to the nucleus of macrophages and B cells (H.S. Goodridge & M. M. Harnett, 
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unpublished data). After several experiments confirming that ES-62 was internalised by 
bmDCs after 18 h of stimulation (for example; Fig. 4.24 D), the accumulation of the 
protein in the cytoplasm but not the nucleus was confirmed (Fig. 4.24 A). Though lacking 
in similar subcellular fractionation data for LPS, a clear movement of PKCδ from the 
cytoplasm into the nucleus upon LPS treatment (18 h) was visualised utilising confocal 
microscopy in bmDCs (Fig. 4.25), where its diffuse expression in resting cells was 
redistributed to the nucleus (though a cytoplasmic component is still evident).   
The data from several ES-62 and LPS stimulations over an 18 h time course 
revealed both, but particularly LPS, induced the dynamic regulation of PKCδ cleavage in 
the cell (Fig. 4.26 A-B). Endotoxin progressively down-regulated its expression 
throughout the time course, with the lowest levels observed 6 hours after stimulation 
(0.048 ± 0.018, n=3). On the other hand, ES-62 transiently increased its expression 
(peaking at 2 h; 1.22 ± 0.04, n=3) before its downregulation, with the percentages of 
cleaved PKCδ relative to the total amounts (cleaved and full length protein) in the cell 
revealing it induced a small but steady increase in the relative amounts of cleaved PKCδ 
(Fig. 4.26 B). However, this is not the case upon LPS stimulation where the large decrease 
in the levels of cleaved PKCδ is not reciprocated with the full length protein. 
Interestingly, the results from the addition of the proteosomal (lactacystin) and 
lysosomal inhibitors (E-64-D/Pepstatin A and ammonium chloride), revealed differential 
effects, which were dependent on the nature of the TLR4 stimulus. Inhibition with either 
E-64-D/Pepstatin A or ammonium chloride did not prevent the long-term degradation of 
cleaved PKCδ by ES-62, however they did prolong (from 2 to 6 h) and enhance its 
transient up-regulation (Fig. 4.26 A & C). The relative percentages of cleaved to total 
cellular PKCδ, reveal both lysosomal inhibitors induce the transient accumulation of the 
cleaved form (though ammonium chloride sustains this until 6 h, unlike E-64-D/Pepstatin 
A), which is followed by a sharp decrease after stimulation for 18 h. Thus, in the absence 
of lysosomal degradation, ES-62 induces a reduction of cleaved to total cellular PKCδ after 
18 h, although this may simply reflect the inhibitors preventing the 78 kDa form of PKCδ 
from being down-regulated. On the other hand, lactacystin accentuates the degradation of 
cleaved PKCδ and as revealed by analysis of their relative proportions, there is some 
correlation between the transient degradation and recovery of both the cleaved and full-
length protein (Fig. 4.22). By contrast, LPS stimulation induces the marked reduction of 
cleaved PKCδ (Fig. 4.26 A & D), while of the lysosomal degradation inhibitors, only E-
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64-D/Pepstatin A prevented a small fraction of the LPS induced down-regulation of the 
cleaved protein. However pre-treating the cells with lactacystin reversed the LPS induced 
effect while mediating a dramatic transient increase of cleaved protein relative to the total 
amounts of PKCδ within the cell. Although the cleaved form is a very minor component by 
18 h, it suggests that this transient protection may reflect prevention of proteosomal 
degradation of full length PKCδ while that of the cleaved PKCδ is being processed via a 
non-proteosomal route. Hence, LPS differentially modulates these distinct forms of PKCδ.  
The long-term effects of ES-62 and LPS on the expression of cleaved PKCδ (18 h) 
were reproducible over several experiments (Fig. 4.27) and the maturation of the bmDCs 
with ES-62 did not modulate its down-regulation in response to LPS. In this context, it was 
clear that ES-62 was consistently down-regulating both the whole and cleaved forms of 
PKCδ, as the percentage of the cleaved relative to the total amounts in the cell remained 
constant (Fig. 4.27 C). The collected data for the effects of the proteosomal (lactacytsin) 
and lysosomal/endosomal trafficking (ammonium chloride) inhibitors confirmed that 
inhibition of the proteosome rescued down-regulation of cleaved PKCδ and induced its 
accumulation in response to LPS (Fig. 4.27 D-F).  
4.2.4.3.2 Phosphorylation of PKCδ 
The phosphorylation of PKCδ at various sites is very important in influencing its 
localisation, stability, protease/phosphatase resistance, protein-protein interactions and 
substrate specificity52,72. This isoform is unusual among the PKC family, however, as it can 
function as a kinase even without phosphorylation of its A-loop (at Threonine 505 
[Thr505]), which is crucial for the other isoforms71. However, phosphorylation at the A-
loop region is associated with inducing its cleavage and helps to regulate PKCδ substrate 
specificity, rather than absolute activity of both the cleaved and full length protein. PKCδ 
can also be phosphorylated at several other conserved C-terminal sites, namely the 
transmembrane (TM) and hydrophobic motifs (HM) through both auto-phosphorylation 
and transphosphorylation mechanisms (depending on the isoform and context). The auto-
phosphorylation site, Ser643 in the TM is important for maintaining certain catalytic 
functions of the protein510,511. PKCδ also has several sites outside the C-terminal tail that 
are phosphorylated to a range of diverse stimuli and are important in the protein’s 
function53,73. For example, phosphorylation of the Tyr311/Tyr332 residues in the hinge 
region, which can be mediated via Src tyrosine kinase, provides docking sites for several 
signalling molecules on PKCδ52. 
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Based on these findings the effect of LPS and ES-62 on the state of PKCδ 
phosphorylation in bmDCs was investigated (Fig. 4.28 – 4.30). Both TLR4 agonists 
induced the phosphorylation of the A-loop on the full length protein (78 kDa), which was 
consistent with its degradation, while ES-62 specifically stimulated a higher transient 
increase through 2 to 6 h (Fig. 4.28 A-B). Upon longer exposures, LPS was observed to 
regulate the phosphorylation of the A-loop on both cleaved (38 kDa) and whole (78 kDa) 
PKCδ, with LPS inducing a transient down-regulation of A-loop phosphorylation over 6 h 
of stimulation, suggesting that the low levels of cleaved PKCδ remaining at 18 h must be 
heavily phosphorylated at this site, perhaps indicating it could be associated in its targeting 
for degradation. It should be borne in mind, however, that these results could reflect either 
the direct phosphorylation of cleaved PKCδ or the full length protein (78 kDa), which is 
subsequently cleaved. The relative levels of phosphorylated PKCδ to the total protein in 
the cell also suggest that ES-62 may utilise this mechanism to downregulate levels of full 
length PKCδ in the cell (Fig. 4.28 A & C). The up-regulation of this type of 
phosphorylation of PKCδ over several experiments by both TLR4 agonists even after 18 h 
of stimulation was found to be significant for LPS (2.79 ± 0.92, n=4) and consistently 
reproducible for ES-62 (1.765 ± 0.23, n=3) (Fig. 4.28 D-E).  
Subsequently, the phosphorylation of PKCδ at a further two sites were investigated, 
Ser643 and Tyr311, as these are important in maintaining catalytic stability and directing 
protein-protein interactions, respectively. These studies were performed in conjunction 
with E-64-D/Pepstatin A, to identify whether lysosomal degradation is associated with 
these phosphorylated forms of PKCδ. Treatment with ES-62 was found to result in Ser643 
phosphorylation above that of resting cells after 36 h of stimulation, while for LPS, this 
was observed at 18 h, but not 36 h (Fig. 4.29 A and C). Maturation of the bmDCs with ES-
62 had negligible effects upon subsequent LPS induced up-regulation of Ser643 
phosphorylation. In this context, pre-treatment of the cells with E-64-D/pepstatin A 
changed the dynamics of these effects. For example, blocking of lysosomal degradation 
induced transient (18 but not 36 h) accumulation of ES-62 stimulated Ser643 
phosphorylated PKCδ. Thus it appeared to convert ES-62 to a more LPS-like phenotype 
although this treatment acted to suppress the LPS response, perhaps by increasing the 
kinetics as ES-62 induced an increase in the levels of Ser643 phosphorylated PKCδ 
relative to the total amount in the cell and this effect is similarly abolished after 36 h of 
stimulation by E-64-D/Pepstatin A (Fig. 4.29 D).  
  
176 
Under non-stimulatory conditions the dynamics of the phosphorylation of PKCδ on 
Tyr311 suggest a high turnover through the lysosomes, as E-64-D/Pepstatin induced a 
strong accumulation of this form of PKCδ in resting cells (Fig. 4.30 A & C). Upon 
stimulation with either ES-62 or LPS a transient increase in the phosphorylation of this site 
occurs over the 36 h period, although this is less pronounced in response to ES-62. The 
prior maturation of the cells with ES-62 does not inhibit the ability of LPS to induce the 
Tyr311 phosphorylation of PKCδ. These effects are also observed when the 
phosphorylation of Tyr311 is expressed relative to the amounts of PKCδ observed in the 
cell (Fig. 4.30 A & D). By blocking lysosomal degradation with E-64-D/Pepstatin A, an 
accumulation is observed of this phosphorylated form of PKCδ in response to ES-62 
relative to the immuno-modulator alone (Fig. 4.30 C), although this effect is particularly 
prominent on the ES-62 matured cells subsequently exposed to LPS. By contrast, 
inhibition of lysosomal degradation inhibition actually reduced LPS induced 
phosphorylation of Tyr311. Thus, it appears as though lysosomal degradation is associated 
with ES-62’s modulation of this form of PKCδ phosphorylation. In this context, ES-
62/LPS stimulated levels of Tyr311 phosphorylated PKCδ decrease relative to the total 
amounts in the cell upon inhibition of lysosomal degradation (Fig. 4.30 D). However, 
when ES-62 matured cells are stimulated with LPS there is a dramatic increase in PKCδ 
phosphorylation on Tyr311 relative to total amounts observed in the cell, perhaps 
suggesting that this phosphorylation may be associated with lysosomal targeting.  
4.2.4.4 The effects of specifically inhibiting lysosomal degradation on DC 
cytokine production in response to ES-62 and/or LPS 
Collectively ES-62 was observed to target the lysosomal degradation of important 
mediators in the activation of NF-κB by TLR4 signalling. Thus, to determine whether ES-
62 was suppressing DC cytokine responses by inducing lysosomal degradation of key 
regulatory elements, the effect of pretreating bmDCs with the lysosomal protease inhibitors 
E-64-D/Pepstatin A and ammonium chloride prior to ES-62 and/or LPS-stimulation on the 
secretion of various cytokines was tested (Fig. 4.31 & 4.32).  
Exposure to E-64-D/Pepstatin A did indeed significantly block ES-62 mediated 
suppression of the key pro-inflammatory cytokine, Il-12p70 (Fig. 4.31). Rather 
surprisingly, however, this effect was specific to IL-12p70 as the downregulation of IL-23 
and TNF-α responses remained unaffected. Moreover, the endotoxin induced secretion of 
IL-23 and IL-27 was significantly inhibited by E-64-D/Pepstatin A, but in respect to IL-27 
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this was prevented by the prior maturation of DCs with ES-62. However, pretreatment of 
the cells with ammonium chloride resulted in very little change in the secretion of LPS 
induced cytokines and did not disrupt the ability of ES-62 to down-regulate such responses 
(Fig. 4.32).  
4.2.5 ES-62 and autophagy; a step towards TLR4 regulation 
To explore the role of autophagy in ES-62 mediated lysosomal degradation of key 
signalling adaptors, the expression of LC3 was quantified as an indicator of the levels of 
this mechanism engaged in the cells differentially treated with ES-62 and/or LPS (Fig. 
4.33). LC3 exists in two forms; the soluble LC3 type I (LC3-I) form, which upon 
conjugation to phosphatidylethanolamine (PE) by the E2-like enzyme ATG3 is 
transformed into the LC3-II form, which is important in the elongation of isolation 
membranes and autophagosome formation468,479. This lipidated ‘LC3-II’ migrates with a 
lower apparent molecular weight of 17 kDa in SDS gel electrophoresis than LC3-I (19 
kDa)480, allowing a quantitative measure of the levels of autophagic flux. The extended 
treatment of bmDCs with LPS resulted in a noticeable increase and slight decrease of LC3-
I and LC3-II expression, respectively (Fig. 4.33 B & E). When the levels of LC3-II were 
expressed as a ratio relative to LC3-I as a measure of autophagic flux, endotoxin 
stimulation was observed reduce the expression of LC3-II relative to LC3-I below basal 
levels (unstimulated cells; Fig. 4.33 C & F). On the other hand, ES-62 induced a marginal 
increase in the expression of LC3-II and the LC3-II/LC3-I ratio (Fig. 4.33 B-C & E-F). 
Maturation of DCs with ES-62 also had little effect on the relative changes in LC3-I and 
LC3-II expression noted upon stimulation with endotoxin. To identify whether LC3 was 
being turned over and hence, responses masked by autophagic flux induced by the various 
stimuli, inhibitors of lysosomal trafficking and degradation were utilised including the 
combination of E-64-D and Pepstatin A to inhibit lysosomal proteases and ammonium 
chloride. The pretreatment of bmDCs with either E-64-D/Pepstatin A and ammonium 
chloride resulted in an increase in LC3-II levels in response to ES-62 and/or LPS 
suggesting that both TLR4 agonists might be inducing autophagy and autolysosomal 
degradation. This accumulation of LC3-II relative to LC3-I induced by ES-62 was clear 
when utilising the specific lysosomal protease inhibitor E-64-D/Pepstatin A, an effect that 
was maintained over a 36 h period (Fig. 4.33 C). This was less evident for LPS stimulation 
as the inhibitor increased both LC3-I and LC3-II levels with the resultant ratio of LC3-
II/LC3-I still being less than that for unstimulated cells. 
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Based on these results another marker of autophagic flux, p62 was investigated to 
identify whether ES-62 could be utilising this important autophagy adaptor/cargo 
recognition protein in its immunomodulation of bmDCs (Fig. 4.34). TLR signalling in 
macrophages appears to induce the interaction of p62 with TRAF6 to coordinate orderly 
regulation of ubiquitin mediated processes to promote cytokine secretion associated with 
NF-κB activation505. In bmDC, two detectable forms of p62, which were approximated to 
be 47 kDa (p47) and 60 kDa (p60) in size, were identified utilising a polyclonal Ab 
obtained from NOVUS biologicals (NBP1-42821; Fig 4.34 A). Both of these bands could 
be specifically blocked by pretreating the Ab with its immunising peptide. Of these two 
protein sizes, ES-62 downregulated the expression of the larger p60 band relative to 
unstimulated (control) bmDC. Quantitative analysis of ES-62-mediated downregulation of 
the p60 protein over several experiments revealed it halved its expression relative to 
unstimulated cells (0.52 ± 0.05 n=5), while having little effect on the p47 protein (1.07 ± 
0.23 n=4) (Fig. 4.34 C). By contrast, LPS stimulation resulted in strong upregulation of 
both forms, although this was greater for the p60 (2.59 ± 0.94 n=5) than the p47 protein 
(2.19 ± 0.92 n=4). Pretreament of the cells with both E-64-D/Pepstatin A and ammonium 
chloride resulted in the significant upregulation of the p60 form of p62 upon stimulation 
with ES-62, whereas only a slight increase was observed with the p47 protein, suggesting 
that ES-62-mediated utilisation of p62 was being masked to some extent by autophagic 
flux (Fig. 4.34 B). However, upon LPS stimulation inhibition of lysosomal degradation 
resulted only in a slight increase in the expression of both protein sizes suggesting that the 
strong upregulation by LPS did not reflect autophagy. Moreover, the maturation of bmDCs 
with ES-62 partially limited their ability to upregulate the expression of p62, particularly 
the p47 form in response to LPS (Fig. 4.35 A-C). Inhibition of lysosomal degradation with 
E-64-D/Pepstain A increased the expression of both forms of p62; perhaps suggesting it 
was mediating this downregulation via autophagy (Fig. 4.35 D). This proposal was further 
supported by the finding that an increase in the expression of p60 and to a lesser extent p47 
upon stimulation with ES-62, which was achieved through pretreatment of the bmDCs 
with a pharmacological inhibitor of autophagy, 3-methyladenine (3-MA; Fig. 4.36)512. 
Based on the apparent induction of autophagic flux, the ubiquitination of p62 and 
several other ES-62 modulated TLR4-signalling adaptors (including TRAF6, c-Cbl and 
PKCδ) was analysed via the selective isolation of ubiquitinated protein conjugates (from 
cell lysates) utilising a Ubiqapture-Q kit (Enzo life sciences) and analysed by Western 
blotting (Fig. 4.37). The ubiquitination of these proteins was of particular interest due to 
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the known ability of p62 to directly associate with ubiquitinated (mono and poly) proteins 
via its UBA domain as well as LC3-II to deliver these proteins into the autophagosome for 
degradation503,504. The downregulation of p62 expression, which was rescued by the 
autophagy inhibitor, 3-MA, upon ES-62 stimulation suggested this immunomodulator 
could be inducing their ubiquitination to target their lysosomal degradation via the 
autohagosomes. The use of the KW0150 antibody, which recognises all ubiquitin 
conjugates (mono-, multi-, poly-modified and lysine linkage independent) indicated that 
DCs stimulated with either ES-62 or LPS over an 18 h time frame did not demonstrate any 
dramatic changes to global ubiquitin expression (Fig. 4.37 A). However, upon 
precipitation of the ubiquitin conjugates from these cells it became clear ES-62 induced the 
time specific association of TRAF6, PKCδ, c-Cbl and p62 to ubiquitin complexes and 
potentially their direct conjugation (Fig. 4.37 B). In this context, this association was 
markedly increased after 2 h of stimulation, with the dramatic reduction of ubiquitin 
associated TRAF6 occuring post 6 h. In contrast, LPS induced the progressive association 
to ubiquitin complexes of all these proteins except TRAF6, which was quite surprising as 
the K63 associated (self)polyubiquitination of this E3 ligase is crucial for the propagation 
of positive signals through TLR4 for NF-κB activation28. Interestingly, the levels of 
ubiquintin associated p62 dramatically increased over the 18 h endotoxin stimulation. This 
phenomenon is quite intriguing as accumulation of p62 is usually associated with a block 
in autophagy480 but for this unique multi-functional scaffold protein, it could also be 
associated with its continued interactions with TRAF6 upon positive TLR signalling, 
which is known to maintain NF-κB activation and proinflammatory cytokine secretion505. 
Based on these results the regulation of p62 expression was defined at several 
points over an 18 h period upon ES-62 and LPS stimulation (Fig. 4.38). These experiments 
were performed in parallel with cells pretreated with inhibitors of proteosomal degradation 
(lactacystin) and the lysosomal degradation (E-64-D/Pepstatin A and ammonium chloride), 
to potentially delineate between the role of p62 in autophagy or TLR signalling. In both 
studies, Western blotting analysis of p62 expression yielded only the p60 form upon 
stimulation with ES-62 and LPS (in the absence of inhibitors), thus all quantitation cited 
relates to protein of this size. Treatment with LPS stimulated a clear and sustained increase 
in p62 expression (Fig. 4.38 A-B), which was only enhanced by pretreating the cells with 
lactacystin, suggesting that p62 degradation in response to LPS is primarily by the 
proteosome. Rather than for autophagy, the lactacystin data suggest that p62 may 
predominantly signal to activate NF-κB during the 6-20 h stage of LPS-maturation of 
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bmDC, a proposal consistent with the known time course of NF-κB-dependent pro-
inflammatory cytokine production and release. Perhaps consistent with this, the ammonium 
chloride-induced reduction of p62 expression may relate to inhibition of LPS-mediated 
TLR4 activation associated with trafficking of this complex from the surface of the cell 
and the limiting propagation of signals required for p62 upregulation and NF-κB 
activation. These data provided further support for the proposal that in terms of TLR4/LPS 
signalling the role of p62 could be predominantly linked to its functions within the 
activation of the NF-κB pathway in bmDCs. 
In contrast to endotoxin, ES-62 induces the profound down-regulation of p62 
expression relative to unstimulated cells over an 18 h time course (Fig. 4.38 C-D). Also, as 
described above, the down-regulation of p62 can be prevented by pre-treating the bmDCs 
with E-64-D/Pepstatin A or ammonium chloride suggesting that the down-regulation of 
p62 by ES-62 occurs at least in part via lysosomal degradation. However, pretreating 
bmDCs with lactacystin also rescued ES-62 induced downregulation of p62, particularly at 
early time points (< 6h) suggesting a proteosomal mechanism to its degradation, which 
would be consistent with ES-62 preventing p62-mediated NF-κB activation507,508,513,514.      
Nevertheless, prolonged stimulation by LPS is accompanied by subcellular 
relocalisation of p62 from a rather disperse yet punctate pattern to that of large foci, some 
of which are perinuclear whilst others were cytoplasmic (Fig. 4.39). Whilst staining of 
LC3 also exhibited redistribution of LC3 from a dull diffuse pattern of localisation (Fig. 
4.40) to bright punctuate centres, a hallmark of autophagy480, this appeared to be 
predominantly perinuclear and quite different from that of p62 (Fig. 4.39 C). By contrast, 
upon examination of TRAF 6 expression, the bulk of the staining remained disperse but the 
cytoplasm also contained bright foci reminiscent of those associated with p62 (Fig. 4.41), 
suggesting that there could be interaction between these two proteins in DCs perhaps in 
mediating TLR4-NF-κB responses505, as LPS also induces the upregulation of TRAF6 
expression (Fig. 4.13).  
Thus, to further explore whether p62 preferentially signalled for autophagy or NF-
κB at various time points of LPS stimulation, p62-containing immune complexes were 
probed for the expression of p62-associated proteins focusing on LC3, TRAF6 and PKCδ 
(Fig. 4.42). The former was chosen to identify whether p62 was associating with 
components of autophagic vesicles whilst PKCδ and TRAF6 were investigated for their 
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potential involvement in TLR4 induced activation of NF-κB. In addition, there was also 
the potential for PKCδ to directly interact with p62, as the latter has been shown to express 
domains that allow its direct interaction with various PKC isoforms504. Consistent with the 
proposal that p62 predominantly signals for LPS-mediated activation of NF-κB rather than 
the initiation of autophagy, PKCδ was found to be present in p62-expressing immune 
complexes, an association that increased following stimulation with LPS. By contrast, 
neither TRAF6 nor LC3 expression could be detected in p62-containing immune 
complexes following an 18 h stimulation of bmDCs with LPS, despite there being 
expression of LC3-I and -II (only in the unstimulated cells again suggesting its 
downregulation by LPS) in the depleted lysates. Further analysis revealed that TRAF 6 did 
not appear to associate with p62 at earlier time points whereas association of p62 with 
PKCδ increased in a time-dependent manner, showing a substantial increase at 18 h when 
LPS stimulates strong upregulation of p62 (Fig. 4.42 B).  
Due to the similarities of the immunomodulatory functions of ES-62 and the 
proposed role of autophagy as a negative feedback mechanism for dampening down 
LPS/TLR4-mediated pro-inflammatory responses. The pharmacological inhibitor of 
autophagy, 3-methyladenine (3-MA)512, was utilised to identify whether it could disrupt 
the ES-62-mediated down-regulation of bmDC-derived cytokines associated with driving 
pro-inflammatory responses (Fig. 4.43). As a secondary objective, the effect of this 
inhibitor was investigated on LPS induced cytokine secretion as although it has been well 
catalogued that TH1 and TH2 polarising cytokines tend to promote and inhibit autophagy, 
respectively501, little has been reported on its involvement in the direct secretion of such 
cytokines, particularly in relation to DCs. It was clear that pretreatment of DCs with 3-MA 
resulted in a significant reduction in LPS stimulated IL-6, IL-12p70 and TNF-α secretion. 
In contrast, it induced an increase in the production of IL-23 suggesting a selective role for 
autophagy in mediating negative feedback inhibition of LPS/TLR4 pro-inflammatory 
signalling. A similat pattern was replicated with ES-62 matured bmDCs stimulated with 
endotoxin, albeit the secretion of the cytokines (apart from IL-6) was at a lower level due 
to the immunomodulatory effects of ES-62. However, 3-MA did not reverse any of the 
downregulatory effects of ES-62, perhaps suggesting that these were not mediated by 
autophagy. Although it should be borne in mind that, as a PI3K inhibitor, the effects of 3-
MA could reflect dampening of PI3K- dependent signalling pathways, a known target of 
ES-62 in a variety of cells of the immune system301,515. 
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4.3 Disscussion 
4.3.1 The inflammatory environment of a DC may dictate the 
regulation of TLR mediated activation of NF-κB by ES-62 
It was clear that LPS induced the early activation of NF-κB with the transient 
(within 2 h) degradation of both IκB-α and IκB-β (Fig. 4.3), which was unaffected by 
treatment of the cells with the lysosomal protease inhibitor combination, E-64-D/Pepstatin 
A. However, this treatment did induce a marked increase in both isoforms 6 h post 
endotoxin stimulation. These results suggested that lysosomal degradation has an 
important role in the prolonged (post 4-6 h) endosomal TRAM-TRIF mediated phase of 
LPS recognition by TLR4327, which maintains the activation of NF-κB15. In conjunction 
with this, the degradation of TLR4 in the late endosomes and lysosomes is an important 
negative feedback mechanism in regulating TLR4 signalling328,329. Thus, by inhibiting 
lysosomal degradation and the cells ability to regulate TLR4 signalling they may respond 
by upregulating IκB expression to sequester and limit the activation of NF-κB330, which 
could account for the increased expression of both isoforms. However, it could also reflect 
that in maintaining NF-κB within its activated state the TRAM-TRIF pathway may 
potentially induce the continual degradation of IκB within the lysosomes. Directly related 
to these affects on IκB, endotoxin induced the secretion of a range of proinflammatory 
cytokines (IL-12p70, TNF-α, IL-27 and IL-23) from the bmDCs, all of which were 
significantly reduced by E-64-D/Pepstatin A treatment (Fig. 4.31). This suggested that of 
the two proposed scenarios, bmDCs upregulate IκB production to sequester and limit the 
activation of NF-κB, as observed by the attenuated production of the various 
proinflammatory cytokines.  
In contrast, ES-62 induced a slight oscillating pattern of expression for both IκB-α 
and -β (Fig. 4.3 C). This indicated that despite the requirement of TLR4 for the 
immunomodulation of DCs by ES-62301, this association does not stimulate the activation 
(post 2 h) of NF-κB. Several results suggested that ES-62 may progressively upregulate 
(18 h) expression of IκB-β but not IκB-α (Fig. 4.3 & Fig. 4.4 A-B). As IκB-β is 
commonly associated in the delayed activation (through its degradation) of NF-κB516, its 
upregulation could provide a potential mechanism for attenuating protracted endotoxin 
responses, however this affect was limited (1.28 ± 0.22, n=3) indicating it is unlikely to be 
a predominant method of regulation. In relation to this result, the costimulation of GM-
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CSF alongside ES-62 maturation, induced the time sensitive upregulation of IκB-β (3 h) in 
response to stimulation with LPS (Fig. 4.6).  
GM-CSF is best known as a regulator of the functions of granulocyte and 
macrophage derived populations acting throughout their development509 and is frequently 
employed to differentiate DCs from bone marrow progenitors and peripheral blood517. 
Much of the literature suggests it is involved in mediating the inflammatory responses of 
these cells (and other more diverse populations), as it is not only able to augment the 
function of monocytes, macrophages and DCs518 but prime mice to secrete a range of 
proinflammatory cytokines in response to the administration of LPS519. Thus, in the 
presence of a potentially more pro-inflammatory environment induced by GM-CSF, ES-62 
may take a more proactive role in modulating the maturation of bmDCs through the 
expression of proteins such as IκB-β520.  
The most compelling evidence for this was the rapid downregulation of MyD88 
expression induced by ES-62 (Fig. 4.7 E-F), an effect that was reversed upon removal of 
GM-CSF from the stimulatory culture medium (Fig. 4.7 C-D & Fig. 4.8). MyD88 
associates with all the TLRs (except TLR3) to induce the activation of NF-κB and the 
expression of a range of proinflammatory cytokine genes14. Thus, its specific 
downregulation in a proinflammatory environment would be a crucial step for ES-62 to 
uncouple the inflammatory capacity of DCs, which is in keeping with some of its in vivo 
functions in both TH1/TH17310,324 and TH2321,325 associated pro-inflammatory responses. In 
the absence of GM-CSF, MyD88 upregulation could reflect the differential modulation of 
the components involved in TLR signalling (for example PKCε and PKCδ), indicating the 
potential environment specific immunomodulatory capacity of ES-62 on DCs. The 
upregulation of MyD88 may even reflect the maturation of a DC primed to induce a TH2 
biased, yet anti-inflammatory response by ES-62, which is associated with this parasite 
product160. 
It was clear from these results that ES-62 is targeting several signalling adaptors 
involved in the propagation of TLR responses (specifically TLR4) in a proinflammatory 
environment, which is in keeping with its observed abilities to attenuate associated 
signalling responses291,301,323,521,522. Building upon this, the presence of GM-CSF in the 
stimulation medium induced ES-62 to mediate the degradation of the E3 ligase, c-Cbl 
(Fig.4.17 A-B), which in the cytokines absence was upregulated by ES-62 at both the 
mRNA transcript and protein levels (Fig. 4.15). Collectively, these data may indicate that 
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in the absence of GM-CSF, ES-62 encourages the upregulation of c-Cbl to limit the 
potential activation of NF-κB as it is involved in mediating the regulatory capacity of p50 
and its precursor p105 (an NF-κB subunit)453,454. However, in a proinflammatory 
environment brought about by the presence of GM-CSF, ES-62 may target its degradation 
to limit other potential roles it may have in mediating positive TLR signalling.  
In contrast, the downregulation of TRAF6 by ES-62 was GM-CSF independent 
(Fig. 4.13) but inclusion of the cytokine did lead to the complete ablation of its expression 
by ES-62 (Fig. 4.14 A-B). In this context, the presence of GM-CSF was also observed to 
further limit the expression of TRAF6 in response to endotoxin from ES-62 matured DCs 
(Fig. 4.14 C-D). This targeting of TRAF6 expression suggests that ES-62 acts to attenuate 
its pivotal role in mediating proinflammatory signalling through TLR4, important for the 
secretion of IL-6 and IL-12p70 and up-regulation of MHC class II in DCs26,27. However, 
IL-6 responses are maintained within ES-62 matured DCs (Fig. 3.11). Based upon these 
observations the GM-CSF independent upregulation of PKCα expression by ES-62 (Fig. 
4.19) could maintain IL-6 secretion in response to LPS as studies have demonstrated its 
importance in inducing its secretion from macrophages upon positive TLR4 signalling116-
120. Contrary to these observations however, a study in peritoneal macrophages 
conclusively demonstrating that ES-62 renders these cells hyporesponsive to LPS in terms 
of limited IL-6 secretion both in vitro and in vivo363. This is coupled with observations in 
the CIA model, where GM-CSF is important in disease progression523, where ES-62 was 
able to mediate the downregulation of IL-6 secretion324,352,524. Collectively, these results 
suggest the complex environment specific functions of ES-62.  
4.3.2 The differential regulation of PKC expression by ES-62 and 
LPS 
ES-62 was observed to target the degradation of several important TLR4 signalling 
transducers via the lysosomes (in the absence of GM-CSF) within an 18 h stimulation. 
Two prominent examples were PKCε (Fig. 4.20, Fig. 4.21) and PKCδ (Fig. 4.22, Fig. 
4.23), which are important for the activation of NF-κB through their direct interaction with 
MyD88 (PKCε)49,100 and TIRAP (PKCδ)101. By contrast, LPS stimulation induced the 
upregulation of PKCε (exacerbated by blocking proteosomal degradation), which likely 
reflects it role in the secretion of TNF-α and IL-12p70114, while only having marginal 
affects on PKCδ expression. The treatment of DC with E-64-D/Pepstatin A before 
stimulation with ES-62 rescued both PKCε and PKCδ from degradation (Fig. 4.21, Fig. 
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4.23) and restored IL-12p70 secretion (Fig. 4.31), converting an ES-62-TLR4 signalling 
phenotype to that of LPS-TLR4. 
These results are particularly interesting as the PKCs are very important in the 
induction of NF-κB activation by the TLR family of receptors (particularly TLR4) but 
more specifically the stimulation of proinflammatory cytokine secretion. In this context, 
PKCδ has been shown to act as an IKK to phosphorylate and target IκB for 
degradation104,105, inducing the production of numerous pro-inflammatory cytokines 
including TNF-α upon the recognition of LPS by TLR493,102,103, an effect ES-62 
maturation is able to attenuate (Fig. 3.11). In DCs, PKCε fulfils a similar role in mediating 
LPS-induced IKK and NF-κB activation112 but recently has been directly linked to the 
secretion of both TNF-α and IL-12p70 in monocyte derived DC114. Thus, the degradation 
of these adaptors by ES-62 likely reflects its attenuation of proinflammatory cytokine 
responses. However, the parasite product does not ablate the secretion of such cytokines 
and indeed does not prevent the upregulation of both PKCδ and PKCε in response to LPS 
(Fig. 4.21, Fig. 4.23). In conjunction with these results the modulation of LPS responses 
by ES-62 left IL-6 secretion intact, whereby even treatment of E-64-D/Pepstatin A had 
little effect (Fig. 4.31). The maintenance of IL-6 responses may relate to the upregulation 
(Fig. 4.19 A-C) and transient phosphorylation (Thr638; Fig. 4.19 D-E) of PKCα 
expression by ES-62 as this isoform is important for the IL-6 secretion in macrophages 
upon recognition of LPS by TLR4116-120.  
Following on from these results and focusing on the specifics of the degradation of 
these nPKCs in the lysosomes, studies in mast cells have demonstrated that ES-62 can 
subvert TLR4 signalling by mediating its sequestration by a caveolae-lipid raft dependent 
mechanism to target PKCα for lysosomal degradation321. Interestingly, the conventional 
and novel PKCs localise to the caveolae fraction of several cell types59 to drive the 
formation of ceramide at the PM, which is crucial in the formation of lipid rafts and 
caveolae83. Thus, ES-62 could induce the transient activation and translocation of PKCδ 
and PKCε (Fig. 4.20, Fig 4.22), particularly through the phosphorylation of the former 
(Fig. 4.28 – Fig. 4.30), to drive caveolae formation and provide a mechanism for their (and 
potentially other associated adaptors) trafficking to the lysosomes for degradation82.  
As mentioned above the phosphorylation of the A-loop (Thr505; Fig. 4.28) and 
hinge region (Tyr311; Fig. 4.30) by LPS may have an important role in mediating the 
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activation of NF-κB and its interaction with p62, which helps to bridge autophagy and 
TLR4 signalling505,507,508 as demonstrated in Figure 4.42. In this context, it also provides a 
potential mechanism for the coupling of these proteins for ES-62 induced lysosomal 
degradation. These predictions are based on evidence that both phosphorylation at the A-
loop and Tyr311 sites of PKCδ are important in regulating the specificity (and 
consequence) of its interactions with other signalling molecules52,72,73. In this context, the 
induction of phosphorylation at these sites by ES-62 may localise PKCδ (and its associated 
proteins) to the caveolae, mediating their sequestration from important functional sites or 
degradation in the lysosomes.  
Another intriguing facet of the effect of ES-62 was the transient translocation of 
both intact (78 kDa) and cleaved (38 kDa) forms of PKCδ into the nucleus of cell (Fig. 
4.24). Endotoxin induced a similar response (Fig. 4.25) but the confocal microscopy 
analysis did not allow the determination of the proportions of each form of PKCδ. 
However, the Western blotting studies revealed LPS to downregulate the expression of 
cleaved PKCδ (over 18 h) through the proteosome (Fig. 4.26), while ES-62 modulated its 
levels in a similar fashion to the full-length protein (Fig. 4.22). The enzymology of full 
length PKCδ and the cleaved (40-kDa) catalytic domain fragment differ considerably as 
the latter is phospholipid independent, where the relative amounts of both forms can have 
dramatic effects on cellular function56-58. Thus, the LPS induced reduction (via the 
proteosome; Fig. 4.26 D) of the relative levels of cleaved PKCδ to the total (cleaved and 
full-length) amounts in the cell (Fig. 4.26 B), may be important in regulating the activation 
of NF-κB as the relative amounts in microglia directly contributes to the activation of NF-
κB through TLR signalling110,111. In contrast, ES-62 mediated only a marginal increase in 
the relative levels of the cleaved form (Fig. 4.26 B) indicating it is not directing the 
activation of NF-κB. However, the transient translocation of cleaved and full-length PKCδ 
into the nucleus suggest it induces other differential functions relating to the 
immunomodulation of DCs. Inhibiting lysosomal degradation extended and accentuated 
ES-62’s regulation of cleaved PKCδ (Fig. 4.26 C) suggesting a turnover of the protein, 
reinforcing the idea that this form of PKCδ plays some part in mediating the functions of 
ES-62. The induction of the nuclear translocation of PKCδ by ES-62 occurred alongside 
uncoupling of mRNA transcript production of both PKCε and PKCδ giving rise to the 
upregulation of their protein levels (Fig. 4.20 E, Fig. 4.22 F) despite ES-62 not being 
directly observed in the nucleus (Fig. 4.24 A). This result is quite intriguing as the 
internalisation of ES-62 into macrophages and B cells results in its accumulation within the 
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nucleus (H.S. Goodridge & M. M. Harnett, unpublished data), suggesting that in DCs it 
utilises a different mechanism to uncouple (hyper)inflammatory responses.  
Collectively, these results reflect a deep complexity in the function of ES-62 in 
DCs where it acts to inhibit the maximal output/hyper-inflammatory responses to 
pathogenic stimuli through their secretion of proinflammatory cytokines, while 
maintaining their competency in initiating adaptive immune responses (albeit modulated), 
to what could potentially be a fatal infection in the host if left unchecked. Several of its 
targets indicate ES-62 acts to limit proinflammatory cytokine secretion through modulation 
of NF-κB activation, however it does not drastically alter other important aspects of the 
inflammatory biology of DCs, including co-stimulatory molecule expression114. 
4.3.3 The role of ubiquitination (and its mediators) in the 
immunomodulation of DCs by ES-62 
The mechanism of ubiquitination and the proteins that mediate this process have an 
important role in shaping the cellular response to inflammatory stimuli. For example, the 
E3 ubiquitin ligase, TRAF6 is crucial in the propagation of signals from TLR4 and the 
subsequent activation of NF-κB upon its recognition of LPS through its modulation of the 
ubiquitination of several TLR signalling adaptors24,44. Thus, due to the anti-inflammatory 
potential of ES-62, it came as little surprise that it induced the lysosomal degradation of 
TRAF6 (Fig. 4.11 - Fig. 4.13), where a caveolae-lipid raft-dependent mechanism could be 
involved in its shuttling to the lysosomes321. By contrast, endotoxin induced an oscillating 
pattern of TRAF6 expression resulting in its protracted upregulation (post 6 h), 
exacerbated by inhibiting proteosomal but not lysosomal degradation (Fig. 4.11). This 
result suggests the cell utilises the proteosome to rapidly degrade and limit the propagation 
of TAK1 and IKK complex activation by TRAF6 and subsequently that of NF-κB44. These 
affects on TRAF6 were coupled to the increased expression of another E3 ligase by ES-62 
that has several emerging roles in TLR4 signalling, c-Cbl (Fig. 4.15) and could reflect its 
involvement in maintaining the integrity of the inactive NF-κB complex451,452,454. 
Interestingly, endotoxin induced its degradation, which maybe involved in the activation, 
translocation and induction of proinflammatory cytokine secretion of NF-κB454. The 
degradation of c-Cbl is rescued by inhibition of lysosomal and proteosomal degradation 
but the latter induces the accumulation of the protein, indicating DCs utilise the 
proteosome as the predominant regulatory mechanism of c-Cbl expression (Fig. 4.15). The 
regulation of these E3 ligases were reflected (to an extent) in the expression of mRNA 
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transcript produced by the cells (Fig. 4.11 D, Fig 4.15 E) and suggest that ES-62 
specifically targets their expression (at both the protein and mRNA transcript level) to 
differentially mature the DC and alter its ability to stimulate hyper-inflammatory responses 
(such as cytokine production).  
The ubiquitination of proteins is important in their trafficking within the cell and 
the establishment of scaffolding complexes in the propagation of intracellulat signalling 
cascades28,29. In this respect, the differential signalling induced by ES-62, which results in 
the lysosomal degradation of TRAF6, p62, PKCδ and PKCε was thought to involve the 
ubiquitination of these signalling adaptors. Thus, the transient association of ubiquitin 
conjugates to these proteins (≥ 2 h) upon the stimulation of bmDCs with ES-62 suggested 
that this maybe the required impetus for the degradation of these proteins in the lysosome 
(Fig. 4.37). The proteosome has little involvement in mediating the downregulatory effects 
of ES-62, indicating this association is unlikely to involve the K48 associated linkage of 
ubiquitin, which targets proteins for degradation by this complex41. In light of this it is 
more likely to reflect the association of Lys-63-linked polyubiquitin chains, which are 
associated with directing proteins for non-proteosomal functions and potentially lysosomal 
degradation42. In this respect, through adaptor proteins such as p62, which can directly 
bind to ubiquitin through a specialised UBA domain, the association of ubiquitin 
conjugates can allow (and associated complexes) the transport of proteins into 
autophagosomes, via the direct binding of LC3-II on the inside of forming isolation 
membranes by p62, facilitating lysosomal degradation460. Thus, the ES-62 promoted 
induction of: the association of ubiquitin conjugates to several modulated proteins 
(TRAF6, p62 and PKCδ), autophagic flux as defined by increased LC3-II expression 
(particularly upon pretreatment wit E-64-D/Pepstatin A; Fig. 4.33) and downregulation of 
p62 (Fig. 4.34), may reflect its selective targeting of these proteins for lysosomal 
degradation via autophagosomes/autolysosomes. 
By contrast, LPS induced the progressive association of PKCδ, c-Cbl and p62 
(which is quite prominent) to ubiquitin conjugates but not TRAF6 (Fig. 4.37). The absence 
of TRAF6 association to ubiquitin conjugates was quite surprising as in canonical 
activation of NF-κB, (self)polyubiquitination via a K63 linked ubiquitin chain is required 
for its interaction with the TAK1 complex24. Thus, this affect may have been overlooked in 
this analysis (for example it may occur < 2 h) or the dynamics of this pathway may differ 
slightly in DCs. However, endotoxin clearly induced the ubiquitination of p62 suggesting 
this process may have a role in mediating the induction of certain proinflammatory 
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responses by TLR4 in DCs. In this context, there is growing evidence that p62 acts as a 
scaffold to regulate K63 polyubiquitination via its interaction with TRAF6 of proteins in a 
number of complexes associated with the activation of NF-κB507, with both proteins often 
observed to co-localise to discrete punctuate structures upon stimulation of p62 signalling 
pathways508. Thus in DCs, the ubiquitination of p62 but not TRAF6 may be important in 
the protracted (< 2 h) or maintenance of NF-κB activation and proinflammatory cytokine 
production.  
4.3.4 The role of autophagy in LPS and ES-62 stimulated cytokine 
production 
In the investigation into the involvement of autophagy upon the stimulation of 
bmDCs with ES-62 and/or LPS, it became clear that both stimuli exhibited differential 
effects on the expression of several important proteins associated with mediating 
autophagic flux. Consistent with this, when the cells were pretreated with 3-MA, a well 
known inhibitor of autophagy, through its persistent and transient inhibition of Class I and 
III PI3K activity, respectively, there was a general down regulation of LPS induced 
cytokine secretion from the DCs, apart from IL-23 (Fig. 4.43). However, as autophagy has 
previously been proposed to downregulate LPS-induced inflammatory responses, this 
finding was somewhat surprising, particularly since the TLRs are known to activate Class I 
PI3Ks via MyD88525, and we and others have previously shown that activation of Class I 
PI3Ks is associated with the downregulation of TNF-α, IL-12p70 and IL-12/23p40 
secretion via blocking mRNA transcript expression of the p35 and p40 subunit in 
macrophages and DCs526,527. As such, DCs derived from mice which lack the Class I PI3K 
regulatory subunit p85, ablating Class I PI3K activity, show increased secretion of IL-
12p70 and the shared IL-12/23 p40 subunit, which is attributed to an enhanced activation 
of p38 MAPK, a positive regulator of IL-12 production526. This could perhaps suggest that 
the effect on IL-23 may simply reflect inhibition of PI3K signalling although it has been 
noted by other groups that treatment of bmDCs with 3-MA increases the production of IL-
23 in response to stimulation with LPS but the exact mechanism for this affect has not been 
defined528. However, the clear reduction in LPS induced secretion of TNF-α and IL-6, 
when the cells are pretreated with 3-MA, has previously been reported in the literature at 
both the protein and transcriptional level529 and could potentially reflect proposals that both 
of these cytokines stimulate autophagy. Moreover, the caveat that because of the generic 
effects of 3-MA on the inhibition of the PI3Ks these effects cannot be confirmed until 
further studies are performed480,530, is perhaps not necessary as no increase in TNF-α and 
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Il-12p70 (associated with a block of PI3K activity) was observed. That these effects are 
mirrored by the ES-62 matured DCs, with 3-MA further able to attenuate the LPS induced 
secretion of cytokines could suggest that either ES-62 does not act to block autophagy as 
effectively as 3-MA or that it is exerting these inhibitory effects in an autophagy-
independent manner: in any case, these data do not identify a clear role for autophagy in 
mediating modulation of LPS responses by ES-62, although like 3-MA, we have 
previously shown ES-62 to inhibit PI3K activity301,331, and presumably via these inhibitory 
actions, Akt319. Interestingly, therefore, in contrast to 3-MA, ES-62 suppressed IL-23 
production and co-treatment with 3-MA did not significantly reverse this effect.  
4.3.5 The complex interplay between TLR4 signalling and 
autophagic flux initiated by ES-62 and LPS 
These changes in cytokine expression were accompanied by effects on the 
expression of the autophagy-associated proteins, p62 and LC3 in DCs. Treatment with LPS 
resulted in the dramatic upregulation of p62 (Fig. 4.38), in a similar fashion to that  
observed in macrophages stimulated with LPS in conjunction with IFN-γ505. Perhaps 
surprisingly therefore, given that p62 is reported to accumulate upon blocking of 
autophagy, the pretreatment of cells with 3-MA resulted in the marked reduction of p62 
(60 kDa) although this could be a contributing factor to the reduction of cytokine secretion 
observed for IL-6, TNF-α and IL-12p70 (Fig. 4.43). Consistent with this, a study on 
human keratinocytes showed that siRNA knockdown of p62 resulted in the reduced 
expression of the mRNA transcript and protein of TNF-α and IL-6 as well as NF-κB 
promoter activity upon stimulation of TLR2/6 (by MALP-2) and TLR4 (by LPS)531. This is 
coupled with data indicating that p62 expression is crucial for the TLR-dependent 
activation of IKKα/β and degradation of IκB-α in this cell type. Collectively, this study 
showed that, rather than transducing autophagy, the cystolic accumulation of p62 may 
trigger TLR4-induced inflammatory responses in keratinocytes through modulation of 
IKK-NF-κB signalling. Thus, the strong accumulation of p62 in response to LPS 
stimulation observed in DCs (Fig. 4.38) could reflect a similar signalling pathway and the 
initial LPS-mediated suppression of autophagy in resting cells. Moreover, treatment of the 
cells with lactacystin (but not lysosomal inhibitors) enhanced LPS induced expression of 
p62 (Fig. 4.38), consistent with the proteosome being the most logical route for the cell to 
regulate this protein if it is participating in mediating LPS-TLR-NF-κB signals.  
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Nevertheless, collected data from several experiments showed endotoxin inducing 
an increase in the levels of LC3-I (1.446 ± 0.189, n=3) and LC3-II (1.124 ± 0.44, n=3) 
after an 18 h stimulation of LPS (relative to unstimulated cells). This effect displayed a 
marked increase upon treatment with E-64-D/pepsatain A for both LC3-I (10.09 ± 8.086, 
n=2) and LC3-II (7.00 ± 5.076, n=2) and was accompanied by an increase in the ratio of 
LC3-II to LC3-I (Fig. 4.33 C & F). However, the effect of E-64-D/Pepstatin A treatment 
on the expression of both LC3-I and LC3-II was accompanied by a decrease in the 
secretion of a host of cytokines including IL-12p70, IL-23, TNF-α and IL-27 (Fig 4.31). 
These latter results are therefore counter to the idea that the high levels of p62 observed at 
18 h were associated with the induction of autophagy to limit responses, as under these 
conditions it would be expected that the lysosomal inhibitors would increase the levels of 
LC3-II and promote cytokine production. Interestingly the effects of ammonium chloride 
were relatively marginal relative to E-64-D/Pepstatin A, suggesting that the subsidiary 
effects associated with this compound were a factor in its modulation of LC3 expression.  
As an atypical PKC (aPKC) scaffold protein, p62 plays an important role in the 
activation of NF-κB in response to a number of stimuli as it allows the assembly of an 
aPKC/p62/TRAF6 multiprotein complex532, whereby, the interaction of p62 with TRAF6 
has been shown to be particularly important in the activation of NF-κB by TNF-α or IL-
1533. To determine whether the substantial accumulation of p62 noted here played a similar 
role, p62-containing immune complexes were precipitated upon LPS stimulation of the 
DCs (Fig. 4.42). These results showed that p62 formed a complex containing PKCδ but, 
quite unexpectedly, it did not contain TRAF6 or alternatively, in relation to its potential 
role in autophagy, LC3. Collectively with all the above data, this association with PKCδ 
suggested p62 could have a potential role in the activation of NF-κB after the recognition 
of LPS by TLR4 in DCs.  
However, confocal microscopy revealed that LC3, p62 and TRAF6 were 
upregulated and relocalised to punctate foci upon 18 h stimulation with LPS, where the 
formation of punctate centres by LC3 (and partially p62) is associated with the induction of 
autophagy480. Although p62 and TRAF6 were observed in foci (Fig. 4.39 & 4.41), in 
general they appeared quite different to those of LC3 (Fig. 4.40). Thus, despite the co-
immunoprecipitation study indicating a lack of association between TRAF6 and p62, their 
similar punctuate staining might suggest an interaction (Fig. 4.39) and thus, in this regard, 
it should be noted that a similar pattern did not occur when PKCδ was visualised after LPS 
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stimulation (Fig. 4.25). In relation to these observations, studies have shown that p62 and 
TRAF6 co-localise to discrete punctuate structures upon stimulation of p62 signalling 
pathways508. 
The maturation of DCs with ES-62 prior to LPS stimulation subtly altered the 
expression of p62 (Fig. 4.35). Stimulation with endotoxin significantly increased the 
expression of p62 relative to ES-62 but the power of this significance was reduced upon 
prior maturation with this immunomodulator before LPS stimulation. This suggested a 
potential mechanism for the actions of ES-62, as coupled with the downregulation of 
TRAF6 (Fig. 4.11 – 4.13) and the protection of TRAF and p62 expression by lysosomal 
inhibitors, this could suggest that ES-62 limits LPS responses via autolysosomal 
degradation. The ES-62 mediated downregulation of p62 occurred quite rapidly upon 
stimulation of DCs (within 2 h) and was rescued by both lysosomal and proteosomal 
degradation inhibitors (Fig. 4.38). Interestingly treatment with lactacystin resulted in an 
early increase above both lysosomal degradation inhibitors, suggesting an early 
proteosomal component to this degradation perhaps to mediate rapid inhibition of NF-κB, 
which switches to a more lysosomal route with time to allow downregulation of a cargo of 
signalling elements such as TRAF6, PKCδ, −ε and MyD88 required for TLR4 responses. 
This would fit with the literature as p62 is a multi-module adaptor/scaffold protein crucial 
for selective signal transduction that is commonly associated with its ability to take 
ubiquitinated proteins into forming isolation membranes for degradation in the 
autophagosomes503,504. Consistent with this, the pretreatment of the cells with 3-MA 
resulted in a dramatic increase in levels of p62 in DCs, further supporting the proposal that 
there may be an autophagic component to ES-62-mediated downregulation of p62 (Fig. 
4.36). The rescue of p62 by the lysosomal inhibitors and 3-MA is coupled by the 
observation that ES-62 induces the interaction of this protein with ubiquitin conjugates 
(Fig. 4.37), suggesting ES-62 may target the degradation of this protein by ubiquitin 
associated autophagy in which TRAF6 may have a role503. In relation to this, in TLR 
induced activated macrophages the interactions of p62, help to coordinate orderly 
regulation of K63 polyubiquitination mediated processes ensuring cytokine secretion 
associated with NF-κB activation506,507. Thus the downregulation of this protein by ES-62 
could relate to it diminishing the potential of TLR4 induced p62-TRAF6 interactions and 
NF-κB activation of cytokine secretion. Indeed the upregulation of p62 by LPS is reduced 
by prior ES-62 maturation (Fig. 4.35).  
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Although ES-62 did not appear to dramatically regulate LC3 expression, inducing a 
slight increase in LC3-II expression with little effect on LC3-I, treatment with E-64-
D/Pepstatin A revealed dynamic lysosomal regulation of their expression indicative of 
autophagic flux (Fig. 4.33). This effect became more apparent when the a clear increase in 
LC3-II expression was observed relative to LC3-I (Fig 4.33 C). Thus, combining results 
from three experiments, whilst ES-62 appeared to have little effect on their expression after 
18 h, with LC3-I (1.076 ± 0.049, n=3) and LC3-II (1.151± 0.045, n=3),  treatment of the 
cells with E-64-D/Pepstatin A resulted in levels of  LC3-I (0.06922 ± 0.06408, n=2) and 
LC3-II (1.157 ± 0.490, n=2), indicating a substantial increase in the ratio of LC3-II to 
LC3-I masked by autophagic flux and degradation in the autophagolysosomes. By contrast, 
ammonium chloride had little effect resulting in LC3-I (0.9572 ± 0.2731, n=2) and LC3-II 
(0.9570 ± 0.468, n=2). Thus collectively, the data indicate that ES-62 is utilising autophagy 
to mediate down-regulation of certain intracellular adaptors predominantly via the 
lysosomes, with some potential transient involvement of the proteosome.  
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Figure 4.1 | The processes and regulation of autophagy. 
Panel A, The main cellular events that occur during macroautophagy begin with the 
formation of an isolation membrane (induction), followed by the sequestration of cargo 
that is to be degraded into these elongating vesicles. Once a fully enclosed autophagosome 
is formed, fusion with lysosomes leads to their maturation into autolysosomes and results 
in the degradation of the sequestered cargo. Panel B, There are multiple reported 
membrane sources for autophagosome formation, which include both plasma and nuclear 
membranes but to date the predominant source is the endoplasmic reticulum (ER). In 
respect to these other membrane sources (non-ER) the multispanning membrane protein 
that is essential for autophagy, ATG9, is trafficked between the trans-golgi network and 
endosomes where it maybe important in the formation of autophagosome precursors. Upon 
the induction of autophagy, the ULK1 complex (ULK1-ATG13-FIP200-ATG101) 
translocates to the ER where it transiently associates with VMP1 activating an ER-
localised autophagy-specific class III PI3K complex. This induces the local (on the ER 
membrane) production of PtdIns(3)P, which recruits both DFCP1 and WIPIs to the ER, 
where they induce the formation of the isolation membrane. The ATG12-ATG5-ATG16L1 
complex is then recruited to the outer membrane of the forming autophagosome where it 
helps to drive the elongation process. This process utilises a ubiquitin-like conjugation 
system where phosphatidylethanolamine (PE) is conjugated to LC3/Atg8 (LC3 is one of 
the mammalian homologues of Atg3) by the sequential action of the protease Atg4, the E1-
like enzyme Atg7 and the E2-like enzyme Atg3. Lipid conjugation leads to the conversion 
of the soluble LC3 (named LC3-I) to the autophagic-vesicles-associated (LC3-II/LC3-PE). 
The PE conjugated LC3 is present on both the outer and inner membrane of the isolation 
membrane, where it can act as a tether to attach the autophagic cargo to the isolation 
membrane through specific adaptor proteins. LC3 is also important in the completion of 
the autophagosomes. 
(Adapted from Levine, B. et al., 2011534) 
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Figure 4.2 | The initiation of autophagy by TLR4 signalling and the interactions 
between components of this pathway and p62.  
Signalling through the TLRs leads to the induction of autophagy through a mechanism 
dependent on both TRIF and p38 (possibly through activation of members of the PI3K 
family) but not MyD88. Specifically, TLR4 signalling is known to accelerate phagocytosis 
and autophagosome formation while up-regulating expression of the autophagic 
machinery. In this context, there is a conserved role for PKCδ in the regulation of gram-
negative bacterium degradation by autophagy in mammalian cells in a DAG and Ubiquitin-
dependent manner. The autophagy adaptor/cargo recognition protein, p62 was identified 
for its role in mediating the transfer of organisms (viruses, bacteria and parasites), 
organelles and proteins into forming isolation membranes through ubiquitin-dependent and 
independent mechanisms for lysosomal degradation. This specific targeting to the 
autophagosome is made possible by p62’s LIR (LC3 interacting region)/LRS (LC3 
recognition sequence) domain which can recognise and bind LC3 in the isolation 
membrane but it also has a number of other roles in the cell. Prominent among these is that 
p62 interacts with the E3 ubiquitin ligase, TRAF6, upon IFN-γ/TLR stimulation, causing 
its autoubiquitination and the subsequent activation of NF-κB, leading to the induction of 
pro-inflammatory cytokines. Specifically, following p62 dimerisation through the PB1 
(Phox and Bem1p) domain, dimerised TRAF6 binds to p62 at its TRAF6-binding (TB) site 
allowing transfer of the K63 polyubiquitin chains generated from TRAF6 to specific 
substrates. In this context, p62 coordinates the K63 polyubiquitination of the TRAF6 
specific substrates such as RIP, TRAF6, ERK and caspase 8, allowing p62 to mediate 
control of apoptosis, NF-κB activation and stress responses. Interestingly, K63 tagged 
substrates can interact with the UBA (Ubiquitin associated) domain of p62, allowing it to 
reside at the intersection between two degradation pathways. As the binding of 
polyubiquitin chains associated to a substrate protein by the UBA domain of p62, allows it 
to traffic it to the proteosome or the autophagsomes (though this tends to be for larger 
structures) for degradation. 
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Figure 4.3 | The effect of inhibiting multiple avenues of protein degradation and 
sorting on IκB-α and -β expression upon ES-62 or LPS stimulation.  
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with E-
64-D (10 µg/ml) plus Pepstatin A (10 µg/ml), ammonium chloride (50 µM) or medium as 
indicated for 1 h. The cells were then stimulated with either ES-62 (2 µg/ml) or LPS (1 
µg/ml) for the indicated times. The control (unstimulated) cells were incubated under the 
same conditions for the length of the experiment (18 h). Total protein extracts were 
purified from the samples and analysed by Western blotting for IκB-α and -β expression. 
In panel B, The densitometric analysis of the LPS stimulated samples for both IκB-α and 
IκB-β were normalised against the relevant β-actin loading control. These were expressed 
as a fold change relative to the control cells (unstimulated DC, normalised to 1) from a 
single experiment except for the LPS stimulated samples featuring no chemical treatment 
(-), where data was acquired from three independent experiments and presented as the 
mean estimations ± SEM where n=3. In panel C, The densitometric analysis of the ES-62 
stimulated samples for both IκB-α and IκB-β were normalised against the relevant β-actin 
loading control and expressed as a fold change relative to the control cells (unstimulated 
DC, normalised to 1), from a single experiment. E/P, E-64-D/Pepstatin A; NH4Cl, 
ammonium chloride. 
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Figure 4.4 | Effect of inhibiting multiple avenues of protein degradation and sorting 
on the protracted expression of IκB-α and -β upon ES-62 and/or LPS stimulation. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with 
combinations of medium, ES-62 (2 µg/ml) and LPS (1 µg/ml) for the indicated times 
(hours), where the order of stimulation follows from the top to the bottom. The control 
(unstimulated) cells were incubated under the same conditions for the length of the 
experiment (36 h). Total protein extracts were purified from the samples and analysed by 
Western blotting for IκB-α and IκB-β expression as indicated. In panel B, the 
densitometric analysis of IκB-α and IκB-β expression was normalised against the relevant 
β-actin loading control and the values expressed as a fold change relative to the control 
cells (unstimulated DC, normalised to 1 and represented by the dashed line). Data are 
presented for five (IκB-α) and three (IκB-β) independent experiments as the mean 
estimations ± SEM where n=5 and n=3. 
In panel C, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with 
ammonium chloride (50 µM) or medium as indicated for 1 h. The cells were then 
stimulated with combinations of medium, ES-62 (2 µg/ml) or LPS (1 µg/ml) for the 
indicated times (hours), where the order of stimulation follows from the top to the bottom. 
The control (unstimulated) cells were incubated under the same conditions for the length of 
the experiment (36 h). Total protein extracts were purified from the samples and analysed 
by Western blotting for IκB-α expression. In panel D, the densitometric analysis of IκB-α 
expression was normalised against the relevant β-actin loading control and the values 
expressed as a fold change relative to the control cells in the absence of any chemical 
treatment (Unstimulated DCs, normalised to 1 and represented by the dashed line). NH4Cl, 
ammonium chloride. 
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Figure 4.5 | Effect of inhibiting lysosomal degradation on the protracted expression of 
IκB-α and -β upon ES-62 and/or LPS stimulation. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with E-
64-D (10 µg/ml) plus Pepstatin A (10 µg/ml) or medium as indicated for 1 h. The cells 
were then stimulated with combinations of medium, ES-62 (2 µg/ml) and LPS (1 µg/ml) 
for the indicated times (hours), where the order of stimulation follows from the top to the 
bottom. The control (unstimulated) cells were incubated under the same conditions for the 
length of the experiment (36 h). Total protein extracts were purified from the samples and 
analysed by Western blotting for IκB-α expression. In panel B, the densitometric analysis 
of IκB-α expression was normalised against the relevant β-actin loading control and the 
values expressed as a fold change relative to the DCs stimulated with ES-62 for 18 h in the 
absence of any chemical treatment (media [18] + ES-62 [18], normalised to 1 and 
represented by the dashed line). E/P, E-64-D/Pepstatin A. 
In panel C, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with 
ammonium chloride (50 µM) or medium as indicated for 1 h. The cells were then 
stimulated with combinations of medium, ES-62 (2 µg/ml) and LPS (1 µg/ml) for the 
indicated times (hours), where the order of stimulation follows from the top to the bottom. 
The control (unstimulated) cells were incubated under the same conditions for the length of 
the experiment (36 h). Total protein extracts were purified from the samples and analysed 
by Western blotting for IκB-α expression. In panel D, the densitometric analysis of IκB-α 
expression was normalised against the relevant β-actin loading control and the values 
expressed as a fold change relative to unstimulated DCs in the absence of any chemical 
treatment (Media 36 h, normalised to 1 and represented by the dashed line). E/P, E-64-
D/Pepstatin A; NH4Cl, ammonium chloride. 
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Figure 4.6 | Effect of GM-CSF on modulation of IκB-α and -β expression by ES-62 
and/or LPS. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with 
either ES-62 (2 µg/ml) and/or LPS (1 µg/ml) for the indicated times with GM-CSF 
maintained in the culture. The key above the blots states the duration of each treatment and 
the order each stimulant was added, from the top to the bottom . The control (unstimulated) 
cells were incubated under the same conditions for the relevant length of each set of 
treatments (i.e. 19, 21 and 24 h respectively). Total protein extracts were purified from the 
samples and analysed by Western blotting for IκB-α and -β expression. In panel B and C, 
the densitometric analysis of IκB-α and IκB-β was normalised against the relevant β-actin 
loading control and expressed as a fold change relative to the appropriate control 
(unstimulated DC, normalised to 1) cells for the LPS (B) and ES-62 (C) treated samples. 
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Figure 4.7 | The effect of GM-CSF on the modulation of MyD88 expression by ES-62 
and LPS. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with 
either ES-62 (2 µg/ml) or LPS (1 µg/ml) for the indicated times. The control 
(unstimulated) cells were incubated under the same conditions for the length of the 
experiment (18 h). Total protein extracts were purified from the samples and analysed by 
Western blotting for MyD88 expression. In panel B, the densitometric analysis of MyD88 
was normalised against the relevant β-actin loading control and expressed as a fold change 
relative to the control cells (unstimulated DC, normalised to 1). 
In panel C, bmDCs (2x106/well in a total of 2 ml) were stimulated with either ES-62 (2 
µg/ml) or LPS (1 µg/ml) for 18 h. Total protein extracts were purified from the samples 
and analysed by Western blotting for MyD88 expression. In panel D, the densitometric 
analysis of MyD88 expression was normalised against the relevant β-actin loading control 
and then expressed as a fold change relative to the control cells (unstimulated DC, 
normalised to 1). Data are acquired from four independent experiments and presented as 
the mean estimations ± SEM where n=4.  
In panel E, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with 
ES-62 (2 µg/ml) for the indicated times with GM-CSF maintained in the culture. The 
control (unstimulated) cells were incubated under the same conditions for the length of the 
experiment (18 h). Total protein extracts were purified from the samples and analysed by 
Western blotting for MyD88 expression. In panel F, the densitometric analysis of MyD88 
was normalised against the relevant β-actin loading control and expressed as a fold change 
relative to the control cells (unstimulated DC, normalised to 1). The densitometric analysis 
of DCs treated with ES-62 in the absence of GM-CSF is included for reference. 
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Figure 4.8 | Effect of ES-62 and LPS stimulation on the expression of MyD88 protein 
and mRNA transcript. 
BmDCs (2x106/well in a total of 2 ml) were stimulated with either LPS (1 µg/ml) or ES-62 
(2 µg/ml) for the indicated times (hours). These cells were then fixed and permeabilised 
before being stained with a rabbit polyclonal Ab against MyD88 followed by FITC 
labelled anti-mouse IgG (FL1 channel). The MyD88 Ab conjugated with its immunising 
peptide (blocking peptide) was utilised as a specificity control on unstimulated cells. In 
panel A, the gating of healthy cells of the correct size (FSC-H) and granularity (SSC-H) 
associated with DCs, were defined by their expression of MHC Class II utilising a PE 
conjugated Ab (FL2-H channel). In panel B, data for such gated differentially treated 
bmDCs are presented as histograms of fluorescent intensity of Ag staining versus the %-
Max (section 2.6.1). In panel C, the percentage of positively stained cells (for MyD88) 
induced by both treatments was calculated relative to the specificity control as indicated by 
the markers on the histograms. Data are representative of two experiments. 
In panel D, the total RNA was purified from CD11c expressing bmDCs (2x106/well in a 
total of 2 ml) stimulated with either ES-62 (2 µg/ml) or LPS (1 µg/ml) for the indicated 
times. The production of MyD88 mRNA transcript from these cells was measured by 
Taqman real-time PCR and defined as a percentage relative to GAPDH mRNA expression. 
The data are presented as the mean levels of triplicate estimates from a single experiment ± 
SD. 
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Figure 4.9 | The effect of ES-62 and LPS on TIRAP expression. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with 
either ES-62 (2 µg/ml) or LPS (1 µg/ml) for the indicated times. The control 
(unstimulated) cells were incubated under the same conditions for the length of the 
experiment (18 h). Total protein extracts were purified from the samples and analysed by 
Western blotting for TIRAP (MAL) expression. In panel B, the densitometric analysis of 
TIRAP expression was normalised against the relevant β-actin loading control and the 
values expressed as a fold change relative to the control cells (unstimulated DC, 
normalised to 1). 
In panel C, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with 
either ES-62 (2 µg/ml) or LPS (1 µg/ml) for 18 h. The control (unstimulated) cells were 
incubated under the same conditions for the length of the experiment (18 h). Total protein 
extracts were purified from the samples and analysed by Western blotting for TIRAP 
(MAL) expression. In panel D, the densitometric analysis of TIRAP expression was 
normalised against the relevant β-actin loading control and the values expressed as a fold 
change relative to the control cells (unstimulated DC, normalised to 1 and represented by 
the dashed line). Data are acquired from three independent experiments and presented as 
the mean estimations ± SEM where n=3. 
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Figure 4.10 | Effect of inhibiting lysosomal degradation on the expression of MyD88 
and TIRAP upon protracted ES-62 and/or LPS stimulation. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with E-
64-D (10 µg/ml) plus Pepstatin A (10 µg/ml) or medium as indicated for 1 h. The cells 
were then stimulated with combinations of medium, ES-62 (2 µg/ml) and LPS (1 µg/ml) 
for the indicated times (hours), where the order of stimulation follows from the top to the 
bottom. The control (unstimulated) cells were incubated under the same conditions for the 
length of the experiment (36 h). Total protein extracts were purified from the samples and 
analysed by Western blotting for MyD88 expression. In panel B, the densitometric analysis 
of MyD88 expression was normalised against the relevant β-actin loading control and the 
values expressed as a fold change relative to unstimulated DCs in the absence of any 
chemical treatment (Media 36 h, normalised to 1). 
In panel C, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with E-
64-D (10 µg/ml) plus Pepstatin A (10 µg/ml) or medium as indicated for 1 h. The cells 
were then stimulated with combinations of medium, ES-62 (2 µg/ml) and LPS (1 µg/ml) 
for the indicated times (hours), where the order of stimulation follows from the top to the 
bottom. The control (unstimulated) cells were incubated under the same conditions for the 
length of the experiment (36 h). Total protein extracts were purified from the samples and 
analysed by Western blotting for TIRAP expression. In panel D, the densitometric analysis 
of TIRAP expression was normalised against the relevant β-actin loading control and the 
values expressed as a fold change relative to unstimulated DCs in the absence of any 
chemical treatment (Media 36 h, normalised to 1). E/P, E-64-D/Pepstatin A. 
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Figure 4.11 | Effect of inhibiting multiple avenues of protein degradation on TRAF6 
expression upon ES-62 and LPS stimulation.  
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with 
lactacystin (10 µM), E-64-D (10 µg/ml) plus Pepstatin A (10 µg/ml), ammonium chloride 
(50 µM) or medium as indicated for 1 h. The cells were then stimulated with either ES-62 
(2 µg/ml) or LPS (1 µg/ml) for the indicated times. The control (unstimulated) cells were 
incubated under the same conditions for the length of the experiment (18 h). Total protein 
extracts were purified from the samples and analysed by Western blotting for TRAF6 
expression. In panels B & C, the densitometric analysis of TRAF6 expression for the LPS 
(panel B) and ES-62 (panel C) stimulated samples, including those treated with the various 
proteosomal and lysosomal inhibitors, were normalised against the relevant β-actin loading 
control and expressed as a fold change relative to the appropriate control cells 
(unstimulated DC, normalised to 1). E/P, E-64-D/Pepstatin A; NH4Cl, ammonium 
chloride. 
In panel D, the total RNA was purified from CD11c expressing bmDCs (2x106/well in a 
total of 2 ml) stimulated with either ES-62 (2 µg/ml) or LPS (1 µg/ml) for the indicated 
times. The production of TRAF6 mRNA transcript from these cells was measured by 
Taqman real-time PCR and defined as a percentage relative to GAPDH mRNA expression. 
The data are presented as the mean levels of triplicate estimates from a single experiment ± 
SD.  
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Figure 4.12 | Effect of inhibiting lysosomal degradation on the protracted expression 
of TRAF6 upon ES-62 and/or LPS stimulation. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with E-
64-D (10 µg/ml) plus Pepstatin A (10 µg/ml) or medium as indicated for 1 h. The cells 
were then stimulated with combinations of medium, ES-62 (2 µg/ml) and LPS (1 µg/ml) 
for the indicated times (hours), where the order of stimulation follows from the top to the 
bottom. The control (unstimulated) cells were incubated under the same conditions for the 
length of the experiment (36 h). Total protein extracts were purified from the samples and 
analysed by Western blotting for TRAF6 expression. In panel B, the densitometric analysis 
of TRAF6 expression was normalised against the relevant β-actin loading control and the 
values expressed as a fold change relative to unstimulated DCs in the absence of any 
chemical treatment (Media 36 h, normalised to 1 and represented by the dashed line). E/P, 
E-64-D/Pepstatin A. 
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Figure 4.13 | Effect of inhibiting lysosomal degradation on the expression of TRAF6 
upon ES-62 and/or LPS stimulation. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with E-
64-D (10 µg/ml) plus Pepstatin A (10 µg/ml), ammonium chloride (50 µM) or medium as 
indicated for 1 h. The cells were then stimulated with combinations of medium, ES-62 (2 
µg/ml) and LPS (1 µg/ml) for the indicated times (hours), where the order of stimulation 
follows from the top to the bottom. The control (unstimulated) cells were incubated under 
the same conditions for the length of the experiment (36 h). Total protein extracts were 
purified from the samples and analysed by Western blotting for TRAF6 expression. In 
panel B, the densitometric analysis of TRAF6 expression was normalised against the 
relevant β-actin loading control and the values expressed as a fold change relative to the 
control cells (unstimulated DC, normalised to 1 and represented by the dashed line). Data 
are acquired from four independent experiments and presented as the mean estimations ± 
SEM where n=4. The statistical analysis performed is a Kruskal-Wallis test, utilising a 
Dunn’s Multiple Comparison Post Test (α = p<0.05). E/P, E-64-D/Pepstatin A; NH4Cl, 
ammonium chloride. 
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Figure 4.14 | The effect of GM-CSF on the modulation of TRAF6 expression by ES-62 
and/or LPS. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with 
ES-62 (2 µg/ml) for the indicated times (hours), with GM-CSF maintained in the culture. 
The control (unstimulated) cells were incubated under the same conditions for the length of 
the experiment (18 h). Total protein extracts were purified from the samples and analysed 
by Western blotting for TRAF6 expression. In panel B, the densitometric analysis of 
TRAF6 was normalised against the relevant β-actin loading control and these values were 
adjusted and expressed as a fold change relative to the control cells (unstimulated DC, 
normalised to 1). 
In panel C, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with 
ES-62 (2 µg/ml) and/or LPS (1 µg/ml) for the indicated times (hours), where the order of 
stimulation follows from the top to the bottom. The control (unstimulated) cells were 
incubated under the same conditions for the relevant length of the experiment (22 h). Total 
protein extracts were purified from the samples and analysed by Western blotting for 
TRAF6 and IκB-β expression. In panels D and E, the densitometric analysis of TRAF6 
and IκB-β was normalised against the relevant β-actin loading control and the values 
expressed as a fold change relative to the control cells (unstimulated DC, normalised to 1) 
for both TRAF6 and IκB-β, respectively. 
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Figure 4.15 | Effect of inhibiting multiple avenues of protein degradation on c-Cbl 
expression upon ES-62 and LPS stimulation.  
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with 
lactacystin (10 µM), E-64-D (10 µg/ml) plus Pepstatin A (10 µg/ml), ammonium chloride 
(50 µM) or medium as indicated for 1 h. The cells were then stimulated with either ES-62 
(2 µg/ml) or LPS (1 µg/ml) for the indicated times. The control (unstimulated) cells were 
incubated under the same conditions for the length of the experiment (18 h). Total protein 
extracts were purified from the samples and analysed by Western blotting for c-Cbl 
expression. In panels B and C, the densitometric analysis of c-Cbl expression for the LPS 
(panel B) and ES-62 (panel C) stimulated samples, including those treated with the various 
proteosomal and lysosomal inhibitors, were normalised against the relevant β-actin loading 
control and expressed as a fold change relative to the appropriate control cells 
(unstimulated DC, normalised to 1). In panel D, the normalised and adjusted data of c-Cbl 
expression upon ES-62 and LPS stimulation from three independent experiments are 
presented as the mean estimation ± SEM, where n=3. E/P, E-64-D/Pepstatin A; NH4Cl, 
ammonium chloride. 
In panel E, the total RNA was purified from CD11c expressing bmDCs (2x106/well in a 
total of 2 ml) stimulated with either ES-62 (2 µg/ml) or LPS (1 µg/ml) for the indicated 
times. The production of c-Cbl mRNA transcript from these cells was measured by 
Taqman real-time PCR and defined as a percentage relative to GAPDH mRNA expression. 
The data are presented as the mean levels of triplicate estimates from a single experiment ± 
SD. 
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Figure 4.16 | Effect of inhibiting lysosomal degradation on the expression of c-Cbl 
upon ES-62 and/or LPS stimulation. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with E-
64-D (10 µg/ml) plus Pepstatin A (10 µg/ml) or medium as indicated for 1 h. The cells 
were then stimulated with combinations of medium, ES-62 (2 µg/ml) and LPS (1 µg/ml) 
for the indicated times (hours), where the order of stimulation follows from the top to the 
bottom. The control (unstimulated) cells were incubated under the same conditions for the 
length of the experiment (36 h). Total protein extracts were purified from the samples and 
analysed by Western blotting for c-Cbl expression. In panel B, the densitometric analysis 
of c-Cbl expression was normalised against the relevant β-actin loading control and the 
values expressed as a fold change relative to the control cells (unstimulated DC, 
normalised to 1 and represented as a dashed line). Data are acquired from three 
independent experiments and is presented as the mean estimations ± SEM where n=3. E/P, 
E-64-D/Pepstatin A. 
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Figure 4.17 | The effect of GM-CSF on the modulation of c-Cbl expression by ES-62 
and/or LPS. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with 
ES-62 (2 µg/ml) ± GMCSF in the culture medium as indicated for the stated times (hours). 
The control (unstimulated) cells were incubated under the same conditions for the length of 
the experiment (18 h). Total protein extracts were purified from the samples and analysed 
by Western blotting for c-Cbl expression. In panel B, the densitometric analysis of c-Cbl 
was normalised against the relevant β-actin loading control and these values were adjusted 
and expressed as a fold change relative to the control cells (unstimulated DC, normalised 
to 1). The densitometric analysis of DCs treated with ES-62 in the absence of GM-CSF is 
included for reference. 
In panel C, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with 
ES-62 (2 µg/ml) and/or LPS (1 µg/ml) for the indicated times (hours) with GM-CSF 
maintained in the culture, where the order of stimulation follows from the top to the 
bottom. The control (unstimulated) cells were incubated under the same conditions for the 
relevant length of each set of treatments (19 and 24 h). Total protein extracts were purified 
from the samples and analysed by Western blotting for c-Cbl expression. In panel D, the 
densitometric analysis of c-Cbl was normalised against the relevant β-actin loading control 
and the values expressed as a fold change relative to the control cells (unstimulated DC, 
normalised to 1 and represented by the dashed line).  
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Figure 4.18 | The effect of ES-62 and LPS maturation on the expression of several 
PKC isoforms. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with 
ES-62 (2 µg/ml) for the indicated times. The control (unstimulated) cells were incubated 
under the same conditions for the length of the experiment (18 h). Total protein extracts 
were purified from the samples and analysed by Western blotting for PKCθ expression.  
In panel B, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with 
ES-62 (2 µg/ml) for the indicated times. The control (unstimulated) cells were incubated 
under the same conditions for the length of the experiment (18 h). Total protein extracts 
were purified from the samples and analysed by Western blotting for PKCι and -β 
expression. 
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Figure 4.19 | The effect of ES-62 and LPS on PKCα expression, phosphorylation and 
the influence of GM-CSF. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with ES-62 
(2 µg/ml) or LPS (1 µg/ml) for the indicated times. The control (unstimulated) cells were incubated 
under the same conditions for the length of the experiment (18 h). Total protein extracts were 
purified from the samples and analysed by Western blotting for PKCα expression. In panel B, the 
densitometric analysis of PKCα expression was normalised against the relevant β-actin loading 
control and the values expressed as a fold change relative to the control cells (unstimulated DC, 
normalised to 1). In panel C, of CD11c expressing bmDCs (2x106/well in a total of 2 ml) were 
stimulated with ES-62 (2 µg/ml) or LPS (1 µg/ml) for 18 h. The control (unstimulated) cells were 
incubated under the same conditions for the length of the experiment (18 h). Total protein extracts 
were purified from the samples and analysed by Western blotting for PKCα expression. In panel D, 
the densitometric analysis of PKCα expression was normalised against the relevant β-actin loading 
control and expressed as a fold change relative to the control cells (unstimulated DC, normalised to 
1 and represented by the dashed line). Data are acquired from two independent experiments and 
presented as the mean estimations ± SEM where n=2.  
In panel E, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with ES-62 (2 
µg/ml) for the indicated times alongside unstimulated cells (Control). Total protein extracts were 
purified from the samples and analysed by Western blotting for expression of phosphorylated 
PKCα (Thr 638). In panel F, the densitometric analysis of phospho-PKCα Thr638 expression was 
normalised against the relevant β-actin loading control and the values expressed as a fold change 
relative to the control cells (unstimulated DC, normalised to 1). 
In panel G, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with ES-62 
(2 µg/ml) for the indicated times with GM-CSF maintained in culture. Total protein extracts were 
purified from the samples and analysed by Western blotting for PKCα expression. In panel F, the 
densitometric analysis of PKCα expression was normalised against the relevant β-actin loading 
control and the values expressed as a fold change relative to the control cells (unstimulated DC, 
normalised to 1). The densitometric analysis of bmDCs treated with ES-62 in the absence of GM-
CSF is included for reference 
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Figure 4.20 | Effect of inhibiting multiple avenues of protein degradation on PKCε 
expression upon ES-62 and LPS stimulation.  
In panels A and B, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated 
with lactacystin (10 µM), E-64-D (10 µg/ml) plus Pepstatin A (10 µg/ml), ammonium 
chloride (50 µM) or medium as indicated for 1 h. The cells were then stimulated with 
either ES-62 (2 µg/ml; panel A) or LPS (1 µg/ml; panel B) for the indicated times. The 
control (unstimulated) cells were incubated under the same conditions for the length of the 
experiment (18 h). Total protein extracts were purified from the samples and analysed by 
Western blotting for PKCε expression. In panels C & D, The densitometric analysis of 
PKCε expression for the LPS (panel B) and ES-62 (panel D) stimulated samples, including 
those treated with various proteosomal and lysosomal inhibitors, were normalised against 
the relevant β-actin loading control and expressed as a fold change relative to the 
appropriate control cells (unstimulated DC, normalised to 1). E/P, E-64-D/Pepstatin A; 
NH4Cl, ammonium chloride. 
In panel E, the total RNA was purified from CD11c expressing bmDCs (2x106/well in a 
total of 2 ml) stimulated with either ES-62 (2 µg/ml) or LPS (1 µg/ml) for the indicated 
times. The production of PKCε mRNA transcript from these cells was measured by 
Taqman real-time PCR and defined as a percentage relative to GAPDH mRNA expression. 
The data are presented as the mean levels of triplicate estimates from a single experiment ± 
SD. 
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Figure 4.21 | Effect of inhibiting lysosomal degradation on the protracted expression 
of PKCε upon ES-62 and/or LPS stimulation. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with E-
64-D (10 µg/ml) plus Pepstatin A (10 µg/ml) or medium as indicated for 1 h. The cells 
were then stimulated with combinations of medium, ES-62 (2 µg/ml) and LPS (1 µg/ml) 
for the indicated times (hours), where the order of stimulation follows from the top to the 
bottom. The control (unstimulated) cells were incubated under the same conditions for the 
length of the experiment (36 h). Total protein extracts were purified from the samples and 
analysed by Western blotting for PKCε expression. In panel B, the densitometric analysis 
of PKCε expression was normalised against the relevant β-actin loading control and the 
values expressed as a fold change relative to the control cells (unstimulated DC, 
normalised to 1 and represented by the dashed line). Data are acquired from three 
independent experiments and is presented as the mean estimations ± SEM where n=3. The 
statistical analysis performed is a Kruskal-Wallis test, utilising a Dunn’s Multiple 
Comparison Post Test (α = p<0.05). E/P, E-64-D/Pepstatin A. 
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Figure 4.22 | Effect of inhibiting multiple avenues of protein degradation on PKCδ 
expression upon ES-62 and LPS stimulation.  
In panels A and B, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated 
with lactacystin (10 µM), E-64-D (10 µg/ml) plus Pepstatin A (10 µg/ml), ammonium 
chloride (50 µM) or medium as indicated for 1 h. The cells were then stimulated with 
either ES-62 (2 µg/ml; panel A) or LPS (1 µg/ml; panel B) for the indicated times. The 
control (unstimulated) cells were incubated under the same conditions for the length of the 
experiment (18 h). Total protein extracts were purified from the samples and analysed by 
Western blotting for PKCδ expression. In panels C & D, the densitometric analysis of the 
LPS (panel C) and ES-62 (panel D) stimulated samples, including those treated with 
various proteosomal and lysosomal inhibitors, were normalised against the relevant β-actin 
loading control and expressed as a fold change relative to the appropriate control cells 
(unstimulated DC, normalised to 1). In panel E, the densitometric analysis of ES-62 and 
LPS stimulated samples from three independent experiments were normalised against the 
relevant β-actin loading control and expressed as a fold change relative to the appropriate 
control cells (unstimulated DC, normalised to 1) and presented as the mean estimations ± 
SEM where n=3. The statistical analysis performed is a Kruskal-Wallis test, utilising a 
Dunn’s Multiple Comparison Post Test (α = p<0.05), relative to the control (unstimulated) 
sample. E/P, E-64-D/Pepstatin A; NH4Cl, ammonium chloride. 
In panel F, the total RNA was purified from CD11c expressing bmDCs (2x106/well in a 
total of 2 ml) stimulated with either ES-62 (2 µg/ml) or LPS (1 µg/ml) for the indicated 
times. The production of PKCδ mRNA transcript from these cells was measured by 
Taqman real-time PCR and defined as a percentage relative to GAPDH mRNA expression. 
The data are presented as the mean levels of triplicate estimates from a single experiment ± 
SD. 
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Figure 4.23 | Effect of inhibiting lysosomal degradation on the protracted expression 
of PKCδ upon ES-62 and/or LPS stimulation. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with E-
64-D (10 µg/ml) plus Pepstatin A (10 µg/ml), ammonium chloride (50 µM) or medium as 
indicated for 1 h. The cells were then stimulated with combinations of medium, ES-62 (2 
µg/ml) and LPS (1 µg/ml) for the indicated times (hours), where the order of stimulation 
follows from the top to the bottom. The control (unstimulated) cells were incubated under 
the same conditions for the length of the experiment (36 h). Total protein extracts were 
purified from the samples and analysed by Western blotting for PKCδ expression. In panel 
B, the densitometric analysis of PKCδ expression was normalised against the relevant β-
actin loading control and the values expressed as a fold change relative to the control cells 
(unstimulated DC, normalised to 1 and represented by the dashed line). Data are acquired 
from three independent experiments and is presented as the mean estimations ± SEM 
where n=3. The statistical analysis performed is a Kruskal-Wallis test, utilising a Dunn’s 
Multiple Comparison Post Test (α = p<0.05). E/P, E-64-D/Pepstatin A; NH4Cl, 
ammonium chloride. 
 
 
 
 
  
217 
Figure 4.24 | Sub-cellular expression and localisation of PKCδ in response to ES-62. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with 
ES-62 (2 µg/ml) for the indicated times. The control (unstimulated) cells were incubated 
under the same conditions for the length of the experiment (18 h). Cytoplasmic and nuclear 
fractions were prepared from the samples utilising the Nuclear Extract kit from Active 
motif following the manufacturer’s instructions and analysed by Western blotting for the 
expression of PKCδ, ES-62, GAPDH and VDAC-1. In panels C and D, The densitometric 
analysis of both the full length (panel B) and cleaved (panel C) forms of PKCδ were 
normalised against their relevant cellular localisation loading control (cytoplasm – 
GAPDH; nuclear – HDAC-1) and expressed as a fold change relative to the appropriate 
control cells (unstimulated DC, normalised to 1). 
In panel D, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with 
ES-62 (2 µg/ml) for the indicated times. The control (unstimulated) cells were incubated 
under the same conditions for the length of the experiment (18 h). After thoroughly 
washing the cells with PBS, total protein extracts were purified from the samples and 
analysed by Western blotting for ES-62 expression.  
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Figure 4.25 | Visualisation of PKCδ in response to LPS. 
CD11c expressing bmDCs (3.5x104/chamber in a total of 300 µl) were stimulated with 
LPS (1 µg/ml) or medium for 18 h. After washing, fixing and permeabilising the cells, 
PKCδ was visualised using a polyclonal Ab against the protein followed by a FITC-
labelled anti-rabbit IgG. The nuclei were stained for with DAPI and the cells visualised by 
confocal microscopy in 0.8 µm sections. In panel A, the PKCδ Ab conjugated with its 
immunising peptide (blocking peptide) was utilised as a specificity control. Both FITC and 
DAPI staining is presented (left) alongside both separately (DAPI, middle; FITC, right). In 
panel B, a representative picture in the same format is provided for immature bmDCs and 
in panel C, three representative examples are presented of LPS treated cells. 
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Figure 4.26 | Effect of inhibiting multiple avenues of protein degradation on PKCδ 
cleavage upon ES-62 and LPS stimulation.  
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with 
lactacystin (10 µM), E-64-D (10 µg/ml) plus Pepstatin A (10 µg/ml), ammonium chloride 
(50 µM) or medium as indicated for 1 h. The cells were then stimulated with either ES-62 
(2 µg/ml) or LPS (1 µg/ml) for the indicated times. The control (unstimulated) cells were 
incubated under the same conditions for the length of the experiment (18 h). Total protein 
extracts were purified from the samples and analysed by Western blotting for PKCδ 
expression, whereby cleaved PKCδ shows a distinctive molecular weight band of 38 kDa. 
The cleaved form of PKCδ was visible after extensive exposure and the 78 kDa band is 
shown for reference. In panel B, the densitometric analysis of ES-62 and LPS stimulated 
samples from three independent experiments were normalised against the relevant β-actin 
loading control and expressed as a fold change relative to the appropriate control cells 
(unstimulated DC, normalised to 1) and are presented as the mean estimations ± SEM 
where n=3. In panels C and D, The densitometric analysis of the ES-62 (panel C) and LPS 
(panel D) stimulated samples were normalised against the relevant β-actin loading control 
and expressed as a fold change relative to the control cells (unstimulated DC, normalised 
to 1). To the right of panels B, C and D, the relative amounts of the cleaved form of the 
protein are expressed as a percentage of the total amounts of PKCδ in the cell (cleaved and 
whole). Statistical analysis performed is a Kruskal-Wallis test, utilising a Dunn’s Multiple 
Comparison Post Test (α = p<0.05), relative to the control (unstimulated) sample. E/P, E-
64-D/Pepstatin A; NH4Cl, ammonium chloride. 
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Figure 4.27 | Effect of inhibiting lysosomal and proteosomal degradation on the 
cleavage of PKCδ upon ES-62 and/or LPS stimulation. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with 
combinations of medium, ES-62 (2 µg/ml) and LPS (1 µg/ml) for the indicated times (hours), 
where the order of stimulation follows from the top to the bottom. The control (unstimulated) cells 
were incubated under the same conditions for the length of the experiment (36 h). Total protein 
extracts were purified from the samples and analysed by Western blotting for PKCδ expression. 
The cleaved form of PKCδ (38 kDa) was visible after extensive exposure, with the 78 kDa band 
shown for reference. In panel B, the densitometric analysis of cleaved PKCδ expression was 
normalised against the relevant β-actin loading control and the values expressed as a fold change 
relative to the control cells (unstimulated DC, normalised to 1). Data are acquired from three 
independent experiments and is presented as the mean estimations ± SEM where n=3 and the 
statistical analysis performed is a Kruskal-Wallis test, utilising a Dunn’s Multiple Comparison Post 
Test (α = p<0.05), relative to the control (unstimulated sample). In panel C, the relative amount of 
the cleaved form of the protein is expressed as a percentage of the total amounts of PKCδ in the 
cell (cleaved and full length protein).  
In panel D, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with medium, 
lactacystin (10 µM) or ammonium chloride (50 µM) as indicated for 1 h. The cells were then 
stimulated with combinations of medium, ES-62 (2 µg/ml) and LPS (1 µg/ml) for the indicated 
times (hours), where the order of stimulation follows from the top to the bottom. The control 
(unstimulated) cells were incubated under the same conditions for the length of the experiment (36 
h). Total protein extracts were purified from the samples and analysed by Western blotting for 
PKCδ expression. The cleaved form of PKCδ (38 kDa) was visible after extensive exposure, with 
the 78 kDa band shown for reference. In panel E, the densitometric analysis of cleaved PKCδ 
expression was normalised against the relevant β-actin loading control and the values expressed as 
a fold change relative to the control cells (unstimulated DC, normalised to 1 and represented by the 
dashed line). Data are acquired from two independent experiments and is presented as the mean 
estimations ± SEM where n=2. In panel F, the relative amount of the cleaved form of the protein is 
expressed as a percentage of the total amounts of PKCδ in the cell (cleaved and full length protein). 
NH4Cl, ammonium chloride. 
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Figure 4.28 | The effect of ES-62 and LPS on the phosphorylation of PKCδ at 
Threonine 505 (Thr505). 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with 
ES-62 (2 µg/ml) or LPS (1 µg/ml) for the indicated times. The control (unstimulated) cells 
were incubated under the same conditions for the length of the experiment (18 h). Total 
protein extracts were purified from the samples and analysed by Western blotting for 
phosphorylation of PKCδ on Thr505 of both the cleaved full length proteins. In panel B, 
the densitometric analysis of Thr505 phosphorylation of full length and cleaved PKCδ was 
normalised against the relevant β-actin loading control and the values expressed as a fold 
change relative to the control cells (unstimulated DC, normalised to 1). In panel C, PKCδ-
Thr505 phosphorylation is represented as a percentage relative to the total amount of 
PKCδ observed in the cell under ES-62 treatment.  
In panel D, two batches of CD11c expressing bmDCs, A and B (2x106/well in a total of 2 
ml) were stimulated with ES-62 (2 µg/ml) or LPS (1 µg/ml) for the indicated times. The 
control (unstimulated) cells were incubated under the same conditions for the length of the 
experiment (18 h). Total protein extracts were purified from the samples and analysed by 
Western blotting for phosphorylation of Thr505 on PKCδ. In panel E, the densitometric 
analysis of Thr505 phosphorylation on PKCδ from three experiments was normalised 
against the relevant β-actin loading control and the values expressed as a fold change 
relative to the control cells (unstimulated DC, normalised to 1 and represented as a dashed 
line) and presented as the mean estimation ± SEM where n=3. The statistical analysis 
performed is a Kruskal-Wallis test, utilising a Dunn’s Multiple Comparison Post Test (α = 
p<0.05). 
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Figure 4.29 | Effect of inhibiting lysosomal degradation on the phosphorylation of 
PKCδ on Serine 643 (Ser643) upon ES-62 and/or LPS stimulation. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with E-
64-D (10 µg/ml) plus Pepstatin A (10 µg/ml) or medium as indicated for 1 h. The cells 
were then stimulated with combinations of medium, ES-62 (2 µg/ml) and LPS (1 µg/ml) 
for the indicated times (hours), where the order of stimulation follows from the top to the 
bottom. The control (unstimulated) cells were incubated under the same conditions for the 
length of the experiment (36 h). Total protein extracts were purified from the samples and 
analysed by Western blotting for PKCδ and its phosphorylation at Ser643. In panels B and 
C, the densitometric analysis of PKCδ (panel B) and Ser643 phosphorylation (panel C) 
was normalised against the relevant β-actin loading control and the values expressed as a 
fold change relative to unstimulated DCs in the absence of any chemical treatment (Media 
36 h, normalised to 1 and represented by the dashed line). In panel D, PKCδ Ser643 
phosphorylation is expressed as a percentage relative to the total amount of PKCδ 
observed in the cell under the varying treatments. E/P, E-64-D/Pepstatin A. 
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Figure 4.30 | Effect of inhibiting lysosomal degradation on the phosphorylation of 
PKCδ on Tyrosine 311(Tyr311) upon ES-62 and/or LPS stimulation. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with E-
64-D (10 µg/ml) plus Pepstatin A (10 µg/ml) or medium as indicated for 1 h. The cells 
were then stimulated with combinations of medium, ES-62 (2 µg/ml) and LPS (1 µg/ml) 
for the indicated times (hours), where the order of stimulation follows from the top to the 
bottom. The control (unstimulated) cells were incubated under the same conditions for the 
length of the experiment (36 h). Total protein extracts were purified from the samples and 
analysed by Western blotting for PKCδ and its phosphorylation at Tyr311. In panels B and 
C, the densitometric analysis of PKCδ (panel B) and Tyr311 phosphorylation (panel C) 
was normalised against the relevant β-actin loading control and the values expressed as a 
fold change relative to unstimulated DCs in the absence of any chemical treatment (Media 
36 h, normalised to 1 and represented by the dashed line). In panel D, PKCδ Tyr311 
phosphorylation is expressed as a percentage relative to the total amount of PKCδ 
observed in the cell under the varying treatments. E/P, E-64-D/Pepstatin A. 
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Figure 4.31 | Effect of E-64-D/Pepstatin A on the production of cytokines important in 
differentiating T helper (TH) cell phenotypes upon ES-62 and/or LPS stimulation.  
In panel A, bmDC were derived from bone marrow cells obtained from BALB/c mice by 
culture in vitro in the presence of GM-CSF for 6 days. These bmDC (2x106/well in a total 
of 2 ml) were then pretreated with medium or ES-62 (2 µg/ml) for 18 h followed by 
maturation with medium or LPS (1 µg/ml) for a further 18 h. In parallel cultures, bmDCs 
were treated with a combination of E-64-D (10 µg/ml) and Pepstatin A (10 µg/ml) (E/P) 
for 1 h to block lysosomal degradation before being stimulated with identical combinations 
of ES-62 and LPS as described above. The culture supernatants were then analysed for a 
range of cytokines including TNF-α, IL-12/23 p40, IL-12 p70, IL-23, IL-27 and IL-6, 
associated with the development of particular TH phenotypes. Data are acquired from four 
independent experiments and presented as the means of mean values of triplicate 
estimations ± SEM where n=4. The statistical analysis is by one way-ANOVA, utilising a 
Tukey post test where P* <0.05, **p<0.01 and ***p<0.001. In panel B, control (resting 
cells) and ES-62 stimulated cytokine secretion results are shown on an expanded scale. 
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Figure 4.32 | Effect of ammonium chloride on the production of cytokines important 
in differentiating T helper (TH) cell phenotypes upon ES-62 and/or LPS stimulation.  
In panel A, bmDC were derived from bone marrow cells obtained from BALB/c mice by 
culture in vitro in the presence of GM-CSF for 6 days. These bmDC (2x106/well in a total 
of 2 ml) were then matured with ES-62 (2 µg/ml) and/or LPS (1 µg/ml) and in parallel 
cultures identical stimulations were added to bmDCs pre-treated with ammonium chloride 
(NH4Cl; 50 µM) for 1 hour to block lysosomal degradation. Data is acquired from one 
experiment and presented as the mean value of triplicate estimations ± SD where n=3. In 
panel B, control (resting cells) and ES-62 stimulated cytokine secretion results are shown 
on an expanded scale.  
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Figure 4.33 | Effect of inhibiting lysosomal degradation on the expression of LC3 
upon ES-62 and/or LPS stimulation. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with E-
64-D (10 µg/ml) plus Pepstatin A (10 µg/ml) or medium as indicated for 1 h. The cells 
were then stimulated with combinations of medium, ES-62 (2 µg/ml) and/or LPS (1 µg/ml) 
for the indicated times (hours), where the order of stimulation follows from the top to the 
bottom. The control (unstimulated) cells were incubated under the same conditions for the 
length of the experiment (36 h). Total protein extracts were purified from the samples and 
analysed by Western blotting for LC3 expression. In panel B, the densitometric analysis of 
LC3 type I (LC3-I) and LC3 type II (LC3-II) expression was normalised against the 
relevant β-actin loading control and the values expressed as a fold change relative to 
unstimulated DCs in the absence of any chemical treatment (Media 36 h, normalised to 1 
and represented by the dashed line). In panel C, the expression of LC3-II was calculated as 
a ratio of LC3-I for the various treamtents. E/P, E-64-D/Pepstatin A. 
In panel D, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with 
ammonium chloride (50 µM) or medium as indicated for 1 h. The cells were then 
stimulated with combinations of medium, ES-62 (2 µg/ml) and/or LPS (1 µg/ml) for the 
indicated times (hours), where the order of stimulation follows from the top to the bottom. 
The control (unstimulated) cells were incubated under the same conditions for the length of 
the experiment (36 h). Total protein extracts were purified from the samples and analysed 
by Western blotting for LC3 expression. In panel E, the densitometric analysis of LC3 type 
I (LC3-I) and LC3 type II (LC3-II) expression was normalised against the relevant β-actin 
loading control and the values expressed as a fold change relative to unstimulated DCs in 
the absence of any chemical treatment (Media 36 h, normalised to 1 and represented by the 
dashed line). In panel F, the expression of LC3-II was calculated as a ratio of LC3-I for the 
various treamtents. NH4Cl, ammonium chloride. 
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Figure 4.34 | Effect of inhibiting lysosomal degradation and endocytic processing on 
p62 expression upon ES-62 or LPS stimulation. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with 
either medium or ES-62 (2 µg/ml) for the indicated times. The control (unstimulated) cells 
were incubated under the same conditions for the length of the experiment (18 h). Total 
protein extracts were then purified from the samples and analysed by Western blotting for 
the expression of p62 utilising an antibody against p62 (α-p62) and the same antibody 
conjugated with its immunising peptide (α-p62 + BP), as a specificity control.  
In panel B, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with E-
64-D (10 µg/ml) plus Pepstatin A (10 µg/ml), ammonium chloride (50 µM) or medium as 
indicated. Following these treatments for 1 h, the cells were stimulated with either ES-62 
(2 µg/ml) or LPS (1 µg/ml) for the indicated times. The control (unstimulated) cells were 
incubated under the same conditions for the length of the experiment (18 h). Total protein 
extracts were purified from the samples and analysed by Western blotting for p62 
expression. In panel C, the densitometric analysis of the 47 kDa and 60 kDa bands of p62  
for each treatment were normalised against the relevant β-actin loading control and 
expressed as a fold change relative to the control cells (unstimulated DC, normalised to 1 
and represented by the dashed line). Data from four experiments is presented for the 
indicated stimulations pretreated with/without, E-64-D/Pepstatin A and ammonium 
chloride as the normalised and adjusted values ± SEM, where n=4. The statistical analysis 
performed is a Kruskal-Wallis test utilising a Dunn’s Multiple Comparisons post test (α = 
p<0.05). E/P, E-64-D/Pepstatin A; NH4Cl, ammonium chloride. 
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Figure 4.35 | Effect of inhibiting lysosomal degradation on the protracted expression 
of p62 upon ES-62 and/or LPS stimulation. 
In panels A and B, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated 
with ammonium chloride (50 µM; panel A), E-64-D (10 µg/ml) plus Pepstatin A (10 
µg/ml; panel B) or medium as indicated for 1 h. The cells were then stimulated with 
combinations of medium, ES-62 (2 µg/ml) and LPS (1 µg/ml) for the indicated times 
(hours), where the order of stimulation follows from the top to the bottom. The control 
(unstimulated) cells were incubated under the same conditions for the length of the 
experiment (36 h). Total protein extracts were purified from the samples and analysed by 
Western blotting for p62 expression. In panel C, the densitometric analysis of p62 
expression was normalised against the relevant β-actin loading control and the values 
expressed as a fold change relative to the control cells (unstimulated DC, normalised to 1 
and represented by the dashed line). Data are acquired from four independent experiments 
and is presented as the mean estimations ± SEM where n=4. In panel D, the densitometric 
analysis of p62 expression including the samples treated with ammonium chloride and E-
64-D/Pepstatin A was normalised against the relevant β-actin loading control and the 
values expressed as a fold change relative to the control cells (unstimulated DC, 
normalised to 1 and represented by the dashed line). Data are acquired from three 
independent experiments and is presented as the mean estimations ± SEM where n=3. The 
statistical analysis performed is a Kruskal-Wallis test, utilising a Dunn’s Multiple 
Comparison Post Test (α = p<0.05). 
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Figure 4.36 | Effect of inhibiting autophagy on p62 expression upon ES-62 and/or LPS 
stimulation. 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated with 
either medium or 3-Methyladenine (2 mM; 3-MA) for 1 h before the cells were stimulated 
with either ES-62 (2 µg/ml) and/or LPS (1 µg/ml) for the times indicated. Total protein 
extracts were then purified from the samples and analysed by Western blotting for p62 
expression.  
In panel B, the densitometric analysis of the 47 kDa and 60 kDa bands of p62 were 
normalised against the relevant β-actin loading control and expressed as a fold change 
relative to the control cells (unstimulated DC, normalised to 1 and represented by the 
dashed line).  
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Figure 4.37 | Ubiquitination and association of important proteins in the propagation 
of TLR4 signalling upon stimulation with LPS or ES-62. 
CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with ES-62 (2 
µg/ml) or LPS (1 µg/ml) for the indicated times. In order to isolate all ubiquitin conjugated 
proteins (mono-, multi-, poly-modified and lysine linkage independent) from the cells each 
sample was carefully lysed and treated with the UbiQapture-Q matrix (Enzo life sciences) 
as per the manufacturer’s instructions. In panel A, the expression of ubiquitin (KW0150; 
mono-, multi-, poly-modified and lysine linkage independent) was analysed directly from 
the cell lysates by Western blotting. In panel B, The matrix precipitates were analysed by 
Western blotting for ubiquitin conjugate (KW0150), p62, TRAF6, PKCδ and c-Cbl 
expression.  
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Figure 4.38 | Effect of inhibiting multiple avenues of protein degradation on p62 
expression upon ES-62 and LPS stimulation.  
In panels A and C, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were treated 
with lactacystin (10 µM), E-64-D (10 µg/ml) plus Pepstatin A (10 µg/ml), ammonium 
chloride (50 µM) or medium as indicated for 1 h. The cells were then stimulated with 
either LPS (1 µg/ml; panel A) or ES-62 (2 µg/ml; panel C) for the indicated times. The 
control (unstimulated) cells were incubated under the same conditions for the length of the 
experiment (18 h). Total protein extracts were purified from the samples and analysed by 
Western blotting for p62 expression. In panel B, The densitometric analysis of the LPS 
stimulated samples were normalised against the relevant β-actin loading control and 
expressed as a fold change relative to the appropriate control cells (unstimulated DC, 
normalised to 1). In panel D, The densitometric analysis of the ES-62 stimulated samples 
were normalised against the relevant β-actin loading control and expressed as a fold 
change relative to the appropriate control cells (unstimulated DC, normalised to 1) cells. 
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Figure 4.39 | Visualisation of p62 in response to LPS. 
CD11c expressing bmDCs (3.5x104/chamber in a total of 300 µl) were stimulated with 
LPS (1 µg/ml) or medium for 18 h. After washing, fixing and permeabilising the cells, p62 
was visualised using a polyclonal Ab against the protein followed by a FITC-labelled anti-
rabbit IgG. The nuclei were stained for with DAPI and the cells visualised by confocal 
microscopy in 0.8 µm sections. In panel A, the p62 Ab conjugated with its immunising 
peptide (blocking peptide) was utilised as a specificity control on LPS treated cells. Both 
FITC and DAPI staining is presented (left) alongside both separately (FITC, middle; 
DAPI, right). In panel B, a representative picture in the same format is provided for 
immature bmDCs and in panel C, two representative examples of LPS treated cells. 
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Figure 4.40 | Visualisation of LC3 in response to LPS. 
CD11c expressing bmDCs (3.5x104/chamber in a total of 300 µl) were stimulated with 
LPS (1 µg/ml) or medium for 18 h. After washing, fixing and permeabilising the cells, 
LC3 was visualised using a polyclonal Ab against the protein followed by a FITC-labelled 
anti-rabbit IgG. The nuclei were stained for with DAPI and the cells visualised by confocal 
microscopy in 0.8 µm sections. In panel A, the LC3 Ab conjugated with its immunising 
peptide (blocking peptide) was utilised as a specificity control on LPS treated cells. Both 
FITC and DAPI staining is presented (left) alongside both separately (FITC, middle; 
DAPI, right). In panel B, a representative picture in the same format is provided for 
immature bmDCs and in panel C, two representative examples of LPS treated cells. 
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Figure 4.41 | Visualisation of TRAF6 in response to LPS. 
CD11c expressing bmDCs (3.5x104/chamber in a total of 300 µl) were stimulated with 
LPS (1 µg/ml) or medium for 18 h. After washing, fixing and permeabilising the cells, 
TRAF6 was visualised using a polyclonal Ab against the protein followed by a FITC-
labelled anti-rabbit IgG. The nuclei were stained for with DAPI and the cells visualised by 
confocal microscopy in 0.8 µm sections. In panel A, the TRAF6 Ab conjugated with its 
immunising peptide (blocking peptide) was utilised as a specificity control on LPS treated 
cells. Both FITC and DAPI staining is presented (left) alongside both separately (FITC, 
middle; DAPI, right). In panel B, a representative picture in the same format is provided 
for immature bmDCs and in panel C, two representative examples of LPS treated cells. 
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Figure 4.42 | Protein-protein associations formed by p62 upon stimulation with LPS 
In panel A, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with 
medium or LPS (1 µg/ml) for 18 h. In order to isolate p62 and its associated proteins each 
sample was carefully lysed and treated with anti-p62 associated Dynabeads (Invitrogen) as 
per the manufacturer’s instructions. The subsequent cell lysates and Dynabead precipitates 
were analysed by Western blotting for p62, TRAF6, PKCδ and LC3 expression. In panel 
B, CD11c expressing bmDCs (2x106/well in a total of 2 ml) were stimulated with medium 
or LPS (1 µg/ml) for the indicated times. The control (unstimulated) cells were incubated 
under the same conditions for the length of the experiment (18 h). P62 and its associated 
proteins were isolated from these samples by anti-p62 associated Dynabeads (Invitrogen) 
as per the manufacturer’s instructions and analysed by Western blotting for p62, TRAF6 
and PKCδ expression. A bead only control (no protein lysate) is also included. 
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Figure 4.43 | Effect of inhibiting the initiation of autophagy on the production of 
cytokines important in differentiating T helper (TH) cell phenotypes upon ES-62 
and/or LPS stimulation.  
In panel A, BmDC were derived from bone marrow cells obtained from BALB/c mice by 
culture in vitro in the presence of GM-CSF for 6 days. These bmDC (2x106/well in a total 
of 2 ml) were then pretreated with medium or ES-62 (2 µg/ml) for 18 h followed by 
maturation with medium or LPS (1 µg/ml) for a further 18 h. In parallel cultures, bmDCs 
were treated with 3-Methyladenine (3-MA; used at 2 mM) for 1 h to block autophagy 
before being stimulated with identical combinations of ES-62 and LPS as described above. 
The culture supernatants were then analysed for a range of cytokines including TNF-α, IL-
12 p70, IL-23 and IL-6, associated with the development of particular TH phenotypes. Data 
are acquired from two independent experiments and presented as the means of the 
triplicate estimations ± SEM where n=2 and the statistical analysis is by one way-ANOVA, 
utilising a Tukey post test where p*<0.05, **p<0.01 and ***p<0.001. In panel B, control 
(resting cells) and ES-62 stimulated cytokine secretion results are shown on an expanded 
scale.  
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5 General Discussion 
There is now a wealth of literature proposing that despite both helminth infections and 
atopic diseases sharing many immunological traits, immunoregulation by the parasites 
within the host can dampen responses to allergens and TH2 associated pathologies285. It is 
known that DCs, which are crucial in the interpretation of multiple pathogenic stimuli and 
the development of tailored immune responses, are a target of the immunomodulatory 
affects of ES-62 and the results within this thesis demonstrate a number of avenues by 
which this molecule prevents hyper-inflammatory responses induced by LPS. Although 
associated with driving the development of TH2 biased responses, ES-62 can act to 
attenuate the inflammation associated with various pathological phenotypes in vivo that are 
instigated by aberrant TH1 and/or TH17 (CIA324,352) as well as TH2 (OVA induced airway 
hypersensitivity321) phenotypes. The findings in Chapter 3 directly relate to the role of IL-
17A proinflammatory responses444 and the ability of ES-62 to attenuate the ability of DCs 
to induce the development of TH17 cells. This is coupled in view of recent evidence from 
this laboratory that ES-62 suppresses pathogenesis of CIA driven by aberrant TH17 
function by targeting the IL-17-producing cellular network at multiple sites352. Importantly 
for the ability to fight infection a level of plasticity was demonstrated in such suppression 
of IL-17 responses as these effects could be partially overcome when ES-62 matured DCs 
presented high concentrations of Ag. This presumably reflects how the microenvironment 
and pathogenic burden (represented by the increasing concentration of Ag) may overcome 
the effects of ES-62 on DCs allowing the induction of a limited proinflammatory response 
to prevent immunocompromising the host with respect to subsequent infection. 
The reduction of IL-17A secretion induced by the DCs predominantly stems from 
alterations to the LPS induced pro-inflammatory cytokine environment, as ES-62 had little 
effect on costimulatory molecule expression. Consistent with this, secretion of IL-23 was 
reduced, where this cytokine is important for maintaining a TH17 cell population and 
enhancing its pathogenicity123,444. The targeting of this cytokine may also reflect ES-62 
blunting the potent proinflammatory actions of IL-23, which occurs in conjunction with its 
induction of the development of TH17-type immune response123,209,242,249. By contrast, the 
maintenance of IL-6 secretion may reflect the preservation of the differentiation of a TH17 
cell population that is partially functional and allows restricted development of 
proinflammatory responses. However, it should be noted that contrary to these 
observations, in the inflammatory emvironment mediated in the CIA model, where the 
cytokine GM-CSF is particularly important in the progression of the disease523 and it 
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commonly associated with inflammatory environments518,519, ES-62 mediates the 
downregulation of IL-6324,352,524. In relation to this ex vivo lymph node cultures from mice 
whose Ag specific T cells bear a tg TCR specific for OVA323-339 deomstrated that upon 
immnuisation, prior exposure to ES-62 in vivo (where GM-CSF would also be present) 
modulated the responses to heterologous Ag by inhibition of Ag-specific clonal expansion 
and the secretion of a number of cytokines including IL-6323. Therefore the cytokine 
responses observed upon stimulation of the DCs with combinations of ES-62 and LPS, 
which were preformed in the absence of GM-CSF, could suggest that some of the effects 
of this immunomodulator maybe dictated by the inflammatory environment of the DC. 
Thus, to expand upon these concepts the effects of ES-62 in the presence of GM-CSF 
should be defined, which can be coupled with an investigation on its affect on TGF-β 
secretion, as in conjunction with IL-6 it is important in promoting the development of 
TH17 cells123,124. 
However, immunomodulation of DCs by ES-62 was not limited to reducing their 
ability to induce TH17 differentiation in terms of IL-17A secretion but was accompanied 
by the ablation of IL-22 production (mRNA and protein) from TH cells. Previous studies 
by this laboratory group have identified that the production of IL-17 and IL-22 are rarely 
observed from the same cells (M. Pineda & M.M. Harnett, unpublished observations). 
Although a dedicated TH22 subset has only been recently defined in humans and an 
equivalent in mice is yet to be discovered535, both IL-6 and TNF-α have been highlighted 
to be important for the development of this cell population536. IL-22 is quite unusual as it is 
produced by immune cells but acts only on non-hematopoietic stromal cells and displays 
both pathogenic412,413 and protective414,415,537 properties in a number of inflammatory 
disorders. Thus the ES-62 induced reduction of TNF-α whilst maintaining IL-6 secretion 
could be crucial to the reduced secretion of IL-22 either from as yet undefined cell 
population, or from the many reported to do so including TH1, TH17 and γδ T cells535. The 
targeting of the secretion of IL-22 by ES-62 is as yet unclear but it could relate to its 
importance in inducing the secretion of anti-microbial peptides from non-hematopoietic 
stromal cells402,411. In any case the targeting of the ability of DCs to induce the 
development of TH17 cells justifies the excitement associated with the potential of ES-62 
to provide a platform for the generation of persistent and effective anti-infalmmatory 
therapeutics.  
The results described demonstrate that ES-62 is able to develop flexibility within DCs 
to prime the development of specific immune phenotypes while preventing the hyper-
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inflammatory associated with such responses and these findings are summarised in Figure 
5.1. 
5.1 Modulation of aspects of LPS signalling upon the 
canonical activation of TLR4 
Following the discovery of the TLR family of receptors over two decades ago, the 
role of these proteins in innate immunity continues to expand. This is in part due to the 
increasing diversity of intracellular adaptors they engage to mediate signalling cascades15, 
their dynamic movement throughout resting and stimulated cells13 and the association of a 
diverse array of accessory molecules to mediate different cellular responses538. In this 
respect, the TLR4/MD2 complex is rapidly internalised via lipid rafts upon engagement 
with its canonical ligand, LPS, recruiting both TIRAP and MyD88435,436 for the activation 
of NF-κB, an important transcription factor for the maturation of DCs to secrete a range of 
inflammatory cytokines14,330. The activation of NF-κB by proteosomal degradation of its 
inhibitory subunit IκB is key for its induction of proinflammatory responses in DCs25. 
However, results in Chapter 4 demonstrate that inhibition of lysosomal proteases (with E-
64-D/Pepstatin A) induce an accumulation of both IκB-α and -β, which is coupled with the 
significant attenuation of LPS mediated IL-23 and IL-27 secretion, both TH17 associated 
cytokines. These data are consistent with lysosomal degradation being important in 
maintaining the activation of NF-κB during the late-endosomal TRAM-TRIF mediated 
phase of LPS-TLR4 signalling327, which in turn is important in the development of TH17 
responses by DCs. 
The results presented in Chapter 3 indicate that although this dynamic for 
TLR4/MD2 holds true within bmDCs, it is remarkably different to that of the total cellular 
pool of TLR4, defined by its upregulation both intracellularly and on the surface of the 
cell. This increase in the total cellular pool of TLR4 may reflect the ability of this receptor 
to mediate further functions via interactions with alternative adaptors. For example, the 
recently identified RP105 (CD180), a TLR like molecule that lacks a functional TIR 
domain, is able to interact with TLR4 to limit LPS driven cytokine secretion in DCs, 
suggesting that the association of this or other such molecules may provide further signals 
to control DC maturation and induction of immune responses539. 
The dynamic expression of TLR signalling adaptors induced by LPS extends to 
several members of the E3 ubiquitin ligase family, namely TRAF6 and c-Cbl with both 
 240 
TRAF6 and c-Cbl being important in TLR4 induced MyD88 (in)-dependent modulation of 
NF-κB activation24,44,454. Consistent with this the data in Chapter 4 indicates that prolonged 
proteosomal degradation of c-Cbl and the parabolic regulation of TRAF6 is important in 
the maturation of DCs to endotoxin. The observed upregulation after 18 h of TRAF6 
(protein and mRNA) suggests that the intial downregulation may reflect a negative feed 
back mechanism to LPS, limiting pathogenic TLR4 signalling. By contrast, the proteosmal 
degradation of c-Cbl induced by LPS most likely reflects its proposed role in stabilising 
NF-κB subunits as its deficiency leads to higher levels of IL-12p70 and IL-6454, two direct 
affects of LPS stimulation of DCs.  
This dynamic regulation of NF-κB activation was accompanied by the altered 
expression, cleavage and phosphorylation of several PKC isoforms upon LPS maturation 
of DCs. These lipid-sensitive protein serine/threonine kinases are increasingly emerging as 
important mediators in TLR mediated NF-κB activation, particularly in relation to the 
induction of cytokine secretion. The results in Chapter 4 support this paradigm as LPS 
mediated the upregulation of PKCε and PKCα (as well was the phosphorylation of the 
latter), and directly attributed to these kinases are the release of TNF-α, IL-12p70 and IL-6 
from myeloid derived populations115,119,120. For example, PKCδ can promote inflammatory 
cytokine secretion by activation of NF-κB93,102,103 through IKK dependent101,104,105,540 and 
independent106-108 (through direct phosphorylation of various MAPKs and Akt) pathways.  
Although PKCδ expression was not found to be strikingly altered by LPS, the effect 
on the phosphorylation, localisation and cleavage of the protein suggest a dynamic role in 
TLR4 signalling. In this context, LPS stimulation induced the phosphorylation of the A-
loop, which is important in stabilising the active conformation of the enzyme and defining 
its substrate specificity to allow the activation of NF-κB and AP-162,74. Thus A-loop 
phosphorylation of PKCδ appears to be involved in mediating NF-κB activation as defined 
by upregulation of proinflammatory cytokine and costimulatory marker expression by 
DCs. Interestingly, this phosphorylation was also observed on the cleaved form of the 
protein, where the relative levels of cleaved (the isolated kinase domain fragment) to full 
length PKC can dramatically alter the specificity and cellular function of these kinases56,58 
and often leads to the accumulation of this protein fragment in the nucleus59. Thus the 
observation that LPS induced the proteosomal degradation of the cleaved form suggests 
that this unregulated kinase fragment is not beneficial upon a strong inflammatory stimuli. 
As observed by confocal microscopy this modulation of PKCδ (cleaved and whole) 
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coincides with its distinct nuclear localisation, presumably to mediate the phosphorylation 
of transcription factors or another as yet undefined role. The scaffolding protein p62 has 
been reported to interact with aPKCs506 and TRAF6504,505,507 to mediate NF-κB activation 
and the results presented here expand these associations to include PKCδ but perhaps 
surprisingly not TRAF6. Although the role of these interactions is not clear, the emerging 
importance of p62 and PKCδ in inflammatory signalling suggests that at least in DCs their 
interaction is important in their maturation in response to LPS. However, somewhat in 
disagreement with these results confocal microscopy revealed this same stimulus induced 
the punctate localisation of p62 and TRAF6, which was not replicated by PKCδ, consistent 
with studies demonstrating p62 and TRAF6 colocalise to discrete punctuate centres in 
response to inflammatory stimuli508. 
In relation to the role of TRAF6 the polyubiquitination of this E3 ligase is required 
for its interaction with the TAK1 complex24 allowing the activation of NF-κB, however, 
upon TLR4 stimulation TRAF6 was not observed to associate to ubiquitin complexes but 
this affect could have been overlooked during this analysis (occurring < 2 h). The 
progressive ubiquitination of p62, which is required for the interaction with TRAF6 to 
mediate NF-κB activation507, could suggest a varying dynamic of this pathway within the 
maturation process of DCs and could complement the gradual downregulation and 
assumed regulated signalling of TLR4/MD2 from the cell surface. These results coincided 
with the dramatic upregulation of p62, in a similar fashion to that observed in macrophages 
stimulated with LPS and IFNγ, where p62 was also observed to interact with TRAF6 to 
mediate the activation of NF-κB505. Consistent with this a study of human keratinocytes 
showed that siRNA knockdown of p62 resulted in the reduced expression (mRNA 
transcript and protein) of TNF-α and IL-6 as well as NF-κB promoter activity upon 
TLR2/6 (MALP-2) and TLR4 (LPS) activation due to its proposed role in the activation of 
the IKK complex531. Alongside these studies, the results presented here indicate that the 
LPS induced upregulation and association to ubiquitin complexes of p62 is involved in the 
activation of NF-κB and the maintenance of such responses for the maturation of DCs. 
However, as noted in the keratinocyte study, LPS stimulation also induced autophagic flux, 
where p62 acts as an adaptor protein binding to polyubiquitinated targets to mediate their 
degradation in autolysosomes through its association with LC3-II in developing isolation 
membranes460.  
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Stimulation of the TLRs, and in particular TLR4, is associated with the acceleration 
of phagocytosis and the induction of the autophagic machinery in APCs, as defined by the 
induction of LC3 positive autophagosome formation460,495-497. In conjunction with the 
observations of p62 upregulation, LPS also mediated upregulation of LC3-II, which is the 
PE conjugated form of LC3 associated with autophagic membranes, indicating autophagic 
flux was occurring. However, upon blocking lysosomal degradation p62 was not 
dramatically increased suggesting that although signalling through TLR4 does indeed 
induce the turnover of the autophagic machinery in DCs, this is not directly related to the 
functions of p62 as the data indicate it is more likely involved in the maintenance of 
proinflammatory NF-κB signalling and cytokine responses. 
Interestingly, pretreating bmDCs with 3-MA (a well known inhibitor of autophagy) 
downregulated LPS induced secretion of TNF-α, IL-6 and IL-12p70. This result was 
somewhat unexpected as induction of autophagy is generally associated with 
downregulating LPS induced inflammatory responses and the activation of Class I 
PI3Ks525. However, a step associated with initiation of the autophagic machinery has been 
demonstrated to be involved in the downregulation of TNF-α, IL-12p70 and p40 through 
the blocking of p35 and p40 mRNA transcript in DCs526,527. In this respect DCs from mice 
which lack Class I PI3K activity show increased IL-12p70 and p40 secretion through 
enhanced p38 activity526. Moreover, the reduction of IL-6 and TNF-α secretion upon 3-
MA pretreatment has been previously reported in the literature and could reflect proposals 
that both of these cytokines feed back into the stimulation of autophagy528,529. These 
findings are summarised in Figure 5.2.   
5.2 ES-62 modulation of TLR4 function 
The TLRs are emerging as targets of many ES products, resulting in the biasing of 
DCs towards the induction of TH2-type immune responses. For example, both Schistosoma 
mansoni and Ascaris lumbricoides ES products have been demonstrated to utilise TLR2, 
and potentially TLR4, on DCs to induce a TH2-type immune response300. In regards to ES-
62, a requirement of TLR4 (though not its direct recruitment of MyD88) has been defined 
for the internalisation for ES-62 and its subversion of the proinflammatory functions of this 
receptor301,326, which in a DC result in its bias towards promoting TH2-type responses160. 
The results in Chapter 3, expand upon the current understanding of this dynamic by 
defining how ES-62 affects the internalisation of TLR4 and its LPS recognising complex 
TLR4/MD2, a key step in propagating proinflammatory signals and the activation of NF-
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κB347. The multiple avenues of analysis revealed that although the direct effects of ES-62 
on the expression (at both the mRNA and protein levels) of the receptor are relatively 
subtle, it antagonises the internalisation of TLR4/MD2 and upregulation of TLR4 induced 
by LPS. Interestingly, ES-62 is observed to promote the alternative routing of TLR4 to 
caveolae lipid raft compartments for sequestration and degradation in mast cells321. Related 
to this, the results presented demonstrate that ES-62 induces a similar sequestration of the 
total pools of TLR4 and the TLR4/MD2 complex within the cell but in the DCs this occurs 
specifically in response to inflammatory stimuli, providing a mechanism for the induction 
of TLR4 hyporesponsiveness. In a parallel mechanism the schistosome modulator, SEA, 
which can also function through TLR4, is trafficked into a LAMP2 (an 
endosome/lysosome marker) negative compartment in a clathrin dependent manner443. 
Such trafficking indicates the potential for a similar differential compartmentalisation of 
TLR4, relative to that induced by classical PAMPs, for the subversion of TLR4 signalling 
by ES-62 and (potentially) other helminth products. 
Results in chapter 4 demonstrate that the modulation of DC function by ES-62 is not 
limited to the dysregulation of the receptors involved in the recognition of 
PAMPs301,331,515,541. As described in section 5.1, PKCs are directly responsible for the 
propagation of a number of inflammatory responses including the recognition of LPS by 
TLR4. In murine splenic B cells ES-62 induced the proteolytic degradation of PKCα, -β 
and -δ resulting in the inhibition of the function of a host of transcription factors including 
NF-κB320,333,335. A more recent study has identified the non-proteosomal degradation of 
PKCα following its association to an ES-62-TLR4 complex via a caveolae-lipid raft 
dependent mechanism in mast cells321. Thus it is perhaps no surprise that as with B cells 
and mast cells, the activities of ES-62 in APCs are dependent on the regulation of several 
PKC isoforms, as demonstrated by its induction of the lysosomal degradation of PKCε and 
-δ coupled with the upregulation of PKCα. Accompanying the lysosomal degradation of 
PKCδ and PKCε, ES-62 uncoupled the transcription and translation of these signalling 
enzymes. The targeting of these isoforms can be linked to their role in LPS induced 
activation of NF-κB (particularly PKCδ93,101,102) and in the case of PKCε the secretion of 
TNF-α and IL-12p70 in monocyte derived DC100,114, as ES-62 attenuated the ability of 
LPS stimulated DCs to secrete such cytokines. However, there is a complexity to this 
function as modulation by ES-62 is observed to be plastic, with the subsequent stimulation 
of LPS attenuating the downregulation of these proteins.  
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In relation to this the novel PKCs, including PKCδ localise to the caveolae in several 
cell types to drive the formation of ceramide and lipid rafts at the PM and indeed several 
isoforms have been shown to physically associate with markers (caveolin-1/-3) in 
developing caveolae59,83,84,542. Thus, the initial transient upregulation of PKCδ and PKCε 
observed in response to ES-62, may be an important step in the driving of caveolae 
formation and provide a mechanism for their (and potentially other associated adaptors or 
TLR4) trafficking to the lysosomes for degradation82. The maintenance of PKCα 
expression (and potentially activation) by ES-62 is important for maintaining IL-6 
secretion, as it is known to be important for the maximal production of this cytokine in 
macrophages and DC119,120. 
In conjunction with the results (Chapter 4) indicating that TRAF6 is upregulated 
while c-Cbl is degraded in response to LPS, ES-62 was observed to induce the lysosomal 
degradation of TRAF6 coupled to the increased expression c-Cbl. Such inverse functions 
by canonical (LPS) and novel (ES-62) TLR4 ligands could reflect the diametric roles of 
these two E3 ubiquitin ligases in TLR4 signaling. For example, DCs from TRAF6 
deficient mice present maturation defects in response to LPS resulting in attenuated 
production of IL-12p70 and IL-6 secretion26-28. By contrast, c-Cbl is involved in stabilising 
the inactive NF-κB complex for the prevention of excessive secretion of IL-12p70 and IL-
6454. Thus the combined effects of ES-62 on these E3 ubiquitin ligases suggests that it is 
maturing a DC phenotype that is unable to induce hyper-inflammatory responses to LPS.   
The lysosomal targeting of ES-62 immunomodulation indicated a role for autophagy, 
which as outlined previously, is an emerging effector of TLR-mediated innate and adaptive 
immune responses. The induction of autophagic flux by ES-62, defined by the increase in 
the relative expression of LC3-II to LC3-I was accompanied by the degradation of p62, 
amplified by the pharmacological inhibition of the lysosomal proteases and/or autophagy. 
This approach indicated that ES-62 was inducing the induction of autophagy to mediate the 
selective lysosomal degradation of important adaptors in the TLR4 signalling pathway, 
such as p62, TRAF6 and PKCδ/ε. In relation to this, ES-62 induced the short-term increase 
in the association of TRAF6, PKCδ, c-Cbl and p62 to ubiquitin complexes, which could 
suggest that this maybe the required impetus for the degradation of these proteins in the 
lysosomes. In this respect, through adaptor proteins such as p62, ubiquitination maybe 
required for the targeting of these proteins to the autophagosomes for their selective 
degradation via the autolysosmes, which is rescued upon inhibition of lysosomal proteases 
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(E-64-D/Pepstatin A)460. In this case ES-62, via autophagy may uncouple the signalling 
capacity of p62 (in relation to TLR signalling and NF-κB activaiton) as ES-62 maturation 
of the DCs downregulated the expression of this protein and attenuated its upregulation in 
response to endotoxin.  
The immunomodulatory effects of ES-62 in bmDCs were altered in the presence of 
GM-CSF, a cytokine that is commonly produced in response to inflammatory stimuli such 
as LPS in vivo, where its acts to augment the functions of monocytes, macrophages and 
DCs, priming for the secretion a range of proinflammatory cytokines in response to further 
inflammatory stimuli509. Here, when experimentally mimicking such a ‘proinflammitory’ 
environment by addition of extrinsic GM-CSF, ES-62 dramatically downregulates MyD88, 
TRAF6 and c-Cbl (although not PKCα). Of particular interest was the downregulation of 
MyD88, a crucial mediator of proinflammatory responses via TLRs (except TLR3) and the 
activation of NF-κB14,543, in the presence of GM-CSF as in its absence ES-62 intially 
appeared to have little effect. However, on closer inspection in the absence of GM-CSF, 
use of lysosomal inhibitors revealed that ES-62 acted to maintain basal levels MyD88 by 
directing its lysosomal degradation. These results indicate the downregulation of not only 
MyD88 but also TRAF6 and c-Cbl (for which the involvement in inflammatory TLR4 
signalling is well documented) is a crucial step in the uncoupling of the inflammatory 
capacity of DCs by ES-62. This would be in keeping with some of the in vivo functions of 
ES-62 in both TH1/17310,324 and TH2302,321 associated proinflammatory responses. These 
findings are summarised in Figure 5.3. 
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Figure 5.1 | The effect of ES-62 on LPS induced DC responses 
Through the interaction with TLR4 on the surface of immature DCs, ES-62 and LPS 
induce the differential maturation and trafficking of this receptor. Specifically ES-62 
induces the degradation of certain intracellular adaptors and the differential trafficking of 
TLR4 to potentially attenuate the activation of NF-κB and the IRFs leading to reduced 
production of IL-12/23 p40, IL12p70, TNF-α and IL-23. In this context, ES-62 matured 
DCs were observed to induce fewer TH cells into proliferation upon stimulation with LPS, 
(compared to DCs matured with LPS alone). However, this effect was Ag dose dependent 
as proliferative responses induced by DCs presenting high concentrations of OVA peptide 
weren’t inhibited, indicating a ceratin level of plasticity to prevent the host being 
immunocomprimsed to subsequent pathogenic stimuli. In conjunction with this, evidence 
in this thesis clearly indicates that ES-62 maturation of DCs is able to limit IL-17 and IL-
22 production from differentiating TH cells upon stimulation with LPS, suggesting that it 
acts to attenuate the clonal expansion of the proinflammatory TH17 subset.  
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Figure 5.2 | The intracellular responses of DCs upon stimulation with LPS 
The recognition of LPS by TLR4/MD2 induces the internalisation of the complex 
alongside the upregulation of both surface and intracellular pools of TLR4. The activation 
of NF-κB by LPS-TLR4/MD2 signalling occurs relatively rapidly through the proteosomal 
and degradation of IκB-α and -β. This relates to the early phase of TLR4 signalling, 
however after prolonged stimulation a distinct lysosomal component is observed, which is 
accompanied by a change in the expression of TRAF6, PKCε and PKCα coupled with the 
proteosomal degradation of c-Cbl. These signalling adaptors are involved in the 
propagation of TLR4 signals and induction of proinflammatory cytokine production. The 
expression of p62 is progressively increased and is accompanied by a novel interaction 
with PKCδ but not LC3 (a classical marker of autophagic flux). The phosphorylation and 
relative levels of cleaved to full-length PKCδ are also altered indicating it may be involved 
in maintaining the prolonged activation of NF-κB. As repeated elsewhere, the stimulation 
of TLR4 with LPS induced autophagic flux, as defined by increased levels of LC3-II. 
However, in contrast to the proposal that autophagy provides a negative feedback 
mechanism for TLR4 signalling, inhibition of this cellular process results in the attenuated 
ability of DCs to secrete proinflammatory cytokines. 
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Figure 5.3 | Immunomodulation of DCs by ES-62 
Panel A, upon interaction with TLR4, ES-62 induces a slight increase in the surface 
expression of this receptor, whilst slightly decreasing that of TLR4/MD2. The maturation 
of DCs with ES-62 partially inhibited LPS-mediated internalisation of the TLR4/MD2 
complex and prevented the upregulation of TLR4 to the cell surface. The ES-62 driven 
upregulation of c-Cbl may relate to the stabilisation of the inactive NF-κB complex and 
hence prevent its activation and propagation of hyper-inflammatory responses. Moreover, 
ES-62 specifcally targets the lysosomal degradation of PKCδ, TRAF6 and PKCε, which 
are all associated with the production of various proinflammatory cytokines. This is 
accompanied by the induction of autophagic flux (identified upon the accumulation of 
LC3-II upon inhibition of lysosomal degradation), a process that was accompanied with a 
reduction of p62 expression, presumably due to its role in LPS-induced NF-κB activation. 
This could be facilitated by ubiquitination, as p62 can bind to ubiquintinated proteins and 
deposit them into autophagosomes for degradation. ES-62 also induces the transient 
translocation of full length and cleaved PKCδ into the nucleus of these cells suggesting 
that this plays some role in the alternative maturation of bmDCs by ES-62. Panel B, under 
proinflammatory conditions created by the addition of GM-CSF to the stimulatory culture) 
ES-62 is observed to degrade MyD88, TRAF6 and c-Cbl while maintaining PKCα 
expression. This indicates that under proinflammatory conditions ES-62 acts to prevent 
proinflammatory signalling through degradation of key TLR4 signalling adaptors for the 
activation of NF-κB. 
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